KR20180137057A - Fused-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient - Google Patents
Fused-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient Download PDFInfo
- Publication number
- KR20180137057A KR20180137057A KR1020170075721A KR20170075721A KR20180137057A KR 20180137057 A KR20180137057 A KR 20180137057A KR 1020170075721 A KR1020170075721 A KR 1020170075721A KR 20170075721 A KR20170075721 A KR 20170075721A KR 20180137057 A KR20180137057 A KR 20180137057A
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- pyrimidin
- pyrazolo
- mmol
- substituted
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 51
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title claims abstract description 41
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title claims abstract description 41
- 239000004480 active ingredient Substances 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 106
- 201000010099 disease Diseases 0.000 title abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 19
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 201000011510 cancer Diseases 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 5
- -1 phenyloxy Chemical group 0.000 claims description 258
- 150000001875 compounds Chemical class 0.000 claims description 220
- 238000006243 chemical reaction Methods 0.000 claims description 113
- 239000000203 mixture Substances 0.000 claims description 111
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 97
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 80
- 230000015572 biosynthetic process Effects 0.000 claims description 50
- 238000003786 synthesis reaction Methods 0.000 claims description 50
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 42
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 40
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 30
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 29
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 230000003287 optical effect Effects 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 17
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 14
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims description 7
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 5
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- OEKMNIWVXVRRNZ-UHFFFAOYSA-N N-[3-[[2-(4-morpholin-4-ylanilino)-7H-purin-6-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC1=C2N=CNC2=NC(=N1)NC1=CC=C(C=C1)N1CCOCC1 OEKMNIWVXVRRNZ-UHFFFAOYSA-N 0.000 claims description 4
- CDTURZXNUPGPDL-UHFFFAOYSA-N N-[3-[[2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC=1C2=C(N=C(N=1)NC1=CC=C(C=C1)N1CCOCC1)N=CC=C2 CDTURZXNUPGPDL-UHFFFAOYSA-N 0.000 claims description 4
- WBPDRIJEFCIHJH-UHFFFAOYSA-N N-[3-[[4-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC=1N=C(C2=C(N=1)N=CC=C2)NC1=CC=C(C=C1)N1CCOCC1 WBPDRIJEFCIHJH-UHFFFAOYSA-N 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- YILKRZURHWNZSV-UHFFFAOYSA-N C1COCCN1C2=CC=C(C=C2)NC3=NC(C4=C(N3)NC=C4)(C5=CC(=CC=C5)N)N Chemical compound C1COCCN1C2=CC=C(C=C2)NC3=NC(C4=C(N3)NC=C4)(C5=CC(=CC=C5)N)N YILKRZURHWNZSV-UHFFFAOYSA-N 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 206010028372 Muscular weakness Diseases 0.000 claims description 3
- LDMOPFOPOKGQQR-UHFFFAOYSA-N N-[2-[[6-(4-morpholin-4-ylanilino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=C(C=CC=C1)NC1=C2C(=NC(=N1)NC1=CC=C(C=C1)N1CCOCC1)NN=C2 LDMOPFOPOKGQQR-UHFFFAOYSA-N 0.000 claims description 3
- KTVGHPNNIBRYGA-UHFFFAOYSA-N N-[3-[[6-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC1=C2C(=NC(=N1)C1=CC=C(C=C1)OC1=CC=CC=C1)NN=C2 KTVGHPNNIBRYGA-UHFFFAOYSA-N 0.000 claims description 3
- NGQHWYXGMZZOEZ-UHFFFAOYSA-N N-[3-[[6-[4-(1-methyl-5,6-dihydro-1,2,4-triazin-4-yl)anilino]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound CN1CCN(C=N1)C2=CC=C(C=C2)NC3=NC4=C(C=NN4)C(=N3)NC5=CC(=CC=C5)NC(=O)C=C NGQHWYXGMZZOEZ-UHFFFAOYSA-N 0.000 claims description 3
- ZDWUDDVQPLFHMY-UHFFFAOYSA-N N-[4-[[6-(4-morpholin-4-ylanilino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC=C(C=C1)NC1=C2C(=NC(=N1)NC1=CC=C(C=C1)N1CCOCC1)NN=C2 ZDWUDDVQPLFHMY-UHFFFAOYSA-N 0.000 claims description 3
- YEHSETMEUSGUGT-UHFFFAOYSA-N NC(C(C=C1)=CC=C1N1CCOCC1)(NC1=C2C=CC=N1)N=C2NC(C=C1)=CC=C1N1CCOCC1 Chemical compound NC(C(C=C1)=CC=C1N1CCOCC1)(NC1=C2C=CC=N1)N=C2NC(C=C1)=CC=C1N1CCOCC1 YEHSETMEUSGUGT-UHFFFAOYSA-N 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000036473 myasthenia Effects 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 claims description 2
- GWNADOKGQKZFAK-UHFFFAOYSA-N N-[3-[[2-[4-[1-(2-fluoroethyl)piperidin-4-yl]-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound FCCN1CCC(CC1)C1=CC(=C(C=C1)NC1=NC=C(C(=N1)NC=1C=C(C=CC=1)NC(C=C)=O)C(F)(F)F)OC GWNADOKGQKZFAK-UHFFFAOYSA-N 0.000 claims description 2
- PHFRAHKBIRGPFI-UHFFFAOYSA-N N-[3-[[3-methyl-4-(4-morpholin-4-ylanilino)-2H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC1=NC(=C2C(=N1)NN=C2C)NC1=CC=C(C=C1)N1CCOCC1 PHFRAHKBIRGPFI-UHFFFAOYSA-N 0.000 claims description 2
- DMLUVFUIPCJJSB-UHFFFAOYSA-N N-[3-[[4-(4-morpholin-4-ylanilino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC1=NC(=C2C(=N1)NN=C2)NC1=CC=C(C=C1)N1CCOCC1 DMLUVFUIPCJJSB-UHFFFAOYSA-N 0.000 claims description 2
- KBTZXUGZLJZCDC-UHFFFAOYSA-N N-[3-[[6-(3-morpholin-4-ylanilino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC1=C2C(=NC(=N1)NC1=CC(=CC=C1)N1CCOCC1)NN=C2 KBTZXUGZLJZCDC-UHFFFAOYSA-N 0.000 claims description 2
- YRUMBXKAVZMEOK-UHFFFAOYSA-N N-[3-[[6-(4-morpholin-4-ylanilino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC1=C2C(=NC(=N1)NC1=CC=C(C=C1)N1CCOCC1)NN=C2 YRUMBXKAVZMEOK-UHFFFAOYSA-N 0.000 claims description 2
- CDCZHHMXVKAXNI-UHFFFAOYSA-N N-[4-[[6-(4-morpholin-4-ylanilino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino]cyclohexyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1CCC(CC1)NC1=C2C(=NC(=N1)NC1=CC=C(C=C1)N1CCOCC1)NN=C2 CDCZHHMXVKAXNI-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 abstract description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 271
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 113
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 99
- 239000011541 reaction mixture Substances 0.000 description 96
- 239000000243 solution Substances 0.000 description 93
- 235000019439 ethyl acetate Nutrition 0.000 description 91
- 238000005160 1H NMR spectroscopy Methods 0.000 description 86
- 239000007787 solid Substances 0.000 description 81
- 239000012044 organic layer Substances 0.000 description 76
- 239000002904 solvent Substances 0.000 description 73
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 63
- 230000002829 reductive effect Effects 0.000 description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 48
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 47
- 235000019341 magnesium sulphate Nutrition 0.000 description 47
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 40
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 40
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 34
- 238000004440 column chromatography Methods 0.000 description 34
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 32
- 238000005481 NMR spectroscopy Methods 0.000 description 31
- 238000010898 silica gel chromatography Methods 0.000 description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 239000012141 concentrate Substances 0.000 description 27
- 235000008504 concentrate Nutrition 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 229910000027 potassium carbonate Inorganic materials 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 229910052786 argon Inorganic materials 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
- PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 13
- 229910000024 caesium carbonate Inorganic materials 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 11
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 11
- 238000001953 recrystallisation Methods 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 9
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 8
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 8
- VMIPTJUFAWNUEU-UHFFFAOYSA-N 4,6-dichloro-1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidine Chemical compound C12=NC(Cl)=NC(Cl)=C2C=NN1C1CCCCO1 VMIPTJUFAWNUEU-UHFFFAOYSA-N 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 150000004820 halides Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
- GJHVLSDYBXWNNS-UHFFFAOYSA-N 4,6-dichloro-3-methyl-1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidine Chemical compound C12=NC(Cl)=NC(Cl)=C2C(C)=NN1C1CCCCO1 GJHVLSDYBXWNNS-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 4
- 0 *[n]1ncc(c(N[C@](CC2)CC[C@]2NC(C=C)=O)n2)c1nc2Cl Chemical compound *[n]1ncc(c(N[C@](CC2)CC[C@]2NC(C=C)=O)n2)c1nc2Cl 0.000 description 4
- QSNSZGYDLUPWSV-UHFFFAOYSA-N 2,4-dichloropyrido[2,3-d]pyrimidine Chemical compound C1=CC=NC2=NC(Cl)=NC(Cl)=C21 QSNSZGYDLUPWSV-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101150003085 Pdcl gene Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- HASUWNAFLUMMFI-UHFFFAOYSA-N 1,7-dihydropyrrolo[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)NC2=C1C=CN2 HASUWNAFLUMMFI-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- USCOMDOACQDNHP-UHFFFAOYSA-N NC(C(C=C1)=CC=C1N1CCOCC1)(N=C1NNC=C11)N=C1NC1CCNCC1 Chemical compound NC(C(C=C1)=CC=C1N1CCOCC1)(N=C1NNC=C11)N=C1NC1CCNCC1 USCOMDOACQDNHP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- 229940077388 benzenesulfonate Drugs 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000004210 ether based solvent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- ASNBMEFTEPQHDX-UHFFFAOYSA-N 2,6-dichloro-9-(oxan-2-yl)purine Chemical compound C12=NC(Cl)=NC(Cl)=C2N=CN1C1CCCCO1 ASNBMEFTEPQHDX-UHFFFAOYSA-N 0.000 description 2
- AXNPLLCDFRVNSY-UHFFFAOYSA-N 2-chloro-N-(4-morpholin-4-ylphenyl)pyrido[2,3-d]pyrimidin-4-amine Chemical compound ClC=1N=C(C2=C(N=1)N=CC=C2)NC1=CC=C(C=C1)N1CCOCC1 AXNPLLCDFRVNSY-UHFFFAOYSA-N 0.000 description 2
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- CRRHJAMDQMQGKG-UHFFFAOYSA-N 3-amino-5-methyl-1h-pyrazole-4-carbonitrile Chemical compound CC=1NN=C(N)C=1C#N CRRHJAMDQMQGKG-UHFFFAOYSA-N 0.000 description 2
- HSFCQNQORRYJIU-UHFFFAOYSA-N 3-methyl-1,2-dihydropyrazolo[3,4-d]pyrimidine-4,6-dione Chemical compound O=C1NC(=O)C2=C(C)NNC2=N1 HSFCQNQORRYJIU-UHFFFAOYSA-N 0.000 description 2
- ANKBCMQGOAHISY-UHFFFAOYSA-N 3-methyl-4-N-(4-morpholin-4-ylphenyl)-6-N-(3-nitrophenyl)-1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidine-4,6-diamine Chemical compound CC1=NN(C2=NC(=NC(=C21)NC1=CC=C(C=C1)N1CCOCC1)NC1=CC(=CC=C1)[N+](=O)[O-])C1OCCCC1 ANKBCMQGOAHISY-UHFFFAOYSA-N 0.000 description 2
- WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 229940124291 BTK inhibitor Drugs 0.000 description 2
- LVMRMXXFYCXDMW-UHFFFAOYSA-N C1C(=CC=CC1(C2=C3C=CNC3=NC(=N2)Cl)N)N Chemical compound C1C(=CC=CC1(C2=C3C=CNC3=NC(=N2)Cl)N)N LVMRMXXFYCXDMW-UHFFFAOYSA-N 0.000 description 2
- WTSPIRAHNXXMGC-UHFFFAOYSA-N C1CC(CNC1)N=C2C3=C(NC(N2)(C4=CC=C(C=C4)N5CCOCC5)N)NN=C3 Chemical compound C1CC(CNC1)N=C2C3=C(NC(N2)(C4=CC=C(C=C4)N5CCOCC5)N)NN=C3 WTSPIRAHNXXMGC-UHFFFAOYSA-N 0.000 description 2
- CWISEYZASJPDAF-UHFFFAOYSA-N CC1=C2C(NC(C=C3)=CC=C3N3CCOCC3)=NC(C3=CC(N)=CC=C3)(N)N=C2N(C2OCCCC2)N1 Chemical compound CC1=C2C(NC(C=C3)=CC=C3N3CCOCC3)=NC(C3=CC(N)=CC=C3)(N)N=C2N(C2OCCCC2)N1 CWISEYZASJPDAF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- PKWQTIGUHIICNH-UHFFFAOYSA-N N-[3-[[6-chloro-1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)NC1=C2C(=NC(=N1)Cl)N(N=C2)C1OCCCC1 PKWQTIGUHIICNH-UHFFFAOYSA-N 0.000 description 2
- IQDHRJBHSWPLSX-UHFFFAOYSA-N NC1(C(C=C2)=CC=C2N2CCOCC2)N=C(NC(C=C2)=CC=C2N2CCOCC2)N=C2NNC=C12 Chemical compound NC1(C(C=C2)=CC=C2N2CCOCC2)N=C(NC(C=C2)=CC=C2N2CCOCC2)N=C2NNC=C12 IQDHRJBHSWPLSX-UHFFFAOYSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000005456 alcohol based solvent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- DCNAEEPZTJYBNZ-UHFFFAOYSA-N n-(4-morpholin-4-ylphenyl)-1h-pyrazolo[3,4-d]pyrimidin-6-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC1=NC=C(C=NN2)C2=N1 DCNAEEPZTJYBNZ-UHFFFAOYSA-N 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- LVDSNOXLHFQPQC-UHFFFAOYSA-N 1-(4-aminopiperidin-1-yl)prop-2-en-1-one Chemical compound NC1CCN(C(=O)C=C)CC1 LVDSNOXLHFQPQC-UHFFFAOYSA-N 0.000 description 1
- VLZRARREIQDNHX-UHFFFAOYSA-N 1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidine Chemical compound O1CCCCC1N1C2=NC=NC=C2C=N1 VLZRARREIQDNHX-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- BPUPIIJKNJGPNP-UHFFFAOYSA-N 1-[4-[4-[[6-chloro-1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound ClC1=NC(=C2C(=N1)N(N=C2)C1OCCCC1)NC1=CC=C(C=C1)N1CCN(CC1)C(C)=O BPUPIIJKNJGPNP-UHFFFAOYSA-N 0.000 description 1
- BHWDLGRIMKJQBA-UHFFFAOYSA-N 1-[6-(4-phenoxyphenyl)oxan-2-yl]pyrazole Chemical compound O(C1=CC=CC=C1)C1=CC=C(C=C1)C1CCCC(O1)N1N=CC=C1 BHWDLGRIMKJQBA-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IXIWOUFBDIJQAP-UHFFFAOYSA-N 2,2-dibutylhexanoic acid Chemical compound CCCCC(CCCC)(CCCC)C(O)=O IXIWOUFBDIJQAP-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- ARRUBKNITYSFSP-UHFFFAOYSA-N 2,4-dichloro-3,7-dihydro-1H-pyrrolo[2,3-d]pyrimidine-2,4-diol Chemical compound ClC1(NC(C2=C(N1)NC=C2)(O)Cl)O ARRUBKNITYSFSP-UHFFFAOYSA-N 0.000 description 1
- GHXBPCSSQOKKGB-UHFFFAOYSA-N 2,4-dichloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2C=CNC2=N1 GHXBPCSSQOKKGB-UHFFFAOYSA-N 0.000 description 1
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- XCRVZGVOVULAKF-UHFFFAOYSA-N 2-chloro-9-(oxan-2-yl)purine Chemical compound C12=NC(Cl)=NC=C2N=CN1C1CCCCO1 XCRVZGVOVULAKF-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- JXPDNDHCMMOJPC-UHFFFAOYSA-N 2-hydroxybutanedinitrile Chemical compound N#CC(O)CC#N JXPDNDHCMMOJPC-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZJWLMZURLIHVHE-UHFFFAOYSA-N 3-morpholin-4-ylaniline Chemical compound NC1=CC=CC(N2CCOCC2)=C1 ZJWLMZURLIHVHE-UHFFFAOYSA-N 0.000 description 1
- XJCVRTZCHMZPBD-UHFFFAOYSA-N 3-nitroaniline Chemical compound NC1=CC=CC([N+]([O-])=O)=C1 XJCVRTZCHMZPBD-UHFFFAOYSA-N 0.000 description 1
- SFCRPRMZQXUXOG-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(4-phenoxyphenyl)-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1OC1=CC=CC=C1 SFCRPRMZQXUXOG-UHFFFAOYSA-N 0.000 description 1
- WAVYWHRLGFPXMJ-UHFFFAOYSA-N 4,6-dichloro-3-methyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2C(C)=NNC2=N1 WAVYWHRLGFPXMJ-UHFFFAOYSA-N 0.000 description 1
- OPWFGGOVYQYEDS-UHFFFAOYSA-N 4-N-[6-chloro-1-(oxan-2-yl)pyrazolo[3,4-d]pyrimidin-4-yl]benzene-1,4-diamine Chemical compound C1CCOC(C1)N2C3=NC(=NC(=C3C=N2)NC4=CC=C(C=C4)N)Cl OPWFGGOVYQYEDS-UHFFFAOYSA-N 0.000 description 1
- XARZFDONEYDMJH-CQSZACIVSA-N 4-[(3R)-3-aminopiperidin-1-yl]-N-(4-morpholin-4-ylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine Chemical compound N[C@H]1CN(CCC1)C1=C2C(=NC(=N1)NC1=CC=C(C=C1)N1CCOCC1)NN=C2 XARZFDONEYDMJH-CQSZACIVSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- LNDZXOWGUAIUBG-UHFFFAOYSA-N 6-aminouracil Chemical compound NC1=CC(=O)NC(=O)N1 LNDZXOWGUAIUBG-UHFFFAOYSA-N 0.000 description 1
- SMXRCJBCWRHDJE-UHFFFAOYSA-N 7-deaza-8-aza-2-aminopurine Chemical compound NC1=NC=C2C=NNC2=N1 SMXRCJBCWRHDJE-UHFFFAOYSA-N 0.000 description 1
- LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KJLNVCIPTZQGOZ-UHFFFAOYSA-N C1CCOC(C1)N2C3=NC(=NC(=C3C=N2)C4(C=CC=CC4N)N)Cl Chemical compound C1CCOC(C1)N2C3=NC(=NC(=C3C=N2)C4(C=CC=CC4N)N)Cl KJLNVCIPTZQGOZ-UHFFFAOYSA-N 0.000 description 1
- IQYPKIZJQOIQCI-UHFFFAOYSA-N C1CCOC(C1)N2C3=NC(=NC(=C3C=N2)C4(CC=C(C=C4)N)N)Cl Chemical compound C1CCOC(C1)N2C3=NC(=NC(=C3C=N2)C4(CC=C(C=C4)N)N)Cl IQYPKIZJQOIQCI-UHFFFAOYSA-N 0.000 description 1
- DIFPCOYOVZNWJH-UHFFFAOYSA-N C1CCOC(C1)N2C3=NC=NC(=C3C=N2)C4=CC=C(C=C4)N5CCOCC5 Chemical compound C1CCOC(C1)N2C3=NC=NC(=C3C=N2)C4=CC=C(C=C4)N5CCOCC5 DIFPCOYOVZNWJH-UHFFFAOYSA-N 0.000 description 1
- DXCLPQPGDSGUQW-HDICACEKSA-N C=CC(N[C@H](CC1)CC[C@H]1Nc1nc(Nc(cc2)ccc2N2CCOCC2)nc2c1cc[nH]2)=O Chemical compound C=CC(N[C@H](CC1)CC[C@H]1Nc1nc(Nc(cc2)ccc2N2CCOCC2)nc2c1cc[nH]2)=O DXCLPQPGDSGUQW-HDICACEKSA-N 0.000 description 1
- NYFJIMMSDKDRAR-HDICACEKSA-N C=CC(N[C@H](CC1)CC[C@H]1Nc1nc(Nc(cc2)ccc2Oc2ccccc2)nc2c1cn[nH]2)=O Chemical compound C=CC(N[C@H](CC1)CC[C@H]1Nc1nc(Nc(cc2)ccc2Oc2ccccc2)nc2c1cn[nH]2)=O NYFJIMMSDKDRAR-HDICACEKSA-N 0.000 description 1
- FOQJHZPURACERJ-UHFFFAOYSA-N CB1OC(C)(C)C(C)(C)O1 Chemical compound CB1OC(C)(C)C(C)(C)O1 FOQJHZPURACERJ-UHFFFAOYSA-N 0.000 description 1
- UZDHMXILGQOOMZ-UHFFFAOYSA-N CN(C(CCC1)CN1C(C=C)=O)c1nc(Nc(cc2)ccc2N2CCOCC2)nc2c1cn[nH]2 Chemical compound CN(C(CCC1)CN1C(C=C)=O)c1nc(Nc(cc2)ccc2N2CCOCC2)nc2c1cn[nH]2 UZDHMXILGQOOMZ-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- JSKBMQQUPHIMLQ-UHFFFAOYSA-N Cc1n[nH]c2c1c(NC(CC1)CCC1NC(C=C)=O)nc(Nc(cc1)ccc1N1CCCCC1)n2 Chemical compound Cc1n[nH]c2c1c(NC(CC1)CCC1NC(C=C)=O)nc(Nc(cc1)ccc1N1CCCCC1)n2 JSKBMQQUPHIMLQ-UHFFFAOYSA-N 0.000 description 1
- LTDYHEOJQMGNPP-UHFFFAOYSA-N Cc1n[nH]c2c1c(Nc1ccc(CCN3C(C=C)=O)c3c1)nc(-c(cc1)ccc1Oc1ccccc1)n2 Chemical compound Cc1n[nH]c2c1c(Nc1ccc(CCN3C(C=C)=O)c3c1)nc(-c(cc1)ccc1Oc1ccccc1)n2 LTDYHEOJQMGNPP-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101001050476 Homo sapiens Tyrosine-protein kinase ITK/TSK Proteins 0.000 description 1
- 101000606067 Homo sapiens Tyrosine-protein kinase TXK Proteins 0.000 description 1
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AVMANFIGCQGGCN-UHFFFAOYSA-N N-[3-[2-[(2-chloropyrido[2,3-d]pyrimidin-4-yl)amino]phenyl]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=CC(=CC=C1)C1=C(C=CC=C1)NC=1C2=C(N=C(N=1)Cl)N=CC=C2 AVMANFIGCQGGCN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000004072 Oncogene Addiction Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102000042834 TEC family Human genes 0.000 description 1
- 108091082333 TEC family Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 description 1
- 102100039079 Tyrosine-protein kinase TXK Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- GMCGYLIRFCDMPS-YFKPBYRVSA-N [(3s)-piperidin-3-yl]carbamic acid Chemical compound OC(=O)N[C@H]1CCCNC1 GMCGYLIRFCDMPS-YFKPBYRVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940085298 biotin 10 mg Drugs 0.000 description 1
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- JDWFIHOKPNSLHO-UHFFFAOYSA-N butyl n-piperidin-4-ylcarbamate Chemical compound CCCCOC(=O)NC1CCNCC1 JDWFIHOKPNSLHO-UHFFFAOYSA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108091005434 innate immune receptors Proteins 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- RRKWPXMDCPJEHS-UHFFFAOYSA-N n-(3-aminophenyl)prop-2-enamide Chemical compound NC1=CC=CC(NC(=O)C=C)=C1 RRKWPXMDCPJEHS-UHFFFAOYSA-N 0.000 description 1
- WLGWXZVPEDTYQZ-UHFFFAOYSA-N n-(4-aminocyclohexyl)prop-2-enamide Chemical compound NC1CCC(NC(=O)C=C)CC1 WLGWXZVPEDTYQZ-UHFFFAOYSA-N 0.000 description 1
- LJCYLJXSJJRCQS-UHFFFAOYSA-N n-(4-aminohexyl)prop-2-enamide Chemical compound CCC(N)CCCNC(=O)C=C LJCYLJXSJJRCQS-UHFFFAOYSA-N 0.000 description 1
- PNUJBVDTPXKNDZ-UHFFFAOYSA-N n-methyl-2h-pyridin-1-amine Chemical compound CNN1CC=CC=C1 PNUJBVDTPXKNDZ-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000009210 ongoing activation Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- ZSBDGXGICLIJGD-UHFFFAOYSA-N p-phenoxyphenol Natural products C1=CC(O)=CC=C1OC1=CC=CC=C1 ZSBDGXGICLIJGD-UHFFFAOYSA-N 0.000 description 1
- 125000002972 p-tolylamino group Chemical group [H]N(*)C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 210000005132 reproductive cell Anatomy 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- AKQXKEBCONUWCL-UHFFFAOYSA-N tert-butyl 3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(N)C1 AKQXKEBCONUWCL-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940087380 vitamin b 12 0.2 mg Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Abstract
Description
본 발명은 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다.The present invention relates to a conjugated pyrimidine derivative, a process for producing the same, and a pharmaceutical composition for preventing or treating a Brunei tyrosine kinase activity-related disease containing the same as an active ingredient.
암(cancer)은 유전자 발현의 다양한 변화에 의하여 세포의 사멸이 정상적으로 조절되지 않고 세포의 비성장적인 성장이 야기된 상태로, 암세포는 비정상적으로 분열하며, 분화하는 성질을 가지고 있다. 상기 암세포는 인접한 조직에 침투하여 조직을 파괴하고 다른 부위로 전이하여 결국 사람을 사망하게 한다. Cancer is a state in which cell death is not regulated normally by various changes of gene expression, and nonspecific growth of cells is caused. Cancer cells are abnormally divided and differentiated. The cancer cells penetrate adjacent tissues, destroying the tissues, and transferring them to other sites, eventually leading to death.
암은 신체의 어느 조직에서나 발생할 수 있고, 한가지 요인에 의해 유발되거나, 함께 작용하는 다양한 요인에 의해 유발된다고 알려져있다. 상기 요인들로는 광범위하고 다양한 화학물질, 방사선 등의 환경적 요인, 바이러스감염 등의 감염성 질환 그리고 유전적 인자들을 들 수 있다. It is known that cancer can occur in any tissue of the body, caused by one factor, or caused by various factors acting together. These factors include a wide variety of chemicals, environmental factors such as radiation, infectious diseases such as viral infections, and genetic factors.
암의 2세대 치료방법으로 알려진 표적치료(targeted therapy)는 종양 생장 및 종양 생존에 필수적인 단백질 또는 유전자 등을 선택적으로 억제하는 것을 통해 특정 종양 세포의 생장 및 생존을 억제하여 항암효과를 유도하는 새로운 형태의 항암치료로서, 종래의 암세포를 직접적으로 공격하여 정상세포에도 공격 가능성이 커 부작용 발생 가능성이 큰 1세대 암 치료법인 화학항암제와 비교하여 암세포만 특이적으로 사멸이 가능하다. Targeted therapy, known as second-generation therapy for cancer, is a new form of cancer that inhibits the growth and survival of specific tumor cells by selectively inhibiting proteins or genes essential for tumor growth and tumor survival As cancer treatment, it is possible to specifically kill cancer cells only in comparison with chemotherapeutic drugs, which are first-generation cancer treatment methods, which are likely to attack normal cells by directly attacking conventional cancer cells and have a high possibility of side effects.
상기 표적치료제로는, 만성 골수성 백혈병(Chronic myeloid leukaemia, CML)에 널리 사용되는 imatinib(Gleevec)은 CML 환자에 많이 분포하는 Bcr-Abl 융합(fusion) 단백질의 활성을 억제하여, CML의 감소(regression)를 유도하게 된다. As the target therapeutic agent, imatinib (Gleevec) widely used for chronic myeloid leukemia (CML) inhibits the activity of Bcr-Abl fusion protein distributed widely in CML patients, .
뿐만 아니라, gefitinib 또는 erlotinib 과 같은 EGFR 억제제는 최근 비 소세포 폐암(Non-small-cell lung carcinoma, NSCLC), 췌장암 (pancreatic cancer), 뇌종양 (glioblastoma) 환자 중에서 EGFR 돌연변이(mutation)(L858R, exon19 deletion)로 인해서 EGFR의 활성이 높게 나타나는 종양에 선택적인 효과를 나타낸다고 보고되었다. 또한, 최근에 FDA에서 허가를 받은 crizotinib은 폐암환자중 EML4-ALK 융합 유전자(fusion gene)을 가진 환자에 대해서 선택적으로 높은 치료율을 보이고 있다. In addition, EGFR inhibitors such as gefitinib or erlotinib have recently been identified as EGFR mutations (L858R, exon19 deletion) in patients with non-small cell lung carcinoma (NSCLC), pancreatic cancer, and glioblastoma, And the EGFR activity is high in the tumors. In addition, recently, FDA-approved crizotinib has a high rate of treatment selectively for patients with the EML4-ALK fusion gene among lung cancer patients.
기존의 전통적인 항암치료에 사용되던 항암제 (Traditional antineoplastics:TANs)는 종양세포의 ‘빠른 세포 분열’ 특징을 표적으로 하여 제작되었으므로, ‘빠른 세포 분열’을 하는 종양세포 뿐만 아니라, 상대적으로 빠른 세포 분열을 하는 정상 세포(예, 모근세포, 위장관 세포, 골수세포, 생식세포)등을 손상시켜 극심한 부작용을 나타내는 문제가 있었다.Traditional antineoplastics (TANs), which have been used for conventional anticancer therapies, are designed to target the 'rapid cell division' characteristics of tumor cells. Therefore, not only tumor cells that undergo rapid cell division, but also relatively fast cell division (For example, hair follicle cells, gastrointestinal tract cells, bone marrow cells, reproductive cells) and the like, thereby causing severe side effects.
반면, 신개념 항암제(Novel antineoplastics: NANs)는 종양세포에만 특이적으로 작용하여, 종양세포의 생존에 필수적이나 정상세포에는 작용하지 않거나, 영향이 미비한 신호전달 물질들을 표적으로 하여 제작되어, 정상세포에 대한 선택성이 매우 높을 뿐 아니라, 또한, 암세포는 다양한 발암유전자 혹은 종양억제 유전자의 이상을 포함하지만 종양의 성장이나 발암과정은 흔히 하나 혹은 두 개의 신호전달경로의 지속적인 활성화에 의해 유지되므로 암세포의 성장이나 증식은 단 하나의 발암유전자를 불활성화시킴으로 해서 억제될 수 있다는 종양세포의 암유전자 중독(oncogene addiction)의 특징을 고려할 때 종양특이적인 신호전달 물질을 표적으로 하는 신개념 항암제의 종양선택성은 매우 우수한 것으로 나타났다. Novel antineoplastics (NANs), on the other hand, act specifically on tumor cells and are produced by targeting signal transduction substances essential for the survival of tumor cells but not acting on or affecting normal cells, In addition to being highly selective for cancer cells, cancer cells also contain a variety of oncogenes or tumor suppressor genes, but tumor growth or carcinogenesis is often sustained by the ongoing activation of one or two signaling pathways, Considering the characteristics of oncogene addiction of tumor cells that proliferation can be inhibited by inactivating only one oncogenic gene, the tumor selectivity of new-concept anticancer drugs that target tumor-specific signaling agents is very good appear.
한편, 브루톤 티로신 키나제(Bruton's tyrosine kinase, BTK)는 비 수용체 티로신 키나제(Non-receptor tyrosine kinases)이며, 염색체 Xq22에 위치하고 있다. 또한, BTK는 Tec 패밀리 키나제로서 BTK 외에도 TEC, ITK, TXK가 이 부류에 속한다. 다른 조직에서는 거의 발현하지 않으며, 혈액세포 중에서도 T 세포(T cell)에는 전혀 존재하지 않고 B 세포(B cell)에서만 존재하는 단백질이다.On the other hand, Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase and is located on chromosome Xq22. In addition, BTK belongs to this category as TEC family kinases, as well as BTK, TEC, ITK, and TXK. It is rarely expressed in other tissues, and it is a protein that exists only in B cells (B cells), not in T cells (T cells) among blood cells.
최근, 상기 B-세포 항원 수용체 신호전달 경로에서 중요한 말단 효소인 브루톤 티로신 키나제는 새로운 타겟으로 부상되고 있으며, 그 하위 신호전달 단백질은 정상 B-세포가 성장, 분화, 및 림프구로서 기능을 하는데 중요한 신호전달 역할을 하고 있다. 더욱이, 브루톤 티로신 키나제는 성숙 B-세포 림프증식성 질환들의 개시, 생존, 진행에 관련되어있는 것으로 알려져있어, 브루톤 티로신 키나제의 신호전달을 조절할 수 있는 치료제가 개발되면, 암종 및 브로톤 키나제와 관련된 다양한 면역관련 질환의 치료제로 개발될 가능성이 매우 크다. Recently, brutonyl tyrosine kinase, an important terminal enzyme in the B-cell antigen receptor signaling pathway, has emerged as a new target, and its downstream signaling proteins are important for normal B-cell function as growth, differentiation, and lymphocyte Signal transmission. Furthermore, it has been known that bruton tyrosine kinase is involved in the initiation, survival, and progression of mature B-cell lymphoproliferative diseases. When a therapeutic agent capable of regulating the signal transduction of bruton tyrosine kinase has been developed, Related diseases. ≪ / RTI >
특히, BTK는 성장인자, B-세포 항원, 케모카인의 수용체와 선천적 면역 수용체(innate immune receptor)의 하위신호 전달에 중요한 기능을 함으로써 세포성장, 생존, 분화, 병인, 신생혈관생성, 신호전달물질 생성, 항원제시와 같은 여러 세포활동에 중요하게 관여를 하고 있는 단백질으로, B-세포의 면역, 염증, 항암 등의 신호전달에 중요한 역할을 담당하고 있기 때문에, BTK 억제제(inhibitor)는 다른 조직은 공격하지 않고 오직 BTK의 활성이 있는 B 세포 종양만을 타겟으로 할 수 있으므로 암치료 과정에서 환자에게 일어나는 부작용을 최소화 할 수 있다는 장점이 있다. In particular, BTK plays a crucial role in the downstream signaling of growth factors, B-cell antigens, chemokine receptors and innate immune receptors, thereby inducing cell growth, survival, differentiation, pathogenesis, neovascularization, , And antigen presenting. Since BTK plays an important role in the signal transduction of B-cell immunity, inflammation, and anti-cancer, the BTK inhibitor inhibits other tissues from attacking But only B-cell tumors with active BTK activity can be targeted, thereby minimizing adverse effects on the patient during cancer treatment.
특히, BTK 억제제가 타겟으로 하는 백혈병(Leukemia)은 BTK의 기능이 중요한 역할을 하는 B 세포 수용체 신호전달(B cell receptor signaling, BCR signaling)이 만성적으로 활성화(chronic activation)되어 있으므로 BTK 억제제는 종양만을 선택적으로 타겟화 할 수 있다. In particular, the leukemia targeted by the BTK inhibitor is a chronic activation of B cell receptor signaling (BCR signaling), which plays an important role in the function of BTK. Therefore, And can be selectively targeted.
기존의 만성 림프모구 백혈병(Chronic lymphocytic leukemia, CLL) 치료를 위한 화합요법제들은 저연령의 어린 환자들에게서는 생존 기간을 증대시켰으나 고연령의 환자의 경우 골수억제 및 감염증가라는 심각한 부작용을 야기했으며, 이로인해서 CLL 치료제는 이제 표적치료를 추구하는 방향으로 연구되고 있다. Combination therapies for the treatment of chronic lymphocytic leukemia (CLL) have increased the survival period in younger patients, but have resulted in serious side effects of bone marrow suppression and infectious disease in older patients, CLL therapeutics are now being studied to pursue targeted therapies.
따라서, BTK를 억제하는 표적치료법을 통해 환자의 부작용을 최소화하면서 다양한 암종 및 면역에 관여하는 질병을 효과적으로 치료할 수 있다. Thus, target treatment that inhibits BTK can effectively treat various cancer and immune-related diseases while minimizing the side effects of the patients.
이에, 본 발명자들은 브루톤 티로신 키나제를 억제하는 효과를 나타내는 화합물을 개발하기 위해 노력하던 중, 본 발명에 따른 특정 구조의 접합 피리미딘 유도체가 브루톤 티로신 키나제 또는 TMD80의 활성을 우수하게 억제함으로써, 브루톤 티로신 키나제 활성 관련 질환의 예방 및 치료제로 사용될 수 있다는 것을 알아내고 본 발명을 완성하였다.Accordingly, the present inventors have made efforts to develop a compound exhibiting an effect of inhibiting brutonyl tyrosine kinase, so that the conjugated pyrimidine derivative having a specific structure according to the present invention excellently inhibits the activity of the bruton tyrosine kinase or TMD80, And can be used as a prophylactic and therapeutic agent for diseases related to Bruton's tyrosine kinase activity.
본 발명의 목적은 접합 피리미딘 유도체, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 제공하는 것이다.It is an object of the present invention to provide a conjugated pyrimidine derivative, an optical isomer thereof or a pharmaceutically acceptable salt thereof.
본 발명의 다른 목적은 상기 접합 피리미딘 유도체의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a process for producing the above-mentioned conjugated pyrimidine derivative.
본 발명의 또 다른 목적은 상기 접합 피리미딘 유도체, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 브루톤 티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Still another object of the present invention is to provide a pharmaceutical composition for preventing or treating a glutathione kinase activity-related disease containing the above-mentioned conjugated pyrimidine derivative, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 다른 목적은 상기 접합 피리미딘 유도체, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 브루톤 티로신 키나제 활성 관련 질환의 예방 또는 개선용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition for preventing or ameliorating a disease associated with bruton tyrosine kinase activity, which comprises the above-mentioned conjugated pyrimidine derivative, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
상기 목적을 달성하기 위하여, In order to achieve the above object,
본 발명은 하기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 제공한다:The present invention provides a compound represented by the following general formula (1), an optical isomer thereof or a pharmaceutically acceptable salt thereof:
[화학식 1][Chemical Formula 1]
(상기 화학식 1에서, (In the formula 1,
n은 0 또는 1이고;n is 0 or 1;
A는 단일 결합, -NH- 또는 -O-이고;A is a single bond, -NH- or -O-;
D1은 CR4 또는 N이고, 이때, 상기 R4는 수소 또는 직쇄 또는 측쇄의 C1- 5알킬이고;D 1 is CR 4 or N, wherein said R 4 is hydrogen or linear or branched C 1- 5 alkyl;
D2는 CH 또는 N 이고;D 2 is CH or N;
D3은 N 또는 NH이고;D 3 is N or NH;
은 단일결합 또는 이중결합이고; Is a single bond or a double bond;
R1은 비치환 또는 치환된 C6-10아릴이고, R 1 is unsubstituted or substituted C 6-10 aryl,
여기서, 상기 치환된 C6- 10아릴은, 직쇄 또는 측쇄의 C1- 5알킬; 아크릴로일아민; 비치환된 C6- 10아릴; 비치환된 C6- 10아릴옥시; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7 원자의 비치환 또는 치환된 헤테로사이클로알킬 또는 헤테로사이클로알케닐;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있으며, Wherein the substituted C 6- 10 aryl, straight or branched C 1- 5 alkyl; Acryloylamine; Unsubstituted C 6- 10 aryl; Unsubstituted C 6- 10 aryloxy; And 5 to 7-membered unsubstituted or substituted heterocycloalkyl or heterocycloalkenyl containing at least one heteroatom selected from the group consisting of N, O and S; and at least one member selected from the group consisting of Which may be substituted with one or more substituents,
이때, 상기 치환된 헤테로사이클로알킬 및 헤테로사이클로알케닐은, 직쇄 또는 측쇄의 C1- 5알킬; 및 직쇄 또는 측쇄의 C1- 5알킬카보닐;으로 이루어지는 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있고, In this case, the substituted heterocycloalkyl and heterocycloalkyl alkenyl, linear or branched C 1- 5 alkyl; And linear or branched C 1- 5 alkyl-carbonyl; and 1 or more substituents selected from the group consisting of consisting of one or more optionally substituted,
R2 및 R3은 독립적으로 각각 독립적으로, 수소; 비치환 또는 치환된 C6- 10아릴; N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7 원자의 비치환 또는 치환된 헤테로사이클로알킬; 비치환된 또는 치환된 C3-7사이클로알킬; 또는 비치환 또는 치환된 인돌리닐이거나;R 2 and R 3 are each independently and independently hydrogen; Unsubstituted or substituted C 6- 10 aryl; An unsubstituted or substituted heterocycloalkyl of 5 to 7 atoms containing at least one heteroatom selected from the group consisting of N, O and S; Unsubstituted or substituted C 3-7 cycloalkyl; Or an unsubstituted or substituted indolinyl;
이들이 결합한 N원자와 함께 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7원자의 비치환 또는 치환된 헤테로사이클로알킬을 형성할 수 있고, Together with the N atom to which they are attached may form an unsubstituted or substituted heterocycloalkyl of 5 to 7 atoms containing at least one heteroatom selected from the group consisting of N, O and S,
여기서, 상기 치환된 C6- 10아릴, 치환된 헤테로사이클로알킬, 치환된 C3- 7사이클로알킬 및 치환된 인돌리닐은 -NH2; 아크릴로일; 아크릴로일아민; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7 원자의 비치환 또는 직쇄 또는 측쇄의 C1- 5알킬카보닐로 하나 이상 치환된 헤테로사이클로알킬;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있다).Wherein the substituted C 6- 10 aryl, substituted heterocycloalkyl, substituted C 3- 7 cycloalkyl, and substituted indolinyl is -NH 2; Acryloyl; Acryloylamine; And N, O and one or more C 1- to 5-alkyl-carbonyl of from 5 to 7 atoms or an unsubstituted straight or branched chain containing one or more heteroatoms at least one selected from the group consisting of S-substituted heterocycloalkyl; (S) may be substituted with one or more substituents.
또한, 본 발명은 하기 반응식 1에 나타낸 바와 같이, Also, as shown in the following Reaction Scheme 1,
화학식 3으로 표시되는 화합물과 화학식 4로 표시되는 화합물을 반응시켜 화학식 2로 표시되는 화합물을 제조하는 단계(단계 1); 및Reacting a compound represented by formula (3) with a compound represented by formula (4) to prepare a compound represented by formula (2) (step 1); And
상기 단계 1에서 얻은 화학식 2로 표시되는 화합물과 화학식 5로 표시되는 화합물을 반응시켜 화학식 1로 표시되는 화합물을 얻는 단계(단계 2)를 포함하는 제1항의 화학식 1로 표시되는 화합물의 제조방법을 제공한다:A process for producing a compound represented by formula (1) according to claim 1, comprising the step of reacting a compound represented by the formula (2) and a compound represented by the formula (5) obtained in the step 1 to obtain a compound represented by the formula (1) to provide:
[반응식 1][Reaction Scheme 1]
(상기 반응식 1에서, (In the above Reaction Scheme 1,
n, A, D1, D2, D3, R1, R2, R3 및 는 제1항의 화학식 1에서 정의한 바와 같고;n, A, D 1, D 2, D 3, R 1, R 2, R 3 and Is as defined in claim 1;
X1 및 X2는 각각 독립적으로 동일 또는 상이한 할로겐이다).X 1 and X 2 are each independently the same or different halogen).
나아가, 본 발명은 하기 반응식 2에 나타낸 바와 같이, Further, the present invention provides a compound represented by the following formula (2)
화학식 3으로 표시되는 화합물과 화학식 5로 표시되는 화합물을 반응시켜 화학식 6으로 표시되는 화합물을 제조하는 단계(단계 1); 및Reacting a compound represented by formula (3) with a compound represented by formula (5) to prepare a compound represented by formula (6) (step 1); And
상기 단계 1에서 얻은 화학식 6으로 표시되는 화합물과 화학식 4로 표시되는 화합물을 반응시켜 화학식 1로 표시되는 화합물을 얻는 단계(단계 2)를 포함하는 제1항의 화학식 1로 표시되는 화합물의 제조방법을 제공한다:A process for producing a compound represented by the general formula (1), which comprises the step of reacting a compound represented by the formula (6) and a compound represented by the formula (4) to obtain a compound represented by the formula (1) to provide:
[반응식 2][Reaction Scheme 2]
(상기 반응식 2에서, (In the above Reaction Scheme 2,
n, A, D1, D2, D3, R1, R2, R3 및 는 제1항의 화학식 1에서 정의한 바와 같고;n, A, D 1, D 2, D 3, R 1, R 2, R 3 and Is as defined in claim 1;
X1 및 X2는 각각 독립적으로 동일 또는 상이한 할로겐이다).X 1 and X 2 are each independently the same or different halogen).
또한, 본 발명은 상기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 브루톤 티로신 키나제 활성과 관련된 질환의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the prevention or treatment of diseases related to the brutonyl tyrosine kinase activity, which comprises the compound represented by the formula (1), an optical isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
나아가, 본 발명은 상기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 브루톤 티로신 키나제 활성과 관련된 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.Further, the present invention provides a health functional food composition for preventing or ameliorating diseases related to the bruton tyrosine kinase activity, which comprises the compound represented by the formula (1), an optical isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient .
본 발명에 따른 접합 피리미딘 유도체는 브루톤 티로신 키나제 또는 TMD80의 활성을 억제하는 능력이 우수하므로, 브루톤 티로신 키나제 활성과 관련된 질환, 특히 암 또는 자가면역질환을 예방 또는 치료하는데 유용하게 사용할 수 있다.The conjugated pyrimidine derivative according to the present invention is excellent in the ability to inhibit the activity of brutonyl tyrosine kinase or TMD80, and thus can be usefully used for the prevention or treatment of diseases related to bruton tyrosine kinase activity, particularly cancer or autoimmune diseases .
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 하기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 제공한다.The present invention provides a compound represented by the following general formula (1), an optical isomer thereof or a pharmaceutically acceptable salt thereof.
[화학식 1][Chemical Formula 1]
상기 화학식 1에서, In Formula 1,
n은 0 또는 1이고;n is 0 or 1;
A는 단일 결합, -NH- 또는 -O-이고;A is a single bond, -NH- or -O-;
D1은 CR4 또는 N이고, 이때, 상기 R4는 수소 또는 직쇄 또는 측쇄의 C1- 5알킬이고;D 1 is CR 4 or N, wherein said R 4 is hydrogen or linear or branched C 1- 5 alkyl;
D2는 CH 또는 N 이고;D 2 is CH or N;
D3은 N 또는 NH이고;D 3 is N or NH;
은 단일결합 또는 이중결합이고; Is a single bond or a double bond;
R1은 비치환 또는 치환된 C6- 10아릴이고, R 1 is a C 6- 10 aryl unsubstituted or substituted,
여기서, 상기 치환된 C6- 10아릴은, 직쇄 또는 측쇄의 C1- 5알킬; 아크릴로일아민; 비치환된 C6- 10아릴; 비치환된 C6- 10아릴옥시; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7 원자의 비치환 또는 치환된 헤테로사이클로알킬 또는 헤테로사이클로알케닐;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있으며, Wherein the substituted C 6- 10 aryl, straight or branched C 1- 5 alkyl; Acryloylamine; Unsubstituted C 6- 10 aryl; Unsubstituted C 6- 10 aryloxy; And 5 to 7-membered unsubstituted or substituted heterocycloalkyl or heterocycloalkenyl containing at least one heteroatom selected from the group consisting of N, O and S; and at least one member selected from the group consisting of Which may be substituted with one or more substituents,
이때, 상기 치환된 헤테로사이클로알킬 및 헤테로사이클로알케닐은, 직쇄 또는 측쇄의 C1- 5알킬; 및 직쇄 또는 측쇄의 C1- 5알킬카보닐;으로 이루어지는 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있고, In this case, the substituted heterocycloalkyl and heterocycloalkyl alkenyl, linear or branched C 1- 5 alkyl; And linear or branched C 1- 5 alkyl-carbonyl; and 1 or more substituents selected from the group consisting of consisting of one or more optionally substituted,
R2 및 R3은 독립적으로 각각 독립적으로, 수소; 비치환 또는 치환된 C6- 10아릴; N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7 원자의 비치환 또는 치환된 헤테로사이클로알킬; 비치환된 또는 치환된 C3- 7사이클로알킬; 또는 비치환 또는 치환된 인돌리닐이거나;R 2 and R 3 are each independently and independently hydrogen; Unsubstituted or substituted C 6- 10 aryl; An unsubstituted or substituted heterocycloalkyl of 5 to 7 atoms containing at least one heteroatom selected from the group consisting of N, O and S; An unsubstituted or substituted C 3- 7 cycloalkyl; Or an unsubstituted or substituted indolinyl;
이들이 결합한 N원자와 함께 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7원자의 비치환 또는 치환된 헤테로사이클로알킬을 형성할 수 있고, Together with the N atom to which they are attached may form an unsubstituted or substituted heterocycloalkyl of 5 to 7 atoms containing at least one heteroatom selected from the group consisting of N, O and S,
여기서, 상기 치환된 C6- 10아릴, 치환된 헤테로사이클로알킬, 치환된 C3- 7사이클로알킬 및 치환된 인돌리닐은 -NH2; 아크릴로일; 아크릴로일아민; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7 원자의 비치환 또는 직쇄 또는 측쇄의 C1- 5알킬카보닐로 하나 이상 치환된 헤테로사이클로알킬;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있다.Wherein the substituted C 6- 10 aryl, substituted heterocycloalkyl, substituted C 3- 7 cycloalkyl, and substituted indolinyl is -NH 2; Acryloyl; Acryloylamine; And N, O and one or more C 1- to 5-alkyl-carbonyl of from 5 to 7 atoms or an unsubstituted straight or branched chain containing one or more heteroatoms at least one selected from the group consisting of S-substituted heterocycloalkyl; (S), and the like.
바람직하게는, Preferably,
상기 n은 0 또는 1이고;N is 0 or 1;
A는 단일 결합, -NH- 또는 -O-이고;A is a single bond, -NH- or -O-;
D1은 CR4 또는 N이고, 이때, 상기 R4는 수소 또는 직쇄 또는 측쇄의 C1- 3알킬이고;D 1 is CR 4 or N, wherein said R 4 is hydrogen or linear or branched C 1- 3 alkyl;
D2는 CH 또는 N 이고;D 2 is CH or N;
D3은 N 또는 NH이고;D 3 is N or NH;
은 단일결합 또는 이중결합이고; Is a single bond or a double bond;
R1은 비치환 또는 치환된 페닐이고, R < 1 > is unsubstituted or substituted phenyl,
여기서, 상기 치환된 페닐은, 직쇄 또는 측쇄의 C1- 5알킬; 아크릴로일아민; 비치환된 페닐; 비치환된 페닐옥시; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 6 원자의 비치환 또는 치환된 헤테로사이클로알킬 또는 헤테로사이클로알케닐;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있으며, Where the substituted phenyl, linear or branched C 1- 5 alkyl; Acryloylamine; Unsubstituted phenyl; Unsubstituted phenyloxy; And unsubstituted or substituted heterocycloalkyl or heterocycloalkenyl of 5 to 6 atoms each containing at least one heteroatom selected from the group consisting of N, O and S; and at least one selected from the group consisting of Which may be substituted with one or more substituents,
이때, 상기 치환된 헤테로사이클로알킬 및 헤테로사이클로알케닐은, 직쇄 또는 측쇄의 C1- 3알킬; 및 직쇄 또는 측쇄의 C1- 3알킬카보닐;으로 이루어지는 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있고, In this case, the substituted heterocycloalkyl and heterocycloalkyl alkenyl, linear or branched C 1- 3 alkyl; And straight chain or C 1- 3 alkyl-carbonyl in the side chain; and 1 or more substituents selected from the group consisting of consisting of one or more optionally substituted,
R2 및 R3은 독립적으로 각각 독립적으로, 수소; 비치환 또는 치환된 페닐; N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 6 원자의 비치환 또는 치환된 헤테로사이클로알킬; 비치환된 또는 치환된 C3- 6사이클로알킬; 또는 비치환 또는 치환된 인돌리닐이거나;R 2 and R 3 are each independently and independently hydrogen; Unsubstituted or substituted phenyl; An unsubstituted or substituted heterocycloalkyl of 5 to 6 atoms containing at least one heteroatom selected from the group consisting of N, O and S; Unsubstituted or substituted C 3- 6 cycloalkyl; Or an unsubstituted or substituted indolinyl;
이들이 결합한 N원자와 함께 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 6원자의 비치환 또는 치환된 헤테로사이클로알킬을 형성할 수 있고, Together with the N atom to which they are attached may form an unsubstituted or substituted heterocycloalkyl of 5 to 6 atoms containing at least one heteroatom selected from the group consisting of N, O and S,
여기서, 상기 치환된 페닐, 치환된 헤테로사이클로알킬, 치환된 C3- 6사이클로알킬 및 치환된 인돌리닐은 -NH2; 아크릴로일; 아크릴로일아민; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 6 원자의 비치환 또는 직쇄 또는 측쇄의 C1- 3알킬카보닐로 하나 이상 치환된 헤테로사이클로알킬;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있다.Where the substituted phenyl, substituted heterocycloalkyl, substituted C 3- 6 cycloalkyl, and substituted indolinyl is -NH 2; Acryloyl; Acryloylamine; And N, O and one or more of a C 1- 3 alkyl-carbonyl of from 5 to 6 atoms unsubstituted or straight or branched chain containing one or more heteroatoms at least one selected from the group consisting of S-substituted heterocycloalkyl; (S), and the like.
보다 바람직하게는, More preferably,
상기 n은 0 또는 1이고;N is 0 or 1;
A는 단일 결합, -NH- 또는 -O-이고;A is a single bond, -NH- or -O-;
D1은 CR4 또는 N이고, 이때, 상기 R4는 수소 또는 메틸이고;D 1 is CR 4 or N, wherein R 4 is hydrogen or methyl;
D2는 CH 또는 N 이고;D 2 is CH or N;
D3은 N 또는 NH이고;D 3 is N or NH;
은 단일결합 또는 이중결합이고; Is a single bond or a double bond;
R1은 비치환 또는 치환된 페닐이고, R < 1 > is unsubstituted or substituted phenyl,
여기서, 상기 치환된 페닐은, 메틸; 아크릴로일아민; 비치환된 페닐; 비치환된 페닐옥시; 및 비치환 또는 치환된 모폴리닐, 피페라지닐, 피페리디닐 또는 1, 4, 5, 6-테트라하이드로-1, 2, 4-트리아지닐;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있으며, Wherein said substituted phenyl is selected from the group consisting of methyl; Acryloylamine; Unsubstituted phenyl; Unsubstituted phenyloxy; And one or more substituents selected from the group consisting of unsubstituted or substituted morpholinyl, piperazinyl, piperidinyl or 1,4,5,6-tetrahydro-1,2,4-triazinyl; Or more,
이때, 상기 치환된 모폴리닐, 피페라지닐, 피페리디닐 및 1, 4, 5, 6-테트라하이드로-1, 2, 4-트리아지닐은, 메틸 및 아세틸으로 이루어지는 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있고, Wherein said substituted morpholinyl, piperazinyl, piperidinyl and 1,4,5,6-tetrahydro-1,2,4-triazinyl are optionally substituted with one or more substituents selected from the group consisting of methyl and acetyl Lt; / RTI > may be substituted by one or more,
R2 및 R3은 독립적으로 각각 독립적으로, 수소; 비치환 또는 치환된 페닐; 또는 비치환 또는 치환된 피롤리디닐 또는 피페리디닐; 비치환된 또는 치환된 사이클로헥실; 또는 비치환 또는 치환된 인돌리닐이거나;R 2 and R 3 are each independently and independently hydrogen; Unsubstituted or substituted phenyl; Or unsubstituted or substituted pyrrolidinyl or piperidinyl; Unsubstituted or substituted cyclohexyl; Or an unsubstituted or substituted indolinyl;
이들이 결합한 N원자와 함께 비치환 또는 치환된 피페라지닐을 형성할 수 있고, Together with the N atom to which they are attached can form an unsubstituted or substituted piperazinyl,
여기서, 상기 치환된 페닐, 피롤리디닐, 피페리디닐, 피페라지닐, 사이클로헥실 및 인돌리닐은 -NH2; 아크릴로일; 아크릴로일아민; 모폴리닐; 및 아세틸이 치환된 피페라지닐;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있다.Wherein said substituted phenyl, pyrrolidinyl, piperidinyl, piperazinyl, cyclohexyl, and indolinyl are optionally substituted with --NH 2 ; Acryloyl; Acryloylamine; Morpholinyl; And acetyl-substituted piperazinyl; and at least one substituent selected from the group consisting of
본 발명에 따른 상기 화학식 1로 표시되는 화합물의 바람직한 예로는 하기의 화합물들을 들 수 있다: Preferable examples of the compound represented by the formula (1) according to the present invention include the following compounds:
<1> 1-(4-(4-((6-(p-톨릴아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온;1) Preparation of 1- (4- (4 - ((6- (p-tolylamino) -1H-pyrazolo [3,4- d] pyrimidin- ) Ethan-1-one;
<2> 1-(4-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온;Amino] phenyl) piperazine (hereinafter referred to as " 1- (4- (4 - ((6- 1-yl) ethan-1-one;
<3> (R)-N-(1-(6-(4-모폴리노페닐아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드;3) Preparation of (R) -N- (1- (6- (4-morpholinophenylamino) -1H-pyrazolo [3,4- d] pyrimidin- ) Acrylamide;
<4> (S)-N-(1-(6-((4-모포리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드;<4> Synthesis of (S) -N- (1- (6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) acrylamide;
<5> 1-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;<5> A process for preparing 1- (4 - ((6 - ((4- morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) prop-2-en-1-one;
<6> 1-(4-((6-((4-(피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘 -1-일)프로페-2-엔-1-온;(6) Synthesis of 1- (4 - ((6 - ((4- (piperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 1-yl) prop-2-en-1-one;
<7> 4(R)-N-(1-(6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드;Pyrazolo [3,4-d] pyrimidin-4-yl) piperidine-l-carboxylic acid tert- 3-yl) acrylamide;
<8> (S)-1-(3-((6-((4-(4-아세틸피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;(S) -1- (3 - ((6 - ((4- (4-Acetylpiperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidine- 4-yl) amino) piperidin-1-yl) prop-2-en-1-one;
<9> 1-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로판-1-온;<9> Synthesis of 1- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) propan-1-one;
<10> (S)-1-(3-((6-((4-(피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;(S) -1- (3 - ((6 - ((4- (piperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- ) Amino) piperidin-1-yl) prop-2-en-1-one;
<11> 1-(4-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;(11) Synthesis of 1- (4 - ((6- (4-phenoxyphenyl) -lH-pyrazolo [3,4- d] pyrimidin-4- yl) amino) piperidin- 2-en-1-one;
<12> 1-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;<12> The compound according to any one of <1> to <13>, wherein the compound is 1- (3 - ((6- ( Yl) prop-2-en-1-one;
<13> 1-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;[13] d) pyrimidin-4-yl) amino) piperidine-l- Yl) prop-2-en-1-one;
<14> N-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;<14> N- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide;
<15> N-((1s, 4s)-4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;3,4-d] pyrimidin-4-yl) amino) -1H-pyrazolo [3,4-d] pyrimidin- Cyclohexyl) acrylamide;
<16> (R)-1-(3-((6-([1, 1'-디페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;(R) -1- (3 - ((6 - ([1,1'-diphenyl] -4-ylamino) -1H-pyrazolo [3,4- d] pyrimidin- ) Amino) pyrrolidin-1-yl) prop-2-en-1-one;
<17> (R)-1-(3-((6-([1, 1'-디페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;(R) -1- (3 - ((6 - ([1,1'-diphenyl] -4-ylamino) -1 H- pyrazolo [3,4- d] pyrimidin- ) Amino) pyrrolidin-1-yl) prop-2-en-1-one;
<18> (R)-1-(3-((6-((4-페녹시페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;(R) -1- (3 - ((6 - ((4-phenoxyphenyl) amino) -lH- pyrazolo [3,4- d] pyrimidin-4- yl) amino) pyrrolidine -1-yl) prop-2-en-1-one;
<19> (R)-1-(3-((6-((4-(피페리딘-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;3,4-d] pyrimidin-4-ylmethyl) -1H-pyrazolo [3,4-d] pyrimidin- Yl) amino) pyrrolidin-1-yl) prop-2-en-1-one;
<20> N-((1s, 4s)-4-((3-메틸-6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;<20> Synthesis of N - ((1s, 4s) -4 - ((3-methyl- Yl) amino) cyclohexyl) acrylamide;
<21> N-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;<21> N- (3 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
<22> N-((1s, 4s)-4-((6-(4-페녹시페닐) -1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;(1S, 4S) -4 - ((6- (4-phenoxyphenyl) -lH-pyrazolo [3,4- d] pyrimidin-4-yl) amino) cyclohexyl) amides;
<23> N-((1s, 4s)-4-((6-(4-페녹시페녹시)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;Amino] cyclohexyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) Acrylamide;
<24> N-((1s, 4s)-4-((3-메틸-6-((4-(피페리딘-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;Preparation of N - ((1S, 4S) -4 - ((3-Methyl-6 - ((4- (piperidin- 1 -yl) phenyl) amino) -1H-pyrazolo [ ] Pyrimidin-4-yl) amino) cyclohexyl) acrylamide;
<25> (R)-1-(3-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;Pyrazolo [3,4-d] pyrimidin-4-yl) amino) pyrrolidine-l- (3 - ((6- (4-phenoxyphenyl) Yl) prop-2-en-1-one;
<26> N-((1s, 4s)-4-((6-([1, 1'-비페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;4-ylamino) -lH-pyrazolo [3,4-d] pyrimidin-4 (2S) -Yl) amino) cyclohexyl) acrylamide;
<27> N-((1s, 4s)-4-((2-((4-모폴리노페닐)아미노)-7H-피롤로[2, 3-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;Pyrrolo [2,3-d] pyrimidin-4-yl) amino) -7H-pyrrolo [2,3- d] pyrimidin- Cyclohexyl) acrylamide;
<28> N-(2-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;<28> N- (2 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
<29> N-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;<29> N- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
<30> N4, N6-bis(4-모폴리노페닐)-1H-피라졸로[3,4-d]피리미딘-4, 6-디아민;<30> N 4, N 6 -bis (4-morpholinophenyl) -1H-pyrazolo [3,4-d] pyrimidine-4,6-diamine;
<31> N4-(3-아미노페닐)-N2-(4-모폴리노페닐)-7H-피롤로[2, 3-d]피리미딘-2, 4-디아민;<31> N 4 - (3-aminophenyl) -N 2 - (4-morpholinophenyl) -7H-pyrrolo [2,3-d] pyrimidine-2,4-diamine;
<32> N-(3-((4-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드;<32> N- (3 - ((4 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-6-yl) amino) phenyl) acrylamide;
<33> N-(3-((2-((4-모폴리노페닐)아미노)-9H-퓨린-6-일)아미노)페닐)아크릴아미드;<33> N- (3 - ((2 - ((4-morpholinophenyl) amino) -9H-purin-6-yl) amino) phenyl) acrylamide;
<34> N-(3-((2-((4-모폴리노페닐)아미노)피리도[2, 3-d]피리미딘-4-일)아미노)페닐)아크릴아미드;<34> N- (3 - ((2 - ((4-morpholinophenyl) amino) pyrido [2,3-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
<35> N-(3-((4-((4-모폴리노페닐)아미노)피리도[2, 3-d]피리미딘-2-일)아미노)페닐)아크릴아미드;N- (3 - ((4 - ((4-morpholinophenyl) amino) pyrido [2,3-d] pyrimidin-2-yl) amino) phenyl) acrylamide;
<36> N2, N4-비스(4-모폴리노페닐)피리도[2, 3-d]피리미딘-2, 4-디아민;N 2, N 4 -bis (4-morpholinophenyl) pyrido [2,3-d] pyrimidine-2,4-diamine;
<37> N-(3-((6-((4-(4-아세틸피페라진-1-일)페닐)아미노)-3-메틸-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;3-methyl-1H-pyrazolo [3,4-d] pyrimidine-2-carboxylic acid ethyl ester was prepared from N- (3 - ((6- 4-yl) amino) phenyl) acrylamide;
<38> N-(3-((6-((4-(1-메틸-5, 6-디히드로-1, 2, 4-트리아진-4(1H)-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드; <38> N - (3 - ((6 - ((4- (1- methyl-5, 6-dihydro-1, 2,4-triazine -4 (1H) - yl) phenyl) amino) -1H -Pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
<39> 1-(6-((6-((4-모포리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온;3,4-d] pyrimidin-4-yl) amino) indolin-1-yl) amino] 2-en-1-one;
<40> 1-(6-((2-((4-모폴리노페닐)아미노)피리도[2, 3-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온;Amino] pyrido [2,3-d] pyrimidin-4-yl) amino) indolin-1-yl) propane 2-en-1-one;
<41> N-(3-((6-((3-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;N- (3 - ((6 - ((3-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
<42> N-(3-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드; N - (3 - ((6- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
<43> 1-(6-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온;Amino] indolin-1-yl) propyl] -1H-pyrazolo [3,4-d] pyrimidin- 2-en-1-one;
<44> 1-(6-((3-메틸-6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온;(3-methyl-6- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4- yl) amino) indolin- ) Prop-2-en-1-one;
<45> N-(3-((3-메틸-4-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드; 및 <45> N - (3 - ((3- methyl-4 - ((4-morpholinophenyl) amino) -1H- pyrazolo [3,4-d] pyrimidin-6-yl) amino) phenyl) Acrylamide; And
<46> N-(3-((3-메틸-6-((4-모폴리노페닐)아미노)-1H-피라조로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드. <46> N - (3 - ((3- methyl-6 - ((4-morpholinophenyl) amino) -1H- pyrazol twos [3,4-d] pyrimidin-4-yl) amino) phenyl) Acrylamide.
본 발명의 상기 화학식 1로 표시되는 화합물은 약학적으로 허용가능한 염의 형태로 사용할 수 있으며, 염으로는 약학적으로 허용가능한 유리산(free acid)에 의해 형성된 산 부가염이 유용하다. 산 부가염은 염산, 질산, 인산, 황산, 브롬화수소산, 요드화수소산, 아질산, 아인산 등과 같은 무기산류, 지방족 모노 및 디카르복실레이트, 페닐-치환된 알카노에이트, 하이드록시 알카노에이트 및 알칸디오에이트, 방향족 산류, 지방족 및 방향족 설폰산류 등과 같은 무독성 유기산, 아세테이트, 안식향산, 구연산, 젖산, 말레인산, 글루콘산, 메탄설폰산, 4-톨루엔설폰산, 주석산, 푸마르산 등과 같은 유기산으로부터 얻는다. 이러한 약학적으로 무독한 염의 종류로는 설페이트, 피로설페이트, 바이설페이트, 설파이트, 바이설파이트, 니트레이트, 포스페이트, 모노하이드로겐 포스페이트, 디하이드로겐 포스페이트, 메타포스페이트, 피로포스페이트 클로라이드, 브로마이드, 아이오다이드, 플루오라이드, 아세테이트, 프로피오네이트, 데카노에이트, 카프릴레이트, 아크릴레이트, 포메이트, 이소부티레이트, 카프레이트, 헵타노에이트, 프로피올레이트, 옥살레이트, 말로네이트, 석시네이트, 수베레이트, 세바케이트, 푸마레이트, 말리에이트, 부틴-1, 4-디오에이트, 헥산-1, 6-디오에이트, 벤조에이트, 클로로벤조에이트, 메틸벤조에이트, 디니트로 벤조에이트, 하이드록시벤조에이트, 메톡시벤조에이트, 프탈레이트, 테레프탈레이트, 벤젠설포네이트, 톨루엔설포네이트, 클로로벤젠설포네이트, 크실렌설포네이트, 페닐아세테이트, 페닐프로피오네이트, 페닐부티레이트, 시트레이트, 락테이트, β-하이드록시부티레이트, 글리콜레이트, 말레이트, 타트레이트, 메탄설포네이트, 프로판설포네이트, 나프탈렌-1-설포네이트, 나프탈렌-2-설포네이트, 만델레이트 등을 포함한다.The compound represented by the formula (1) of the present invention can be used in the form of a pharmaceutically acceptable salt, and as the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. Acid addition salts include those derived from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, phosphorous acid and the like, aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, And organic acids such as acetic acid, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid, fumaric acid and the like are obtained from non-toxic organic acids such as dicarboxylic acids, Examples of such pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate chloride, bromide, But are not limited to, but are not limited to, but are not limited to, but are not limited to, but are not limited to, halides, halides, halides, halides, halides, halides, But are not limited to, but are not limited to, lactose, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1, 6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, Methoxybenzoate, phthalate, terephthalate, benzene sulfonate, toluene sulfonate, chloro Such as benzenesulfonate, benzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate,? -Hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene- 1-sulfonate, naphthalene-2-sulfonate, mandelate and the like.
본 발명에 따른 산 부가염은 통상의 방법으로 제조할 수 있으며, 예를 들면 화학식 1의 유도체를 메탄올, 에탄올, 아세톤, 메틸렌클로라이드, 아세토니트릴 등과 같은 유기용매에 녹이고 유기산 또는 무기산을 가하여 생성된 침전물을 여과, 건조시켜 제조하거나, 용매와 과량의 산을 감압 증류한 후 건조시켜 유기용매 하에서 결정화시켜셔 제조할 수 있다. The acid addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving a derivative of the formula (1) in an organic solvent such as methanol, ethanol, acetone, methylene chloride, acetonitrile and the like, Followed by filtration and drying. Alternatively, the solvent and excess acid may be distilled off under reduced pressure, followed by drying and crystallization in an organic solvent.
또한, 염기를 사용하여 약학적으로 허용가능한 금속염을 만들 수 있다. 알칼리 금속 또는 알칼리 토금속 염은 예를 들면 화합물을 과량의 알칼리 금속 수산화물 또는 알칼리 토금속 수산화물 용액 중에 용해하고, 비용해 화합물 염을 여과하고, 여액을 증발, 건조시켜 얻는다. 이때, 금속염으로는 나트륨, 칼륨 또는 칼슘염을 제조하는 것이 제약상 적합하다. 또한, 이에 대응하는 염은 알칼리 금속 또는 알칼리 토금속 염을 적당한 음염(예, 질산은)과 반응시켜 얻는다.In addition, bases can be used to make pharmaceutically acceptable metal salts. The alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess amount of an alkali metal hydroxide or an alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is preferable for the metal salt to produce sodium, potassium or calcium salt. In addition, the corresponding salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable salt (such as silver nitrate).
나아가, 본 발명은 상기 화학식 1로 표시되는 화합물 및 이의 약학적으로 허용가능한 염뿐만 아니라, 이로부터 제조될 수 있는 용매화물, 광학 이성질체, 수화물 등을 모두 포함한다.Furthermore, the present invention encompasses the compounds represented by the formula (1) and pharmaceutically acceptable salts thereof as well as solvates, optical isomers and hydrates thereof which can be prepared therefrom.
또한, 본 발명은 하기 반응식 1에 나타낸 바와 같이, Also, as shown in the following Reaction Scheme 1,
화학식 3으로 표시되는 화합물과 화학식 4로 표시되는 화합물을 반응시켜 화학식 2로 표시되는 화합물을 제조하는 단계(단계 1); 및Reacting a compound represented by formula (3) with a compound represented by formula (4) to prepare a compound represented by formula (2) (step 1); And
상기 단계 1에서 얻은 화학식 2로 표시되는 화합물과 화학식 5로 표시되는 화합물을 반응시켜 화학식 1로 표시되는 화합물을 얻는 단계(단계 2)를 포함하는 제1항의 화학식 1로 표시되는 화합물의 제조방법을 제공한다.A process for producing a compound represented by formula (1) according to claim 1, comprising the step of reacting a compound represented by the formula (2) and a compound represented by the formula (5) obtained in the step 1 to obtain a compound represented by the formula (1) to provide.
[반응식 1][Reaction Scheme 1]
상기 반응식 1에서, In the above Reaction Scheme 1,
n, A, D1, D2, D3, R1, R2, R3 및 는 제1항의 화학식 1에서 정의한 바와 같고;n, A, D 1, D 2, D 3, R 1, R 2, R 3 and Is as defined in claim 1;
X1 및 X2는 각각 독립적으로 동일 또는 상이한 할로겐이고; 및X 1 and X 2 are each independently the same or different halogen; And
L1은 수소 또는 이다.L 1 is hydrogen or to be.
이하, 본 발명에 따른 상기 반응식 1로 표시되는 제조방법에 대하여 상세히 설명한다.Hereinafter, the production method represented by Reaction Scheme 1 according to the present invention will be described in detail.
본 발명에 따른 상기 반응식 1로 표시되는 제조방법에 있어서, 상기 단계 1은 화학식 3으로 표시되는 화합물과 화학식 4로 표시되는 화합물을 반응시켜 화학식 2로 표시되는 화합물을 제조하는 단계이며, 구체적으로, 화학식 3으로 표시되는 화합물의 할로겐과 화학식 4로 표시되는 화합물의 L1이 반응하여 화학식 2로 표시되는 화합물을 얻는 단계이다.In the production method represented by Reaction Scheme 1 according to the present invention, the above Step 1 is a step of reacting a compound represented by Formula 3 and a compound represented by Formula 4 to prepare a compound represented by Formula 2, The halogen of the compound represented by the formula (3) is reacted with the L 1 of the compound represented by the formula (4) to obtain the compound represented by the formula (2).
구체적으로, L1이 수소일 경우, 염기 존재하에 반응이 진행될 수 있으며, 상기 염기로는 특히 한정되는 것은 아니나, 피리딘, 트리에틸아민, N, N-디이소프로필에틸아민, 1, 8-디아자비사이클로[5.4.0]-7-운데센(DBU)등과 같은 유기염기 또는 수산화나트륨, 탄산나트륨, 탄산칼륨, 탄산세슘, 수산화바륨 등과 같은 무기염기를 단독 또는 혼합하여, 당량 또는 과량으로 사용할 수 있다.Specifically, when L 1 is hydrogen, the reaction may proceed in the presence of a base. Examples of the base include, but are not limited to, pyridine, triethylamine, N, N-diisopropylethylamine, 1,8- (DBU), or an inorganic base such as sodium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, barium hydroxide or the like may be used alone or in combination as an equivalent or an excess amount .
또한, 상기 반응에서 사용 가능한 용매로는 특히 한정되는 것은 아니나, 테트라하이드로퓨란, 다이옥산, 디클로로메탄, 1, 2-디메톡시에탄 등의 에테르계 용매; 벤젠, 톨루엔, 자일렌 등의 아로마틱 하이드로카본용매; 메탄올, 에탄올 등의 알코올계 용매; 디메틸포름아미드(DMF), 디메틸설폭사이드, 아세토나이트릴, 물 등이 있으며, 이를 단독 또는 혼합하여 사용할 수 있다.Examples of the solvent that can be used in the reaction include, but are not limited to, ether solvents such as tetrahydrofuran, dioxane, dichloromethane and 1,2-dimethoxyethane; Aromatic hydrocarbon solvents such as benzene, toluene and xylene; Alcohol solvents such as methanol and ethanol; Dimethylformamide (DMF), dimethylsulfoxide, acetonitrile, water and the like, which may be used alone or in combination.
L1이 또는 일 경우, 금속 촉매 및 염기 조건하에 반응시킬 수 있다.L 1 is or , They can be reacted under metal catalyst and base conditions.
이때, 상기 보론산 화합물은 상업적으로 시판되는 화합물들을 사용하거나, 대응되는 할라이드 화합물로부터 공지의 방법으로 제조하여 사용할 수 있다.At this time, the boronic acid compound may be commercially available compounds or may be prepared from the corresponding halide compound by a known method.
상기 금속 촉매로는 팔라듐 촉매를 사용할 수 있으며, 사용가능한 팔라듐 촉매는 Pd/C, Pd(PPh3)4, PdCl2, Pd(OCOCH3)2, Pd(pph3)2Cl2 등을 사용할 수 있다. 바람직하게는 Pd(pph3)2Cl2을 사용할 수 있으나, 이에 한정하지는 않는다.As the metal catalyst may be a palladium catalyst, usable palladium catalyst, or the like Pd / C, Pd (PPh 3 ) 4, PdCl 2, Pd (OCOCH 3) 2, Pd (pph 3) 2 Cl 2 have. Preferably, Pd (pph 3 ) 2 Cl 2 can be used, but is not limited thereto.
상기 염기로는 피리딘, 트리에틸아민, N, N-디이소프로필에틸아민, 1, 8-디아자비사이클로[5.4.0]-7-운데센(DBU)등과 같은 유기염기 또는 수산화나트륨, 탄산나트륨, 탄산칼륨, 탄산세슘, 수산화바륨 등과 같은 무기염기를 단독 또는 혼합항, 당량 또는 과량으로 사용할 수 있으나, 이에 한정하지는 않는다.Examples of the base include an organic base such as pyridine, triethylamine, N, N-diisopropylethylamine, 1,8-diazabicyclo [5.4.0] -7-undecene (DBU) Potassium carbonate, cesium carbonate, barium hydroxide and the like can be used alone or in combination, in an equivalent amount or in an excess amount, but the present invention is not limited thereto.
상기 반응에서 사용 가능한 용매로는 테트라하이드로퓨란, 다이옥산, 디클로로메탄, 1, 2-디메톡시에탄 등의 에테르계 용매; 벤젠, 톨루엔, 자일렌 등의 아로마틱 하이드로카본용매; 메탄올, 에탄올 등의 알코올계 용매; 디메틸포름아미드(DMF), 디메틸설폭사이드, 아세토나이트릴, 물 등이 있으며, 이를 단독 또는 혼합하여 사용할 수 있다.Examples of the solvent usable in the reaction include ether solvents such as tetrahydrofuran, dioxane, dichloromethane and 1,2-dimethoxyethane; Aromatic hydrocarbon solvents such as benzene, toluene and xylene; Alcohol solvents such as methanol and ethanol; Dimethylformamide (DMF), dimethylsulfoxide, acetonitrile, water and the like, which may be used alone or in combination.
본 발명에 따른 상기 반응식 1로 표시되는 제조방법에 있어서, 상기 단계 2는 상기 단계 1에서 얻은 화학식 2로 표시되는 화합물과 화학식 5로 표시되는 화합물을 반응시켜 화학식 1로 표시되는 화합물을 얻는 단계이며, 구체적으로, 화학식 2로 표시되는 화합물의 할로겐과 화학식 5로 표시되는 화합물의 2차 아민이 아미네이션 반응하여 화학식 4로 표시되는 화합물을 얻는 단계이다.In the production method represented by the reaction formula 1 according to the present invention, the step 2 is a step of reacting the compound represented by the formula 2 and the compound represented by the formula 5 obtained in the step 1 to obtain the compound represented by the formula 1 Specifically, the halogenation of the compound represented by the formula (2) and the secondary amine of the compound represented by the formula (5) are aminated to obtain the compound represented by the formula (4).
상기 반응에서 사용가능한 용매는 테트라하이드로퓨란, 다이옥산, 디클로로메탄, 1, 2-디메톡시에탄 등과 같은 에테르계 용매; 메탄올, 에탄올, 프로판올, 부탄올 등과 같은 저급알코올; 디메틸포름아미드(DMF); 디메틸설폭사이드(DMSO); 아세토나이트릴, 물 등을 단독 또는 혼합하여 사용할 수 있다.Solvents usable in the above reaction include ether solvents such as tetrahydrofuran, dioxane, dichloromethane, 1,2-dimethoxyethane and the like; Lower alcohols such as methanol, ethanol, propanol, butanol and the like; Dimethylformamide (DMF); Dimethyl sulfoxide (DMSO); Acetonitrile, water, etc., may be used alone or in combination.
나아가, 본 발명은 하기 반응식 2에 나타낸 바와 같이, Further, the present invention provides a compound represented by the following formula (2)
화학식 3으로 표시되는 화합물과 화학식 5로 표시되는 화합물을 반응시켜 화학식 6으로 표시되는 화합물을 제조하는 단계(단계 1); 및Reacting a compound represented by formula (3) with a compound represented by formula (5) to prepare a compound represented by formula (6) (step 1); And
상기 단계 1에서 얻은 화학식 6으로 표시되는 화합물과 화학식 4로 표시되는 화합물을 반응시켜 화학식 1로 표시되는 화합물을 얻는 단계(단계 2)를 포함하는 제1항의 화학식 1로 표시되는 화합물의 제조방법을 제공한다.A process for producing a compound represented by the general formula (1), which comprises the step of reacting a compound represented by the formula (6) and a compound represented by the formula (4) to obtain a compound represented by the formula (1) to provide.
[반응식 2][Reaction Scheme 2]
상기 반응식 2에서, In the above Reaction Scheme 2,
n, A, D1, D2, D3, R1, R2, R3 및 는 제1항의 화학식 1에서 정의한 바와 같고;n, A, D 1, D 2, D 3, R 1, R 2, R 3 and Is as defined in claim 1;
X1 및 X2는 각각 독립적으로 동일 또는 상이한 할로겐이고; 및X 1 and X 2 are each independently the same or different halogen; And
L1은 수소 또는 이다.L 1 is hydrogen or to be.
상기 반응식 2에서, 단계 1의 상세한 설명은 반응식 1의 단계 2와 동일하고, In Scheme 2, the detailed description of Step 1 is the same as Step 2 of Scheme 1,
단계 2의 상세한 설명은 반응식 1의 단계 1과 동일하다.The detailed description of Step 2 is the same as Step 1 of Scheme 1.
나아가, 본 발명은 상기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 브루톤 티로신 키나제 활성과 관련 질환의 예방 또는 치료용 약학적 조성물을 제공한다.Further, the present invention provides a pharmaceutical composition for preventing or treating Bruton tyrosine kinase activity and related diseases containing the compound represented by the above-mentioned formula (1), an optical isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
여기서, 상기 브루톤 티로신 키나제 활성과 관련 질환은 암, 자가면역질환 등을 포함할 수 있다.Herein, the Bruton tyrosine kinase activity-related diseases may include cancer, autoimmune diseases and the like.
이때, 상기 암은 혈액암, 난소암, 자궁경부암, 유방암, 대장암, 간암, 위암, 췌장암, 결장암, 복막 전이암, 피부암, 방광암, 전립선암, 갑상선암, 폐암, 골육종, 섬유성 종양 및 뇌종양으로 이루어지는 군으로부터 선택되는 어느 하나이며, 자가면역 질환은 류머티스성 관절염, 전신 홍반성 루푸스, 다발성 경화증, 제1형 당뇨병, 갑상선 기능 항진증, 근무력증, 크론병, 강직성 척추염, 건선, 자가면역성 악성빈혈 및 쇼그렌 증후군으로 이루어지는 군으로부터 선택되는 어느 하나이다.The cancer may be selected from the group consisting of blood cancer, ovarian cancer, cervical cancer, breast cancer, colon cancer, liver cancer, stomach cancer, pancreatic cancer, colon cancer, peritoneal metastasis cancer, skin cancer, bladder cancer, prostate cancer, thyroid cancer, lung cancer, osteosarcoma, Wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, hyperthyroidism, myasthenia, Crohn's disease, ankylosing spondylitis, psoriasis, autoimmune malignant anemia, Syndrome, < / RTI >
본 발명에 따른 접합 피리미딘 유도체의 브루톤 티로신 키나제 활성 억제 능력 및 TMD80 활성 억제 능력을 평가한 결과, 본 발명에 따른 접합 피리미딘 유도체는 10 μM 이하의 IC50 값으로 브루톤 티로신 키나제의 활성을 억제하고, 실시예 3, 5, 12, 14-21, 24, 27, 28, 30, 32, 33, 37-39, 41, 45 및 46 화합물은 0.05 μM 이하즉, 50 nM 이하의 낮은 IC50 값을 나타내어, 우수한 브루톤 티로신 키나제 활성 억제능을 나타냄을 알 수 있으며, 특히, 실시예 14, 15, 19-21, 33, 37-39 및 41 화합물은 0.008 μM, 즉, 8 nM 이하의 현저하게 IC50 값으로 브루톤 티로신 키나제 활성을 억제하는 것을 확인하였다(실험예 1 및 표 3 참조).As a result of evaluating the ability of the conjugated pyrimidine derivatives according to the present invention to inhibit the brutonyl tyrosine kinase activity and the TMD80 activity, the conjugated pyrimidine derivatives according to the present invention showed an activity of the bruton tyrosine kinase with an IC 50 value of 10 μM or less And the compounds of Examples 3, 5, 12, 14-21, 24, 27, 28, 30, 32, 33, 37-39, 41, 45 and 46 exhibited low IC 50 The compounds of Examples 14, 15, 19-21, 33, 37-39, and 41 exhibited a significant inhibitory effect on the activity of 0.007 [mu] M, i.e., 8 nM or less It was confirmed that the IC 50 value inhibited the bruton tyrosine kinase activity (see Experimental Example 1 and Table 3).
또한, 본 발명에 따른 접합 피리미딘 유도체는 10 μM 이하의 IC50 값으로 TMD80의 활성을 억제하고, 실시예 11, 21, 27, 28 및 46 화합물은 0.05 μM 이하즉, 50 nM 이하의 낮은 IC50 값을 나타내어, 우수한 TMD80 활성 억제능을 나타내는 것을 확인하였다(실험예 2 및 표 3 참조).In addition, the conjugated pyrimidine derivatives according to the present invention inhibit the activity of TMD80 with an IC 50 value of 10 μM or less, while the compounds of Examples 11, 21, 27, 28 and 46 inhibit the activity of low IC 50 , indicating excellent TMD80 activity inhibitory activity (see Experimental Example 2 and Table 3).
따라서, 본 발명에 따른 접합 피리미딘 유도체는 브루톤 티로신 키나제 또는 TMD80의 활성을 억제하는 능력이 우수하므로, 브루톤 티로신 키나제 활성과 관련된 질환, 특히 암 또는 자가면역질환을 예방 또는 치료하는데 유용하게 사용할 수 있다.Therefore, the conjugated pyrimidine derivative according to the present invention is excellent in the ability to inhibit the activity of brutonyl tyrosine kinase or TMD80, so that it is useful for preventing or treating diseases related to the bruton tyrosine kinase activity, particularly cancer or autoimmune diseases .
본 발명에 따른 약학적 조성물에 있어서, 상기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염은 임상 투여시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충전제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 제조될 수 있다.In the pharmaceutical composition according to the present invention, the compound represented by the formula (1), its optical isomer or pharmaceutically acceptable salt thereof may be administered in various formulations for oral administration and parenteral administration at the time of clinical administration. May be prepared by using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants, etc. which are usually used.
경구 투여용 제형으로는 예를 들면 정제, 환제, 경/연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 과립제, 엘릭시르제, 트로키제 등이 있는데, 이들 제형은 유효성분 이외에 희석제(예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로즈 및/또는 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및/또는 폴리에틸렌 글리콜)를 함유하고 있다. 정제는 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 메틸셀룰로즈, 나트륨 카복시메틸셀룰로즈 및/또는 폴리비닐피롤리딘 등과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염 등과 같은 붕해제 또는 비등 혼합물 및/또는 흡수제, 착색제, 향미제, 및 감미제를 함유할 수 있다.Examples of formulations for oral administration include tablets, pills, light / soft capsules, liquids, suspensions, emulsions, syrups, granules, elixirs and troches, , Dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine), lubricants (such as silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycols). The tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine and may optionally contain binders such as starch, agar, alginic acid or sodium salts thereof Release or boiling mixture and / or absorbent, colorant, flavor, and sweetening agent.
본 발명에 따른 상기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 유효 성분으로 하는 약학적 조성물은 비경구 투여할 수 있으며, 비경구 투여는 피하주사, 정맥주사, 근육 내 주사 또는 흉부 내 주사를 주입하는 방법에 의한다. The pharmaceutical composition comprising the compound of Formula 1, its optical isomer or its pharmaceutically acceptable salt as an active ingredient according to the present invention can be administered parenterally, and parenteral administration can be carried out by subcutaneous injection, intravenous injection, muscle Intravenous injection or intra-thoracic injection.
이때, 비경구 투여용 제형으로 제제화하기 위하여 상기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용가능한 염을 안정제 또는 완충제와 함께 물에 혼합하여 용액 또는 현탁액으로 제조하고, 이를 앰플 또는 바이알 단위 투여형으로 제조할 수 있다. 상기 조성물은 멸균되고/되거나 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 보조제, 및 기타 치료적으로 유용한 물질을 함유할 수 있으며, 통상적인 방법인 혼합, 과립화 또는 코팅 방법에 따라 제제화할 수 있다.In this case, in order to formulate the composition for parenteral administration, the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof may be mixed with water or a stabilizer or a buffer to prepare a solution or suspension, . The compositions may contain sterilized and / or preservatives, stabilizers, wettable or emulsifying accelerators, adjuvants such as salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances, Or may be formulated according to the coating method.
또한, 본 발명의 상기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 유효 성분으로 하는 약학적 조성물의 인체에 대한 투여량은 환자의 나이, 몸무게, 성별, 투여형태, 건강상태 및 질환 정도에 따라 달라질 수 있으며, 바람직하게는 0.01 내지 200 mg/kg/일의 양으로 의사 또는 약사의 판단에 따라 일정시간 간격을 1일 수회, 바람직하게는 1일 1회 내지 3회로 분할하여 경구 또는 비경구적 경로를 통해 투여할 수 있다.The dose of the pharmaceutical composition containing the compound represented by the formula (1) of the present invention, its optical isomer or a pharmaceutically acceptable salt thereof as an active ingredient to the human body depends on the age, body weight, sex, May be varied depending on the health condition and the degree of disease, preferably 0.01 to 200 mg / kg / day, depending on the judgment of the physician or pharmacist, at intervals of several times a day, preferably once to three times a day May be administered by oral or parenteral route.
나아가, 본 발명의 상기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염을 유효 성분으로 하는 약학적 조성물은 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료를 위하여 단독으로, 또는 수술, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.Furthermore, the pharmaceutical composition comprising the compound represented by the formula (1) of the present invention, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient may be used alone or in combination with a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of a glutathione kinase activity- Surgery, hormonal therapy, chemotherapy, and methods using biological response modifiers.
또한, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 브루톤 티로신 키나제 활성과 관련 질환의 예방 또는 개선용 건강식품 조성물을 제공한다.In addition, the present invention provides a health food composition for preventing or ameliorating bruton tyrosine kinase activity and related diseases, which comprises the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
여기서, 상기 브루톤 티로신 키나제 활성과 관련 질환은 암 또는 자가면역질환 등을 포함할 수 있다.Herein, the disease associated with the Bruton tyrosine kinase activity may include cancer or autoimmune diseases and the like.
이때, 상기 암은 혈액암, 난소암, 자궁경부암, 유방암, 대장암, 간암, 위암, 췌장암, 결장암, 복막 전이암, 피부암, 방광암, 전립선암, 갑상선암, 폐암, 골육종, 섬유성 종양 및 뇌종양으로 이루어지는 군으로부터 선택되는 어느 하나이며, 자가면역 질환은 류머티스성 관절염, 전신 홍반성 루푸스, 다발성 경화증, 제1형 당뇨병, 갑상선 기능 항진증, 근무력증, 크론병, 강직성 척추염, 건선, 자가면역성 악성빈혈 및 쇼그렌 증후군으로 이루어지는 군으로부터 선택되는 어느 하나이다.The cancer may be selected from the group consisting of blood cancer, ovarian cancer, cervical cancer, breast cancer, colon cancer, liver cancer, stomach cancer, pancreatic cancer, colon cancer, peritoneal metastasis cancer, skin cancer, bladder cancer, prostate cancer, thyroid cancer, lung cancer, osteosarcoma, Wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, hyperthyroidism, myasthenia, Crohn's disease, ankylosing spondylitis, psoriasis, autoimmune malignant anemia, Syndrome, < / RTI >
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 드링크제, 육류, 소시지, 빵, 비스킷, 떡, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알코올 음료 및 비타민 복합제, 유제품 및 유가공 제품 등이 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the foods to which the above substances can be added include dairy products including dairy products, meat, sausage, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, Beverages, alcoholic beverages and vitamin complexes, dairy products, and dairy products, all of which include health functional foods in a conventional sense.
본 발명에 따른 상기 화학식 1로 표시되는 화합물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합량은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 건강식품 중의 상기 화합물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The compound represented by the formula (1) according to the present invention can be added directly to food or used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement). Generally, the amount of the compound in the health food may be 0.1 to 90 parts by weight of the total food. However, in the case of long-term intake intended for health and hygiene purposes or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
또한, 본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 화합물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 제조 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 g당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.In addition, the health functional beverage composition of the present invention has no particular limitation on other ingredients other than those containing the above-mentioned compounds as essential ingredients in the indicated ratios, and may contain various flavoring agents or natural carbohydrates as additional ingredients such as ordinary beverages have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and prepared flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 g of the composition of the present invention.
나아가, 상기 외에 본 발명에 따른 화학식 1로 표시되는 화합은 여러 가지 영양제, 비타민, 광물(전해질), 제조 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 화학식 1로 표시되는 화합물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. In addition, in addition to the above, the compound represented by formula (1) according to the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), manufacturing flavorings and natural flavors, coloring agents and intermediates such as cheese and chocolate, Acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compound represented by formula (1) of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the present invention is not limited to the following Examples and Experimental Examples.
<실시예 1> 1-(4-(4-((6-(p-톨릴아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온의 제조Example 1 Synthesis of 1- (4- (4 - ((6- (p-tolylamino) -1H-pyrazolo [3,4-d] pyrimidin- -Yl) ethan-1-one < / RTI >
단계 1 : 1-(4-(4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온의 제조Step 1: Preparation of l- (4- (4-chloro-l- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidin- Amino) phenyl) piperazin-1-yl) ethan-1-one
4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (200 mg, 0.73 mmol) 과 1-(4-(4-아미노페닐)피페라진-1-일)에탄-1-온 (193 mg, 0.88 mmol) 을 부탄올 (2 mL)에 녹이고, 여기에 탄산칼륨 (152 mg, 1.1 mmol)을 가한다. 반응물을 13시간 동안 교반한다. 반응이 완결 되면, 감압 증류하여 용매를 제거하고, 디클로로메탄과 물을 가하여, 생성물을 유기층으로 추출한다. 유기층을 황산마그네슘으로 건조한 다음, 농축하고 컬럼크로마토그라피로 생성물 1-(4-(4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온 (340 mg, 88%)을 얻었다.(80 mg, 0.73 mmol) and l- (4- (4-fluorophenyl) -1H-pyrazolo [ 1-yl) ethan-1-one (193 mg, 0.88 mmol) was dissolved in butanol (2 mL) and potassium carbonate (152 mg, 1.1 mmol) was added thereto. The reaction is stirred for 13 hours. When the reaction is completed, the solvent is removed by distillation under reduced pressure, dichloromethane and water are added, and the product is extracted into the organic layer. The organic layer was dried over magnesium sulfate and then concentrated to give the product 1- (4- (4- ((6-chloro-1- (tetrahydro-2H-pyran-2-yl) -1H- pyrazolo [3 , 4-d] pyrimidin-4-yl) amino) phenyl) piperazin-1-yl) ethan-1-one (340 mg, 88%).
1H NMR (300 MHz, CDCl3) δ 7.77 (s, 1H), 7.22 (m, 3H), 6.92 (d, J = 6.5 Hz, 1H), 5.87 (brs, 1H), 4.02 (m, 1H), 3.75 (m, 2H), 3.68 (m, 2H), 3.30 (m, 2H), 2.48 (m, 1H), 2.21 (s, 3H), 2.12 (s, 1H), 1.82 (m, 1H), 1.78~1.52 (t, 9H), 0.98 (m, 2H). 1 H NMR (300 MHz, CDCl 3) δ 7.77 (s, 1H), 7.22 (m, 3H), 6.92 (d, J = 6.5 Hz, 1H), 5.87 (brs, 1H), 4.02 (m, 1H) , 3.75 (m, 2H), 3.68 (m, 2H), 3.30 (m, 1.78 ~ 1.52 (t, 9H), 0.98 (m, 2H).
단계 2: 1-(4-(4-((1-(테트라히드로-2H-피란-2-일)-6-(p-톨릴아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온의 제조Step 2: Preparation of l- (4- (4 - ((1- (tetrahydro-2H-pyran-2-yl) -6- (p- tolylamino) -1H- pyrazolo [3,4- d] pyrimidine Yl) amino) phenyl) piperazin-1-yl) ethan-1-one
밀폐된 압력용기 (sealed tube)에 1-(4-(4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온 (30 mg, 0.065 mmol), 톨루이딘 (8 mg, 0.074 mmol), Pd2dba3 (3 mg, 0.006 mmol), X-phos (9 mg, 0.021 mmol), 탄산칼륨 (18 mg, 0.13 mmol)을 부탄올 (2 mL)에 가하고, 90 ℃에서 15 시간 동안 반응시켰다. 반응 용액을 에틸아세테이트 (20 mL)와 물 (5 mL)로 추출하고, 유기층을 황산마그네슘으로 건조하고, 여과, 농축하였다. 관크로마토그라피로 1-(4-(4-((1-(테트라히드로-2H-피란-2-일)-6-(p-톨릴아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온 (30 mg, 88%)을 얻었다..A sealed tube was charged with 1- (4- (4 - ((6-chloro-1- (tetrahydro-2H-pyran-2-yl) -1H- pyrazolo [3,4- (30 mg, 0.065 mmol), toluidine (8 mg, 0.074 mmol) and Pd 2 dba 3 (3 mg, 0.006 mmol) in DMF , X-phos (9 mg, 0.021 mmol) and potassium carbonate (18 mg, 0.13 mmol) were added to butanol (2 mL) and reacted at 90 ° C for 15 hours. The reaction solution was extracted with ethyl acetate (20 mL) and water (5 mL), and the organic layer was dried over magnesium sulfate, filtered, and concentrated. The title compound was obtained as a colorless oil from 1- (4- (4 - ((1- (tetrahydro-2H-pyran-2-yl) -6- (p- tolylamino) -1H-pyrazolo [3,4- Yl) amino) phenyl) piperazin-1-yl) ethan-1-one (30 mg, 88%).
1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 4.9 Hz, 2H), 7.37 (m, 2H), 7.15 (d, J = 4.9 Hz, 2H), 6.95 (m, 4H), 5.80 (d, J = 5.1 Hz, 1H), 4.12 (m, 1H), 3.75 (m, 2H), 3.65 (m, 2H), 3.18 (m, 4H), 2.54 (m, 1H), 2.24 (s, 3H), 2.19 (s, 3H), 1.94 (m, 5H), 1.65 (m, 1H). 1 H NMR (300 MHz, CDCl 3) δ 7.56 (d, J = 4.9 Hz, 2H), 7.37 (m, 2H), 7.15 (d, J = 4.9 Hz, 2H), 6.95 (m, 4H), 5.80 (d, J = 5.1 Hz, IH), 4.12 (m, IH), 3.75 (m, 2H), 3.65 (m, 2H), 3.18 3H), 2.19 (s, 3H), 1.94 (m, 5H), 1.65 (m, 1H).
단계 3: 1-(4-(4-((6-(p-톨릴아미노)-1H-피라졸로[3,4-d]?리미딘-4-일)아미노)페닐)피레라진-1-일)에탄-1-온의 제조Step 3: Preparation of 1- (4- (4 - ((6- (p-tolylamino) -1H-pyrazolo [3,4- Yl) ethan-1-one
1-(4-(4-((1-(테트라히드로-2H-피란-2-일)-6-(p-톨릴아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온 (30 mg, 0.057 mmol)을 1, 4-디옥산 (1 mL)에 녹이고, 여기에 염산용액 (4 N, 1,4-디옥산, 0.5 mL)를 가하였다. 반응 용액을 15분 동안 상온에서 교반하고, 감압증류하여 용매를 제거하였다. 재결정하여 생성물을 얻었다 (13 mg, 43%).Pyrazolo [3,4-d] pyrimidin-4-ylmethyl) -1- (4- (4 - ((1- (tetrahydro- 1-yl) ethan-1-one (30 mg, 0.057 mmol) was dissolved in 1, 4-dioxane (1 mL) -Dioxane, 0.5 mL) was added. The reaction solution was stirred at room temperature for 15 minutes and the solvent was distilled off under reduced pressure. Recrystallization gave the product (13 mg, 43%).
1H NMR (300 MHz, DMSO-d6) δ 7.65 (d, J = 4.9 Hz, 2H), 7.37 (m, 2H), 7.15 (d, J = 4.9 Hz, 2H), 7.01 (m, 4H), 3.62 (m, 4H), 3.12 (m, 4H), 2.26 (s, 3H), 2.04 (s, 3H). 1 H NMR (300 MHz, DMSO -d 6) δ 7.65 (d, J = 4.9 Hz, 2H), 7.37 (m, 2H), 7.15 (d, J = 4.9 Hz, 2H), 7.01 (m, 4H) , 3.62 (m, 4H), 3.12 (m, 4H), 2.26 (s, 3H), 2.04 (s, 3H).
<실시예 2> 1-(4-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온의 제조Example 2 Synthesis of 1- (4- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- ) Piperazin-1-yl) ethan-1-one
단계 1 : 1-(4-(4-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐l)피페라진-1-일)에탄-1-온의 제조Step 1: Preparation of l- (4- (4 - ((6 - ((4- morpholinophenyl) amino) - l- (tetrahydro- 2H- pyran- 2-yl) -lH- pyrazolo [3,4 d] pyrimidin-4-yl) amino) phenyl) piperazin-1-yl) ethan-
밀폐된 압력용기 (sealed tube)에 1-(4-(4-((6-클로로-1-(테트라하이드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온 (30 mg, 0.065 mmol), 4-모폴리노아닐린 (8 mg, 0.074 mmol), Pd2dba3(3 mg, 0.006 mmol), X-phos (9mg, 0.021 mmol), 탄산칼륨 (18 mg, 0.13 mmol)을 n-부탄올 (2 mL)에 가하고, 90 ℃에서 15 시간 동안 반응시켰다. 반응 용액을 에틸아세테이트 (20 mL)와 물 (5 mL)로 추출하고, 유기층을 황산마그네슘으로 건조하고, 여과, 농축하였다. 관크로마토그라피로 1-(4-(4-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐l)피페라진-1-일)에탄-1-온(40 mg, 88%)을 합성하였다.A sealed tube was charged with 1- (4- (4 - ((6-chloro-1- (tetrahydro-2H-pyran-2-yl) -1H- pyrazolo [3,4- 4-yl) amino) phenyl) piperazin-1-yl) ethane-1-one (30 mg, 0.065 mmol), 4- morpholino aniline (8 mg, 0.074 mmol), Pd 2 dba 3 (3 mg, 0.006 mmol), X-phos (9 mg, 0.021 mmol), potassium carbonate (18 mg, 0.13 mmol) were added to n-butanol (2 mL) and reacted at 90 ° C for 15 hours. The reaction solution was extracted with ethyl acetate (20 mL) and water (5 mL), and the organic layer was dried over magnesium sulfate, filtered, and concentrated. The title compound was obtained as a colorless oil from 1- (4- (4 - ((6 - ((4-morpholinophenyl) amino) -1- (tetrahydro- 4-yl) amino) phenyl) piperazin-1-yl) ethan-1-one (40 mg, 88%).
1H-NMR (500 MHz, CDCl3) δ 7.46 (d, J = 9 Hz, 1H), 7.18 (d, J = 9.0 Hz, 2H), 6.90-6.81 (m, 5H), 5.68 (d, J = 9.1Hz, 1H), 3.85-3.53 (m, 5H), 3.50 (s,2H), 3.20-3.00 (m, 5H), 2.45-2.41 (m, 2H), 2.10-1.95 (m, 2H), 1.80-1.65 (m, 6H), 1.55-1.48 (m, 2H), 0.67-0.63 (m, 3H). 1 H-NMR (500 MHz, CDCl 3) δ 7.46 (d, J = 9 Hz, 1H), 7.18 (d, J = 9.0 Hz, 2H), 6.90-6.81 (m, 5H), 5.68 (d, J 2H), 2.10-1.95 (m, 2H), 3.85-3.53 (m, 2H) 1.80-1.65 (m, 6H), 1.55-1.48 (m, 2H), 0.67-0.63 (m, 3H).
단계 2: 1-(4-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온의 제조Step 2: Preparation of l- (4- (4 - ((6 - ((4- morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 1-yl) ethan-1-one < / RTI >
1-(4-(4-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐l)피페라진-1-일)에탄-1-온 (50 mg, 0.057 mmol)을 1,4-디옥산 (1 mL)에 녹이고, 여기에 염산 (4 N, 1,4-디옥산, 3 mL)를 가하였다. 반응 용액을 15분 동안 상온에서 교반하고, 감압증류하여 용매를 제거하였다. 재결정하여 생성물을 얻었다 (27 mg, 78%).Pyrazolo [3,4-d] pyrimidin-2-yl] -1H-pyrazolo [l, 5- 1-yl) ethan-1-one (50 mg, 0.057 mmol) was dissolved in 1,4-dioxane (1 mL), and hydrochloric acid (4 N, 1,4-dioxane, 3 mL) was added. The reaction solution was stirred at room temperature for 15 minutes and the solvent was distilled off under reduced pressure. Recrystallization gave the product (27 mg, 78%).
1H-NMR (500 MHz, CDCl3) δ 7.72-7.69 (m, 2H), 7.51-7.50 (m, 2H), 7.30-7.25 (d, J = 15.1 Hz, 5H), 3.78 (s, 3H), 3.55 (s, 3H), 3.41-3.27 (m, 11H), 3.17 (s, 2H), 2.08 (s, 3H): LCMS calculated for C27H31N9O2 = 513.26, found: 513.59. 1 H-NMR (500 MHz, CDCl 3) δ 7.72-7.69 (m, 2H), 7.51-7.50 (m, 2H), 7.30-7.25 (d, J = 15.1 Hz, 5H), 3.78 (s, 3H) , 3.55 (s, 3H), 3.41-3.27 (m, 11H), 3.17 (s, 2H), 2.08 (s, 3H): LCMS calculated for C 27 H 31 N 9 O 2 = 513.26, found: 513.59.
<실시예 3> (R)-N-(1-(6-(4-모폴리노페닐아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드의 제조Example 3 Synthesis of (R) -N- (1- (6- (4-morpholinophenylamino) -1H-pyrazolo [3,4- d] pyrimidin- -Yl) acrylamide < / RTI >
단계 1: t-부틸 ((3R)-1-(6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)카바메이트의 제조Step 1: tert-Butyl ((3R) -1- (6-chloro-1- (tetrahydro-2H-pyran- ) Piperidin-3-yl) carbamate
t-부틸 (S)-피페리딘-3-일카바메이트 (81 mg, 0.41 mmol)과 4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (100 mg, 0.37 mmol), 탄산칼슘 (112 mg, 0.81 mmol)을 디메틸포름아미드 (2 mL)에 가하고, 6시간 교반하였다. 결과된 용애을 에틸아세테이트 (15 mL)와 물 (5 mL)로 추출하고, 유기층을 황산마그네슘으로 건조, 여과, 농축하였다. 관크로마토그라피를 하여 생성물을 얻었다. (145 mg, 70%)(S) -piperidin-3-ylcarbamate (81 mg, 0.41 mmol) and 4,6-dichloro-1- (tetrahydro-2H- 3,4-d] pyrimidine (100 mg, 0.37 mmol), calcium carbonate (112 mg, 0.81 mmol) were added to dimethylformamide (2 mL), and the mixture was stirred for 6 hours. The resulting solids were extracted with ethyl acetate (15 mL) and water (5 mL), and the organic layer was dried over magnesium sulfate, filtered, and concentrated. The product was obtained by column chromatography. (145 mg, 70%).
1H NMR (300 MHz, CDCl3) δ 8.23 (brs, 1H), 8.01 (s, 1H), 5.93 (d, J = 6.7 Hz, 1H), 4.62 (s, 1H), 4.48-4.21 (m, 2H), 4.14 (m, 1H), 3.81 (m, 2H), 3.42 (m, 1H), 2.51 (m, 1H), 2.18 (m, 2H), 1.82 (m, 2H), 1.79 (m, 2H), 1.65 (m, 2H), 1.45 (s, 9H). 1 H NMR (300 MHz, CDCl 3) δ 8.23 (brs, 1H), 8.01 (s, 1H), 5.93 (d, J = 6.7 Hz, 1H), 4.62 (s, 1H), 4.48-4.21 (m, 2H), 1.79 (m, 2H), 1.79 (m, 2H), 3.81 (m, ), 1.65 (m, 2H), 1.45 (s, 9H).
단계 2: t-부틸 ((3R)-1-(6-((4-모포리노페틸)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)카바메이트의 제조Step 2: tert-Butyl ((3R) -1- (6 - ((4-morpholinopetyl) amino) -1- (tetrahydro-2H-pyran- -d] pyrimidin-4-yl) piperidin-3-yl) carbamate
t-부틸 ((3R)-1-(6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)카바메이트 (48 mg, 0.11 mmol), 4-모폴리노아닐린 (19 mg, 0.11 mmol), Pd2(dba)3 (6.3 mg, 0.011 mmol), X-Phos (14 mg, 0.03 mol), 탄산칼륨 (31 mg, 22 mml)을 t-부탄올 (1 mL)에 녹이고, 90 ℃에서 15시간 동안 반응시켰다. 반응 용액을 에틸아세테이트 (15 mL)와 물 (5 mL)로 추출하고, 유기층을 황산마그네슘으로 건조, 여과, 농축하였다. 관크로마토그라피를 하여 생성물을 얻었다. (34 mg, 60%)(3R) -1- (6-chloro-l- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidin- 3-yl) carbamate (48 mg, 0.11 mmol), 4-morpholinoaniline (19 mg, 0.11 mmol), Pd 2 (dba) 3 (6.3 mg, 0.011 mmol), X-Phos (14 mg, 0.03 mol), potassium carbonate (31 mg, 22 mmol) was dissolved in t-butanol (1 mL) and reacted at 90 占 폚 for 15 hours. The reaction solution was extracted with ethyl acetate (15 mL) and water (5 mL), and the organic layer was dried over magnesium sulfate, filtered, and concentrated. The product was obtained by column chromatography. (34 mg, 60%).
1H-NMR (500 MHz, CDCl3) δ 8.00 (s, 1H), 7.52 (d, J = 9Hz, 2H), 6.90 (d, J = 6 Hz, 2H), 6.79 (s, 1H), 5.81 (d, J = 12 Hz, 1H), 4.16-4.11 (m,2H), 3.89-3.86 (m, 3H), 3.15-3.10 (m, 4H), 1.68-1.56 (m, 4H), 1.47-1.25 (m, 9H). 1 H-NMR (500 MHz, CDCl 3) δ 8.00 (s, 1H), 7.52 (d, J = 9Hz, 2H), 6.90 (d, J = 6 Hz, 2H), 6.79 (s, 1H), 5.81 (d, J = 12 Hz, 1H), 4.16-4.11 (m, 2H), 3.89-3.86 (m, 3H), 3.15-3.10 (m, 4H), 1.68-1.56 (m, 4H), 1.47-1.25 (m, 9H).
단계 3: (R)-4-(3-아미노피페리딘-1-일)-N-(4-모포리노페닐)-1H-피라졸로[3,4-d]피리미딘-6-아민의 제조Step 3: Preparation of (R) -4- (3-aminopiperidin-l-yl) -N- (4- morpholinophenyl) -lH- pyrazolo [3,4- d] pyrimidin- Produce
t-부틸 ((3R)-1-(6-((4-모포리노페틸)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)카바메이트 (34 mg, 0.051 mmol)을 메탄올 (1 mL)에 녹이고, 여기에 염산 (4 N, 1,4-디옥산, 1 mL)를 가하고, 2시간 동안 상온으로 교반 하였다. 반응 용액을 감압농축하고, 재결정하여 생성물을 얻었다. (20 mg, 84%)(tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4-d] pyrimidin- 3-yl) carbamate (34 mg, 0.051 mmol) was dissolved in methanol (1 mL), hydrochloric acid (4 N, 1,4-dioxane, And the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure and recrystallized to obtain a product. (20 mg, 84%).
1H-NMR (500 MHz, CDCl3) δ 10.20 (s, 1H), 8.58 (s, 3H), 7.51 (s, 1H), 7.27 (s, 1H), 4.56 (s, 1H), 3.78 (s, 6H), 3.08 (s, 6H), 1.87 (s, 1H), 1.72-1.69 (m, 1H),1.62-1.60 (m, 2H): LCMS calculated for C20H26N8O = 394.22, found: 394.47. 1 H-NMR (500 MHz, CDCl 3 )? 10.20 (s, IH), 8.58 (s, 3H), 7.51 (s, IH), 7.27 , 6H), 3.08 (s, 6H), 1.87 (s, 1H), 1.72-1.69 (m, 1H), 1.62-1.60 (m, 2H): LCMS calculated for C 20 H 26 N 8 O = 394.22, found : 394.47.
단계 4: (R)-4-(3-아미노피페리딘-1-일)-N-(4-모폴리노페닐)-1H-피라졸로[3,4-d]피리미딘-6-아민의 제조Step 4: (R) -4- (3-Aminopiperidin-l-yl) -N- (4- morpholinophenyl) -lH- pyrazolo [3,4- d] pyrimidin- 6- amine Manufacturing
(R)-4-(3-아미노피페리딘-1-일)-N-(4-모포리노페닐)-1H-피라졸로[3,4-d]피리미딘-6-아민 (12 mg, 0.03 mmol), 아크릴산 (4.4 mg, 0.061 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (24 mg, 0.15 mmol), HOBt (21 mg, 0.15 mmol)과 디이소프로필에틸아민 (20 mg, 0.15 mmol)을 디클로로메탄에 가하였다. 반응물을 15시간 동안 교반 한 다음, 반응 용액을 에틸아세테이트 (15 mL)와 물 (5 mL)로 추출하고, 유기층을 황산마그네슘으로 건조, 여과, 농축하였다. 관크로마토그라피를 하여 생성물을 얻었다. (3 mg, 23%)Pyrazolo [3,4-d] pyrimidin-6-amine (12 mg, 0.25 mmol) was added to a solution of (R) (24 mg, 0.15 mmol), HOBt (21 mg, 0.15 mmol) and diisopropylethyl (4-hydroxyphenyl) carbamate Amine (20 mg, 0.15 mmol) was added to dichloromethane. After the reaction was stirred for 15 hours, the reaction solution was extracted with ethyl acetate (15 mL) and water (5 mL), and the organic layer was dried over magnesium sulfate, filtered, and concentrated. The product was obtained by column chromatography. (3 mg, 23%).
1H-NMR (500 MHz, CDCl3) δ 8.00 (s, 1H), 7.48 (d, J =6 Hz, 2H), 6.85 (d, J = 6 Hz, 2H), 6.75 (s,1H), 6.35 (d, J = 6 Hz,1 H), 6.08-5.89 (m, 2H),5.60 (d, J = 6 Hz, 1H), 3.89-3.75 (m, 4H), 3.70-3.68 (m, 1H), 3.06-3.00 (m, 4H); LCMS calculated for C23H28N8O2 = 448.23, found: 448.52. 1 H-NMR (500 MHz, CDCl 3) δ 8.00 (s, 1H), 7.48 (d, J = 6 Hz, 2H), 6.85 (d, J = 6 Hz, 2H), 6.75 (s, 1H), 6.35 (d, J = 6 Hz , 1 H), 6.08-5.89 (m, 2H), 5.60 (d, J = 6 Hz, 1H), 3.89-3.75 (m, 4H), 3.70-3.68 (m, 1H ), 3.06-3.00 (m, 4H); LCMS calculated for C 23 H 28 N 8 O 2 = 448.23, found: 448.52.
<실시예 4> (S)-N-(1-(6-((4-모포리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드의 제조Example 4 Synthesis of (S) -N- (1- (6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 3-yl) acrylamide
디클로로메탄 (2 mL)에 (S)-4-(3-아미노피레리딘-1-일)-N-(4-모폴리노페닐)-1H-피라졸로[3,4-d]피리미딘-6-아민 (12 mg, 0.030 mmol)을 녹이고, 아크릴산 (4.2 μL, 0.061 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (24 mg, 0.15 mmol), 히드록시벤조트리아졸 (21 mg, 0.15 mmol), 디이소프로필에틸아민 (28 μL, 0.15 mmol)을 가한 후, 상온에서 13시간 동안 교반 한다. 반응 종료 후, 디클로로메탄과 물을 가하고, 층분리하여 얻은 유기층을 황산마그네슘으로 건조하고 농축하였다. 결과된 거친 생성물을 5% 메탄올/디클로로메탄으로 컬럼크로마토그래피하여 목적화합물을 얻었다. (3 mg, 23%)To a dichloromethane (2 mL) was added (S) -4- (3-aminopyrrolidin- 1 -yl) -N- (4- morpholinophenyl) -1 H- pyrazolo [3,4- d] pyrimidine Amine (12 mg, 0.030 mmol), acrylic acid (4.2 μL, 0.061 mmol), 1-ethyl-3- (3- dimethylaminopyridine) carbodiimide (24 mg, 0.15 mmol), hydroxybenzo (21 mg, 0.15 mmol) and diisopropylethylamine (28 [mu] L, 0.15 mmol) were added thereto, followed by stirring at room temperature for 13 hours. After completion of the reaction, dichloromethane and water were added, and the organic layer obtained by layer separation was dried with magnesium sulfate and concentrated. The resulting coarse product was subjected to column chromatography with 5% methanol / dichloromethane to obtain the target compound. (3 mg, 23%).
1H-NMR (500 MHz, CDCl3) δ 8.00 (s, 1H), 7.48 (d, J = 6 Hz, 2H), 6.85 (d, J = 6 Hz, 2H), 6.75 (s, 1H), 6.35 (d, J = 6 Hz, 1H), 6.08-5.89 (m, 2H), 5.60 (d, J = 6 Hz, 1H), 3.89-3.75 (m, 4H), 3.70-3.68 (m, 1H), 3.06-3.00 (m, 4H): LCMS calculated for C23H28N8O2 = 448.23, found : 448.52. 1 H-NMR (500 MHz, CDCl 3) δ 8.00 (s, 1H), 7.48 (d, J = 6 Hz, 2H), 6.85 (d, J = 6 Hz, 2H), 6.75 (s, 1H), 6.35 (d, J = 6 Hz , 1H), 6.08-5.89 (m, 2H), 5.60 (d, J = 6 Hz, 1H), 3.89-3.75 (m, 4H), 3.70-3.68 (m, 1H) , 3.06-3.00 (m, 4H): LCMS calculated for C 23 H 28 N 8 O 2 = 448.23, found: 448.52.
<실시예 5> 1-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Example 5 Synthesis of 1- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 1-yl) prop-2-en-1-one
단계 1: t-부틸 4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트의 제조Step 1: tert-Butyl 4 - ((6-chloro-l- (tetrahydro-2H-pyran-2-yl) -lH-pyrazolo [3,4- d] pyrimidin- Preparation of peridine-1-carboxylate
N,N-디메틸포름아미드 (1 mL)에 4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (100 mg, 0.36 mmol)을 녹인 뒤, t-부틸 4-아미노피페리딘-1-카르복실레이트 (81 mg, 0.40 mmol), 탄산칼륨 (10 mg, 0.74 mmol)을 넣고, 상온에서 13 시간 동안 교반한다. 반응이 종결되면, 에틸아세테이트 (5 mL)와 물 (1 mL)로 반응 후처리 하고 유기층을 황산마그네슘으로 건조하고, 농축하여 얻은 생성물을 30% 에틸아세테이트/헥산으로 컬럼크로마토그래피하여 목적 화합물을 얻었다. (110 mg, 69%)To a solution of 4,6-dichloro-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4-d] pyrimidine (100 mg, 0.36 mmol), t-butyl 4-aminopiperidine-1-carboxylate (81 mg, 0.40 mmol), potassium carbonate (10 mg, 0.74 mmol), and the mixture was stirred at room temperature for 13 hours. After the reaction was completed, the reaction mixture was treated with ethyl acetate (5 mL) and water (1 mL), and the organic layer was dried over magnesium sulfate. The product was concentrated and the resulting product was subjected to column chromatography using 30% ethyl acetate / hexane to obtain the target compound . (110 mg, 69%).
1H NMR (300 MHz, CDCl3) δ 7.93 (s, 1H), 5.93~5.81 (d, 1H), 5.80 (brs, 1H), 4.08 (q, 3H), 3.75 (t, 1H), 2.91 (t, 2H), 2.47 (q, 1H), 2.05 (d, 4H), 1.86 (d, 1H), 1.68 (t, 2H), 1.58 (d, 1H), 1.47 (s, 9H), 1.28~1.23 (t, 1H). 1 H NMR (300 MHz, CDCl3 ) δ 7.93 (s, 1H), 5.93 ~ 5.81 (d, 1H), 5.80 (brs, 1H), 4.08 (q, 3H), 3.75 (t, 1H), 2.91 (t 2H), 2.47 (q, 1H), 2.05 (d, 4H), 1.86 (d, t, 1 H).
단계 2: t-부틸 4-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트의 제조Step 2: t -Butyl 4 - ((6 - ((4- morpholinophenyl) amino) -1- (tetrahydro-2H- Pyrimidin-4-yl) amino) piperidine-1-carboxylate
t-부탄올 (2 mL)에 t-부틸 4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트 (110 mg, 0.25 mmol)을 녹이고, 여기에 4-모폴리노아닐린 (45 mg, 0.25 mmol)과 Pd2(dba)3 (1.5 mg, 0.0025 mmol), X-Phos (3.2 mg, 0.0076 mmol), 탄산칼륨 (71 mg, 0.51 mmol)을 가하고, 질소를 충전시킨 후, 90 oC에서 밤새 교반한다. 반응이 종결되면, 용액을 식힌 후, 용매를 제거하고, 농축액을 에틸아세테이트와 물로로 반응 후처리를 하고 에틸아세테이트층을 황산마그네슘으로 건조하고 농축하여, 5% 메탄올/디클로로메탄으로 관컬럼크로마토그래피한다. (95 mg, 66%) To a solution of t-butyl 4 - ((6-chloro-l- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidin- (45 mg, 0.25 mmol) and Pd 2 (dba) 3 (1.5 mg, 0.0025 mmol) were dissolved in a mixture of tetrahydrofuran mmol), X-Phos (3.2 mg, 0.0076 mmol), potassium carbonate (71 mg, 0.51 mmol) were added, and the mixture was stirred at 90 ° C overnight. After the reaction was completed, the solution was cooled, the solvent was removed, and the concentrate was reacted with ethyl acetate and water, followed by treatment. The ethyl acetate layer was dried over magnesium sulfate, concentrated, and purified by column chromatography with 5% methanol / dichloromethane do. (95 mg, 66%).
1H NMR (300 MHz, CDCl3) δ 7.74 (s, 1H), 7.73~7.52 (d,2H),6.87 (d, 2H), 5.76 (d, 1H), 4.08 (d, 4H), 3.86 (s, 4H), 3.09 (s, 4H), 2.87 (t, 2H), 2.48 (q, 1H), 2.02 (q, 4H), 1.89 (d, 2H), 1.78 (s, 2H), 1.47 (s, 9H), 1.27 (t, 1H). 1 H NMR (300 MHz, CDCl 3) δ 7.74 (s, 1H), 7.73 ~ 7.52 (d, 2H), 6.87 (d, 2H), 5.76 (d, 1H), 4.08 (d, 4H), 3.86 ( 2H), 1.47 (s, 2H), 2.48 (s, 2H), 2.47 , ≪ / RTI > 9H), 1.27 (t, 1H).
단계 3: N6-(4-모폴리노페닐)-N4-(피페리딘-4-일)-1H-피라졸로[3,4-d]피리미딘-4, 6-디아민의 제조Step 3: Preparation of N 6 - (4-morpholinophenyl) -N 4 - (piperidin-4-yl) -1H-pyrazolo [3,4-d] pyrimidine-4,6-diamine
t-부틸 4-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트 (95 mg 0.16 mmol)에 염산 (4 M, 1,4-디옥산, 6 mL)을 가하고, 메탄올 (1 mL)을 추가로 가하고, 15분간 상온에서 교반한다. 반응이 종결되면, 용매를 제거하고, 디에틸에테르로 재결정하여 목적화합물을 얻었다. (40 mg, 82%)(4-morpholinophenyl) amino] -1- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidine- (4 M, 1, 4-dioxane, 6 mL) was added to methanol (1 mL) Stir at room temperature for 15 minutes. When the reaction was completed, the solvent was removed, and recrystallization from diethyl ether gave the desired compound. (40 mg, 82%).
1H NMR (300 MHz, MeOH-d4) δ 8.49 (s, 1H), 7.83~7.75 (q, 4H), 4.14 (s, 4H), 3.71 (s, 4H), 4.39 (t, 1H), 3.49~3.47 (m, 3H), 3.19 (t, 1H), 3.25~3.15 (t, 1H), 1.92~1.91 (q, 2H). 1 H NMR (300 MHz, MeOH -d 4) δ 8.49 (s, 1H), 7.83 ~ 7.75 (q, 4H), 4.14 (s, 4H), 3.71 (s, 4H), 4.39 (t, 1H), (M, 3H), 3.19 (t, IH), 3.25-3.15 (t, IH), 1.92-1.91 (q, 2H).
단계 4: 1-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Step 4: Preparation of 1- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) prop-2-en-1-one
N6-(4-모폴리노페닐)-N4-(피페리딘-4-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민 (66 mg, 0.16 mmol)을 디클로로메탄 (1 mL)에 녹인 후, 아크릴산 (14 mg, 0.2 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (130 mg, 0.83 mmol), 히드록시벤조트리아졸 (113 mg, 0.83 mmol), 디이소프로필에틸아민 (110 mg, 0.83 mmol)을 가한 후, 상온에서 13 시간 동안 교반한다. 반응이 종결되면, 디클로로메탄과 물로 추출하고, 유기층을 황산마그네슘으로 건조하고 농축하여 5% 메탄올/디클로로메탄으로 관컬럼크로마토그래피한다. (2.7 mg, 5%)N 6 - (4- morpholinophenyl) -N4- (piperidin-4-yl) -1H- pyrazolo [3,4-d] pyrimidine-4,6-diamine (66 mg, 0.16 mmol) Was dissolved in dichloromethane (1 mL), and then acrylic acid (14 mg, 0.2 mmol), 1-ethyl-3- (3- dimethylaminopyridine) carbodiimide (130 mg, 0.83 mmol), hydroxybenzotriazole 113 mg, 0.83 mmol) and diisopropylethylamine (110 mg, 0.83 mmol) were added thereto, followed by stirring at room temperature for 13 hours. Upon completion of the reaction, extraction is carried out with dichloromethane and water, the organic layer is dried over magnesium sulfate, concentrated and subjected to column chromatography on a column of 5% methanol / dichloromethane. (2.7 mg, 5%).
1H NMR (300 MHz, MeOH-d4) δ 8.27 (s, 1H), 7.38~7.35 (d, 2H), 7.08~7.05 (d, 2H), 6.41~6.35 (d, 1H), 6.19~6.10 (q, 1H), 5.90~5.86 (d, 1H), 4.41 (t, 2H), 3.82 (t, 3H), 3.16 (t, 3H), 2.81 (t, 2H), 2.17~1.98 (m, 2H), 1.52~1.48 (m ,2H), 1.35~1.26 (m, 2H). 1 H NMR (300 MHz, MeOH -d 4) δ 8.27 (s, 1H), 7.38 ~ 7.35 (d, 2H), 7.08 ~ 7.05 (d, 2H), 6.41 ~ 6.35 (d, 1H), 6.19 ~ 6.10 (t, 2H), 2.17-1.98 (m, 2H), 2.39 (t, 2H) ), 1.52-1.48 (m, 2H), 1.35-1.26 (m, 2H).
<실시예 6> 1-(4-((6-((4-(피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘 -1-일)프로페-2-엔-1-온의 제조Example 6 Synthesis of 1- (4 - ((6 - ((4- (piperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- ) Piperidin-1-yl) prop-2-en-1-one
단계 1: 1-(4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온Step 1: Preparation of l- (4 - ((6-chloro- l- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidin- 1-yl) prop-2-en-1-one
실시예 5의 단계 1 방법대로 실시하여 목적화합물을 얻었다. (74%): LCMS calculated for C18H23ClN6O2 = 390.87, found:391.07.The procedure of Step 1 of Example 5 was repeated to obtain the target compound. (74%): LCMS calculated for C 18 H 23 ClN 6 O 2 = 390.87, found: 391.07.
단계 2: t-부틸 4-(4-((4-((1-아크릴로일피페리딘-4-일)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)피페라딘-1-카르복실레이트Step 2: tert -Butyl 4- (4 - ((4 - ((1-acryloylpiperidin-4-yl) amino) -1- (tetrahydro-2H- 4-yl] pyrimidin-6-yl) amino) phenyl) piperazin-1-carboxylate
실시예 5의 단계 2에서 실시한 방법대로 실시하여 목적화합물을 얻었다. (13%)The objective compound was obtained in the same manner as in the step 2 of Example 5. (13%)
1H-NMR (300 MHz, CDCl3)δ7.78(s, 1H), 7.55(d, J = 8.4 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 6.60 (m, 1H), 6.28 (d, J = 18.0 Hz, 1H), 5.78 (d, J = 12.0 Hz, 1H), 5.70 (d, J = 12.0 Hz, 1H), 5.42 (s, 1H), 4.68 (s, 1H), 4.32 (s, 1H), 4.07 (s, 3H), 3.75 (s, 2H), 3.59 (t, J = 3.0 Hz, 4H), 3.23 (s, 2H), 3.07 (t, J = 3.0 Hz, 4H), 2.88 (s, 2H), 2.56 (s, 2H), 2.15 (s, 4H), 2.04 (s, 1H), 1.48 (s, 9H). 1 H-NMR (300 MHz, CDCl 3 )? 7.78 (s, 1H), 7.55 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 6.60 (m, 1H), 6.28 (d, J = 18.0 Hz, 1H), 5.78 (d, J = 12.0 Hz, 1H), 5.70 (d, J = 12.0 Hz , 1H), 5.42 (s, 1H), 4.68 (s, 1H), 4.32 (s, 1H), 4.07 (s, 3H), 3.75 (s, 2H), 3.59 (t 2H, J = 3.0 Hz, 4H), 3.23 (s, 2H), 3.07 (t, J = 3.0 Hz, 4H), 2.88 (s, 1 H), 1.48 (s, 9 H).
단계 3: 1-(4-((6-((4-(피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온Step 3: Preparation of 1- (4 - ((6 - ((4- (piperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 1-yl) prop-2-en-1-one
실시예 5에서 실시된 단계 3의 방법대로 합성하였다. (100%)The title compound was synthesized by the method of Step 3 in Example 5. (100%)
LCMS calculated for C23H29N9O = 447.54, found:448.05LCMS calculated for C 23 H 29 N 9 O = 447.54, found: 448.05
<실시예 7> 4(R)-N-(1-(6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드의 제조Example 7 Synthesis of 4 (R) -N- (1- (6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Pyridin-3-yl) acrylamide
단계 1: t-부틸 (3S)-3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트의 제조Step 1: tert-Butyl (3S) -3 - ((6-chloro-1- (tetrahydro- ) Amino) piperidine-1-carboxylate
실시예 3-1의 방법대로 실시하여 목적화합물을 얻었다. (80%)The procedure of Example 3-1 was repeated to obtain the target compound. (80%)
1H-NMR (500 MHz, CDCl3)δ8.00-7.95(m, 1H), 6.60(s, 1H), 5.90(d, J = 9 Hz, 1H), 4.15-4.08(m, 1H), 3.80-3.51(m, 1H), 3.00(s, 4H), 2.89(s, 3H), 2.55-2.43(m, 1H), 1.80-1.75(m, 1H), 1.73-1.48(m, 6H), 1.45(s, 9H) 1 H-NMR (500 MHz, CDCl 3 )? 8.00-7.95 (m, IH), 6.60 (s, IH), 5.90 (d, J = 9 Hz, 1H), 1.80-1.75 (m, 1H), 1.73-1.48 (m, 6H), 3.80-3.51 (m, 1.45 (s, 9 H)
단계 2: t-부틸(3S)-3-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트의 제조Step 2: tert-Butyl (3S) -3 - ((6 - ((4-morpholinophenyl) amino) -1- (tetrahydro- 4-d] pyrimidin-4-yl) amino) piperidine-1-carboxylate
실시예 3-2의 방법대로 실시하여 목적화합물을 얻었다 (74%).The objective compound was obtained (74%) by following the procedure of Example 3-2.
1H-NMR (500 MHz, CDCl3) δ 7.75 (s, 1H), 7.54 (d, J = 9 Hz, 2H) ,6.89 (d, J = 9 Hz, 2H), 5.77 (d, J = 9 Hz, 1H), 3.87-3.85 (m, 4H), 3.78-3.75 (m, 2H), 3.74-3.48 (m, 2H), 3.45-3.27 (m, 2H), 3.20-3.10 (m, 4H), 2.60-2.45 (m, 9H). 1 H-NMR (500 MHz, CDCl 3) δ 7.75 (s, 1H), 7.54 (d, J = 9 Hz, 2H), 6.89 (d, J = 9 Hz, 2H), 5.77 (d, J = 9 2H), 3.45-3.27 (m, 2H), 3.20-3.10 (m, 4H), 3.74-3. 2.60-2.45 (m, 9H).
단계 3: (S)-N6-(4-모폴리노페닐)-N4-(피페리딘-3-일)-1H-피라졸로[3,4-d]피리미딘-4, 6-디아민의 제조Step 3: (S) -N 6 - (4- morpholinophenyl) -N 4 - (piperidin-3-yl) -1H- pyrazolo [3,4-d] pyrimidine-4, 6- Preparation of diamine
실시예 3-3의 방법대로 실시하여 목적화합물을 얻었다. (82%)The procedure of Example 3-3 was followed to obtain the desired compound. (82%)
1H-NMR (500 MHz, CDCl3) δ 8.94 (s, 1H), 8.57 (s, 1H), 7.89 (d, J = 6 Hz, 2H), 7.80 (d, J = 6 Hz, 2H), 7.61 (s, 1H), 4.63 (s, 1H), 4.17 (s, 3H), 3.81-3.70 (m, 3H), 3.52-3.48 (m, 1H), 3.40-3.32 (m, 6H), 2.21-2.23 (m, 1H), 2.02-1.99 (m, 1H), 1.85-1.83 (m, 1H). 1 H-NMR (500 MHz, CDCl 3) δ 8.94 (s, 1H), 8.57 (s, 1H), 7.89 (d, J = 6 Hz, 2H), 7.80 (d, J = 6 Hz, 2H), (M, 6H), 2.21 (s, 3H), 3.61-3.52 (m, 3H) 2.23 (m, 1 H), 2.02-1.99 (m, 1 H), 1.85-1.83 (m, 1 H).
LCMS calculated for C19H22N10 = 394.22, found:394.47LCMS calculated for C 19 H 22 N 10 = 394.22, found: 394.47
단계 4: (R)-N-(1-(6-((4- 모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드의 제조Step 4: (R) -N- (1- (6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- -Yl) acrylamide < / RTI >
실시예 3-4의 방법대로 실시하여 목적화합물을 얻었다. (30%)The procedure of Example 3-4 was followed to obtain the desired compound. (30%)
1H-NMR (500 MHz, CDCl3)δ7.89(s, 1H), 7.60-7.51(m, 2H), 6.78(d, J = 6.1 Hz, 2H), 6.48-6.45 (m, 1H), 6.23 (d, J = 9.0 Hz, 1H), 6.02 (d, J = 15.1 Hz, 1H), 5.76 (d, J = 6.1 Hz, 1H), 5, 45-5.47 (m, 1H), 4.20-4.18 (m, 1H), 4.02 (d, J = 12.1 Hz, 2H), 3.79 (d, J = 9.1 Hz, 4H), 3.02 (d, J = 9.1 Hz, 4H), 2.15-2.10 (m, 1H), 2.00-1.9 5(m, 2H), 1.90-1.85 (m, 1H), 1.35 (s, 2H): LCMS calculated for C23H28N8O2 = 448.23, found : 448.52. 1 H-NMR (500 MHz, CDCl 3) δ7.89 (s, 1H), 7.60-7.51 (m, 2H), 6.78 (d, J = 6.1 Hz, 2H), 6.48-6.45 (m, 1H), 6.23 (d, J = 9.0 Hz, 1H), 6.02 (d, J = 15.1 Hz, 1H), 5.76 (d, J = 6.1 Hz, 1H (M, 1H), 4.02 (d, J = 12.1 Hz, 2H), 3.79 (d, J = 9.1 Hz, 4H), 3.02 J = 9.1 Hz, 4H), 2.15-2.10 (m, 1H), 2.00-1.9 5 (m, 2H), 1.90-1.85 (m, 1H), 1.35 (s, 2H): LCMS calculated for C 23 H 28 N 8 O 2 = 448.23, found: 448.52.
<실시예 8> (S)-1-(3-((6-((4-(4-아세틸피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Example 8 Synthesis of (S) -1- (3 - ((6 - ((4- (4-acetylpiperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- Yl) amino) piperidin-1-yl) prop-2-en-1-one
실시예 3 단계 3의 방법대로 실시하여 목적화합물을 얻었다. (35%, 15 mg) The procedure of Example 3, Step 3 was followed to obtain the target compound. (35%, 15 mg)
LCMS calculated for C25H31N9O2=489.57, found:489.93.LCMS calculated for C 25 H 31 N 9 O 2 = 489.57, found: 489.93.
<실시예 9> 1-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로판-1-온의 제조Example 9 Synthesis of 1- (4 - ((6 - ((4-morpholinophenyl) amino) -1 H -pyrazolo [3,4-d] pyrimidin- -1-yl) propan-1-one
N6-(4-모폴리노페닐)-N4-(피페리딘-4-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민 (50 mg, 0.12 mmol)을 테트라히드로퓨란 (3 mL)에 녹이고, 디이소프로필에틸아민 (82 mg, 0.63 mmol)을 가한 후 0 oC에서 10분간 교반한다. 그 후, 프로피오닐클로라이드 (14 mg, 0.15 mmol)을 가하고, 10분 더 교반한다. N,N-디메닐아미노피리딘 (18 mg, 0.15 mmol)을 가한 다음, 10분 동안 교반 한 후, 에틸아세테이트와 물로 반응 후 처리하고, 유기층을 황산마그네슘으로 건조하여 농축하였다. 결과물을 관 컬럼크로마토그래피하여 목적화합물을 얻었다. (3.7mg, 6.2%)N 6 - (4- morpholinophenyl) -N 4 - (piperidin-4-yl) -1H- pyrazolo [3,4-d] pyrimidine-4,6-diamine (50 mg, 0.12 mmol ) Was dissolved in tetrahydrofuran (3 mL), diisopropylethylamine (82 mg, 0.63 mmol) was added thereto, and the mixture was stirred at 0 ° C for 10 minutes. Then propionyl chloride (14 mg, 0.15 mmol) was added and stirred for an additional 10 minutes. N, N-Dimethylaminopyridine (18 mg, 0.15 mmol) was added to the solution, and the mixture was stirred for 10 minutes. The mixture was treated with ethyl acetate and water, and the organic layer was dried over magnesium sulfate and concentrated. The resulting product was subjected to column chromatography to obtain the target compound. (3.7 mg, 6.2%).
1H NMR (300 MHz, Acetone-d6) δ 7.80 (s, 1H), 7.58-7.72 (d, 2H), 6.98-6.91 (t, 2H), 4.56-4.50 (d, 1H), 4.38-4.34 (q, 1H), 4.03-3.97 (d, 1H), 3.79-3.75 (t, 4H), 3.08-3.05 (t, 4H), 3.18-3.13 (t, 1H), 2.70-2.72 (d, 2H), 2.41-2.33 (q, 2H), 1.50-1.40 (m, 2H), 1.08-1.02 (t, 3H). 1 H NMR (300 MHz, Acetone -d 6) δ 7.80 (s, 1H), 7.58-7.72 (d, 2H), 6.98-6.91 (t, 2H), 4.56-4.50 (d, 1H), 4.38-4.34 (t, 1H), 2.70-2.72 (d, 2H), 3.79-3.75 (d, 1H), 3.79-3.75 (t, 4H), 3.08-3.05 , 2.41-2.33 (q, 2H), 1.50-1.40 (m, 2H), 1.08-1.02 (t, 3H).
<실시예 10> (S)-1-(3-((6-((4-(피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Example 10 Synthesis of (S) -1- (3 - ((6 - ((4- (piperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- -Yl) amino) piperidin-1-yl) prop-2-en-1-one
상기 실시예 9와 동일한 방법을 수행하여 목적 화합물을 얻었다(7 mg).The target compound was obtained by carrying out the same procedure as in Example 9 (7 mg).
LCMS calculated for C23H29N9O = 447.54, found:448.05LCMS calculated for C 23 H 29 N 9 O = 447.54, found: 448.05
<실시예 11> 1-(4-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Example 11 Synthesis of 1- (4 - ((6- (4-phenoxyphenyl) -lH-pyrazolo [3,4-d] pyrimidin- 4- yl) amino) piperidin- Prop-2-en-1-one
단계 1: t-부틸 (1-아크릴로일피페리딘-4-일)카바메이트의 제조Step 1: Preparation of t-butyl (1-acryloylpiperidin-4-yl) carbamate
디클로로메탄 (20 mL)에 t-부틸 피페리딘-4-일 카바메이트 (1 g, 5 mmol)을 녹이고, 아크릴산 (1.8 g, 25 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (EDCI, 4.8 g, 25 mmol), 히드록시벤조트리아졸 (HOBt, 1.35 g, 25 mmol), 디이소프로필에틸아민 (3.1 g, 25 mmol)을 가한 후, 상온에서 14시간 동안 교반 한다. 반응 종료 후, 디클로로메탄과 물을 가하고, 생성물을 유기층으로 추출한다. 유기층을 황산마그네슘으로 건조하고, 농축하였다. 농축물을 30% 에틸아세테이트/헥산으로 컬럼 크로마토그래피하여 목적화합물을 얻었다. (750 mg, 60%)Butylpiperidin-4-ylcarbamate (1 g, 5 mmol) was dissolved in dichloromethane (20 mL), and acrylic acid (1.8 g, 25 mmol), 1-ethyl- ), Carbodiimide (EDCI, 4.8 g, 25 mmol), hydroxybenzotriazole (HOBt, 1.35 g, 25 mmol) and diisopropylethylamine (3.1 g, 25 mmol) Lt; / RTI > After completion of the reaction, dichloromethane and water are added, and the product is extracted into an organic layer. The organic layer was dried over magnesium sulfate and concentrated. The concentrate was subjected to column chromatography using 30% ethyl acetate / hexane to obtain the target compound. (750 mg, 60%).
1H-NMR (300 MHz, CDCl3) δ 6.57 (dd, J = 10.2, 6.6 Hz, 1H), 6.26 (d, J = 9.9 Hz, 1H), 5.68 (d, J = 6.6 Hz, 1H), 4.54 (s, 2H), 3.94 (d, J = 7.8 Hz, 1H), 3.69 (s, 1H), 3.16 (t, J = 7.5 Hz, 1H), 2.83 (t, J = 7.5 Hz, 1H), 2.01 (m, 2H), 1.45 (s, 9H), 1.32 (s, 2H). 1 H-NMR (300 MHz, CDCl 3) δ 6.57 (dd, J = 10.2, 6.6 Hz, 1H), 6.26 (d, J = 9.9 Hz, 1H), 5.68 (d, J = 6.6 Hz, 1H), 4.54 (s, 2H), 3.94 (d, J = 7.8 Hz, 1H), 3.69 (s, 1H), 3.16 (t, J = 7.5 Hz, 1H), 2.83 (t, J = 7.5 Hz, 1H), 2.01 (m, 2H), 1.45 (s, 9H), 1.32 (s, 2H).
단계 2: 1-(4-아미노피페리딘-1-일)프로페-2-엔-1-온의 제조Step 2: Preparation of 1- (4-aminopiperidin-1-yl) prop-2-en-
t-부틸 (1-아크릴로일피페리딘-4-일)카바메이트 (750 mg, 2.95 mmol)을 메탄올 (20 mL)에 가하고, 여기에 염산 (4 N, 1,4-디옥산, 20 mL)을 가하였다. 상온에서 15분간 교반하고, 반응이 종결되면 용매를 감압 증류하여 제거하고, 에테르로 재결정하여 목적화합물을 얻었다. (40 mg, 82%)(750 mg, 2.95 mmol) was added to methanol (20 mL), and thereto was added hydrochloric acid (4 N, 1, 4-dioxane, 20 mL ). The mixture was stirred at room temperature for 15 minutes. When the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was recrystallized with ether to obtain the target compound. (40 mg, 82%).
1H NMR (300 MHz, MeOH-d4) δ 6.85-6.75 (q, 1H), 6.23-6.17 (d, 1H), 5.78-5.74 (d, 1H), 4.62 (d, 1H), 4.21-4.20 (d, 1H), 4.08-4.06 (d, 1H), 2.85-2.75 (m, 1H), 2.15-2.04 (q, 2H), 1.61-1.45 (q, 2H). 1 H NMR (300 MHz, MeOH-d 4 )? 6.85-6.75 (q, IH), 6.23-6.17 (d, IH), 5.78-5.74 (d, 1H), 4.08-4.06 (d, 1H), 2.85-2.75 (m, 1H), 2.15-2.04 (q, 2H), 1.61-1.45 (q, 2H).
단계 3: 1-(4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온Step 3: l- (4 - ((6-Chloro-l- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidin- 1-yl) prop-2-en-1-one
4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (300 mg, 1.1 mmol)을 디메틸포름아미드 (1 mL)에 녹인 후, 1-(4-아미노피페리딘-1-일)프로페-2-엔-1-온 (186 mg, 1.2 mmol), 탄산칼륨 (760 mg, 5.5 mmol)을 가하고, 상온에서 밤새 교반한다. 반응이 종결되면, 에틸아세테이트와 물을 가하여, 생성물을 유기층으로 추출하고, 유기층을 황산마그네슘으로 건조하고 농축하였다. 농축물을 컬럼크로마토그래피하여 목적화합물을 얻었다. (110 mg, 69%)Pyrazolo [3,4-d] pyrimidine (300 mg, 1.1 mmol) was dissolved in dimethylformamide (1 mL) to a solution of 4,6-dichloro-1- (tetrahydro- After dissolving, 1- (4-aminopiperidin-1-yl) prop-2-en-1-one (186 mg, 1.2 mmol) (760 mg, 5.5 mmol), and the mixture was stirred overnight at room temperature. When the reaction was completed, ethyl acetate and water were added, the product was extracted into an organic layer, and the organic layer was dried with magnesium sulfate and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (110 mg, 69%).
1H NMR (300 MHz, CDCl3) δ 8.07 (s, 1H), 6.85-6.80 (q, 1H), 6.76-6.18 (d, 1H), 5.82-5.73 (q, 2H), 4.55 (d, 1H), 4.40 (t, 1H), 4.13 (d, 1H), 4.00 (d, 1H), 3.74 (t, 1H), 2.87-2.85 (m, 3H), 2.42 (q, 1H), 2.12-2.08 (m, 4H), 2.78 (m, 3H). 1 H NMR (300 MHz, CDCl 3) δ 8.07 (s, 1H), 6.85-6.80 (q, 1H), 6.76-6.18 (d, 1H), 5.82-5.73 (q, 2H), 4.55 (d, 1H ), 4.40 (t, IH), 4.13 (d, IH), 4.00 (d, IH), 3.74 (t, IH), 2.87-2.85 m, 4H), 2.78 (m, 3H).
단계 4: 1-(4-((6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Step 4: l- (4 - ((6- (4-phenoxyphenyl) -l- (tetrahydro-2H-pyran- 2- yl) -lH- pyrazole [3,4- d] pyrimidin- -Yl) amino) piperidin-1-yl) prop-2-en-1-one
1,4-디옥산 (1.5 mL)와 물 (0.5 mL)에 1-(4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온 (18 mg, 0.046 mmol)을 1,4-디옥산 (1.5 mL)와 물 (0.5 mL)에 녹이고, 4,4,5,5-테트라메틸-2-(4-페녹시페닐)-1,3,2-디옥사보롤레인 (14 mg, 0.051 mmol), pd(dppf)2Cl2 (2 mg, 0.0023 mmol), 탄산칼륨 (13 mg, 0.092 mmol)을 가한 후, 질소를 충분히 주입한 뒤, 90 ℃에서 13시간 동안 반응시켰다. 반응이 종결되면, 용액을 식힌 후, 에틸아세테이트와 물을 가하여 생성물을 유기층으로 추출하였다. 유기층을 황산마그네슘으로 건조하고, 농축한 다음, 컬럼크로마토그래피하여 목적화합물을 얻었다. (7 mg, 27%)To a solution of l- (4 - ((6-chloro-l- (tetrahydro-2H-pyran-2-yl) En-1-one (18 mg, 0.046 mmol) was dissolved in 1,4-dioxane (1.5 mL) and tetrahydrofuran Was dissolved in water (0.5 mL), and 4,4,5,5-tetramethyl-2- (4-phenoxyphenyl) -1,3,2-dioxaborolane (14 mg, 0.051 mmol), pd (dppf ) 2 Cl 2 (2 mg, 0.0023 mmol), potassium carbonate (13 mg, 0.092 mmol) was added thereto. After sufficiently injecting nitrogen, the reaction was allowed to proceed at 90 占 폚 for 13 hours. When the reaction was completed, the solution was cooled, and ethyl acetate and water were added to extract the product into an organic layer. The organic layer was dried over magnesium sulfate, concentrated and then subjected to column chromatography to obtain the target compound. (7 mg, 27%).
1H NMR (300 MHz, CDCl3) δ 8.47 (d, 2H), 7.99 (s, 1H), 7.40 (s, 1H), 7.40-7.30 (t, 2H), 7.17-7.01 (m, 4H), 6.65-6.55 (t, 1H), 6.32-6.23 (d, 1H), 6.09-6.03 (d, 1H), 5.93-5.86 (m, 1H), 5.72-5.66 (d, 1H), 4.64-4.52 (d, 2H), 4.17-4.01 (m, 2H), 3.77 (t, 1H), 3.67 (s, 1H), 3.26 (t, 1H), 2.89 (t, 1H), 2.55 (t, 1H), 2.35-2.06 (m, 4H), 1.98-1.92 (d, 1H), 1.84-1.76 (m, 3H). 1 H NMR (300 MHz, CDCl 3) δ 8.47 (d, 2H), 7.99 (s, 1H), 7.40 (s, 1H), 7.40-7.30 (t, 2H), 7.17-7.01 (m, 4H), (D, 1H), 4.64-4.52 (d, 1H), 6.65-6.55 (m, 1H), 6.32-6.23 1H), 2.35 (t, 1H), 2.55 (t, 1H), 2.35 (t, 2.06 (m, 4H), 1.98-1.92 (d, 1H), 1.84-1.76 (m, 3H).
단계 5: 1-(4-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Step 5: Preparation of l- (4 - ((6- (4-phenoxyphenyl) -lH-pyrazolo [3,4- d] pyrimidin-4- yl) amino) piperidin- 2-en-1-one
1-(4-((6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온 (7 mg, 0.013 mmol)에 염산 (4 M, 1,4-디옥산, 1.5 mL)을 가하고, 메탄올 (0.3 mL)를 가하였다. 반응 용액을 15분간 상온에서 교반 한다. 반응이 종결되면 용매를 감압증류하여 제거하고, 에테르로 재결정하여 목적화합물을 얻었다. (5.1 mg, 82%)Pyrazole [3,4-d] pyrimidin-4-yl) -1H-pyrazole- (4 M, 1, 4-dioxane, 1.5 mL) was added to a solution of 4-amino-2- ) Was added. The reaction solution is stirred at room temperature for 15 minutes. When the reaction was completed, the solvent was distilled off under reduced pressure, and the residue was recrystallized with ether to obtain the target compound. (5.1 mg, 82%).
1H NMR (300 MHz, MeOH-d4) δ 8.57 (s, 1H), 8.27 (s, 2H), 7.41 (s, 2H), 7.37 (s, 1H), 7.14 (s, 4H), 6.78 (t, 1H), 6.18 (d, 1H), 5.74 (d, 1H), 4.59 (d, 1H), 4.18 (d, 1H), 2.96 (t, 1H), 2.16 (m, 2H), 1.61 (t, 2H), 1.49 (d, 1H), 1.14 (t, 1H). 1 H NMR (300 MHz, MeOH -d 4) δ 8.57 (s, 1H), 8.27 (s, 2H), 7.41 (s, 2H), 7.37 (s, 1H), 7.14 (s, 4H), 6.78 ( (d, 1H), 6.18 (d, 1H), 5.74 (d, 1H), 4.59 , ≪ / RTI > 2H), 1.49 (d, 1H), 1.14 (t, 1H).
<실시예 12> 1-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Example 12 Synthesis of 1- (3 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 1-yl) prop-2-en-1-one
단계 1: t-부틸 3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트의 제조Step 1: tert-Butyl 3 - ((6-chloro-l- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidin- Preparation of peridine-1-carboxylate
4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (100 mg, 0.36 mmol)을 디메틸포름아미드 (1 mL)에 녹인 뒤, t-부틸 3-아미노피페리딘-1-카르복실레이트 (81 mg, 0.40 mmol), 탄산칼륨 (138 mg, 0.81 mmol)을 가하고 상온에서 13시간 동안 교반 한다. 반응이 종결되면, 에틸아세테이트와 물을 가하여 생성물을 유기층으로 추출하고, 유기층을 황산마그네슘으로 건조, 농축하였다. 농축물을 컬럼크로마토그래피하여 목적화합물을 얻었다. (151 mg, 78%)Pyrazolo [3,4-d] pyrimidine (100 mg, 0.36 mmol) was dissolved in dimethylformamide (1 mL) to a solution of 4,6-dichloro-1- (tetrahydro- After dissolving, t-butyl 3-aminopiperidine-1-carboxylate (81 mg, 0.40 mmol) and potassium carbonate (138 mg, 0.81 mmol), and the mixture is stirred at room temperature for 13 hours. When the reaction was completed, ethyl acetate and water were added to extract the product into an organic layer, and the organic layer was dried over magnesium sulfate and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (151 mg, 78%).
1H NMR (500 MHz, CDCl3) δ 8.02-7.98 (m, 1H), 5.85 (d, J = 12.0 Hz, 1H), 4.40 (s, 1H), 3.85-3.80 (m, 1H), 3.90 (s, 1H), 3.85 (s, 1H), 2.55-2.48 (m, 1H), 1.90-1.85 (m, 2H), 1.83-1.70 (m, 2H), 1.65-1.53 (m, 2H), 1.45 (s, 9H). 1 H NMR (500 MHz, CDCl 3) δ 8.02-7.98 (m, 1H), 5.85 (d, J = 12.0 Hz, 1H), 4.40 (s, 1H), 3.85-3.80 (m, 1H), 3.90 ( 2H), 1.65-1.53 (m, 2H), 1.45 (m, 2H), 3.85 s, 9H).
단계 2: t-부틸 3-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-알)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트의 제조Step 2: t-Butyl 3 - ((6 - ((4- morpholinophenyl) amino) -1- (tetrahydro-2H- Pyrimidin-4-yl) amino) piperidine-1-carboxylate
t-부틸-3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트 (50 mg, 0.11 mmol)을 t-부탄올 (2mL)에 녹이고, 4-모폴리노아닐린 (21 mg, 0.11 mmol)과 Pd2(dba)3 (7 mg, 0.011 mmol), XPhos (15 mg, 0.034 mmol), 탄산칼륨 (33 mg, 0.24 mmol)을 가하고, 질소를 충전시킨 후, 90 oC에서 13 시간 동안 교반 한다. 반응이 종결되면, 감압증류하여 용매를 제거하고, 농축액을 에틸아세테이트와 물을 가하여 생성물을 유기층으로 추출하였다. 유기층을 황산마그네슘으로 건조하고, 농축하여 얻은 농축물을 컬럼크로마토그래피하여 목적화합물을 얻었다. (42 mg, 64%)pyrazolo [3,4-d] pyrimidin-4-yl) amino) piperidine < EMI ID = (50 mg, 0.11 mmol) was dissolved in t- butanol (2 mL), and 4-morpholinoaniline (21 mg, 0.11 mmol) and Pd 2 (dba) 3 (7 mg, 0.011 mmol), XPhos (15 mg, 0.034 mmol) and potassium carbonate (33 mg, 0.24 mmol) were added and the mixture was stirred at 90 ° C for 13 hours. When the reaction was completed, the solvent was removed by distillation under reduced pressure, and ethyl acetate and water were added to the concentrate, and the product was extracted into an organic layer. The organic layer was dried over magnesium sulfate and concentrated. The resulting concentrate was subjected to column chromatography to obtain the target compound. (42 mg, 64%).
1H-NMR (500 MHz, CDCl3) δ 8.32 (s, 1H), 7.34 ( d, J = 15.0 Hz, 2H), 7.04 (d, J = 15.0 Hz, 2H), 5.50 (d, J = 9.0 Hz, 1H), 4.10 (s, 2H), 3.90-3.85 (m, 6H), 3.25-3.17 (m, 6H), 2.65 (s, 2H), 2.10-2.08 (m, 2H), 1.93-1.85 (m, 2H), 1.70-1.65 (m, 2H), 1.30 (s, 9H). 1 H-NMR (500 MHz, CDCl 3) δ 8.32 (s, 1H), 7.34 (d, J = 15.0 Hz, 2H), 7.04 (d, J = 15.0 Hz, 2H), 5.50 (d, J = 9.0 2H), 2.10-2.08 (m, 2H), 1.93-1.85 (m, 6H) m, 2H), 1.70-1.65 (m, 2H), 1.30 (s, 9H).
단계 3: N6-(4-모폴리노페닐)-N4-(피페리딘-3-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민의 제조Step 3: Preparation of N 6 - (4-morpholinophenyl) -N 4 - (piperidin-3-yl) -1H-pyrazolo [3,4-d] pyrimidine-4,6-diamine
t-부틸-3-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-카르복실레이트에 염산 (4 M, 1,4-디옥산, 4mL)을 가하고, 메탄올 (1 mL)에 가하고, 15분간 상온에서 교반 한다. 반응이 종결되면 용매를 제거하고, 에테르로 재결정하여 목적화합물을 얻었다. (32 mg, 78%)(tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4-d] pyrimidine (4 M, 1, 4-dioxane, 4 mL) was added to methanol (1 mL), and the mixture was stirred at room temperature for 15 minutes. When the reaction was completed, the solvent was removed, and recrystallization with ether gave the desired compound. (32 mg, 78%).
1H NMR (500 MHz, CDCl3) δ 10.2 (s. 1H), 10.0 (s, 1H), 9.19 (s, 2H), 8.64 (s, 1H), 7.46 (d,J = 9.0 Hz, 2H), 7.14 (d, J = 9.0 Hz, 2H), 4.38 (s, 1H), 3.85 (s, 5H), 3.25 (s, 7H), 2.91 (s, 1H), 1.93-1.90 (m, 1H), 1.70-1.67 (m, 1H): LCMS calculated for C20H26N8O = 394.22, found: 394.4. 1 H NMR (500 MHz, CDCl 3) δ 10.2 (s. 1H), 10.0 (s, 1H), 9.19 (s, 2H), 8.64 (s, 1H), 7.46 (d, J = 9.0 Hz, 2H) , 7.14 (d, J = 9.0 Hz, 2H), 4.38 (s, IH), 3.85 (s, 5H), 3.25 1.70-1.67 (m, 1H): LCMS calculated for C 20 H 26 N 8 O = 394.22, found: 394.4.
단계 3: 1-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Step 3: Preparation of 1- (3 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) prop-2-en-1-one
N6-(4-모폴리노페닐)-N4-(피페리딘-3-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민 (50 mg, 0.13 mmol)을 테트라히드로퓨란 (3 mL)에 가하고, 디이소프로필에틸아민 (117 μL, 0.63 mmol)을 가한 후 0 oC에서 10분 간 교반 한다. 그 후, 아세틸크로라이드 (12 μL, 0.15 mmol)을 가하고 10분 더 교반 한다. N,N-메틸아미노피리딘 (18 mg, 0.15 mmol)을 가한 다음, 10분 더 교반 한 뒤, 에틸아세테이트와 물로 반응 후 처리 하고, 유기층을 황산마그네슘으로 건조, 농축하였다. 농축물을 관컬럼크로마토그래피하여 목적화합물을 얻었다. (8 mg, 14%)N 6 - (4- morpholinophenyl) -N 4 - (piperidin-3-yl) -1H- pyrazolo [3,4-d] pyrimidine-4,6-diamine (50 mg, 0.13 mmol ) Was added to tetrahydrofuran (3 mL), diisopropylethylamine (117 μL, 0.63 mmol) was added thereto, and the mixture was stirred at 0 ° C. for 10 minutes. Then, acetyl chloride (12 μL, 0.15 mmol) was added and stirring was continued for 10 minutes. N, N -methylaminopyridine (18 mg, 0.15 mmol) was added to the mixture, and the mixture was stirred for 10 minutes. The reaction mixture was treated with ethyl acetate and water, and the organic layer was dried over magnesium sulfate and concentrated. The concentrate was subjected to column chromatography on a column to obtain the target compound. (8 mg, 14%).
1H-NMR (500 MHz, CDCl3) δ 8.33-8.30 (m, 1H), 7.41 (d, J = 15.1 Hz, 2H), 7.12 (d, J = 15.1 Hz, 2H), 6.85-6.80 (m, 2H), 6.26-6.23 (m, 1H), 6.02-5.90 (m, 1H), 5.80-5.78 (m, 1H), 5.55-5.50 (m, 1H), 4.18-4.16 (m, 1H), 4.05-4.01 (m, 1H), 3.95-3.85 (m, 3H), 3.30-3.20 (m, 3H), 3.05 (s, 1H), 2.87 (s, 1H), 2.41 (s. 1H), 2.20-2.13 (m, 1H), 1.78-1.74 (m, 1H), 1.60-1.55 (m, 1H), 1.44-1.41 (m, 1H), 1.38 (s, 1H), 1.30 (s, 1H): LCMS calculated for C23H28N8O2 = 448.24, found: 448.52. 1 H-NMR (500 MHz, CDCl 3) δ 8.33-8.30 (m, 1H), 7.41 (d, J = 15.1 Hz, 2H), 7.12 (d, J = 15.1 Hz, 2H), 6.85-6.80 (m 2H), 6.26-6.23 (m, IH), 6.02-5.90 (m, IH), 5.80-5.78 (m, IH), 5.55-5.50 1H), 2.41 (s, 1H), 2.20-2.13 (m, 2H), 3.41-3.55 (m, (m, 1H), 1.78-1.74 (m, 1H), 1.60-1.55 (m, 1H), 1.44-1.41 C 23 H 28 N 8 O 2 = 448.24, found: 448.52.
<실시예 13> 1-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온의 제조Example 13 Synthesis of 1- (3 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 1-yl) prop-2-en-1-one
1-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온(50 mg, 0.12 mmol)을 테트라히드로퓨란 (3 mL)에 녹이고, 디이소프로필에틸아민 (86 μL, 0.63 mmol)을 가한 후 0 oC에서 10분간 교반 한다. 반응혼합물에 프로피오닐크로라이드 (18 μL, 0.25 mmol)을 가하고 10분 더 교반한다. N,N-디메틸아미노피리딘 (19 mg, 0.25 mmol)을 가하고, 10분 더 교반 한 뒤, 에틸아세테이트와 물로 반응 후 처리 하고, 유기층을 황산마그네슘으로 건조, 농축하였다. 농축물을 관컬럼크로마토그래피하여 목적화합물을 얻었다. (8 mg, 14%)Yl) amino) piperidin-1-yl) propyl) -1 H-pyrazolo [3,4- d] pyrimidin- 2-en-1-one (50 mg, 0.12 mmol) was dissolved in tetrahydrofuran (3 mL), diisopropylethylamine (86 μL, 0.63 mmol) was added and the mixture was stirred at 0 ° C. for 10 minutes . Propionyl chloride (18 L, 0.25 mmol) was added to the reaction mixture and stirred for an additional 10 minutes. N, N -Dimethylaminopyridine (19 mg, 0.25 mmol) was added. After stirring for 10 minutes, the mixture was treated with ethyl acetate and water, and the organic layer was dried over magnesium sulfate and concentrated. The concentrate was subjected to column chromatography on a column to obtain the target compound. (8 mg, 14%).
LCMS calculated for C23H30N8O2 = 450.24, found: 450.98.LCMS calculated for C 23 H 30 N 8 O 2 = 450.24, found: 450.98.
<실시예 14> N-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Example 14 Synthesis of N- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 4- yl) amino) cyclohexyl) Preparation of amide
단계 1: t-부틸 (4-아크릴아미노시클로헥실)카바메이트의 제조Step 1: Preparation of t-butyl (4-acrylaminocyclohexyl) carbamate
디클로로메탄 (6 mL)에 t-부틸 (4-아미노시클로헥실) 카바메이트 (100 mg, 0.46 mmol)을 가하고, 아크릴산 (48 μL, 0.69 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (EDCI, 362 mg, 2.3 mmol), 히드록시벤조트리아졸 (HOBt, 316 mg, 2.3 mmol), 디이소프로필에틸아민 (431 μL, 431 mmol)을 가한 후, 상온에서 13시간 교반 한다. 반응 종료 후, 디클로로메탄 (5 mL)와 물 (2 mL)를 가하여 추출하고, 유기층을 황산마그네슘으로 건조, 농축해서 얻은 농축물을 컬럼크로마토그래피 한다. (97 mg, 77%)Butyl (4-aminocyclohexyl) carbamate (100 mg, 0.46 mmol) was added to dichloromethane (6 mL), and acrylic acid (48 μL, 0.69 mmol), 1-ethyl- ), Carbodiimide (EDCI, 362 mg, 2.3 mmol), hydroxybenzotriazole (HOBt, 316 mg, 2.3 mmol) and diisopropylethylamine (431 μL, 431 mmol) do. After completion of the reaction, dichloromethane (5 mL) and water (2 mL) were added and extracted, and the organic layer was dried over magnesium sulfate and concentrated. The resulting concentrate was subjected to column chromatography. (97 mg, 77%).
1H-NMR (500 MHz, CDCl3) δ 6.39 (d, J = 18.0 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.0 Hz, 1H), 5.65-5.50 (m, 1H), 4.50-4.41 (m, 1H), 3.93 (s, 1H), 3.62 (s, 1H), 2.60-2.52 (m, 1H), 1.75-1.70 (m, 2H), 1.60-1.55 (m, 3H), 1.48 (s, 9H), 1.17 (s, 1H), 0.83-0.82 (m, 1H). 1 H-NMR (500 MHz, CDCl 3) δ 6.39 (d, J = 18.0 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.0 Hz, 1H), 5.65-5.50 (m (M, 2H), 1.60-1.55 (m, 1H), 4.50-4.41 (m, 1H), 3.93 , 3H), 1.48 (s, 9H), 1.17 (s, 1H), 0.83-0.82 (m, 1H).
단계 2: N-(4-아미노시클로헥실)아크릴아미드의 제조Step 2: Preparation of N- (4-aminocyclohexyl) acrylamide
t-부틸 (4- t-부틸 (4-아크릴아미노시클로헥실)카바메이트 (97 mg 0.36 mmol)에 염산 (4 M, 1,4-디옥산, 20 mL)을 가하고, 메탄올 (2mL)을 가하여 녹인 후, 15분간 상온에서 교반한다. 반응이 종결되면, 용매를 제거고, 에테르로 재결정하여 목적화합물을 얻었다. (89 mg, 70%)hydrochloric acid (4 M, 1,4-dioxane, 20 mL) was added to t-butyl (4-t-butyl (4-acrylaminocyclohexyl) carbamate (97 mg, 0.36 mmol) After the reaction was completed, the solvent was removed and the residue was recrystallized with ether to obtain the target compound (89 mg, 70%).
1H-NMR (500 MHz, CDCl3) δ 6.39 (d, J = 18.0 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.0 Hz, 1H), 5.65-5.50 (m, 1H), 4.50-4.41 (m, 1H), 3.93 (s, 1H), 3.62 (s, 1H), 2.60-2.52 (m, 1H), 1.75-1.70 (m, 2H), 1.60-1.55 (m, 3H), 1.17 (s, 2H), 0.83-0.82 (m, 1H). 1 H-NMR (500 MHz, CDCl 3) δ 6.39 (d, J = 18.0 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.0 Hz, 1H), 5.65-5.50 (m (M, 2H), 1.60-1.55 (m, 1H), 4.50-4.41 (m, 1H), 3.93 , 3H), 1.17 (s, 2H), 0.83 - 0.82 (m, 1H).
단계 3: N-(4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 3: N- (4 - ((6-Chloro-1- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidin- Hexyl) acrylamide
N,N-디메틸포름아미드 (1 mL)에 4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (28 mg, 0.11 mmol)을 녹인 뒤, N-(4-아미노헥실)아크릴아미드 (30 mg, 0.11 mmol), 탄산칼륨 (146 mg, 1.11 mmol)을 가하고, 상온에서 13 시간 동안 교반한다. 반응 종료 후, 디클로로메탄 (5 mL)와 물 (2 mL)를 가하여 추출하고, 유기층을 황산마그네슘으로 건조, 농축해서 얻은 농축물을 컬럼크로마토그래피 한다. (68 mg, 44%) To a solution of 4,6-dichloro-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4- d] pyrimidine (28 mg, 0.11 mmol), N- (4-aminohexyl) acrylamide (30 mg, 0.11 mmol) and potassium carbonate (146 mg, 1.11 mmol), and the mixture was stirred at room temperature for 13 hours. After completion of the reaction, dichloromethane (5 mL) and water (2 mL) were added and extracted, and the organic layer was dried over magnesium sulfate and concentrated. The resulting concentrate was subjected to column chromatography. (68 mg, 44%).
1H NMR (500 MHz, CDCl3) δ 8.22 (s, 1H), 6.00 (d, J = 9.1 Hz, 1H), 4,15-4.12 (m, 1H), 3.85-3.80 (m, 1H), 2.60-2.53 (m, 1H), 2.35-2.20 (m, 1H), 2.18-2.10 (m, 1H), 2.00-1.95 (m, 1H), 1.74-1.63 (m, 2H), 1.60-1.52 (m, 1H), 1.30-1.23 (m, 1H). 1 H NMR (500 MHz, CDCl 3 )? 8.22 (s, IH), 6.00 (d, J = 9.1 Hz, IH), 4.15-4.12 (m, IH), 3.85-3.80 2H), 1.60-1.52 (m, 1H), 2.60-2.53 (m, 1H), 2.35-2.20 , ≪ / RTI > 1H), 1.30-1.23 (m, 1H).
단계 4: N-(4-((6-((4-모폴리노)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 4: Preparation of N - (4 - ((6 - ((4-morpholino) amino) -1- (tetrahydro-2H-pyran-2-yl) -lH-pyrazolo [3,4- 4-yl) amino) cyclohexyl) acrylamide
t-부탄올 (2 mL)에 N-(4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (30 mg, 0.17 mmol)을 녹이고, 4-모폴리노아닐린 (14 mg, 0.17 mmol)과 Pd2(dba)3 (4 mg, 0.017 mmol), XPhos (22 mg, 0.052 mmol), K2CO3 (21 mg, 0.23 mmol)을 가하고, 질소를 충전시킨 후 90 oC에서 15 시간 동안 교반 한다. 반응이 종결되면, 에틸아세테이트와 물로 반응 후 처리 하고, 유기층을 황산마그네슘으로 건조, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (20 mg, 50%) To a solution of N - (4 - ((6-chloro- 1- (tetrahydro-2H-pyran-2-yl) -1H- pyrazolo [3,4- d] pyrimidin- (14 mg, 0.17 mmol) and Pd 2 (dba) 3 (3 mg, 0.17 mmol) were dissolved in tetrahydrofuran (4 mg, 0.017 mmol), XPhos (22 mg, 0.052 mmol), K 2 CO 3 (21 mg, 0.23 mmol) were added, and the mixture was stirred at 90 ° C for 15 hours. After the reaction was completed, the reaction was conducted with ethyl acetate and water, and the organic layer was dried over magnesium sulfate and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (20 mg, 50%).
1H-NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 7.55 (d, J = 12.1 Hz, 2H), 6.89 (d, J = 12.1 Hz, 2H), 6.45-6.36 (m, 1H), 6.15-6.07 (m, 1H), 5.80-5.76 (m, 2H), 5.58-5.50 (m, 1H), 4.50-4.45 (m, 1H), 4.15-4.06 (m, 2H), 3.85-3.75 (m, 3H), 3.15-3.10 (m, 3H), 2.58-2.52 (m, 1H), 2.25-2.00 (m, 6H), 1.80-1.78 (m, 1H), 1.75-1.55 (m, 4H), 1.50-1.25 (m, 2H). 1 H-NMR (500 MHz, CDCl 3) δ 7.74 (s, 1H), 7.55 (d, J = 12.1 Hz, 2H), 6.89 (d, J = 12.1 Hz, 2H), 6.45-6.36 (m, 1H ), 6.15-6.07 (m, IH), 5.80-5.76 (m, 2H), 5.58-5.50 (m, IH), 4.50-4.45 (m, 3H), 3.15-3.10 (m, 3H), 2.58-2.52 (m, 1H), 2.25-2.00 (m, 6H), 1.80-1.78 , 1.50-1.25 (m, 2H).
단계 5: N-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 5: Preparation of N - (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 4-yl) amino) cyclohexyl) Produce
MeOH (0.5 mL)에 N-(4-((6-((4-모폴리노)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드을 가하고, 여기에 염산 (4 M, 1,4-디옥산용액, 4mL)을 가하고, 15분간 상온에서 교반 한다. 반응이 종결되면 용매를 제거고, 에테르로 재결정하여 목적화합물을 얻었다. (24 mg, 64%)To a solution of N - (4 - ((6 - ((4- morpholino) amino) -1- (tetrahydro-2H-pyran- d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide was added thereto, hydrochloric acid (4 M, 1,4-dioxane solution, 4 mL) was added and stirred at room temperature for 15 minutes. When the reaction was completed, the solvent was removed and recrystallization with ether gave the desired compound. (24 mg, 64%).
1H-NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 7.55 (d, J = 12.1 Hz, 2H), 6.89 (d, J = 12.1 Hz, 2H), 6.45-6.36 (m, 1H), 6.15-6.07 (m, 1H), 5.58-5.50 (m, 1H), 4.50-4.45 (m, 1H), 4.15-4.06 (m, 2H), 3.85-3.75 (m, 3H), 3.15-3.10 (m, 3H), 2.25-2.00 (m, 6H), 1.50-1.25 (m, 2H): LCMS calculated for C24H30N8O2 = 462.25, found: 462.54. 1 H-NMR (500 MHz, CDCl 3) δ 7.74 (s, 1H), 7.55 (d, J = 12.1 Hz, 2H), 6.89 (d, J = 12.1 Hz, 2H), 6.45-6.36 (m, 1H ), 6.15-6.07 (m, IH), 5.58-5.50 (m, IH), 4.50-4.45 (m, IH), 4.15-4.06 (m, 2H), 3.85-3.75 (m, 3H), 2.25-2.00 ( m, 6H), 1.50-1.25 (m, 2H): LCMS calculated for C 24 H 30 N 8 O 2 = 462.25, found: 462.54.
<실시예 15> N-((1s, 4s)-4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Example 15 Synthesis of N - ((1s, 4s) -4 - ((6 - ((4-morpholinophenyl) amino) -1H- pyrazolo [3,4- d] pyrimidin- Amino) cyclohexyl) acrylamide < / RTI >
단계 1: t-뷰틸 ((1s, 4s)-4-아크릴아미도시클로헥실)카바메이트의 제조Step 1: Preparation of t-butyl ((ls, 4s) -4-acrylamidocyclohexyl) carbamate
디클로로메탄 (6 mL)에 t-부틸 ((1s,4s)-4-아미노시클로헥실)카바메이트 (517 mg, 2.42 mmol)을 가하고, 아크릴산 (668 μL, 9.6 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (2.9 g, 19.3 mmol), 히드록시벤조트리아졸 (2.6 g, 19.3 mmol), 디이소프로필에틸아민 (3.6 mL, 19.3 mmol)을 가한 후, 상온에서 14시간 동안 교반 한다. 반응이 종결되면, 에틸아세테이트와 물로 반응 후 처리 하고, 유기층을 황산마그네슘으로 건조, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (175 mg, 30%)((1s, 4s) -4-aminocyclohexyl) carbamate (517 mg, 2.42 mmol) was added to dichloromethane (6 mL), and acrylic acid (668 L, 9.6 mmol) (2.9 g, 19.3 mmol), hydroxybenzotriazole (2.6 g, 19.3 mmol) and diisopropylethylamine (3.6 mL, 19.3 mmol) were added to a solution of the compound Lt; / RTI > After the reaction was completed, the reaction was conducted with ethyl acetate and water, and the organic layer was dried over magnesium sulfate and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (175 mg, 30%).
1H-NMR (500 MHz, CDCl3) δ 6.39 (d, J = 18.1 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.1 Hz, 1H), 5.65-5.50 (m, 1H), 4.50-4.41 (m, 1H), 3.93 (s, 1H), 3.62 (s, 1H), 2.60-2.52 (m, 1H), 1.75-1.70 (m, 2H), 1.60-1.55 (m, 3H), 1.48 (s, 9H), 1.17 (s, 1H), 0.83-0.82 (m, 1H). 1 H-NMR (500 MHz, CDCl 3) δ 6.39 (d, J = 18.1 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.1 Hz, 1H), 5.65-5.50 (m (M, 2H), 1.60-1.55 (m, 1H), 4.50-4.41 (m, 1H), 3.93 , 3H), 1.48 (s, 9H), 1.17 (s, 1H), 0.83-0.82 (m, 1H).
단계 2: N-((1s,4s)-4-아미노시클로헥실)아크릴아미드의 제조Step 2: Preparation of N - ((1s, 4s) -4-aminocyclohexyl) acrylamide
t-부틸 ((1s,4s)-4-아크릴아미도시클로헥실)카바메이트 (150 mg, 0.81 mmol)에 염산 (4M 1,4-디옥산 용액, 20 mL)을 가하고, 메탄올 (2mL)를 가하고, 15분간 상온에서 교반 한다. 반응이 종결되면, 용매를 제거하고, 에테르로 재결정하여 목적화합물을 얻었다. (150 mg, 70%)hydrochloric acid (4M 1,4-dioxane solution, 20 mL) was added to t-butyl ((1s, 4s) -4-acrylamidocyclohexyl) carbamate (150 mg, 0.81 mmol) And stirred at room temperature for 15 minutes. When the reaction was completed, the solvent was removed and recrystallization with ether gave the desired compound. (150 mg, 70%).
1H NMR (500 MHz, CDCl3) δ 6.39 (d, J = 18.0 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.1 Hz, 1H), 5.65-5.50 (m, 1H), 4.50-4.41 (m, 1H), 3.93 (s, 1H), 3.62 (s, 1H), 2.60-2.52 (m, 1H), 1.75-1.70 (m, 2H), 1.60-1.55 (m, 3H), 1.17 (s, 2H), 0.83-0.82 (m, 1H). 1 H NMR (500 MHz, CDCl 3) δ 6.39 (d, J = 18.0 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.1 Hz, 1H), 5.65-5.50 (m, 1H), 4.50-4.41 (m, 1H), 3.93 (s, IH), 3.62 (s, IH), 2.60-2.52 3H), 1.17 (s, 2H), 0.83 - 0.82 (m, 1H).
단계 3: N-((1s,4s)-4-((6-클로로-1-(테트라히드로-2H-p-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 3: N - ((ls, 4s) -4 - ((6-Chloro-1- (tetrahydro- -Yl) amino) cyclohexyl) acrylamide < / RTI >
N,N-디메틸포름아미드 (2 mL)에 4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (185 mg, 0.68 mmol)을 가하고, N-((1s,4s)-4-아미노시클로헥실)아크릴아미드 (200 mg, 0.74 mmol), 탄산칼륨 (935 mg, 6.7 mmol)을 가하고, 상온에서 14 시간 동안 교반한다. 반응이 종결되면, 에틸아세테이트와 물로 반응 후 처리 하고, 유기층을 황산마그네슘으로 건조, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (100 mg, 33%) To a solution of 4,6-dichloro-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4- d] pyrimidine (185 mg, (200 mg, 0.74 mmol) and potassium carbonate (935 mg, 6.7 mmol) were added to the mixture, and the mixture was stirred at room temperature for 14 hours . After the reaction was completed, the reaction was conducted with ethyl acetate and water, and the organic layer was dried over magnesium sulfate and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (100 mg, 33%).
1H-NMR (500 MHz, CDCl3) δ 7.89 (s, 1H) ,6.34-6.28 (m, 1H), 6.13-6.10 (m, 1H), 5.95-5.91 (m, 1H), 5.68-5.65 (m, 1H), 4.10-4.60 (m, 2H), 3.75-3.79 (m, 1H), 3.00-2.88 (m, 1H), 2.60-2.57 (m, 1H), 2.35-2.20 (m, 2H), 1.95-1.80 (m, 4H), 1.78-1.68 (m, 2H), 1.58 (s, 3H). 1 H-NMR (500 MHz, CDCl 3) δ 7.89 (s, 1H), 6.34-6.28 (m, 1H), 6.13-6.10 (m, 1H), 5.95-5.91 (m, 1H), 5.68-5.65 ( 2H), 3.75-3.79 (m, 1H), 3.00-2.88 (m, 1H), 2.60-2.57 1.95-1.80 (m, 4H), 1.78-1.68 (m, 2H), 1.58 (s, 3H).
단계 4: N-((1s,4s)-4-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 4: Preparation of N - ((1s, 4s) -4 - ((6 - ((4-morpholinophenyl) amino) -1- (tetrahydro- 3,4-d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide
t-부탄올 (2 mL)에 N-((1s,4s)-4-((6-클로로-1-(테트라히드로-2H-p-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (52 mg, 0.12 mmol)을 녹이고, 4-모폴리노아닐린 (23 mg, 0.13 mmol)과 Pd2(dba)3 (8 mg, 0.012 mmol), X-Phos (17 mg, 0.038 mmol), 탄산칼륨 (37 mg, 0.26 mmol)을 가하고, 질소를 충전시킨 후, 90 oC에서 14시간 동안 교반 한다. 반응이 종결되면, 에틸아세테이트와 물로 반응 후 처리 하고, 유기층을 황산마그네슘으로 건조, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (60 mg, 86%) To a solution of N - ((ls, 4s) -4 - ((6-chloro-l- (tetrahydro-2H-p- 2- yl) -1H- pyrazolo [3,4- d (23 mg, 0.13 mmol) and Pd 2 (dba) 3 (0.15 mmol) were dissolved in anhydrous tetrahydrofuran (8 mg, 0.012 mmol), X-Phos (17 mg, 0.038 mmol), potassium carbonate (37 mg, 0.26 mmol) were added, and the mixture was stirred at 90 ° C for 14 hours. After the reaction was completed, the reaction was conducted with ethyl acetate and water, and the organic layer was dried over magnesium sulfate and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (60 mg, 86%).
1H-NMR (500 MHz, CDCl3) δ 7.85 (s, 1H), 7.50 (d, J = 12.1 Hz, 2H), 7.15-6.90 (m, 2H), 6.48-6.35 (m, 2H), 6.30-6.20 (m, 1H), 5.85-5.70 (m, 2H), 5.55-5.50 (d, J = 12.1 Hz, 1H), 4.12-4.00 (m, 1H), 3.87 (s, 3H), 3.78-3.75 (m, 1H), 3.17-3.10 (m, 3H), 2.65-2.60 (m, 1H), 2.28-2.20 (m, 1H), 1.85-1.60 (m, 10H), 1.38-1.25 (m, 4H). 1 H-NMR (500 MHz, CDCl 3) δ 7.85 (s, 1H), 7.50 (d, J = 12.1 Hz, 2H), 7.15-6.90 (m, 2H), 6.48-6.35 (m, 2H), 6.30 1H), 3.87 (s, 3H), 3.78-3.75 (m, 2H), 5.55-5.50 (d, J = (m, 3H), 2.65-2.60 (m, 1H), 2.28-2.20 (m, 1H), 1.85-1.60 .
단계 5: N-((1s,4s)-4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 5: Preparation of N - ((lS, 4s) -4 - ((6- ((4-morpholinophenyl) amino) -1H- pyrazolo [3,4- d] pyrimidin- Cyclohexyl) acrylamide
메탄올 (1 mL)에 N-((1s,4s)-4-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드에 염산 (4 M, 1,4-디옥산, 4 mL)을 가하고, 15분간 상온에서 교반 한다. 반응이 종결되면, 용매를 제거하고, 에테르로 재결정하여 목적화합물을 얻었다. (34 mg, 87%)To a solution of N - ((1s, 4s) -4 - ((6 - ((4-morpholinophenyl) amino) -1- (tetrahydro- (4 M, 1, 4-dioxane, 4 mL) was added to a solution of 4-amino-3- [3- (trifluoromethyl) pyrazolo [3,4- d] pyrimidin-4-yl) amino) cyclohexyl] acrylamide. When the reaction was completed, the solvent was removed and recrystallization with ether gave the desired compound. (34 mg, 87%).
1H-NMR (500 MHz, CDCl3) δ 10.19 (s, 1H), 9.50 (s, 1H), 8.55 (s, 1H), 8.11 (s, 1H), 7.49 (d, J = 3.1 Hz, 2H), 7.14 (d, J = 3.1 Hz, 2H), 6.38-6.35 (m, 1H), 6.07 (d, J = 9.1 Hz, 1H), 5.57 (d, J = 9.1 Hz, 1H), 3.80-3.64 (m, 5H), 3.15-3.00 (m, 5H), 1.60 (s, 7H), 1.58-1.56 (m, 2H): LCMS calculated for C24H30N8O2 = 462.25, found:462.55. 1 H-NMR (500 MHz, CDCl 3) δ 10.19 (s, 1H), 9.50 (s, 1H), 8.55 (s, 1H), 8.11 (s, 1H), 7.49 (d, J = 3.1 Hz, 2H ), 7.14 (d, J = 3.1 Hz, 2H), 6.38-6.35 (m, 1H), 6.07 (d, J = 9.1 Hz, 1H), 5.57 (d, J = 9.1 Hz, 1H), 3.80-3.64 (m, 5H), 3.15-3.00 ( m, 5H), 1.60 (s, 7H), 1.58-1.56 (m, 2H): LCMS calculated for C 24 H 30 N 8 O 2 = 462.25, found: 462.55.
<실시예 16> (R)-1-(3-((6-([1, 1'-디페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 의 제조Example 16 Synthesis of (R) -1- (3 - ((6 - ([1,1'-diphenyl] -4-ylamino) -1 H- pyrazolo [3,4- d] pyrimidin- Yl) amino) pyrrolidin-1-yl) prop-2-en-1-one
단계 1: N-((1s, 4s)-4-((6-((4-페녹시페닐) 아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 1: Preparation of N - ((1 S, 4 S) -4 - ((6 - ((4- phenoxyphenyl) amino) -1 H- pyrazolo [3,4- d] pyrimidin- Hexyl) acrylamide
N-((1s,4s)-4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (90 mg, 0.22 mmol) 를 1,4-디옥산 (3 mL) 에 녹인 용액에 4-페녹시아닐린 (49 mg, 0.27 mmol), Pd2(dba)3 (10 mg, 0.01 mmol), Xantphos (6 mg ,0.01 mmol), 세슘카보네이트 (217 mg, 0.67 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 충진 하고 마이크로웨이브반응기를 이용하여 150 oC에서 10분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후, 물을 가하여 반응을 종료시키고, 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매 제거한 후, 실리카겔 칼럼 하에서 헥산/에틸아세테이트를 이용 정제하여 흰색 고체 N-((1s,4s)-4-((6-((4-페녹시페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (32 mg, 27%, 0.054 mmol, 42%)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) -1H-pyrazolo [l, 5- 4-phenoxyaniline (49 mg, 0.27 mmol), Pd 2 (dba) 3 (10 mg, 0.27 mmol) was dissolved in 1,4- dioxane mg, 0.01 mmol), Xantphos (6 mg, 0.01 mmol), cesium carbonate (217 mg, 0.67 mmol). The reaction mixture was charged with argon for 10 minutes and stirred in a microwave reactor at 150 ° C for 10 minutes. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered and then evaporated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography using hexane / ethyl acetate to obtain a white solid N - ((1s, 4s) -4- Amino] cyclohexyl) acrylamide (32 mg, 27%, 0.054 mmol, 42%) was obtained as a colorless amorphous substance from 4- (4-phenoxyphenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin- .
1H-NMR (300 MHz, CDCl3) δ 1.61-2.18 (m, 14H), 2.55-2.64 (m, 1H), 3.72-3.79 (m, 1H), 4.09-4.20 (m, 3H), 5.49 (br, 1H), 5.61 (d, J = 11.1 Hz, 1H), 5.80 (d, J = 8.4 Hz, 1H), 6.05-6.14 (m, 1H), 6.26-6.31 (m, 1H), 6.98-7.09 (m, 6H), 7.29-7.35 (m, 2H), 7.63 (d, J = 9.0 Hz, 1H), 7.79 (s, 1H), 8.74 (br, 1H). 1 H-NMR (300 MHz, CDCl 3) δ 1.61-2.18 (m, 14H), 2.55-2.64 (m, 1H), 3.72-3.79 (m, 1H), 4.09-4.20 (m, 3H), 5.49 ( (m, 1H), 5.61 (d, J = 11.1 Hz, 1H), 5.80 (d, J = 8.4 Hz, 1H), 6.05-6.14 (m, 6H), 7.29-7.35 (m, 2H), 7.63 (d, J = 9.0 Hz, 1H), 7.79 (s, 1H), 8.74 (br, 1H).
단계 2: (R)-1-(3-((6-([1,1'-디페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Step 2: (R) -1- (3 - ((6 - ([1,1'-diphenyl] -4-ylamino) -lH- pyrazolo [3,4- d] pyrimidin- ) Amino) pyrrolidin-1-yl) prop-2-en-1-one
N-((1s,4s)-4-((6-((4-페녹시페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 을 메탄올 (1 mL) 에 녹인 용액에 염산 (4 N, 1,4-디옥산, 1 mL) 을 첨가하고 상온에서 12시간 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후 에틸아세테이트를 이용하여 세척한 후, 흰색 고체로 목적화합물 (25 mg, 86%, 0.049 mmol)을 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) amino) cyclohexyl) acrylic acid (hereinafter referred to as " Amide in methanol (1 mL) was added hydrochloric acid (4 N, 1, 4-dioxane, 1 mL), and the mixture was stirred at room temperature for 12 hours. The reaction mixture was distilled under reduced pressure to remove the solvent, and the residue was washed with ethyl acetate to obtain the target compound (25 mg, 86%, 0.049 mmol) as a white solid.
1H-NMR (300 MHz, CD3OD) δ 1.52-1.91 (m, 9H), 3.57-3.73 (m, 1H), 3.96 (brs, 1H), 4.18 (brs, 1H), 5.65 (d, J = 9.9 Hz, 1H), 6.19-6.41 (m, 2H), 7.01-7.16 (m, 5H), 7.35-7.49 (m, 4H), 8.43 (s, 1H); LC/MS 470.03 [M + H+], 940.32 [2M + H+]. 1 H-NMR (300 MHz, CD 3 OD) δ 1.52-1.91 (m, 9H), 3.57-3.73 (m, 1H), 3.96 (brs, 1H), 4.18 (brs, 1H), 5.65 (d, J = 9.9 Hz, 1H), 6.19-6.41 (m, 2H), 7.01-7.16 (m, 5H), 7.35-7.49 (m, 4H), 8.43 (s, 1H); LC / MS 470.03 [M + H < + >], 940.32 [2M + H < + >].
<실시예 17> (R)-1-(3-((6-([1, 1'-디페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Example 17 Synthesis of (R) -1- (3 - ((6 - ([1,1'-diphenyl] -4-ylamino) -1 H- pyrazolo [3,4- d] pyrimidin- Yl) amino) pyrrolidin-1-yl) prop-2-en-1-one
단계 1: 1-((3R)-3-((6-([1, 1'-바이페닐]-4-일아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Step 1: 1 - ((3R) -3 - ((6 - ([1,1'-biphenyl] -4-ylamino) Pyrazolo [3,4-d] pyrimidin-4-yl) amino) pyrrolidin-1-yl) prop-
1-((3R)-3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 (50 mg, 0.13 mmol) 를 1,4-디옥산 (2 mL) 에 녹인 용액에 [1,1'-바이페닐]-4-아민 (27 mg, 0.16 mmol), Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (3 mg, 0.007 mmol), 세슘카보네이트 (130 mg, 0.40 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 용존산소를 제거하고 마이크로웨이브반응기를 이용하여 140 oC에서 20분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트 으로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트를 이용 정제하여 흰색 고체로 목적화합물 (42 mg, 63%, 0.082 mmol)를 얻었다.3,4-d] pyrimidin-4-yl) amino) -1H-pyrazolo [l, 5- Ene-1-one (50 mg, 0.13 mmol) in 1,4-dioxane (2 mL) was added [1,1'-biphenyl] - 4-amine (27 mg, 0.16 mmol), Pd 2 (dba) 3 (6 mg, 0.007 mmol), Xphos (3 mg, 0.007 mmol), cesium carbonate (130 mg, 0.40 mmol). The reaction mixture was degassed with argon for 10 minutes and stirred at 140 ° C for 20 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The solvent was distilled off under reduced pressure, and the solvent was removed. The residue was purified by silica gel column chromatography using hexane / ethyl acetate to give the desired compound (42 mg, 63%, 0.082 mmol) as a white solid.
1H-NMR (300 MHz, CDCl3) δ 1.59-2.63 (m, 10H), 3.56-3.88 (m, 5H), 4.13 (d, J = 11.4 Hz, 1H), 4.79-5.00 (m, 1H), 5.59-5.68 (m, 1H), 5.83 (d, J = 9.3 Hz, 1H), 6.31-6.39 (m, 2H), 7.16-7.17 (m, 1H), 7.29-7.33 (m, 1H), 7.40-7.45 (m, 2H), 7.56-7.62 (m, 4H) 7.76-7.80 (m, 2H), 7.99-8.09 (m, 1H); LC/MS 509.97 [M + H+]. 1 H-NMR (300 MHz, CDCl 3 )? 1.59-2.63 (m, 10H), 3.56-3.88 (m, 5H), 4.13 (d , J = 11.4 Hz, 2H), 7.16-7.17 (m, 1H), 7.29-7.33 (m, 1H), 7.40 (d, J = -7.45 (m, 2H), 7.56-7.62 (m, 4H), 7.76-7.80 (m, 2H), 7.99-8.09 (m, 1H); LC / MS 509.97 [M + H < + >].
단계 2: (R)-1-(3-((6-([1,1'-디페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Step 2: (R) -1- (3 - ((6 - ([1,1'-diphenyl] -4-ylamino) -lH- pyrazolo [3,4- d] pyrimidin- ) Amino) pyrrolidin-1-yl) prop-2-en-1-one
1-((3R)-3-((6-([1,1'-바이페닐]-4-일아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 (42 mg, 0.082 mmol)을 메탄올 (1 mL) 에 녹인 용액에 염산 (4 N, 에틸에테르 용액, 1 mL) 을 첨가하고, 상온에서 20분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후 에틸아세테이트로 세척한 후, 흰색 고체인 목적화합물 (30 mg, 83%, 0.065 mmol)를 얻었다.(Tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [l, 1-yl) prop-2-en-1-one (42 mg, 0.082 mmol) in methanol (1 mL) was added dropwise to a solution of Hydrochloric acid (4 N, ethyl ether solution, 1 mL) was added, and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was distilled under reduced pressure to remove the solvent and washed with ethyl acetate to obtain the target compound (30 mg, 83%, 0.065 mmol) as a white solid.
1H-NMR (300 MHz, CD3OD) δ 2.16-2.44 (m, 2H), 3.60-4.18 (m, 4H), 4.60-4.89 (m, 1H), 5.69-6.24 (m, 1H), 6.27-6.54 (m, 1H), 6.57-6.71 (m, 1H), 7.26-7.29 (m, 1H), 7.37-7.42 (m, 2H), 7.53-7.60 (m, 4H), 7.82 (d, J = 7.8 Hz, 2H), 7.94 (s, 1H); LC/MS 425.93 [M + H+], 851.21 [2M + H+]. 1 H-NMR (300 MHz, CD 3 OD)? 2.16-2.44 (m, 2H), 3.60-4.18 (m, 4H), 4.60-4.89 (M, 2H), 7.53-7.60 (m, 4H), 7.82 (d, J = 7.8 Hz, 2H), 7.94 (s, 1 H); LC / MS 425.93 [M + H < + >], 851.21 [2M + H < + >].
<실시예 18> (R)-1-(3-((6-((4-페녹시페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 의 제조Example 18 Synthesis of (R) -1- (3 - ((6 - ((4-phenoxyphenyl) amino) -1 H-pyrazolo [3,4- d] pyrimidin- Yl) prop-2-en-1-one < EMI ID =
단계 1: 1-((3R)-3-((6-((4-페녹시페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Step 1: 1 - ((3R) -3 - ((6 - ((4-phenoxyphenyl) amino) -1- (tetrahydro-2H- pyran- -d] pyrimidin-4-yl) amino) pyrrolidin-1-yl) prop-
1-((3R)-3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 (50 mg, 0.13 mmol) 를 1,4-디옥산 (2 mL) 에 녹인 용액에 4-페녹시아닐린 (29 mg, 0.16 mmol), Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (3 mg, 0.007 mmol), 세슘카보네이트 (130 mg, 0.40 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 용존산소를 제거 하고 마이크로웨이브반응기를 이용하여 140 oC에서 20분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후, 실리카겔 칼럼 하에서 헥산/에틸아세테이트로 정제하여 흰색 고체 목적화합물 (45 mg, 65%, 0.086 mmol)를 얻었다.3,4-d] pyrimidin-4-yl) amino) -1H-pyrazolo [l, 5- (50 mg, 0.13 mmol) in 1,4-dioxane (2 mL) was added 4-phenoxyaniline (29 mg, 0.16 mmol), Pd 2 (dba) 3 (6 mg, 0.007 mmol), Xphos (3 mg, 0.007 mmol), cesium carbonate (130 mg, 0.40 mmol). The reaction mixture was degassed with argon for 10 minutes and stirred at 140 ° C for 20 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added thereto to terminate the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography with hexane / ethyl acetate to obtain a white solid compound (45 mg, 65%, 0.086 mmol).
1H-NMR (300 MHz, CDCl3) δ 1.57-2.34 (m, 9H), 2.56-2.63 (m, 1H), 3.55-3.86 (m, 5H), 4.09-4.13 (m, 1H), 4.75-4.87 (m, 1H), 5.59-5.68 (m, 1H), 5.79 (d, J = 9.9 Hz, 1H), 6.29-6.38 (m, 2H), 6.99-7.02 (m, 4H), 7.06-7.11 (m, 2H), 7.29-7.35 (m, 2H), 7.65-7.69 (m, 2H), 7.99-8.08 (m, 1H); LC/MS 525.96 [M + H+]. 1 H-NMR (300 MHz, CDCl 3 )? 1.57-2.34 (m, 9H), 2.56-2.63 (m, 1H), 3.55-3.86 (m, 5H), 4.09-4.13 4.87 (m, 1H), 5.59-5.68 (m, 1H), 5.79 (d, J = 9.9 Hz, 1H), 6.29-6.38 (m, 2H), 6.99-7.02 (m, 4H), 7.06-7.11 ( m, 2H), 7.29-7.35 (m, 2H), 7.65-7.69 (m, 2H), 7.99-8.08 (m, 1H); LC / MS 525.96 [M + H < + >].
단계 2: (R)-1-(3-((6-((4-페녹시페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 의 제조Step 2: (R) -1- (3 - ((6 - ((4-phenoxyphenyl) amino) -lH- pyrazolo [3,4- d] pyrimidin- 4- yl) amino) pyrrolidine -1-yl) prop-2-en-1-one
1-((3R)-3-((6-((4-페녹시페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 (45 mg, 0.086 mmol)를 메탄올 (1 mL) 에 녹인 염산 용액 (4 N, 디에틸에테르, 1 mL) 을 첨가하고 상온에서 20분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후, 에틸아세테이트를 이용하여 씻어준 후 흰색 고체로 목적화합물 (28 mg, 78%, 0.059 mmol)를 얻었다.3,4-d] pyrimidin-2-yl) -1H-pyrazolo [3,4-d] pyrimidin- 1-one (45 mg, 0.086 mmol) was dissolved in a hydrochloric acid solution (4 N, diethyl (2-ethylpiperidin-4-yl) amino) pyrrolidin- Ether, 1 mL) was added, and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was distilled off under reduced pressure to remove the solvent. The residue was washed with ethyl acetate and the desired compound (28 mg, 78%, 0.059 mmol) was obtained as a white solid.
1H-NMR (300 MHz, CD3OD) δ 2.16-2.42 (m, 2H), 3.63-4.00 (m, 1H), 4.76 (br, 1H), 5.72-5.79 (m, 1H), 6.24-6.32 (m, 1H), 6.49-6.65 (m, 1H), 7.01-7.16 (m, 5H), 7.35-7.49 (m, 4H), 8.38 (s, 1H); LC/MS 441.91 [M + H+], 883.14 [2M+H+]. 1 H-NMR (300 MHz, CD 3 OD)? 2.16-2.42 (m, 2H), 3.63-4.00 (m, 1H), 6.49-6.65 (m, 1H), 7.01-7.16 (m, 5H), 7.35-7.49 (m, 4H), 8.38 (s, 1H); LC / MS 441.91 [M + H & lt ; + & gt ; ], 883.14 [2M + H & lt ; + & gt ; ].
<실시예 19> (R)-1-(3-((6-((4-(피페리딘-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 의 제조Example 19 Synthesis of (R) -1- (3 - ((6 - ((4- (piperidin- 1 -yl) phenyl) amino) -1 H- pyrazolo [3,4- d] pyrimidine- Yl) amino) pyrrolidin-1-yl) prop-2-en-1-one
단계 1: 1-((3R)-3-((6-((4-(피페리딘-1-일)페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Step 1: 1 - ((3R) -3 - ((6 - ((4- (Piperidin- 1 -yl) phenyl) amino) - l- (tetrahydro- -Pyrazolo [3,4-d] pyrimidin-4-yl) amino) pyrrolidin-1-yl) prop-
1-((3R)-3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 (50 mg, 0.13 mmol) 를 1,4-디옥산 (2 mL) 에 녹인 용액에 4-(피페리딘-1-일)아닐린 (28 mg, 0.16 mmol), Pd2(dba)3 (6 mg, 0.007 mmol), Xphos (3 mg, 0.007 mmol), 세슘카보네이트 (130 mg, 0.40 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 용존산소를 제거하고, 마이크로웨이브반응기를 이용하여 140 oC에서 20분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트 으로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트를 이용 정제하여 흰색 고체 목적화합물 (31 mg, 46%, 0.060 mmol)를 얻었다.3,4-d] pyrimidin-4-yl) amino) -1H-pyrazolo [l, 5- En-1-one (50 mg, 0.13 mmol) in 1,4-dioxane (2 mL) was added 4- (piperidin- ) Aniline (28 mg, 0.16 mmol), Pd 2 (dba) 3 (6 mg, 0.007 mmol), Xphos (3 mg, 0.007 mmol), cesium carbonate (130 mg, 0.40 mmol). The reaction mixture was degassed with argon for 10 minutes and stirred at 140 ° C for 20 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted twice with ethyl acetate. The extracted organic layer was dried with magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column using hexane / ethyl acetate to obtain white solid compound (31 mg, 46%, 0.060 mmol).
1H-NMR (300 MHz, CDCl3) δ 1.51-2.24 (m, 15H), 2.98 (br, 5H), 3.45-3.54 (m, 4H), 3.56-3.69 (m, 2H), 3.89-3.99 (m, 2H), 4.59-4.66 (m, 1H), 5.64-5.68 (m, 2H), 6.09-6.15 (m, 1H), 6.48-6.66 (m, 1H), 6.82 (d, J = 8.7 Hz, 2H), 7.50-7.70 (m, 2H), 7.91 (s, 1H), 8.04-8.07 (m, 1H), 8.95 (s, 1H); LC/MS 517.05 [M + H+],753.06[2M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.51-2.24 (m, 15H), 2.98 (br, 5H), 3.45-3.54 (m, 4H), 3.56-3.69 (m, 2H), 3.89-3.99 ( m, 2H), 4.59-4.66 (m , 1H), 5.64-5.68 (m, 2H), 6.09-6.15 (m, 1H), 6.48-6.66 (m, 1H), 6.82 (d, J = 8.7 Hz, 2H), 7.50-7.70 (m, 2H), 7.91 (s, 1H), 8.04-8.07 (m, 1H), 8.95 (s, 1H); LC / MS 517.05 [M + H & lt ; + & gt ; ], 753.06 [2M + H & lt ; + & gt ; ].
단계 2: (R)-1-(3-((6-((4-(피페리딘-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Step 2: (R) -1- (3 - ((6 - ((4- (piperidin- 1 -yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) amino) pyrrolidin-1-yl) prop-2-en-1-one
1-((3R)-3-((6-((4-(피페리딘-1-일)페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 (31 mg, 0.060 mmol)를 메탄올 (1 mL) 에 녹인 용액에 4N 염산 디에틸에테르 용액 (1 mL) 을 첨가하고 상온에서 20분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후 에틸아세테이트를 이용하여 씻어준 후, 흰색 고체 목적화합물 (25 mg, 93%, 0.053 mmol)를 얻었다.1 - ((3R) -3 - ((6 - ((4- (piperidin- 1 -yl) phenyl) amino) -1- (tetrahydro- 1-yl) prop-2-en-1-one (31 mg, 0.060 mmol) in methanol (1 mL) was added dropwise to a solution of Was added 4N hydrochloric acid diethyl ether solution (1 mL), and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was distilled under reduced pressure to remove the solvent, and the residue was washed with ethyl acetate. (25 mg, 93%, 0.053 mmol).
1H-NMR (300 MHz, CD3OD) δ 1.84-2.44 (m, 8H), 3.59-4.03 (m, 8H), 4.74 (brs, 1H), 5.77-5.81 (m, 1H), 6.28 (d, J = 16.5 Hz, 1H), 6.57-6.71 (m, 1H), 7.84 (brs, 4H), 8.49 (s, 1H); LC/MS 432.94 [M + H+], 865.19 [2M + H+]. 1 H-NMR (300 MHz, CD 3 OD)? 1.84-2.44 (m, 8H), 3.59-4.03 (m, 8H), 4.74 (br s, 1H), 5.77-5.81 , J = 16.5 Hz, 1H), 6.57-6.71 (m, 1H), 7.84 (brs, 4H), 8.49 (s, 1H); LC / MS 432.94 [M + H < + >], 865.19 [2M + H & lt ; + & gt ; ].
<실시예 20> N-((1s, 4s)-4-((3-메틸-6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Example 20 Synthesis of N - ((1s, 4s) -4 - ((3-Methyl-6 - ((4-morpholinophenyl) amino) -1 H- pyrazolo [3,4- d] pyrimidine- 4-yl) amino) cyclohexyl) acrylamide
단계 1: 2-에톡시-1, 1-디이소시아노프로프-1-엔의 제조Step 1: Preparation of 2-ethoxy-1, 1-diisocyanoproff-1-ene
말로니트릴 (3 g, 45 mmol)에 1, 1, 1-트리에톡시에탄 (10 mL, 54 mmol)을 가하고, 초산 (2 mL) 가한 다음, 90 oC에서 에탄올을 제거한다. 반응 용액을 140 oC로 조정하고, 30분간 교반 한다. 반응이 종결되면, 흰색고체를 여과하여 목적화합물을 얻었다. (2.9 g, 87%) 1,1,1 Triethoxyethane (10 mL, 54 mmol) was added to malonitrile (3 g, 45 mmol), acetic acid (2 mL) was added, and ethanol was removed at 90 ° C. The reaction solution is adjusted to 140 ° C and stirred for 30 minutes. When the reaction was completed, the white solid was filtered to obtain the target compound. (2.9 g, 87%).
1H NMR (500 MHz, CDCl3)δ4.45(q, J = 9.1 Hz, 2H), 2.45 (s, 3H), 1.42 (t, J = 9.1 Hz, 3H). 1 H NMR (500 MHz, CDCl 3) δ4.45 (q, J = 9.1 Hz, 2H), 2.45 (s, 3H), 1.42 (t, J = 9.1 Hz, 3H).
단계 2: 5-아미노-3-메틸-1H-피라졸-4-카보니트릴의 제조Step 2: Preparation of 5-amino-3-methyl-1H-pyrazole-4-carbonitrile
2-에톡시-1, 1-디이소프로페-1-엔 (1 g, 7.3 mmol)에 히드라진 단수화물 (720μL, 14.6 mmol)을 가하고, 에탄올 (10 mL)를 0 ℃에서 가하여, 녹인 후, 80 ℃에서 90분간 교반 시켜준다. 반응 종료 시 냉각하고, 에틸아세테이트와 물을 가하여 생성물을 유기츠응로 추출하고, 유기층을 무수망초로 건조, 여과, 농축한 다음, 농축액을 관크로마토그래피하여 목적화합물을 얻었다. (920 mg, 92%)Hydrazine monohydrate (720 μL, 14.6 mmol) was added to 1 g (7.3 mmol) of 2-ethoxy-1,1-diisoprop-1-ene and ethanol , And the mixture is stirred at 80 DEG C for 90 minutes. After completion of the reaction, the reaction mixture was cooled, and ethyl acetate and water were added thereto. The product was extracted with an organic layer, and the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the desired compound. (920 mg, 92%).
1H NMR (500 MHz, CDCl3)δ2.22(s, 3H). 1 H NMR (500 MHz, CDCl 3 )? 2.22 (s, 3H).
단계 3: 3-메틸-1H-피라졸로[3,4-d]피리미딘-4, 6-디올의 제조Step 3: Preparation of 3-methyl-1H-pyrazolo [3,4-d] pyrimidine-4,6-diol
5-아미노-3-메틸-1H-피라졸-4-카보니트릴 (0.92 g, 7.5 mmol)을 0oC에서 20% 수산칼륨 (4.5 ml)와 10 ml 디메틸설폭사이드를 가하고, 12시간 동안 교반 시켜 준다. 다음으로, CS2를 0 oC에서 서서히 가해준 후, 30분 교반시킨다. 그리고 상온에서 한시간 더 교반 시킨다. 반응 용액에 요오드메탄을 30분 동안 서서히 가한다. 상온에서 2시간 교반 시킨 후, 반응물을 얼음물에 가한 다음, 생성된 고체를 여과 하여 얻는다. (620 mg, 75%). 다음으로, 아세트산 (30 mL), 과산화수소 (30%, 7mL)를 가한 다음, 70 ℃에서 5시간 교반시켜 준다. 용매를 제거하고, 물을 가하여 생성된 흰색 고체를 여과해서 목적화합물을 얻었다. (100 mg, 37%)5-Amino-3-methyl-1H-pyrazole-4-carbonitrile (0.92 g, 7.5 mmol) was added 20% potassium hydroxide (4.5 ml) and 10 ml dimethylsulfoxide at 0 ° C and stirred for 12 hours I will. Next, CS 2 is gradually added at 0 ° C, and then stirred for 30 minutes. Then, the mixture is stirred at room temperature for one hour. Add iodomethane to the reaction solution slowly for 30 min. After stirring at room temperature for 2 hours, the reaction product is added to ice water, and the resulting solid is filtered. (620 mg, 75%). Next, acetic acid (30 mL) and hydrogen peroxide (30%, 7 mL) were added, followed by stirring at 70 ° C for 5 hours. The solvent was removed, and water was added, and the resulting white solid was filtered to obtain the desired compound. (100 mg, 37%).
1H NMR (500 MHz, CDCl3) δ 12.92 (s, 1H), 11.15 (s, 1H), 10.49 (s, 1H), 2.46 (d, J = 12.1 Hz, 3H). 1 H NMR (500 MHz, CDCl 3 )? 12.92 (s, IH), 11.15 (s, IH), 10.49 (s, IH), 2.46 (d, J = 12.1 Hz, 3H).
단계 4: 4,6-디클로로-3-메틸-피라졸로[3,4-d]피리미딘의 제조Step 4: Preparation of 4,6-dichloro-3-methyl-pyrazolo [3,4-d] pyrimidine
3-메틸-1H-피라졸로[3,4-d]피리미딘-4,6-디올 (100 mg, 0.60 mmol)을 POCl3 (10mL)에 가하고, PCl5 (417 mg, 2.0mmol)를 가하였다. 반응 용액을 12 시간 동안 환류시켜 주고, 반응이 종료되면, 반응물을 얼음물에 가하고, 에틸아세테이트로 추출한다. 유기층을 무수망초로 건조시키고, 여과, 농축한 다음, 관크로마토 그라피로 목적화합물을 얻었다. (70 mg)3-methyl -1H- pyrazolo [3,4-d] pyrimidine-4,6-diol (100 mg, 0.60 mmol) was added to POCl 3 (10mL), that the PCl 5 (417 mg, 2.0mmol) Respectively. The reaction solution is refluxed for 12 hours. When the reaction is completed, the reaction product is added to ice water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated, and the desired compound was obtained by column chromatography. (70 mg)
LCMS calculated for C6H4Cl2N4 = 201.98, found: 202.34.LCMS calculated for C 6 H 4 Cl 2 N 4 = 201.98, found: 202.34.
단계 5: 4, 6-디클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘의 제조Step 5: Preparation of 4,6-dichloro-3-methyl-1- (tetrahydro-2H-pyran-2-yl) -lH-pyrazolo [3,4-d] pyrimidine
4,6-디클로로-3-메틸-1H-피라졸로[3,4-d]피리미딘 (70 mg, 0.34 mmol)을 에틸아세테이트 (2 mL)에 가하고, 디히드로피란 (0.2 mL, 2.3 mmol)와 p-톨루엔설폰산 (3 mg)를 가하였다. 50 ℃에서 12시간 교반시켜 준다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (30 mg, 54%)3,4-d] pyrimidine (70 mg, 0.34 mmol) was added to ethyl acetate (2 mL), and dihydropyran (0.2 mL, 2.3 mmol) And p-toluenesulfonic acid (3 mg) were added. The mixture was stirred at 50 占 폚 for 12 hours. Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (30 mg, 54%).
1H-NMR (500 MHz, CDCl3) δ 5.99-5.51 (d, J = 9.1 Hz, 1H), 5.88 (d, J = 9.1 Hz, 1H), 3.98-3.96 (m, 1H), 3.75-3.73 (m, 1H), 2.65 (s, 3H), 2.47-2.45 (m, 1H), 2.10-2.00 (m, 1H), 1.85-1.78 (m, 1H), 1.65-1.55 (m, 2H), 1.26 (s. 1H). 1 H-NMR (500 MHz, CDCl 3) δ 5.99-5.51 (d, J = 9.1 Hz, 1H), 5.88 (d, J = 9.1 Hz, 1H), 3.98-3.96 (m, 1H), 3.75-3.73 (m, 1H), 2.65 (s, 3H), 2.47-2.45 (m, 1H), 2.10-2.00 (s, 1H).
단계 6: t-부틸 ((1s,4s)-4-아크릴아미도시클로헥실)카바메이트의 제조Step 6: Preparation of t-butyl ((1s, 4s) -4-acrylamidocyclohexyl) carbamate
디클로로메탄 (6 mL)에 t-부틸 ((1s,4s)-4-아미노시클로헥실)카바메이트 (517 mg, 2.4 mmol)을 녹이고, 아크릴산 (668 μL, 9.6 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (2.9 g, 19.3 mmol), 히드록시벤조트리아졸 (2.6 g, 19.3 mmol), 디이소프로필에틸아민 (3.6 mL, 19.3 mmol)을 가한 후, 상온에서 13 시간 동안 교반한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (175 mg, 30%)(517 mg, 2.4 mmol) was dissolved in dichloromethane (6 mL) and acrylic acid (668 L, 9.6 mmol) and 1-ethyl-3- (2.9 g, 19.3 mmol), hydroxybenzotriazole (2.6 g, 19.3 mmol) and diisopropylethylamine (3.6 mL, 19.3 mmol) were added to a solution of Lt; / RTI > Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (175 mg, 30%).
1H-NMR (500 MHz, CDCl3) δ 6.39 (d, J = 18.1 Hz, 1H), 6.16-6.06 (m, 1H), 5.87 (d, J = 9.1 Hz, 1H), 5.85-5.84 (m, 1H), 4.60-4.45 (m, 1H), 3.93 (s, 1H), 3.62 (s, 1H), 2.55-2.52 (m, 1H), 1.85-1.75 (m, 2H), 1.65-1.50 (m, 2H), 1.48 (s, 9H), 1.35-1.25 (m, 2H), 0.83-0.80 (m, 1H). 1 H-NMR (500 MHz, CDCl 3 )? 6.39 (d, J = 18.1 Hz, 1H), 6.16-6.06 (m, 1H), 5.87 (d, J = 9.1 Hz, 1H), 5.85-5.84 1H), 4.60-4.45 (m, 1H), 3.93 (s, 1H), 3.62 (s, 1H), 2.55-2.52 , 2H), 1.48 (s, 9H), 1.35-1.25 (m, 2H), 0.83-0.80 (m, 1H).
단계 7: N-((1s,4s)-4-아미노시클로헥실)아크릴아미드의 제조Step 7: Preparation of N - ((1s, 4s) -4-aminocyclohexyl) acrylamide
t-부틸 ((1s,4s)-4-아크릴아미도시클로헥실)카바메이트 (150 mg, 0.82 mmol)에 염산 (4M in 1,4-디옥산, 20 mL)을 가하고, 메탄올 (2 mL)를 가하고 녹인 후, 15분간 상온에서 교반한다. 반응이 종결되면 용매를 제거하고, 에테르로 재결정하여 목적화합물을 얻었다. (150 mg, 70%)(4M in 1,4-dioxane, 20 mL) was added to t-butyl ((1s, 4s) -4- acrylamidocyclohexyl) carbamate (150 mg, 0.82 mmol) And the mixture is stirred at room temperature for 15 minutes. When the reaction was completed, the solvent was removed, and recrystallization with ether gave the desired compound. (150 mg, 70%).
1H-NMR (500 MHz, CDCl3) δ 6.39 (d, J = 18.1 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.1 Hz, 1H), 5.65-5.50 (m, 1H), 4.50-4.41 (m, 1H), 3.93 (s, 1H), 3.62 (s, 1H), 2.60-2.52 (m, 1H), 1.75-1.70 (m, 2H), 1.60-1.55 (m, 3H), 1.17 (s, 2H), 0.83-0.82 (m, 1H). 1 H-NMR (500 MHz, CDCl 3) δ 6.39 (d, J = 18.1 Hz, 1H), 6.16-6.06 (m, 1H), 5.88 (d, J = 12.1 Hz, 1H), 5.65-5.50 (m (M, 2H), 1.60-1.55 (m, 1H), 4.50-4.41 (m, 1H), 3.93 , 3H), 1.17 (s, 2H), 0.83 - 0.82 (m, 1H).
단계 8: N-((1s,4s)-4-((6-클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 8: Preparation of N - ((ls, 4s) -4 - ((6-Chloro-3-methyl-1- (tetrahydro- Pyrimidin-4-yl) amino) cyclohexyl) acrylamide
디메틸포름아미드 (6mL)에 4,6-디클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (362 mg, 1.26 mmol)을 녹인 뒤, N-((1s,4s)-4-아미노시클로헥실)아크릴아미드 (234 mg, 1.39 mmol), 탄산칼륨 (1.7 mg, 12.6 mmol)을 넣고 상온에서 13시간 동안 교반한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (30 mg, 6%)To a solution of 4,6-dichloro-3-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H- pyrazolo [3,4- d] pyrimidine (362 mg, 1.26 mmol), and then N - ((1s, 4s) -4-aminocyclohexyl) acrylamide (234 mg, 1.39 mmol) and potassium carbonate (1.7 mg, 12.6 mmol), and the mixture was stirred at room temperature for 13 hours. Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (30 mg, 6%).
1H-NMR (500 MHz, CDCl3 δ 6.35-6.34 (m, 1H), 6.10-6.05 (m, 1H), 5.90-5.81 (m, 1H), 5.70-5.57 (m, 2H), 4.36 (s, 1H), 3.80-3.73 (m, 2H), 2.59 (s, 2H), 2.50-2.44 (m, 1H), 2.16 (s, 3H), 1.90-1.85 (m, 2H), 1.80-1.65 (m, 6H), 1.54 (s, 4H). 1 H-NMR (500 MHz, CDCl 3 (m, 2H), 4.36 (s, 1H), 3.80-3.73 (m, 2H), 5.70-5.57 2H), 2.59 (s, 2H), 2.50-2.44 (m, 1H), 2.16 (s, 3H), 1.90-1.85 .
단계 9: N-((1s,4s)-4-((3-메틸-6-((4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 9: N - ((lS, 4S) -4 - ((3-Methyl-6- Gt; [3,4-d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide
t-부탄올 (2 mL)에 N-((1s,4s)-4-((6-클로로-3-메틸-1-(테트라히드로-2H-피란-2-yl)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (25 mg, 0.059 mmol)을 용해시키고, 4-모폴리노아닐린 (11 mg, 0.059 mmol)과 Pd2(dba)3 (4 mg, 0.006 mmol), XPhos (8 mg, 0.017 mmol), 탄산칼륨 (25 mg, 0.17 mmol)을 가하고, 질소를 충전시킨 후, 90oC에서 14시간 교반 한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (14 mg, 42%) To a solution of N - ((1s, 4s) -4 - ((6-chloro-3-methyl-1- (tetrahydro- , 4-d] pyrimidin-4-yl) amino) cyclohexyl) dissolving acrylamide (25 mg, 0.059 mmol) and 4-morpholino aniline (11 mg, 0.059 mmol) and Pd 2 (dba) 3 (4 mg, 0.006 mmol), XPhos (8 mg, 0.017 mmol), potassium carbonate (25 mg, 0.17 mmol), and the mixture was stirred at 90 ° C for 14 hours. Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (14 mg, 42%).
1H-NMR (500 MHz, CDCl3) δ 7.58 (d, J = 12.1 Hz, 2H), 6.95-6.91 (d, J = 12.1 Hz, 2H), 6.30-6.23 (m, 2H), 5.65-5.62 (m, 2H), 4.25-4.20 (m, 1H), 4.10-3.95 (m, 2H), 3.72-3.68 (m, 3H), 3.12-3.07 (m, 3H), 2.51 (s, 3H), 2.41 (s, 1H), 2.05-1.88 (m, 2H), 1.80-1.75 (m, 6H), 1.60-1.50 (m, 2H), 1.35-1.25 (m, 6H), 0.87-0.83 (m, 4H). 1 H-NMR (500 MHz, CDCl 3) δ 7.58 (d, J = 12.1 Hz, 2H), 6.95-6.91 (d, J = 12.1 Hz, 2H), 6.30-6.23 (m, 2H), 5.65-5.62 (m, 3H), 2.51 (s, 3H), 2.41 (m, 2H), 4.25-4.20 (m, (m, 2H), 1.35-1.25 (m, 6H), 0.87-0.83 (m, 4H) .
단계 10: N-((1s,4s)-4-((3-메틸-6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 10: N - ((lS, 4s) -4 - ((3-Methyl-6 - ((4-morpholinophenyl) amino) -lH- pyrazolo [3,4- d] pyrimidin- Yl) amino) cyclohexyl) acrylamide < / RTI >
N-((1s,4s)-4-((3-메틸-6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (14 mg, 0.025 mmol)에 염산 (4M, 1,4-디옥산, 4 mL)을 가하고, 메탄올 (1 mL)를 가하고 녹인 후, 15 분 간 상온에서 교반 한다. 반응이 종결되면 용매를 제거하고, 에테르로 재결정하여 목적화합물을 얻었다. (6 mg, 87%)N - ((1 S, 4 S) -4 - ((3-Methyl-6 - ((4-morpholinophenyl) amino) -1- (tetrahydro-2H- (4M, 1, 4-dioxane, 4 mL) was added to a solution of 4-amino-3- [3,4-d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide (14 mg, 0.025 mmol) ), And the mixture is stirred at room temperature for 15 minutes. When the reaction was completed, the solvent was removed, and recrystallization with ether gave the desired compound. (6 mg, 87%).
1H-NMR (500 MHz, CDCl3) δ 8.00 (s, 4H), 6.80-6.75 (m, 2H), 5.50 (d, J = 9.1 Hz, 1H), 4.50 (s, 1H), 4.44-4.30 (m, 4H), 4.28-4.25 (s, 1H), 4.00-3.90 (m, 5H), 3.55 (s, 1H), 2.98 (s, 3H), 2.80-1.98 (m, 7H): LCMS calculated for C25H32N8O2 = 476.26, found: 476.57. 1 H-NMR (500 MHz, CDCl 3) δ 8.00 (s, 4H), 6.80-6.75 (m, 2H), 5.50 (d, J = 9.1 Hz, 1H), 4.50 (s, 1H), 4.44-4.30 (m, 4H), 4.28-4.25 (s, 1H), 4.00-3.90 (m, 5H), 3.55 (s, C 25 H 32 N 8 O 2 = 476.26, found: 476.57.
<실시예 21> N-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Example 21 Synthesis of N- (3 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin- Manufacturing
단계 1: N-(3-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 1: Preparation of N- (3 - ((6 - ((4- morpholinophenyl) amino) -1- (tetrahydro-2H-pyran- Pyrimidin-4-yl) amino) phenyl) acrylamide
N-(3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드 (50 mg, 0.13 mmol) 를 1,4-디옥산 (2 mL) 에 녹인 용액에 4-모폴리노아닐린 (27 mg, 0.15 mmol), Pd2(dba)3 (6 mg, 0.006 mmol), Xphos (3 mg, 0.006 mmol) 과 세슘카보네이트 (122 mg, 0.38 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 140 oC에서 20분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 무수망초 (Na2SO4)로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트를 이용 정제하여 흰색 고체 목적화합물 (21 mg, 31%, 0.039 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide (27 mg, 0.15 mmol) and Pd 2 (dba) 3 (6 mg, 0.006 mmol) in DMF (50 mg, 0.13 mmol) Xphos (3 mg, 0.006 mmol) and cesium carbonate (122 mg, 0.38 mmol). The reaction mixture was degassed with argon for 10 minutes and stirred in a microwave reactor at 140 ° C for 20 minutes. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate (Na 2 SO 4 ) and then filtered. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography using hexane / ethyl acetate to obtain 21 mg (31% .
1H-NMR (300 MHz, CDCl3) δ 1.61-1.74 (m, 4H), 1.91-1.95 (m, 1H), 2.05-2.11 (m, 2H), 2.20-2.60 (m, 1H), 3.09-3.13 (m, 4H), 3.77-3.88 (m, 5H), 4.11-4.14 (m,1H), 5.72-5.83 (m,2H), 6.24-6.28 (m,1H), 6.43 (d, J = 6.8 Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H), 7.16-7.23 (m, 2H) 7.47-7.55 (m, 5H), 7.94 (s, 1H); LC/MS 541.00 [M + H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.61-1.74 (m, 4H), 1.91-1.95 (m, 1H), 2.05-2.11 (m, 2H), 2.20-2.60 (m, 1H), 3.09- 1H), 6.43 (d, J = 6.8 (m, 2H) Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H), 7.16-7.23 (m, 2H) 7.47-7.55 (m, 5H), 7.94 (s, 1H); LC / MS 541.00 [M + H & lt ; + & gt ; ].
단계 2: N-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 2: Preparation of N- (3 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-
N-(3-((6-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드 (20 mg, 0.039 mmol) 를 메탄올 (1 mL) 에 녹인 용액에 염산 (4 N, 에틸에테르, 1 mL) 을 가하고, 상온에서 30분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후, 에틸아세테이트를 이용하여 씻어준 후 흰색 고체 목적화합물 (11 mg, 61%, 0.022 mmol)를 얻었다Pyrazolo [3,4-d] pyrimidin-2-yl) - lH-pyrrolo [2,3- (4 N, ethyl ether, 1 mL) was added to a solution of 4-amino-4-hydroxyphenyl) acrylamide (20 mg, 0.039 mmol) in methanol (1 mL) and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was distilled off under reduced pressure to remove the solvent, and the residue was washed with ethyl acetate to obtain a white solid compound (11 mg, 61%, 0.022 mmol)
1H-NMR (300 MHz, CD3OD) δ 3.67 (brs, 4H), 4.12-4.15 (m, 4H), 5.81 (dd, J = 9.8 Hz, 2.1 Hz, 1H) 6.35-6.54 (m, 2H), 7.41-7.74 (m, 7H), 8.05 (s, 1H), 8.57 (s, 1H); LC/MS 456.95 [M + H+], 913.25 [2M+H+]. 1 H-NMR (300 MHz, CD 3 OD) δ 3.67 (brs, 4H), 4.12-4.15 (m, 4H), 5.81 (dd, J = 9.8 Hz, 2.1 Hz, 1H) 6.35-6.54 (m, 2H ), 7.41-7.74 (m, 7H), 8.05 (s, 1H), 8.57 (s, 1H); LC / MS 456.95 [M + H & lt ; + & gt ; ], 913.25 [2M + H & lt ; + & gt ; ].
<실시예 22> N-((1s, 4s)-4-((6-(4-페녹시페닐) -1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Example 22 Synthesis of N - ((1s, 4s) -4 - ((6- (4-phenoxyphenyl) -1 H- pyrazolo [3,4- d] pyrimidin- ) Preparation of acrylamide
단계 1: N-((1s,4s)-4-((6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 1: Preparation of N - ((1 S, 4 S) -4 - ((6- (4- phenoxyphenyl) -1- (tetrahydro- d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide
N-((1s,4s)-4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (50 mg, 0.12 mmol) 를 1,4-디옥산 (2 mL)에 녹인 용액에 (4-페녹시페닐)보론산 (32 mg, 0.15 mmol), PdCl2(PPh3)2. (6 mg, 0.006 mmol) 을 가하였다. 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 130 ℃에서 15분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후, 물을 가하여 반응을 종료시키고 에틸아세테이트로 추출하였다. 추출한 유기층을 무수망초 (Na2SO4)로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트를 이용 정제하여 흰색 고체 목적화합물 (31 mg, 46%, 0.060 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) -1H-pyrazolo [l, 5- (4-phenoxyphenyl) boronic acid (32 mg, 0.15 mmol) and PdCl 2 (PPh 3 ) were dissolved in 1,4-dioxane (2 mL) 3 ) 2. (6 mg, 0.006 mmol) was added. The reaction mixture was degassed with argon for 10 minutes and stirred at 130 < 0 > C for 15 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate (Na 2 SO 4 ) and filtered. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using hexane / ethyl acetate to obtain 31 mg (46% .
1H-NMR (300 MHz, CDCl3) δ 1.64-2.18 (m, 14H), 2.59-2.63 (m, 1H), 3.79-3.86 (m, 1H), 4.07-4.16 (m, 2H), 4.40 (brs, 1H), 5.62 (d, J = 9.9 Hz, 1H), 5.75 (brs, 1H), 6.08-6.14 (m, 2H), 6.28 (d, J = 17.1 Hz, 1H), 7.06-7.17 (m, 5H), 7.34-7.39 (m, 2H), 7.44-7.69 (m, 2H), 7.94 (s, 1H), 8.47 (d, J = 8.7 Hz, 2H); LC/MS 538.98 [M + H+]. 1 H-NMR (300 MHz, CDCl3) δ 1.64-2.18 (m, 14H), 2.59-2.63 (m, 1H), 3.79-3.86 (m, 1H), 4.07-4.16 (m, 2H), 4.40 (brs , 1H), 5.62 (d, J = 9.9 Hz, 1H), 5.75 (brs, 1H), 6.08-6.14 (m, 2H), 6.28 (d, J = 17.1 Hz, 1H), 7.06-7.17 (m, 5H), 7.34-7.39 (m, 2H), 7.44-7.69 (m, 2H), 7.94 (s, 1H), 8.47 (d, J = 8.7 Hz, 2H); LC / MS 538.98 [M + H & lt ; + & gt ; ].
단계 2: N-((1s,4s)-4-((6-(4-페녹시페닐) -1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 2: Preparation of N - ((1s, 4s) -4 - ((6- (4- phenoxyphenyl) -lH- pyrazolo [3,4- d] pyrimidin- 4- yl) amino) cyclohexyl) Preparation of amide
N-((1s,4s)-4-((6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (30 mg, 0.060 mmol) 를 메탄올 (1 mL) 에 녹인 용액에 염산 (4 N, 디에틸에테르, 0.2 mL)을 가하고, 상온에서 30분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후, 에틸아세테이트를 이용하여 씻어준 후 흰색 고체 목적화합물 (22 mg, 81%, 0.045 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) -1H-pyrazolo [3,4- Hydrochloric acid (4 N, diethyl ether, 0.2 mL) was added to a solution obtained by dissolving 30 mg (0.060 mmol) of the title compound in methanol (1 mL) . The reaction mixture was evaporated under reduced pressure to remove the solvent, and the residue was washed with ethyl acetate to obtain a white solid compound (22 mg, 81%, 0.045 mmol).
1H-NMR (300 MHz, CD3OD) δ 1.93-2.02 (m, 8H), 4.01 (brs, 1H), 4.61 (brs, 1H), 5.61 (d, J = 10 Hz, 2.1 Hz, 1H), 6.20-6.36 (m, 2H), 7.12-7.29 (m, 4H), 7.44-7.65 (m, 3H), 8.26 (d, J = 9.0 Hz, 1H), 8.69 (s, 1H); LC/MS 454.99 [M+H+], 909.27[2M+H+]. 1 H-NMR (300 MHz, CD 3 OD) δ 1.93-2.02 (m, 8H), 4.01 (brs, 1H), 4.61 (brs, 1H), 5.61 (d, J = 10 Hz, 2.1 Hz, 1H) , 6.20-6.36 (m, 2H), 7.12-7.29 (m, 4H), 7.44-7.65 (m, 3H), 8.26 (d, J = 9.0 Hz, 1H), 8.69 LC / MS 454.99 [M + H < + >], 909.27 [2M + H & lt ; + & gt ; ].
<실시예 23> N-((1s, 4s)-4-((6-(4-페녹시페녹시)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Example 23 Synthesis of N - ((1s, 4s) -4 - ((6- (4-phenoxyphenoxy) -lH- pyrazolo [3,4- d] pyrimidin- Hexyl) acrylamide
단계 1: N-((1s,4s)-4-((6-(4-페녹시페녹시)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 1: Preparation of N - ((1 s, 4s) -4 - ((6- (4- phenoxyphenoxy) -l- (tetrahydro-2H-pyran- -d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide
N-((1s,4s)-4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (50 mg, 0.12 mmol) 를 디메틸프름아미드 (2 mL) 에 녹인 용액에, 4-페녹시페놀 (34 mg, 0.19 mmol), 구리 (Cu, 9 mg, 0.15 mmol), 세슘카보네이트 (120 mg, 0.37 mmol), 에틸렌디아민 (촉매량) 을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 150 oC에서 15분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트 으로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트를 이용, 정제하여 흰색 고체 목적화합물 (36 mg, 53%, 0.065 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) -1H-pyrazolo [l, 5- 4-phenoxyphenol (34 mg, 0.19 mmol) and copper (Cu, 9 mg, 0.15 mmol) were dissolved in dimethylformamide (2 mL) , Cesium carbonate (120 mg, 0.37 mmol) and ethylenediamine (catalytic amount). The reaction mixture was degassed with argon for 10 minutes and stirred at 150 ° C for 15 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography using hexane / ethyl acetate to obtain 36 mg (53%, 0.065 mmol) of white solid.
1H-NMR (300 MHz, CDCl3) δ 1.59-2.18 (m, 12H), 2.50-2.64 (m, 1H), 3.69-3.81 (m, 1H), 4.02-4.10 (m, 3H), 5.62 (d, J = 9.9 Hz, 1H), 5.80-5.84 (m, 3H), 6.07-6.12 (m, 1H), 6.27 (d, J = 16.8 Hz, 1H), 6.89-7.08 (m, 4H), 7.10-7.19 (m, 3H), 7.32-7.37 (m, 2H), 7.87 (s, 1H); LC/MS 555.04 [M+H+]. 1 H-NMR (300 MHz, CDCl 3 )? 1.59-2.18 (m, 12H), 2.50-2.64 (m, 1H), 3.69-3.81 d, J = 9.9 Hz, 1H ), 5.80-5.84 (m, 3H), 6.07-6.12 (m, 1H), 6.27 (d, J = 16.8 Hz, 1H), 6.89-7.08 (m, 4H), 7.10 -7.19 (m, 3 H), 7.32-7.37 (m, 2 H), 7.87 (s, 1 H); LC / MS 555.04 [M + H & lt ; + & gt ; ].
단계 2: N-((1s,4s)-4-((6-(4-페녹시페녹시)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 2: N - ((ls, 4s) -4 - ((6- (4- phenoxyphenoxy) -lH- pyrazolo [3,4- d] pyrimidin- 4- yl) amino) cyclohexyl) Preparation of acrylamide
N-((1s,4s)-4-((6-(4-페녹시페녹시)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (30 mg) 를 메탄올 (1 mL) 에 녹인 용액에 염산 (4 N, 디에틸에테르, 0.2 mL)을 가하고, 상온에서 30분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후 에틸아세테이트를 이용하여 씻어준 후 흰색 고체로 목적화합물 (26 mg, 81%, 0.051 mmol)를 얻었다. N - ((1s, 4s) -4 - ((6- (4- phenoxy-phenoxy) - 1 - (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] (4 N, diethyl ether, 0.2 mL) was added to a solution obtained by dissolving the compound of formula (1) in methanol (1 mL), and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was distilled under reduced pressure to remove the solvent. The residue was washed with ethyl acetate and the desired compound (26 mg, 81%, 0.051 mmol) was obtained as a white solid.
1H-NMR (300 MHz, CD3OD) δ 1.53-1.85 (m, 8H), 3.82 (brs, 1H), 3.93 (brs, 1H), 5.64 (dd, J = 9.9 Hz, 2.1 Hz, 1H), 6.19-6.39 (m, 2H), 7.02-7.19 (m, 5H), 7.31-7.43 (m, 4H), 8.59 (s, 1H); LC/M S470.98 [M+H+], 941.20[2M+H+]. 1 H-NMR (300 MHz, CD 3 OD) δ 1.53-1.85 (m, 8H), 3.82 (brs, 1H), 3.93 (brs, 1H), 5.64 (dd, J = 9.9 Hz, 2.1 Hz, 1H) , 6.19-6.39 (m, 2H), 7.02-7.19 (m, 5H), 7.31-7.43 (m, 4H), 8.59 (s, 1H); LC / M S470.98 [M + H & lt ; + & gt ; ], 941.20 [2M + H & lt ; + & gt ; ].
<실시예 24> N-((1s, 4s)-4-((3-메틸-6-((4-(피페리딘-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Example 24 Synthesis of N - ((1S, 4S) -4 - ((3-Methyl-6 - ((4- (piperidin- 1 -yl) phenyl) amino) -1H-pyrazolo [ -d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide
단계 1: N-((1s,4s)-4-((3-메틸-6-((4-(피페리딘-1-일)페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 1: N - ((lS, 4s) -4 - ((3-Methyl-6 - ((4- (piperidin- 1- yl) phenyl) amino )- 1- (tetrahydro- Yl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide
t-부탄올 (2 mL)에 N-((1s,4s)-4-((6-클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (20 mg, 0.047 mmol)을 녹이고, 4-(피페리딘-1-일)아닐린 (8 mg, 0.048 mmol), Pd2(dba)3 (3 mg, 4.7 μmol), X-Phos (7 mg, 0.014 mmol), 탄산칼륨 (14 mg, 0.098 mmol)을 가하고, 질소를 충전시킨 후, 90 oC에서 14 시간 동안 교반 한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (15 mg, 86%) To a solution of N - ((ls, 4s) -4 - ((6-chloro-3-methyl-1- (tetrahydro- (Piperidin-1-yl) aniline (8 mg, 0.048 mmol) and Pd (4 mg) were dissolved in a mixture of tetrahydrofuran 2 (dba) 3 (3 mg, 4.7 μmol), X-Phos (7 mg, 0.014 mmol), potassium carbonate (14 mg, 0.098 mmol) were added, and the mixture was stirred at 90 ° C for 14 hours. Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (15 mg, 86%).
1H NMR (500 MHz, CDCl3) δ 7.49 (d, J = 12.1 Hz, 2H), 6.90 (d, J = 12.1 Hz, 2H), 6.76 s, 1H), 6.31-6.28 (m, 2H), 5.70-5.60 (m, 3H), 4.80-4.75 (m, 7H), 4.30-4.10 (m, 4H), 3.63-3.43 (m, 3H), 2.50 (s, 3H), 0.79-0.65 (m, 5H). 1 H NMR (500 MHz, CDCl 3) δ 7.49 (d, J = 12.1 Hz, 2H), 6.90 (d, J = 12.1 Hz, 2H), 6.76 s, 1H), 6.31-6.28 (m, 2H), (M, 3H), 4.80-4.75 (m, 7H), 4.30-4.10 (m, 4H), 3.63-3.43 ).
단계 2: N-((1s,4s)-4-((3-메틸-6-((4-(피페리딘-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 2: N - ((lS, 4s) -4 - ((3-Methyl-6 - ((4- (piperidin- l-yl) phenyl) amino) -1H-pyrazolo [ ] Pyrimidin-4-yl) amino) cyclohexyl) acrylamide
N-((1s,4s)-4-((3-메틸-6-((4-(피페리딘-1-일)페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (25 mg, 0.052 mmol)을 메탄올 (1 mL)에 가하고, 여기에 염산 (4 N, 1,4-디옥산, 4 mL)을 가한 다음, 15분간 상온에서 교반한다. 반응이 종결되면 용매를 제거하고, 에테르로 재결정하여 목적화합물을 얻었다. (2 mg, 12%)Amino] -1- (tetrahydro-2H-pyran-2-yl) - N - ((1S, 4S) -4- Yl) amino) cyclohexyl) acrylamide (25 mg, 0.052 mmol) was added to methanol (1 mL), and hydrochloric acid (4 N, 1,4-dioxane, 4 mL), and the mixture is stirred at room temperature for 15 minutes. When the reaction was completed, the solvent was removed, and recrystallization with ether gave the desired compound. (2 mg, 12%).
1H NMR (500 MHz, CDCl3) δ 7.85-7.72 (m, 4H), 6.30-6.25 (m, 2H), 5.64 (d, J = 9.1 Hz, 1H), 3.75-3.65 (m, 6H), 3.60-3.55 (m, 4H), 3.06 (s, 3H), 2.72 (s, 1H), 2.28-2.05 (m, 3H), 1.95-1.75 (m, 3H), 1.55-1.35 (m, 3H), 1.22 (s, 4H), 0.86 (s, 1H): LCMS calculated for C26H34N8O = 474.29, found : 474.60. 1 H NMR (500 MHz, CDCl 3 )? 7.85-7.72 (m, 4H), 6.30-6.25 (m, 2H), 5.64 (d, J = 9.1 Hz, (M, 3H), 1.45-1. 75 (m, 3H), 1.55-1. 35 (m, 3H) 1.22 (s, 4H), 0.86 (s, 1H): LCMS calculated for C 26 H 34 N 8 O = 474.29, found: 474.60.
<실시예 25> (R)-1-(3-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Example 25 Synthesis of (R) -1- (3 - ((6- (4-phenoxyphenyl) -lH- pyrazolo [3,4- d] pyrimidin-4-yl) amino) pyrrolidine- 1-yl) prop-2-en-1-one
단계 1: 1-((3R)-3-((6-(4- 페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Step 1: Preparation of l- ((3R) -3 - ((6- (4-phenoxyphenyl) -1- (tetrahydro- Pyrimidin-4-yl) amino) pyrrolidin-1-yl) prop-2-en-
1-((3R)-3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 (50 mg, 0.13 mmol)를 1,4-디옥산 (2 mL)에 녹인 용액에 (4-페녹시페닐 보론산 (34 mg, 0.16 mmol), 탄산나트륨 (42 mg, 0.39 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 110 oC에서 10분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후, 물을 가하여 반응을 종료시키고 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트를 이용 정제하여 흰색 고체 목적화합물 (30 mg, 45%, 0.058 mmol)를 얻었다.3,4-d] pyrimidin-4-yl) amino) -1H-pyrazolo [l, 5- 2-en-1-one (50 mg, 0.13 mmol) was dissolved in 1,4-dioxane (2 mL) was added (4-phenoxyphenylboronic acid mg, 0.16 mmol), sodium carbonate (42 mg, 0.39 mmol). The reaction mixture was degassed with argon for 10 minutes and stirred at 110 ° C for 10 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography using hexane / ethyl acetate to obtain a white solid compound (30 mg, 45%, 0.058 mmol).
1H-NMR (300 MHz, CDCl3) δ 1.60-2.63 (m, 9H), 3.64-3.96 (m, 5H), 4.12-4.16 (m, 1H), 4.96-5.17 (brs, 1H), 5.59-5.69 (m, 1H), 6.07 (d, J = 9.9 Hz, 1H), 6.31-6.42 (m, 2H), 7.07-7.26 (m, 5H), 7.36-7.69 (m, 4H), 8.19-8.24 (m, 1H), 8.50 (d, J = 8.7 Hz, 2H); LC/MS 510.98 [M+H+]. 1 H-NMR (300 MHz, CDCl 3 )? 1.60-2.63 (m, 9H), 3.64-3.96 (m, 5H), 4.12-4.16 5.69 (m, 1H), 6.07 (d, J = 9.9 Hz, 1H), 6.31-6.42 (m, 2H), 7.07-7.26 (m, 5H), 7.36-7.69 (m, 4H), 8.19-8.24 ( m, 1 H), 8.50 (d, J = 8.7 Hz, 2 H); LC / MS 510.98 [M + H & lt ; + & gt ; ].
단계 2: (R)-1-(3-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온의 제조Step 2: (R) -1- (3 - ((6- (4-phenoxyphenyl) -lH-pyrazolo [3,4- d] pyrimidin- 4- yl) amino) pyrrolidin- Yl) prop-2-en-1-one
1-((3R)-3-((6-(4- 페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온 (30 mg) 를 메탄올 (1 mL) 에 녹인 용액에 염산 (4 N, 디에틸에테르용액, 0.2 mL) 을 첨가하고 상온에서 30분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후 에틸아세테이트를 이용하여 씻어준 후 흰색 고체인 목적화합물 (21 mg, 78%, 0.045 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-3-ylmethyl) -1H-pyrazolo [l, 5- 1-yl) propion-2-en-1-one (30 mg) in methanol (1 mL) was added hydrochloric acid (4 N, ) And the mixture was stirred at room temperature for 30 minutes. The reaction mixture was distilled under reduced pressure to remove the solvent, and then washed with ethyl acetate to obtain the target compound (21 mg, 78%, 0.045 mmol) as a white solid.
1H-NMR (300 MHz, CD3OD) δ 2.30-2.55 (m, 2H), 3.74-3.17 (m, 4H), 5.18-5.27 (m, 1H), 5.74-5.82 (m, 1H), 6.27-6.34 (m, 1H), 6.57-6.72 (m, 1H), 7.12-7.29 (m, 5H), 7.44-7.49 (m, 2H), 8.30 (d, J = 8.7 Hz, 2H), 8.65 (s, 1H); LC/MS 426.88 [M + H+], 854.12 [2M+H+]. 1 H-NMR (300 MHz, CD 3 OD)? 2.30-2.55 (m, 2H), 3.74-3.17 (m, 4H), 5.18-5.27 (M, 2H), 8.30 (d, J = 8.7 Hz, 2H), 8.65 (s, 1H), 6.57-6.72 , 1H); LC / MS 426.88 [M + H & lt ; + & gt ; ], 854.12 [2M + H & lt ; + & gt ; ].
<실시예 26> N-((1s, 4s)-4-((6-([1, 1'-비페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Example 26 Synthesis of N - ((1 s, 4s) -4 - ((6 - ([1,1'-biphenyl] -4-ylamino) -1 H- pyrazolo [3,4- d] pyrimidine -4-yl) amino) cyclohexyl) acrylamide
단계 1: N-((1s,4s)-4-((6-([1,1'-비페닐]-4-일아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 1: Preparation of N - ((ls, 4s) -4 - ((6 - ([1,1'-biphenyl] Pyrazolo [3,4-d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide
N-((1s,4s)-4-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (50 mg, 0.12 mmol) 를 1,4-디옥산 (2 mL) 에 녹인 용액에 [1,1'-비페닐]-4-아민 (25 mg, 0.15 mmol), Pd2(dba)3 (6 mg, 0.006 mmol), Xphos (3 mg, 0.006 mmol), 세슘카보네이트 (120 mg, 0.37 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 140 oC에서 20분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트를 이용, 정제하여 흰색 고체 목적화합물 (40 mg, 61%, 0.074 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) -1H-pyrazolo [l, 5- 1,1'-biphenyl] -4-amine (25 mg, 0.15 mmol) was dissolved in 1,4-dioxane (2 mL) Pd 2 (dba) 3 (6 mg, 0.006 mmol), Xphos (3 mg, 0.006 mmol), cesium carbonate (120 mg, 0.37 mmol). The reaction mixture was degassed with argon for 10 minutes and stirred in a microwave reactor at 140 ° C for 20 minutes. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The solvent was distilled off under reduced pressure, and the solvent was removed. The residue was purified by silica gel column chromatography using hexane / ethyl acetate to obtain a white solid compound (40 mg, 61%, 0.074 mmol).
1H-NMR (300 MHz, CDCl3) δ 1.73-2.18 (m, 14H), 2.64 (brs, 1H), 3.60-3.82 (m, 1H), 5.60 (d, J = 10.2 Hz, 2H), 5.82-5.93 (m, 2H), 6.04-6.14 (m, 1H), 6.28 (d, J = 16.8 Hz, 1H), 7.26-7.34 (m, 3H), 7.41-7.46 (m, 2H), 7.55-7.61 (m, 4H), 7.75 (d, J = 8.7 Hz, 1H), 7.82 (s,1H); LC/MS537.97 [M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.73-2.18 (m, 14H), 2.64 (brs, 1H), 3.60-3.82 (m, 1H), 5.60 (d, J = 10.2 Hz, 2H), 5.82 2H), 7.55-7.61 (m, 2H), 6.04-6.14 (m, 1H), 6.28 (d, J = 16.8 Hz, 1H), 7.26-7.34 (m, 4 H), 7.75 (d, J = 8.7 Hz, 1 H), 7.82 (s, 1 H); LC / MS 537.97 [M + H & lt ; + & gt ; ].
단계 2: N-((1s,4s)-4-((6-([1,1'-비페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 의 제조Step 2: Preparation of N - ((1 S, 4 S) -4 - ((6 - ([1,1'-biphenyl] -4-ylamino) -1 H- pyrazolo [3,4- d] pyrimidin- -Yl) amino) cyclohexyl) acrylamide < / RTI >
N-((1s,4s)-4-((6-([1,1'-비페닐]-4-일아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (35 mg)를 메탄올 (1 mL) 에 녹인 용액에 염산 (4 N, 디에틸에테르용액, 0.2 mL) 을 첨가하고 상온에서 30분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후 에틸아세테이트를 이용하여 세척한 후 흰색 고체 목적화합물 (28 mg, 88%, 0.057 mmol)를 얻었다.4-ylamino) -1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazole- (4 N, diethyl ether solution, 0.2 mL) was added to a solution of 4-amino-5-methyl-pyrrolo [3,4-d] pyrimidin-4-yl) amino] cyclohexyl) acrylamide And the mixture was stirred at room temperature for 30 minutes. The reaction mixture was distilled under reduced pressure to remove the solvent, and the residue was washed with ethyl acetate to give the title compound as a white solid (28 mg, 88%, 0.057 mmol).
1H-NMR (300 MHz, CD3OD) δ 1.75-1.95 (m, 8H), 3.98 (brs, 1H), 34.2 (brs, 1H), 5.66 (d, J = 11.7 Hz, 1H), 6.23 (d, J = 17.4 Hz, 1H), 7.32-7.37 (m, 1H), 7.43-7.48 (m, 2H), 7.61-7.72 (m, 6H), 8.48 (s, 1H); LC/MS 453.91 [M+H+] , 907.24 [2M+H+]. 1 H-NMR (300 MHz, CD 3 OD) δ 1.75-1.95 (m, 8H), 3.98 (brs, 1H), 34.2 (brs, 1H), 5.66 (d, J = 11.7 Hz, 1H), 6.23 ( d, J = 17.4 Hz, 1H), 7.32-7.37 (m, 1H), 7.43-7.48 (m, 2H), 7.61-7.72 (m, 6H), 8.48 (s, 1H); LC / MS 453.91 [M + H & lt ; + & gt ; ], 907.24 [2M + H & lt ; + & gt ; ].
<실시예 27> N-((1s, 4s)-4-((2-((4-모폴리노페닐)아미노)-7H-피롤로[2, 3-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Example 27 Synthesis of N - ((1 s, 4s) -4 - ((2 - ((4-morpholinophenyl) amino) -7H- pyrrolo [2,3- d] pyrimidin- Amino) cyclohexyl) acrylamide < / RTI >
단계 1: 7H-피롤로[2,3-d]피리미딘-2,4-디올의 제조Step 1: Preparation of 7H-pyrrolo [2,3-d] pyrimidine-2,4-diol
6-아미노피리미딘-2,4-디올 (2.0 g, 15.7 mmol) 를 물 (20 mL) 에 녹인 용액에 나트륨아세테이트 (1.29 g, 23.60 mmol)을 첨가하고 80 oC로 가열하였다. 반응혼합물에 클로로아세트알데히드를 가한 후 80 oC에서 4시간 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 고체를 여과한 다음, 물로 씻어주어 갈색 고체 7H-피롤로[2,3-d]피리미딘-2,4-디올 (1.60 g, 66%, 10.6 mmol)를 얻었다.To a solution of 6-aminopyrimidine-2,4-diol (2.0 g, 15.7 mmol) in water (20 mL) was added sodium acetate (1.29 g, 23.60 mmol) and heated to 80 ° C. Chloroacetaldehyde was added to the reaction mixture, followed by stirring at 80 ° C for 4 hours. The reaction mixture was cooled to room temperature, and the solid was filtered and washed with water to obtain brown solid 7H-pyrrolo [2,3-d] pyrimidine-2,4-diol (1.60 g, 66%, 10.6 mmol).
1H-NMR (300 MHz, DMSO-d 6 ) δ 4.39 (s, 1H), 6.18 (s, 2H), 10.09 (s, 2H); LC/MS 151.97 [M + H+], 302.98 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 4.39 (s, 1H), 6.18 (s, 2H), 10.09 (s, 2H); LC / MS 151.97 [M + H & lt ; + & gt ; ], 302.98 [2M + H & lt ; + & gt ; ].
단계 2: 2,4-디클로로-7H- 피롤로[2,3-d]피리미딘-2,4-디올의 제조Step 2: Preparation of 2,4-dichloro-7H-pyrrolo [2,3-d] pyrimidine-2,4-
7H-피롤로[2,3-d]피리미딘-2,4-디올 (1.0 g, 6.6 mmol) 를 POCl3(4mL, 43.0 mmol))에 녹인 용액에 N,N-디메틸아닐린 (0.4 g, 3.3 mmol) 을 첨가하였다. 반응혼합물을 180 oC에서 20분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 얼음물을 가하여 반응을 종료시키고 생성된 고체를 여과한 다음, 실리카겔 칼럼 하에서 헥산s/EtOAc을 이용 정제하여 흰색 고체인 목적화합물 (300 mg, 25%, 1.59 mmol)를 얻었다.7H- pyrrolo [2,3-d] pyrimidine-2,4-diol (1.0 g, 6.6 mmol) in a solution dissolved in POCl 3 (4mL, 43.0 mmol) ) N, N- dimethyl aniline (0.4 g, 3.3 mmol). The reaction mixture was stirred at 180 ° C for 20 minutes. The reaction mixture was cooled to room temperature and ice water was added thereto to terminate the reaction. The resulting solid was filtered and purified by silica gel column chromatography using hexane / EtOAc to obtain the title compound (300 mg, 25%, 1.59 mmol) as a white solid .
1H-NMR (300 MHz, DMSO-d 6 ) 6.63 (d, J = 1.5 Hz, 1H), 7.70 (s, 1H), 12.76 (s, 1H); LC/MS 188.02 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) 6.63 (d, J = 1.5 Hz, 1H), 7.70 (s, 1H), 12.76 (s, 1H); LC / MS 188.02 [M + H & lt ; + & gt ; ].
단계 3: N-((1s,4s)-4-((2-클로로-7H-피롤로[2,3-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Step 3: Preparation of N - ((ls, 4s) -4 - ((2-chloro-7H-pyrrolo [2,3- d] pyrimidin-4- yl) amino) cyclohexyl) acrylamide
2,4-디클로로-7H- 피롤로[2,3-d]피리미딘-2,4-디올 (100 mg, 0.53 mmol) 를 디메틸프롬아미드 (2 mL) 에 녹인 용액에 시스-1,4-시클로헥산디아민 (73 mg, 0.64 mmol), K2CO3 (220 mg, 1.59mmol)을 첨가하였다. 반응혼합물을 80 oC에서 14시간 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 감압증류하여 용매 제거한 후 클로로포름:메탄올 (1:1)을 가하였다. 생성된 고체를 제거하고 남은 용액을 감압증류하여 얻은 고체 (100 mg, 0.38 mmol)를 다음, 반응에 그대로 사용하였다. 얻은 고체 (100 mg, 0.38 mmol)를 디메틸프롬아미드에 녹인 용액에 아크릴산 (32 mg, 0.45 mmol), HATU (285 mg, 0.75 mmol) and 트리에틸아민 (0.16 mL, 1.13 mmol)를 가하고 상온에서 12시간 동안 교반시켰다. 반응혼합물을 감압증류하여 용매를 제거한 후, 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트을 이용 정제하여 흰색 고체 목적화합물 (80 mg, 47%, 0.25 mmol)를 얻었다.To a solution of 2,4-dichloro-7H-pyrrolo [2,3-d] pyrimidine-2,4-diol (100 mg, 0.53 mmol) in dimethylformamide (2 mL) cyclohexanediamine (73 mg, 0.64 mmol), K 2 CO 3 (220 mg, 1.59 mmol). The reaction mixture was stirred at 80 o C for 14 hours. The reaction mixture was cooled to room temperature, distilled under reduced pressure to remove the solvent, and then chloroform: methanol (1: 1) was added. The resulting solid was removed and the remaining solution was distilled under reduced pressure. The solid (100 mg, 0.38 mmol) was used in the next reaction. Acrylic acid (32 mg, 0.45 mmol), HATU (285 mg, 0.75 mmol) and triethylamine (0.16 mL, 1.13 mmol) were added to a solution of the resulting solid (100 mg, 0.38 mmol) in dimethylformamide Lt; / RTI > The reaction mixture was distilled under reduced pressure to remove the solvent and then extracted twice with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The solvent was distilled off under reduced pressure, and the solvent was removed. The residue was purified by silica gel column chromatography using hexane / ethyl acetate to obtain a white solid compound (80 mg, 47%, 0.25 mmol).
1H-NMR (300 MHz, DMSO-d 6 ) δ 1.61-1.98 (m, 8H), 3.79 (brs, 1H), 3.99 (brs, 1H), 5.54 (d, J = 9.6 Hz, 1H), 6.05 (d, J = 16.5 Hz, 1H), 6.28-6.65 (m, 1H), 6.65 (s, 1H), 7.05 (s, 1H), 7.54 (s, 1H), 7.94 (s, 1H), 11.62 (s, 1H); LC/MS 319.89 [M + H+], 638.92 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 1.61-1.98 (m, 8H), 3.79 (brs, 1H), 3.99 (brs, 1H), 5.54 (d, J = 9.6 Hz, 1H), 6.05 (d , J = 16.5 Hz, IH), 6.28-6.65 (m, IH), 6.65 (s, IH), 7.05 s, 1H); LC / MS 319.89 [M + H & lt ; + & gt ; ], 638.92 [2M + H & lt ; + & gt ; ].
단계 4: N-((1s,4s)-4-((2-((4-모폴리노페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드의 제조Pyrrolo [2,3-d] pyrimidin-4-yl) amino) - lH-pyrrolo [2,3- Cyclohexyl) acrylamide
N-((1s,4s)-4-((2-클로로-7H-피롤로[2,3-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드 (40 mg, 0.13 mmol) 를 t-부탄올 (2 mL) 에 녹인 용액에 4-모포리노아닐린 (27 mg, 0.15 mmol), Pd2(dba)3 (6 mg, 0.006 mmol), Xphos (3 mg, 0.006 mmol), 세슘카보네이트 (52 mg, 0.38 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 90 oC에서 16시간 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 Na2SO4로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/EtOAc을 이용 정제하여 노란색 고체인 목적화합물 (15 mg, 26%, 0.030 mmol)를 얻었다.Amino) cyclohexyl) acrylamide (40 mg, 0.13 mmol) was added to a solution of N - ((1 s, 4s) -4- 4-morpholinoaniline (27 mg, 0.15 mmol), Pd 2 (dba) 3 (6 mg, 0.006 mmol), Xphos (3 mg, 0.006 mmol), cesium carbonate (52 mg, 0.38 mmol). For 10 minutes the reaction mixture with argon di Singh (degassing) and stirred for 16 hours at 90 o C. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over Na 2 SO 4 and filtered. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography using hexane / EtOAc to obtain the title compound (15 mg, 26%, 0.030 mmol) as a yellow solid.
1H-NMR (300 MHz, CDCl3) δ 1.71-2.05 (m, 8H), 3.09 (brs, 4H), 3.86 (brs, 4H), 4.08-4.11 (m, 1H), 4.23 (brs, 1H), 4.80-5.00 (m, 1H), 5.65 (d, J = 9.3 Hz, 1H), 6.12-6.18 (m, 2H), 6.28-6.33 (m, 1H), 6.49 (s, 1H), 6.71 (s, 1H), 6.89 (d, J = 8.7 Hz, 2H), 7.51 (d, J = 8.7 Hz, 2H), 9.41 (s, 1H); LC/MS 462.01 [M+H+], 923.38 [2M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.71-2.05 (m, 8H), 3.09 (brs, 4H), 3.86 (brs, 4H), 4.08-4.11 (m, 1H), 4.23 (brs, 1H) , 4.80-5.00 (m, 1H), 5.65 (d, J = 9.3 Hz, 1H), 6.12-6.18 (m, 2H), 6.28-6.33 , 6.99 (d, J = 8.7 Hz, 2H), 7.51 (d, J = 8.7 Hz, 2H), 9.41 (s, 1H); LC / MS 462.01 [M + H & lt ; + & gt ; ], 923.38 [2M + H & lt ; + & gt ; ].
<실시예 28> N-(2-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Example 28 Synthesis of N- (2 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin- Manufacturing
단계 1: N1-(6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)벤젠-1,2-디아민의 제조Step 1: N 1 - (6- chloro-l- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-yl) benzene-1,2- Preparation of diamine
4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (500 mg, 1.8 mmol) 를 에탄올 (5 mL) 에 녹인 용액에 1,2-페닐렌디아민 (247 mg, 2.19 mmol)과 Et3N (0.76mL, 5.49 mmol)을 첨가하고 상온에서 30분동안 교반하였다. 생성된 고체를 여과하고, 에탄올로 씻은 후 흰색 고체 목적화합물 (580 mg, 92%, 1.68 mmol)를 얻었다.A solution of 4,6-dichloro-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4- d] pyrimidine (500 mg, 1.8 mmol) Phenylenediamine (247 mg, 2.19 mmol) and Et 3 N (0.76 mL, 5.49 mmol) were added to the mixture, and the mixture was stirred at room temperature for 30 minutes. The resulting solid was filtered and washed with ethanol to give the title compound as a white solid (580 mg, 92%, 1.68 mmol).
LC/MS 344.89 [M + H+], 689.00 [2M+H+].LC / MS 344.89 [M + H & lt ; + & gt ; ], 689.00 [2M + H & lt ; + & gt ; ].
단계 2: N-(2-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 2: Pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide as a starting material, Manufacturing
N1-(6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)벤젠-1,2-디아민 (250 mg, 0.73 mmol) 를 테트라히드로퓨란 (10 mL) 에 녹인 용액에 아크릴산 (63 mg, 0.87 mmol). HATU (550 mg, 1.45 mmol), 트리에틸아민 (0.25 mL, 1.81 mmol)을 0 oC에서 첨가하였다. 반응혼합물을 상온에서 4시간 동안 교반시켰다. 물을 가하여 반응을 종료하고, 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (200 mg, 69%, 0.501 mmol)를 얻었다.N 1 - (6- chloro-l- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-yl) benzene-1,2-diamine (250 mg, 0.73 mmol) in tetrahydrofuran (10 mL) was added acrylic acid (63 mg, 0.87 mmol). HATU (550 mg, 1.45 mmol) and triethylamine (0.25 mL, 1.81 mmol) were added at 0 ° C. The reaction mixture was stirred at room temperature for 4 hours. Water was added to terminate the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the desired compound (200 mg, 69%, 0.501 mmol) as a white solid.
1H-NMR (300 MHz, CDCl3) δ 1.63-2.11 (m, 5H), 2.49 (brs, 1H), 3.79-3.83 (m, 1H), 4.08-4.13 (m, 1H), 5.80 (d, J = 10.2 Hz, 1H), 5.92 (d, J = 9.9 Hz, 1H), 6.20-6.29 (m, 1H), 6.45 (d, J = 16.8 Hz, 1H), 7.18-7.26 (m, 2H), 7.42-7.44 (m, 2H), 8.40 (brs, 2H); LC/MS 398.95 [M+H+], 997.07 [2M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.63-2.11 (m, 5H), 2.49 (brs, 1H), 3.79-3.83 (m, 1H), 4.08-4.13 (m, 1H), 5.80 (d, J = 10.2 Hz, 1H), 5.92 (d , J = 9.9 Hz, 1H), 6.20-6.29 (m, 1H), 6.45 (d, J = 16.8 Hz, 1H), 7.18-7.26 7.42-7.44 (m, 2H), 8.40 (br s, 2H); LC / MS 398.95 [M + H & lt ; + & gt ; ], 997.07 [2M + H & lt ; + & gt ; ].
단계 3: N-(2-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 3: Preparation of N- (2 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin-4- yl) amino) phenyl) acrylamide
N-(2-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드 (120 mg, 0.30 mmol) 를 염산 (0.08 M, 에톡시 에탄올, 3 mL, 10 mmol%)에 녹인 용액을 90 oC에서 16시간 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후, 생성된 고체를 여과하여 에탄올로 씻은 후, 흰색 고체인 목적화합물 (70 mg, 47%, 0.14 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide as a starting material, (120 mg, 0.30 mmol) in hydrochloric acid (0.08 M, ethoxyethanol, 3 mL, 10 mmol%) was stirred at 90 ° C for 16 hours. The reaction mixture was cooled to room temperature, and the resulting solid was filtered and washed with ethanol to obtain the desired compound (70 mg, 47%, 0.14 mmol) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.21 (brs, 4H), 3.83 (brs, 4H), 5.70 (d, J = 10.2 Hz, 1H), 6.21 (d, J = 17.4 Hz, 1H), 6.51-6.57 (m, 1H), 7.11 (brs, 2H), 7.24-7.39 (m, 4H), 7.59 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 6.9 Hz, 1H), 8.60 (br, 1H), 10.21 (brs, 1H), 11.30 (brs, 1H); LC/MS 456.99 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.21 (brs, 4H), 3.83 (brs, 4H), 5.70 (d, J = 10.2 Hz, 1H), 6.21 (d, J = 17.4 Hz, 1H J = 6.9 Hz, 1 H), 6.51-6.57 (m, 1 H), 7.11 (br s, 2H), 7.24-7.39 (m, 4H) , 8.60 (br, IH), 10.21 (brs, IH), 11.30 (brs, IH); LC / MS 456.99 [M + H & lt ; + & gt ; ].
<실시예 29> N-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Example 29 Synthesis of N- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin- Manufacturing
단계 1: N1-(6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)벤젠-1,4-디아민의 제조Step 1: N 1 - (6- chloro-l- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-yl) benzene-1,4- Preparation of diamine
4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (500 mg, 1.83 mmol) 를 에탄올(5 mL) 에 녹인 용액에 1,4-페닐렌디아민 (296 mg, 2.75 mmol) 과 Et3N (0.51 mL, 3.66 mmol)을 첨가하고 상온에서 30분동안 교반하였다. 생성된 고체를 여과하고, 에탄올로 씻은 후 엷은갈색 고체인 목적화합물 (615 mg, 98%, 1.7 mmol)를 얻었다.A solution of 4,6-dichloro-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4- d] pyrimidine (500 mg, 1.83 mmol) Phenylenediamine (296 mg, 2.75 mmol) and Et 3 N (0.51 mL, 3.66 mmol) were added to the mixture, and the mixture was stirred at room temperature for 30 minutes. The resulting solid was filtered and washed with ethanol to give the desired compound (615 mg, 98%, 1.7 mmol) as a pale brown solid.
LC/MS 344.89 [M + H+], 688.93 [2M+H+].LC / MS 344.89 [M + H & lt ; + & gt ; ], 688.93 [2M + H & lt ; + & gt ; ].
단계 2: N1-(6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 2: N 1 - (6- chloro-l- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide Manufacturing
N1-(6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)벤젠-1,4-디아민 (500 mg, 1.45 mmol) 를 디클로로메탄 (10 mL) 에 녹인 용액에 아크릴로일 클로라이드 (144 mg, 1.59 mmol), 트리에틸아민 (0.40 mL, 2.90 mmol)을 0 oC에서 첨가하였다. 반응혼합물을 상온에서 2시간 동안 교반시켰다. 물을 가하여 반응을 종료하고, 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물을 (380 mg, 66%, 0.95 mmol)를 얻었다.N 1 - (6- chloro-l- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-yl) benzene-1,4-diamine (500 acryloyl chloride (144 mg, 1.59 mmol) and triethylamine (0.40 mL, 2.90 mmol) were added at 0 ° C to a solution of the compound of formula The reaction mixture was stirred at room temperature for 2 hours. Water was added to terminate the reaction and extracted twice with ethyl acetate. The extracted organic layer was dried with magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the desired compound (380 mg, 66%, 0.95 mmol) as a white solid.
1H-NMR (300 MHz, CDCl3) δ 1.61-1.90 (m, 4H), 2.05 (brs, 1H), 2.45-2.48 (m, 1H), 3.76-3.82 (m, 1H), 4.08-4.14 (m, 1H), 5.81 (d, J = 9.9 Hz, 1H), 5.92 (d, J = 9.9 Hz, 1H), 6.24-6.33 (m, 1H), 6.45-6.50 (m, 1H), 7.36 (d, J = 8.4 Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.77 (s, 1H), 8.06 (s, 1H); LC/MS 399.00 [M+H+], 797.11 [2M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.61-1.90 (m, 4H), 2.05 (brs, 1H), 2.45-2.48 (m, 1H), 3.76-3.82 (m, 1H), 4.08-4.14 ( 1H), 5.81 (d, J = 9.9 Hz, 1H), 5.92 (d , J = 9.9 Hz, 1H), 6.24-6.33 J = 8.4 Hz, 2H), 7.62 (d, J = 7.5 Hz, 2H), 7.77 (s, 1H), 8.06 (s, 1H); LC / MS 399.00 [M + H & lt ; + & gt ; ], 797.11 [2M + H & lt ; + & gt ; ].
단계 3: N-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 3: Preparation of N- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin-4- yl) amino) phenyl) acrylamide
N1-(6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드 (80 mg, 0.20 mmol) 를 염산 (0.08 M, 에톡시 에탄올, 2 mL, 10 mmol%)에 녹인 용액을 90 oC에서 16시간 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후, 생성된 고체를 여과하여 에탄올로 씻은 후 흰색 고체인 목적화합물 (60 mg, 61%, 0.12 mmol)를 얻었다.N 1 - (6- chloro-l- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide (80 mg , 0.20 mmol) in hydrochloric acid (0.08 M, ethoxyethanol, 2 mL, 10 mmol%) was stirred at 90 ° C for 16 hours. The reaction mixture was cooled to room temperature, and the resulting solid was filtered and washed with ethanol to obtain the desired compound (60 mg, 61%, 0.12 mmol) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.23 (br, 4H), 3.82 (brs, 4H), 5.76 (d, J = 9.9 Hz, 1H), 6.25 (d, J = 16.8 Hz, 1H), 6.44-6.53 (m, 1H), 7.14 (brs, 1H), 7.44 (brs, 1H), 7.69 (s, 4H), 8.69 (brs, 1H), 10.11 (brs, 1H), 10.37 (s, 1H), 11.28 (brs, 1H); LC/MS 457.06 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.23 (br, 4H), 3.82 (brs, 4H), 5.76 (d, J = 9.9 Hz, 1H), 6.25 (d, J = 16.8 Hz, 1H 1H), 7.47 (s, 4H), 7.69 (s, 4H) 1H), 11.28 (br s, 1H); LC / MS 457.06 [M + H & lt ; + & gt ; ].
<실시예 30> N4, N6-bis(4-모폴리노페닐)-1H-피라졸로[3,4-d]피리미딘-4, 6-디아민의 제조Example 30 Preparation of N 4, N 6 -bis (4-morpholinophenyl) -1H-pyrazolo [3,4-d] pyrimidine-4,6-diamine
단계 1: 6-클로로-N-(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-아민의 제조Step 1: 6-Chloro-N- (4-morpholinophenyl) -l- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidin- Manufacturing
4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (500 mg, 1.83 mmol) 를 에탄올 (20 mL) 에 녹인 용액에 4-모폴리노아닐린 (195 mg, 1.09 mmol) 과 Et3N (0.20 mL, 1.46 mmol)을 첨가하고 상온에서 30분동안 교반하였다. 생성된 고체를 여과하고, 에탄올로 씻은 후 엷은노란색 고체인 목적화합물 (269 mg, 89%, 0.64 mmol)를 얻었다.A solution of 4,6-dichloro-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4-d] pyrimidine (500 mg, 1.83 mmol) It was added to 4-morpholino aniline (195 mg, 1.09 mmol) and Et 3 N (0.20 mL, 1.46 mmol) and stirred at room temperature for 30 minutes. The resulting solid was filtered and washed with ethanol to give the desired compound (269 mg, 89%, 0.64 mmol) as a pale yellow solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 1.55-1.97 (m, 5H), 2.35 (brs, 1H), 3.12 (brs, 4H), 3.63-3.77 (m, 5H), 3.91-3.95 (m, 1H), 5.77 (d, J = 9.9 Hz, 1H), 7.01 (d, J = 8.1 Hz, 2H), 7.58 (brs, 2H) 8.35 (brs, 1H), 10.36 (s, 1H); LC/MS 415.11 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6 )? 1.55-1.97 (m, 5H), 2.35 (br s, 1H), 3.12 (brs, 4H), 3.63-3.77 1H), 5.77 (d , J = 9.9 Hz, 1H), 7.01 (d, J = 8.1 Hz, 2H), 7.58 (brs, 2H) 8.35 (brs, 1H), 10.36 LC / MS 415.11 [M + H & lt ; + & gt ; ].
단계 2: N4,N6-비스(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민의 제조Step 2: N 4, N 6 - bis (4-morpholinophenyl) -1- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidine-4, Preparation of 6-diamine
6-클로로-N-(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-아민 (50 mg, 0.12 mmol) 를 1,4-디옥산 (2 mL) 에 녹인 용액에 4-모폴리노아닐린 (26 mg, 0.15 mmol), Pd2(dba)3 (6 mg, 0.006 mmol), Xphos (3 mg, 0.006 mmol), 세슘카보네이트 (118 mg, 0.36 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 120 oC에서 20분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트를 이용 정제하여, 흰색 고체인 목적화합물 (38 mg, 57%, 0.068 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-amine (50 mg, 0.20 mmol) , 0.12 mmol) in 1,4-dioxane (2 mL) was added 4-morpholinoaniline (26 mg, 0.15 mmol), Pd 2 (dba) 3 (6 mg, 0.006 mmol), Xphos (3 mg, 0.006 mmol), cesium carbonate (118 mg, 0.36 mmol). The reaction mixture was degassed with argon for 10 minutes and stirred at 120 ° C for 20 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added thereto to terminate the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography using hexane / ethyl acetate to give the title compound (38 mg, 57%, 0.068 mmol) as a white solid.
1H-NMR (300 MHz, CDCl3+CD3OD) δ 1.63-2.10 (m, 5H), 2.48 (brs, 1H), 3.15-3.17 (m, 8H), 3.74-3.89 (brs, 8H), 4.11 (brs, 1H), 5.77 (d, J = 9.9 Hz, 1H), 6.93-6.95 (m, 4H), 7.36-7.43 (m, 4H), 7.56-7.59 (m, 2H); LC/MS 557.03 [M+H+]. 1 H-NMR (300 MHz, CDCl 3 + CD 3 OD) δ 1.63-2.10 (m, 5H), 2.48 (brs, 1H), 3.15-3.17 (m, 8H), 3.74-3.89 (brs, 8H), 4.11 (brs, 1H), 5.77 (d, J = 9.9 Hz, 1H), 6.93-6.95 (m, 4H), 7.36-7.43 (m, 4H), 7.56-7.59 (m, 2H); LC / MS 557.03 [M + H & lt ; + & gt ; ].
단계 3: N4,N6-bis(4-모폴리노페닐)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민의 제조Step 3: Preparation of N 4 , N 6 -bis (4-morpholinophenyl) -1H-pyrazolo [3,4-d] pyrimidine-4,6-
N4,N6-비스(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민 (33 mg)를 메탄올 (1 mL) 에 녹인 용액에 4N HCl 디에틸에테르용액 (0.2 mL) 을 첨가하고 상온에서 30분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후 디에틸에테르를 이용하여 씻어준 후 흰색 고체인 목적화합물 (28 mg, 93%, 0.055 mmol)를 얻었다.N 4 , N 6 -bis (4-morpholinophenyl) -1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4- d] pyrimidine- (33 mg) in methanol (1 mL) was added 4N HCl diethyl ether solution (0.2 mL), and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was distilled under reduced pressure to remove the solvent, and then washed with diethyl ether to obtain the desired compound (28 mg, 93%, 0.055 mmol) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.31 (brs, 8H), 3.88 (brs, 8H), 7.32-7.37 (m, 1H), 7.28-7.49 (m, 6H), 7.71 (brs, 2H), 8.80 (brs, 1H), 10.34 (s, 1H), 10.45 (brs, 1H); LC/MS 473.04 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.31 (brs, 8H), 3.88 (brs, 8H), 7.32-7.37 (m, 1H), 7.28-7.49 (m, 6H), 7.71 (brs, 2H), 8.80 (br s, 1 H), 10.34 (s, 1 H), 10.45 (brs, 1 H); LC / MS 473.04 [M + H & lt ; + & gt ; ].
<실시예 31> N4-(3-아미노페닐)-N2-(4-모폴리노페닐)-7H-피롤로[2, 3-d]피리미딘-2, 4-디아민의 제조Example 31 Preparation of N 4 - (3-aminophenyl) -N 2 - (4-morpholinophenyl) -7H-pyrrolo [2,3- d] pyrimidine-2,4-diamine
단계 1: N1-(2-클로로-7H-피롤로[2,3-d]피리미딘-4-일)벤젠-1,3-디아민의 제조Step 1: Preparation of N 1 - (2-chloro-7H-pyrrolo [2,3-d] pyrimidin-4-yl) benzene-1,3-diamine
2,4-디클로로-7H-피롤로[2,3-d]피리미딘 (100 mg, 0.53 mmol)를 디메틸설폭사이드 (2 mL) 에 녹인 용액에 4-모폴리노아닐린 (86 mg, 0.79 mmol) 과 디이소프로필에틸아민 (0.19 mL, 1.06 mmol) 을 첨가하고 100 oC에서 6시간 동안 교반하였다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고, 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (100 mg, 72%, 0.38 mmol)를 얻었다.To a solution of 2,4-dichloro-7H-pyrrolo [2,3-d] pyrimidine (100 mg, 0.53 mmol) in dimethylsulfoxide (2 mL) was added 4-morpholinoaniline (86 mg, 0.79 mmol ) And diisopropylethylamine (0.19 mL, 1.06 mmol) were added, and the mixture was stirred at 100 ° C for 6 hours. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (100 mg, 72%, 0.38 mmol) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 5.07 (s, 2H), 6.29 (d, J = 7.8 Hz, 1H), 6.62 (s, 1H), 6.85-6.96 (m, 3H), 7.14 (d, J = 3.3 Hz, 1H), 9.38 (s, 1H), 11.80 (s, 1H); LC/MS 260.09 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 5.07 (s, 2H), 6.29 (d, J = 7.8 Hz, 1H), 6.62 (s, 1H), 6.85-6.96 (m, 3H), 7.14 (d, J = 3.3 Hz, 1 H), 9.38 (s, 1 H), 11.80 (s, 1 H); LC / MS 260.09 [M + H & lt ; + & gt ; ].
단계 2: N4-(3-아미노페닐)-N2-(4-모폴리노페닐)- 7H-피롤로[2,3-d]피리미딘-4-일)벤젠-1,3-디아민의 제조Step 2: N 4 - (3- aminophenyl) -N 2 - (4- morpholinophenyl) - 7H- pyrrolo [2,3-d] pyrimidin-4-yl) benzene-1,3-diamine Manufacturing
N1-(2-클로로-7H-피롤로[2,3-d]피리미딘-4-일)벤젠-1,3-디아민 (100 mg, 0.39 mmol) 를 1,4-디옥산 (2 mL) 에 녹인 용액에 4-모폴리노아닐린 (111 mg, 0.46 mmol), Pd2(dba)3 (18 mg, 0.019 mmol), Xphos (9 mg, 0.019 mmol), 세슘카보네이트 (372 mg, 1.16 mmol).을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 140 oC에서 10분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼 하에서 헥산/에틸아세테이트을 이용, 정제하여 흰색 고체인 목적화합물 (31 mg, 21%, 0.077 mmol)를 얻었다.N 1 - (2- chloro -7H- pyrrolo [2,3-d] pyrimidin-4-yl) benzene-1,3-diamine to 1,4-dioxane (100 mg, 0.39 mmol) ( 2 mL ) Was added 4-morpholinoaniline (111 mg, 0.46 mmol), Pd 2 (dba) 3 (18 mg, 0.019 mmol), Xphos (9 mg, 0.019 mmol), cesium carbonate (372 mg, 1.16 mmol). The reaction mixture was degassed with argon for 10 minutes and stirred at 140 ° C for 10 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added thereto to terminate the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography using hexane / ethyl acetate to obtain the target compound (31 mg, 21%, 0.077 mmol) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 2.98-2.99 (m, 4H), 3.69-3.71 (m, 4H), 4.87 (s, 2H), 6.21 (d, J = 7.5 Hz, 1H), 6.58 (s, 1H), 6.79-6.84 (m, 3H), 6.88-6.94 (m, 1H), 7.00 (d, J = 7.5 Hz, 1H), 7.25 (s, 1H), 7.64 (d, J = 8.7 Hz, 2H), 8.37 (s, 1H), 8.75 (s, 1H), 11.04 (s, 1H); LC/MS 402.24 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 2.98-2.99 (m, 4H), 3.69-3.71 (m, 4H), 4.87 (s, 2H), 6.21 (d, J = 7.5 Hz, 1H) , 6.58 (s, 1H), 6.79-6.84 (m, 3H), 6.88-6.94 (m, 1H), 7.00 (d, J = 7.5 Hz, 1H), 7.25 (s, 1H), 7.64 (d, J = 8.7 Hz, 2H), 8.37 (s, 1H), 8.75 (s, 1H), 11.04 (s, 1H); LC / MS 402.24 [M + H & lt ; + & gt ; ].
<실시예 32> N-(3-((4-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드의 제조Example 32 Synthesis of N- (3 - ((4 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin- Manufacturing
단계 1: N6-(3-아미노페닐)-N4-(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민의 제조Step 1: N 6 - (3- aminophenyl) -N 4 - (4- morpholinophenyl) - 1 - (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d ] Pyrimidine-4,6-diamine
6-클로로-N-(4- 아미노페닐)-1-(테트라히드로-2H-피란-2-일)-1H- 피라졸로 [3,4-d]피리미딘-4- 아민 (100 mg, 0.24 mmol) 를 1,4-디옥산 (2 mL) 에 녹인 용액에 1,3-페닐렌디아민 (39 mg, 0.36 mmol), Pd2(dba)3 (11 mg, 0.012 mmol), Xphos (6 mg, 0.012 mmol), 세슘카보네이트 (236 mg, 0.72 mmol)을 첨가하였다. 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 120 oC에서 20분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (62 mg, 53%, 0.065 mmol)를 얻었다.6-Chloro - N - (4- amino-phenyl) -1- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-amine (100 mg, 0.24 1,3-phenylene diamine (39 mg, 0.36 mmol), Pd 2 (dba) 3 (1 mL) was added to a solution of 4- (11 mg, 0.012 mmol), Xphos (6 mg, 0.012 mmol), cesium carbonate (236 mg, 0.72 mmol). The reaction mixture was degassed with argon for 10 minutes and stirred at 120 ° C for 20 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added thereto to terminate the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (62 mg, 53%, 0.065 mmol) as a white solid.
1H-NMR (300 MHz, CDCl3) δ 1.60-1.80 (m, 2H), 1.88-1.93 (m, 1H), 2.00-2.15 (m, 1H), 2.52 (brs, 1H), 3.18-3.20 (m, 4H), 3.64-3.79 (m, 3H), 3.87-3.89 (m, 4H), 4.11-4.13 (m, 1H), 5.80 (d, J = 9.0 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.89-6.96 (m, 4H), 7.01 (brs, 1H), 7.06-7.11 (m, 1H), 7.19( brs, 1H), 7.35 (d, J = 9.0 Hz, 2H); LC/MS 487.00 [M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.60-1.80 (m, 2H), 1.88-1.93 (m, 1H), 2.00-2.15 (m, 1H), 2.52 (brs, 1H), 3.18-3.20 ( J = 9.0 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 3.64-3.79 (m, 8.4 Hz, 1H), 6.89-6.96 (m, 4H), 7.01 (brs, 1H), 7.06-7.11 (m, 1H), 7.19 (brs, 1H), 7.35 (d, J = 9.0 Hz, 2H); LC / MS 487.00 [M + H & lt ; + & gt ; ].
단계 2: N-(3-((4-((4-모폴리노페닐아미노)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로 [3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드의 제조Step 2: Preparation of N- (3 - ((4 - ((4- morpholinophenylamino) amino) -1- (tetrahydro-2H-pyran-2-yl) -1H- pyrazolo [ ] Pyrimidin-6-yl) amino) phenyl) acrylamide
N6-(3-아미노페닐)-N4-(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민 (50 mg, 0.10 mmol)를 디클로로메탄 (2 mL) 에 녹인 용액에 아크릴산 (0.008 mL, 0.12 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (30 mg, 0.16 mmol), 히드록시벤조트리아졸 (21 mg, 0.16 mmol), 디이소프로필에틸아민 (0.04 mL, 0.21 mmol)을 첨가하고, 상온에서 4시간 동안 교반시켰다. 반응혼합물에 물을 가하여 반응을 종료시키고 디클로로메탄으로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (35 mg, 64%, 0.953 mmol)를 얻었다.N 6 - (3- aminophenyl) -N 4 - (4- morpholinophenyl) - 1 - (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidine (0.008 mL, 0.12 mmol) and 1-ethyl-3- (3-dimethylaminopyridine) carbodiimide (prepared as described in Example 1) were dissolved in dichloromethane 30 mg, 0.16 mmol), hydroxybenzotriazole (21 mg, 0.16 mmol) and diisopropylethylamine (0.04 mL, 0.21 mmol), and the mixture was stirred at room temperature for 4 hours. Water was added to the reaction mixture to terminate the reaction and extracted twice with dichloromethane. The extracted organic layer was dried with magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (35 mg, 64%, 0.953 mmol) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 1.52 (brs, 2H), 1.77-1.81 (m, 2H), 1.96 (brs, 1H), 2.34-2.39 (m, 1H), 3.04 (brs, 4H), 3.72 (brs, 5H), 3.87-3.91 (m, 1H), 5.72-5.74 (m, 1H), 5.87-5.98 (m, 1H), 6.14-6.26 (m, 1H), 6.41-6.51 (m, 1H), 6.90 (d, J = 8.7 Hz, 2H), 7.00 (d, J = 7.2 Hz, 1H), 7.12-7.18 (m, 1H), 7.28 (d, J = 8.4 Hz, 2H), 7.99 (br, 1H), 8.74 (br, 1H), 9.25 (s, 1H), 9.56 (s, 1H), 10.04 (s, 1H); LC/MS 540.11 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 1.52 (brs, 2H), 1.77-1.81 (m, 2H), 1.96 (brs, 1H), 2.34-2.39 (m, 1H), 3.04 (brs, (M, 1H), 3.72 (br s, 5H), 3.87-3.91 (m, 1H), 5.72-5.74 m, 1H), 6.90 (d , J = 8.7 Hz, 2H), 7.00 (d, J = 7.2 Hz, 1H), 7.12-7.18 (m, 1H), 7.28 (d, J = 8.4 Hz, 2H), 7.99 (br, IH), 8.74 (br, IH), 9.25 (s, IH), 9.56 (s, IH), 10.04 (s, IH); LC / MS 540.11 [M + H & lt ; + & gt ; ].
단계 3: N6-(3-아미노페닐)-N4-(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민의 제조Step 3: N 6 - (3- aminophenyl) -N 4 - (4- morpholinophenyl) - 1 - (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d ] Pyrimidine-4,6-diamine
N-(3-((4-((4-모폴리노페닐아미노)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로 [3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드 (30 mg) 를 메탄올 (1 mL) 에 녹인 용액에 염산 용액 (4 N, 디에틸에테르, 0.2 mL) 을 첨가하고 상온에서 30분 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후, 디에틸에테르을 이용하여 씻어준 후 흰색 고체인 목적화합물 (25 mg, 93%, 0.051 mmol)을 얻었다.Amino] -1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4-d] pyrimidine (4 N, diethyl ether, 0.2 mL) was added to a solution of 3-amino-2-pyrrolidin-1-ylmethylamino-phenyl) -acrylamide (30 mg) in methanol (1 mL) and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was distilled under reduced pressure to remove the solvent, and then washed with diethyl ether to obtain the desired compound (25 mg, 93%, 0.051 mmol) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.09 (brs, 4H), 3.74 (brs, 4H), 5.74 (d, J = 11.4 Hz, 1H), 6.23 (d, J = 16.8 Hz, 1H), 6.46-6.51 (m, 1H), 6.95 (brs, 2H), 7.23-7.52 (m, 3H), 7.62 (br, 2H), 7.81 (s, 1H), 8.60 (brs, 1H), 10.32 (s, 1H), 11.10 (brs, 1H); LC/MS 457.10 [M + H+], 913.89 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.09 (brs, 4H), 3.74 (brs, 4H), 5.74 (d, J = 11.4 Hz, 1H), 6.23 (d, J = 16.8 Hz, 1H ), 6.46-6.51 (m, 1H), 6.95 (brs, 2H), 7.23-7.52 (m, 3H), 7.62 (br, 2H) s, 1 H), 11.10 (brs, 1 H); LC / MS 457.10 [M + H & lt ; + & gt ; ], 913.89 [2M + H & lt ; + & gt ; ].
<실시예 33> N-(3-((2-((4-모폴리노페닐)아미노)-9H-퓨린-6-일)아미노)페닐)아크릴아미드의 제조Example 33 Preparation of N- (3 - ((2 - ((4-morpholinophenyl) amino) -9H-purin-6-yl) amino) phenyl) acrylamide
단계 1: 2,6-디클로로-9-(테트라히드로-2H-피란-2-일)-9H-퓨린의 제조Step 1: Preparation of 2,6-dichloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purine
2,6-디클로로-9H-퓨린 (300 mg, 1.59 mol) 를 에틸아세테이트 (5 mL) 에 녹인 용액에 3,4-디히드로-2H-피란 (360 mg, 4.3 mol) 와 p-톨루엔설폰산 (8 mg, 0.05 mmol) 을 첨가하고 50 oC에서 2시간 동안 교반하였다. 반응혼합물을 감압증류 하여 용매 제거한 후 실리카겔컬럼으로 정제하여 흰색 고체인 목적화합물 (301 mg, 70%, 1.1 mmol)를 얻었다.To a solution of 2,6-dichloro-9H-purine (300 mg, 1.59 mol) in ethyl acetate (5 mL) was added 3,4-dihydro-2H-pyran (360 mg, (8 mg, 0.05 mmol), and the mixture was stirred at 50 ° C for 2 hours. The reaction mixture was distilled under reduced pressure to remove the solvent, and the residue was purified by silica gel column chromatography to obtain the desired compound (301 mg, 70%, 1.1 mmol) as a white solid.
1H-NMR (300 MHz, CDCl3) δ 1.64-2.19 (m, 6H), 3.75-3.83 (m, 1H), 4.17-4.21 (m, 1H), 5.77 (dd, J = 2.4 Hz, 10.8 Hz, 1H), 8.34 (s, 1H); LC/MS 273.08 [M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.64-2.19 (m, 6H), 3.75-3.83 (m, 1H), 4.17-4.21 (m, 1H), 5.77 (dd, J = 2.4 Hz, 10.8 Hz , ≪ / RTI > 1H), 8.34 (s, 1H); LC / MS 273.08 [M + H & lt ; + & gt ; ].
단계 2: N-(3-((2-클로로-9-(테트라히드로 -2H-피란-2-일)-9H-퓨린-6-일)아미노)페닐)아크릴아미드의 제조Step 2: Preparation of N- (3- ((2-chloro-9- (tetrahydro-2H-pyran-2-yl) -9H- purin-
2,6-디클로로-9-(테트라히드로-2H-피란-2-일)-9H-퓨린 (100 mg, 0.37 mmol)를 에탄올 (2 mL) 에 녹인 용액에 N-(3-아미노페닐)아크릴아미드 (65 mg, 0.40 mmol)와 트리에틸아민 (0.13 mL, 0.92 mmol)을 첨가하고 80 oC에서 12시간 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 감압증류하고 물을 가한 후 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (78 mg, 56%, 0.19 mmol)를 얻었다.To a solution of 2,6-dichloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purine (100 mg, 0.37 mmol) in ethanol (2 mL) Amide (65 mg, 0.40 mmol) and triethylamine (0.13 mL, 0.92 mmol) were added and stirred at 80 ° C for 12 hours. The reaction mixture was cooled to room temperature, distilled under reduced pressure, and water was added thereto, followed by extraction with ethyl acetate twice. The organic layer was dried over magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the desired compound (78 mg, 56%, 0.19 mmol) as a white solid.
1H-NMR (300 MHz, CDCl3) δ 1.26-1.75 (m, 3H), 1.93-2.10 (m, 3H), 3.69-3.76 (m, 1H), 4.11 (d, J = 12.6 Hz, 1H), 5.66-5.72 (m, 2H), 6.26-6.43 (m, 2H), 7.19-7.28 (m, 1H), 7.37-7.46 (m, 2H), 7.94 (s, 1H), 8.02 (s, 1H), 8.27 (s, 1H), 8.33 (s, 1H); LC/MS 399.00 [M+H+], 797.31 [2M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.26-1.75 (m, 3H), 1.93-2.10 (m, 3H), 3.69-3.76 (m, 1H), 4.11 (d, J = 12.6 Hz, 1H) 2H), 7.94 (s, 1H), 8.02 (s, IH), 7.31-7. , 8.27 (s, 1 H), 8.33 (s, 1 H); LC / MS 399.00 [M + H & lt ; + & gt ; ], 797.31 [2M + H & lt ; + & gt ; ].
단계 3: N-(3-((2-((4-모폴리노페닐)아미노)-9H-퓨린-6-일)아미노)페닐)아크릴아미드의 제조Step 3: Preparation of N- (3 - ((2- ((4-morpholinophenyl) amino) -9H-purin-6-yl) amino) phenyl) acrylamide
N-(3-((2-클로로-9-(테트라히드로-2H-피란-2-일)-9H-퓨린-6-일)아미노)페닐)아크릴아미드 (50 mg, 0.13 mmol)를 HCl 용액 (0.08 M, ethoxy에탄올, 1.5 mL) 에 녹인 용액에 4-모폴리노아닐린 (27 mg, 0.15 mmol)을 가한 후, 100 oC에서 12시간 동안 교반시켰다. 반응혼합물을 상온으로 냉각 시킨 후, 생성된 고체를 여과하여 에탄올로 씻은 후, 회색 고체인 목적화합물 (35 mg, 57%, 0.070 mmol)를 얻었다.Amino) phenyl) acrylamide (50 mg, 0.13 mmol) was dissolved in an HCl solution (5 ml) 4-morpholinoaniline (27 mg, 0.15 mmol) was added to a solution of the compound (0.08 M, ethoxyethanol, 1.5 mL) and the mixture was stirred at 100 ° C for 12 hours. After the reaction mixture was cooled to room temperature, the resulting solid was filtered and washed with ethanol to obtain the desired compound (35 mg, 57%, 0.070 mmol) as a gray solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.11 (brs, 4H), 3.78 (m, 4H), 5.76 (d, J = 10.8 Hz, 1H), 6.27 (d, J = 17.1 Hz, 1H) 6.45-6.59 (m, 1H), 6.96-7.05 (m, 2H), 7.18-7.31 (m, 2H), 7.45-7.67 (m, 3H), 8.16 (s, 1H), 8.55 (s, 1H), 9.40 (s, 1H), 10.22 (s, 1H), 10.38 (s, 1H); LC/MS 457.19 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.11 (brs, 4H), 3.78 (m, 4H), 5.76 (d, J = 10.8 Hz, 1H), 6.27 (d, J = 17.1 Hz, 1H 2H), 7.45-7.67 (m, 3H), 8.16 (s, 1H), 8.55 (s, 1H) , 9.40 (s, 1H), 10.22 (s, 1H), 10.38 (s, 1H); LC / MS 457.19 [M + H & lt ; + & gt ; ].
<실시예 34> N-(3-((2-((4-모폴리노페닐)아미노)피리도[2, 3-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Example 34 Preparation of N- (3 - ((2 - ((4-morpholinophenyl) amino) pyrido [2,3- d] pyrimidin-4- yl) amino) phenyl) acrylamide
단계 1: N-(3-((2-클로로피리도[2,3-d]피리미딘-4-일)아미노페닐)페닐)아크릴아미드의 제조Step 1: Preparation of N- (3 - ((2-chloropyrido [2,3-d] pyrimidin-4-yl) aminophenyl) phenyl) acrylamide
2,4-디클로로피리도[2,3-d]피리미딘 (100 mg, 0.49 mmol) 를 에탄올 (2 mL) 에 녹인 용액에 N-(3-아미노페닐)아크릴아미드 (81 mg, 0.49 mmol) 과 디이소프로필에틸아민 (0.22 mL, 1.25 mmol)을 첨가하고 상온에서 4시간 동안 교반시켰다. 생성된 고체를 여과하고 에탄올로 씻은 후 엷은노란색 고체인 목적화합물 (126 mg, 78%, 0.38 mmol)를 얻었다.(3-aminophenyl) acrylamide (81 mg, 0.49 mmol) was added to a solution of 2,4-dichloropyrido [2,3-d] pyrimidine (100 mg, 0.49 mmol) And diisopropylethylamine (0.22 mL, 1.25 mmol) were added, and the mixture was stirred at room temperature for 4 hours. The resulting solid was filtered and washed with ethanol to give the desired compound (126 mg, 78%, 0.38 mmol) as a pale yellow solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 5.75 (d, J = 10.2 Hz, 1H), 6.25 (dd, J = 1.8 Hz, 17.1 Hz, 1H), 6.41-6.50 (m, 2H), 7.53 (d, J = 7.5 Hz, 1H), 7.63-7.67 (m, 1H), 8.09 (s, 1H), 9.00-9.04 (m, 2H), 10.25 (s, 1H), 10.45 (s, 1H); LC/MS 326.02 [M + H+], 651.10 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 5.75 (d, J = 10.2 Hz, 1H), 6.25 (dd, J = 1.8 Hz, 17.1 Hz, 1H), 6.41-6.50 (m, 2H), 2H), 10.25 (s, 1H), 10.45 (s, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.63-7.67 ; LC / MS 326.02 [M + H & lt ; + & gt ; ], 651.10 [2M + H & lt ; + & gt ; ].
단계 2: N-(3-((2-((4-모폴리노페닐)아미노)피리도[2,3-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 2: Preparation of N- (3 - ((2- ((4- morpholinophenyl) amino) pyrido [2,3- d] pyrimidin-4- yl) amino) phenyl) acrylamide
N-(3-((2-클로로피리도[2,3-d]피리미딘-4-일)아미노페닐)페닐)아크릴아미드 (100 mg, 0.35 mmol) 과 염산 (0.08 M, 에톡시에탄올 용액, 3 mL)을 혼합한 후, 100 oC에서 45분 교반시켰다. 반응혼합물을 상온으로 식힌 후, 생성된 고체를 여과하고, 여과한 고체를 탄산수소나트륨 수용액에 녹인 후, 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 노란색 고체인 목적화합물 (116 mg, 81%, 0.173 mmol)를 얻었다.Acrylamide (100 mg, 0.35 mmol) and hydrochloric acid (0.08 M, ethoxyethanol solution (100 mg, 0.35 mmol) were added to a solution of N- (3-chloropyrido [ , 3 mL) were mixed and stirred at 100 ° C for 45 minutes. The reaction mixture was cooled to room temperature, and the resulting solid was filtered, and the filtered solid was dissolved in an aqueous solution of sodium hydrogencarbonate and extracted twice with ethyl acetate. The extracted organic layer was dried with magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column to obtain the target compound (116 mg, 81%, 0.173 mmol).
1H-NMR (300 MHz, DMSO-d 6 ) δ 2.98 (brs, 4H), 3.70 (brs, 4H), 5.74 (d, J = 12.0 Hz, 1H), 6.25 (d, J = 16.8 Hz, 1H), 6.41-6.50 (m, 1H), 6.79-6.81 (m, 2H), 7.17-7.21 (m, 1H), 7.28-7.34 (m, 1H) 7.38 (d, J = 6.5 Hz, 1H), 7.67 (brs, 1H), 8.05 (s, 1H), 8.72-8.74 (m, 2H), 9.13 (brs, 1H), 9.82 (brs, 1H), 10.18 (s, 1H); LC/MS 467.18 [M + H+], 935.62 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 2.98 (brs, 4H), 3.70 (brs, 4H), 5.74 (d, J = 12.0 Hz, 1H), 6.25 (d, J = 16.8 Hz, 1H ), 6.41-6.50 (m, 1H) , 6.79-6.81 (m, 2H), 7.17-7.21 (m, 1H), 7.28-7.34 (m, 1H) 7.38 (d, J = 6.5 Hz, 1H), 7.67 (br s, 1H), 8.05 (s, 1H), 8.72-8.74 (m, 2H), 9.13 (br s, 1H), 9.82 (br s, 1H), 10.18 LC / MS 467.18 [M + H & lt ; + & gt ; ], 935.62 [2M + H & lt ; + & gt ; ].
<실시예 35> N-(3-((4-((4-모폴리노페닐)아미노)피리도[2, 3-d]피리미딘-2-일)아미노)페닐)아크릴아미드의 제조Example 35 Preparation of N- (3 - ((4 - ((4-morpholinophenyl) amino) pyrido [2,3- d] pyrimidin-2- yl) amino) phenyl) acrylamide
단계 1: 2-클로로-N-(4-모폴리노페닐)피리도[2,3-d]피리미딘-4-아민의 제조Step 1: Preparation of 2-chloro-N- (4-morpholinophenyl) pyrido [2,3-d] pyrimidin-
2,4-디클로로피리도[2,3-d]피리미딘 (200 mg, 0.99 mmol) 를 에탄올 (2 mL) 에 녹인 용액에 4-모폴리노아닐린 (196 mg, 1.09 mmol) 과 디이소프로필에틸아민 (0.44 mL, 2.49 mmol)을 첨가하고 상온에서 6시간 동안 교반시켰다. 생성된 고체를 여과하고 에탄올로 씻은 후 엷은초록색 고체인 목적화합물 (305 mg, 78%, 0.89 mmol)를 얻었다.To a solution of 2,4-dichloropyrido [2,3-d] pyrimidine (200 mg, 0.99 mmol) in ethanol (2 mL), 4-morpholinoaniline (196 mg, 1.09 mmol) and diisopropyl Ethylamine (0.44 mL, 2.49 mmol) was added and stirred at ambient temperature for 6 hours. The resulting solid was filtered and washed with ethanol to give the desired compound (305 mg, 78%, 0.89 mmol) as a pale green solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.11-3.12 (m, 4H), 3.73-3.74 (m, 4H), 7.00 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.7 Hz, 2H), 7.61-7.65 (m, 1H), 8.94 (d, J = 8.7 Hz, 1H), 9.01 (d, J = 4.2 Hz, 1H), 10.35 (s, 1H); LC/MS 341.98 [M + H+], 683.23 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.11-3.12 (m, 4H), 3.73-3.74 (m, 4H), 7.00 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.7 Hz, 2H), 7.61-7.65 (m, 1H), 8.94 (d, J = 8.7 Hz, 1H), 9.01 (d, J = 4.2 Hz, 1H), 10.35 (s, 1H); LC / MS 341.98 [M + H & lt ; + & gt ; ], 683.23 [2M + H & lt ; + & gt ; ].
단계 2: N-(3-((4-((4-모폴리노페닐)아미노)피리도[2,3-d]피리미딘-2-일)아미노)페닐)아크릴아미드의 제조Step 2: Preparation of N- (3 - ((4 - ((4- morpholinophenyl) amino) pyrido [2,3- d] pyrimidin-2- yl) amino) phenyl) acrylamide
2-클로로-N-(4-모폴리노페닐)피리도[2,3-d]피리미딘-4-아민 (50 mg, 0.15 mmol)) 를 디메틸아세트아미드 (3 mL)에 녹인 용액에 N-(3-아미노페닐)아크릴아미드 (28 mg, 0.18 mmol)을 첨가한 후 80 oC에서 6시간 교반시켰다. 반응혼합물을 상온으로 식힌 후 생성된 고체를 여과하여 노란색 고체인 목적화합물 (38 mg, 56%, 0.081 mmol)를 얻었다.To a solution of 2-chloro-N- (4-morpholinophenyl) pyrido [2,3-d] pyrimidin-4-amine (50 mg, 0.15 mmol) in dimethylacetamide - (3-aminophenyl) acrylamide (28 mg, 0.18 mmol) was added thereto, followed by stirring at 80 ° C for 6 hours. The reaction mixture was cooled to room temperature, and the resulting solid was filtered to obtain the desired compound (38 mg, 56%, 0.081 mmol) as a yellow solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.09 (brs, 4H), 3.74 (brs, 4H), 5.76 (d, J = 11.1 Hz, 1H), 6.25 (d, J = 15.9 Hz, 1H), 6.45-6.54 (m, 1H), 6.91 (d, J = 8.7 Hz, 2H), 7.23-7.28 (m, 1H), 7.35 (brs, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.47-7.58 (m, 3H), 7.89 (brs, 1H), 8.80 (d, J = 4.8 Hz, 1H), 9.14 (d, J = 7.8 Hz, 1H), 10.36 (s, 1H), 10.46 (s, 1H), 10.94 (brs, 1H); LC/MS 468.12 [M + H+], 935.62 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.09 (brs, 4H), 3.74 (brs, 4H), 5.76 (d, J = 11.1 Hz, 1H), 6.25 (d, J = 15.9 Hz, 1H ), 6.45-6.54 (m, 1H) , 6.91 (d, J = 8.7 Hz, 2H), 7.23-7.28 (m, 1H), 7.35 (brs, 1H), 7.46 (d, J = 7.8 Hz, 1H) , 7.47-7.58 (m, 3H), 7.89 (br s, 1H), 8.80 (d, J = 4.8 Hz, 1H), 9.14 (d, J = 7.8 Hz, 1H), 10.36 s, 1 H), 10.94 (brs, 1 H); LC / MS 468.12 [M + H & lt ; + & gt ; ], 935.62 [2M + H & lt ; + & gt ; ].
<실시예 36> N2, N4-비스(4-모폴리노페닐)피리도[2, 3-d]피리미딘-2, 4-디아민의 제조 Example 36 Preparation of N 2, N 4 -bis (4-morpholinophenyl) pyrido [2,3-d] pyrimidine-2,4-diamine
단계 1: 2-클로로-N-(4-모폴리노페닐)피리도[2,3-d]피리미딘-4-아민의 제조Step 1: Preparation of 2-chloro- N- (4-morpholinophenyl) pyrido [2,3-d] pyrimidin-
2,4-디클로로피리도[2,3-d]피리미딘 (200 mg, 0.99 mmol) 를 에탄올 (2 mL)에 녹인 용액에 4-모폴리노아닐린 (196 mg, 1.1 mmol) 과 디이소프로필에틸아민 (0.44 mL, 2.49 mmol)을 첨가하고 상온에서 6시간 동안 교반시켰다. 생성된 고체를 여과하고 에탄올로 씻은 후, 엷은초록색 고체인 목적화합물 (305 mg, 78%, 0.89 mmol)를 얻었다.To a solution of 2,4-dichloropyrido [2,3-d] pyrimidine (200 mg, 0.99 mmol) in ethanol (2 mL) was added 4-morpholinoaniline (196 mg, 1.1 mmol) and diisopropyl Ethylamine (0.44 mL, 2.49 mmol) was added and stirred at ambient temperature for 6 hours. The resulting solid was filtered and washed with ethanol to give the desired compound (305 mg, 78%, 0.89 mmol) as a pale green solid.
1H-NMR (300MHz, DMSO-d 6 ) δ 3.11-3.12 (m, 4H), 3.73-3.74 (m, 4H), 7.00 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.7 Hz, 2H), 7.61-7.65 (m, 1H), 8.94 (d, J = 8.7 Hz, 1H), 9.01 (d, J = 4.2 Hz, 1H), 10.35 (s, 1H); LC/MS 341.98 [M + H+], 683.23 [2M+H+]. 1 H-NMR (300MHz, DMSO- d 6) δ 3.11-3.12 (m, 4H), 3.73-3.74 (m, 4H), 7.00 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.7 Hz, 2H), 7.61-7.65 (m, 1H), 8.94 (d, J = 8.7 Hz, 1H), 9.01 (d, J = 4.2 Hz, 1H), 10.35 LC / MS 341.98 [M + H & lt ; + & gt ; ], 683.23 [2M + H & lt ; + & gt ; ].
단계 2: N2,N4-비스(4-모폴리노페닐)피리도[2,3-d]피리미딘-2,4-디아민의 제조Step 2: Preparation of N 2 , N 4 -bis (4-morpholinophenyl) pyrido [2,3-d] pyrimidine-2,4-
2-클로로-N-(4-모폴리노페닐)피리도[2,3-d]피리미딘-4-아민 (50 mg, 0.15 mmol)) 를 디메틸아세트아미드 (3 mL)에 녹인 용액에 4-모폴리노아닐린 (32 mg, 0.18 mmol)을 첨가한 후, 80 oC에서 4시간 교반시켰다. 반응혼합물을 상온으로 식힌 후 생성된 고체를 여과하여 노란색 고체인 목적화합물 (41 mg, 59%, 0.085 mmol)를 얻었다.To a solution of 2-chloro- N- (4-morpholinophenyl) pyrido [2,3- d] pyrimidin-4-amine (50 mg, 0.15 mmol) in dimethylacetamide -Morpholinoaniline (32 mg, 0.18 mmol) was added thereto, followed by stirring at 80 ° C for 4 hours. The reaction mixture was cooled to room temperature, and the resulting solid was filtered to obtain the objective compound (41 mg, 59%, 0.085 mmol) as a yellow solid.
1H-NMR (300 MHz, DMSO-d 6) δ 3.06-3.15 (m, 8H), 3.75-3.76 (m, 8H), 6.89 (d, J = 9.0 Hz, 2H), 6.97 (d, J = 9.0 Hz, 2H), 7.39-7.61 (m, 5H), 8.77 (d, J = 4.2 Hz, 1H), 8.91 (d, J = 7.8 Hz, 1H), 9.77 (br, 1H), 10.41 (br, 1H); LC/MS 484.24 [M + H+], 968.02 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) (m, 8H), 6.89 (d, J = 9.0 Hz, 2H), 6.97 (d, J = 9.0 Hz, 2H), 7.39-7.61 ), 8.77 (d, J = 4.2 Hz, 1H), 8.91 (d, J = 7.8 Hz, 1H), 9.77 (br, 1H), 10.41 (br, 1H); LC / MS 484.24 [M + H & lt ; + & gt ; ], 968.02 [2M + H & lt ; + & gt ; ].
<실시예 37> N-(3-((6-((4-(4-아세틸피페라진-1-일)페닐)아미노)-3-메틸-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Example 37 Synthesis of N- (3 - ((6 - ((4- (4-acetylpiperazin-1-yl) phenyl) amino) -3-methyl-1H-pyrazolo [3,4- 4-yl) amino) phenyl) acrylamide
단계 1: 1-(4-(4-((3-메틸-4-((3-니트로페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)피페라진-1-일)에탄온의 제조Step 1: Preparation of l- (4- (4 - ((3-methyl-4 - ((3-nitrophenyl) amino) -1- (tetrahydro- , 4-d] pyrimidin-6-yl) amino) phenyl) piperazin-1-yl) ethanone
t-부탄올 (2 mL)에 6-클로로-3-메틸-N-(3-니트로페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-아민 (50 mg, 0.12 mmol)을 녹이고, 1-(4-(4-아미노페닐)피페라진-1-일)에탄온 (36 mg, 0.16 mmol)과 Pd2(dba)3 (1.2 mg, 0.0013 mmol), XPhos (1.7 mg, 0.0038 mmol), 탄산칼륨 (43 mg, 0.31 mmol)을 가하고, 질소를 충전시킨 후, 90 oC에서 14 시간 동안 교반 한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (32 mg, 43.5%) To a solution of 6-chloro-3-methyl-N- (3-nitrophenyl) -l- (tetrahydro-2H-pyran-2-yl) -1H- pyrazolo [3,4- d (4-aminophenyl) piperazin-1-yl) ethanone (36 mg, 0.16 mmol) and Pd 2 (dba) 3 (1.2 mg, 0.0013 mmol), XPhos (1.7 mg, 0.0038 mmol), potassium carbonate (43 mg, 0.31 mmol) were added, and the mixture was stirred at 90 ° C for 14 hours. Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (32 mg, 43.5%).
1H NMR (300 MHz, CDCl3) δ 8.58 (s, 1H), 7.95-7.93 (d, 2H), 7.49-7.44 (d, 2H), 6.99-6.95 (d,2H), 6.91-6.88 (d, 2H), 5.77-5.74 (d, 1H), 4.15-4.13 (d, 1H), 3.82-3.75 (t, 3H), 3.65-3.62 (t, 3H), 3.16-3.09 (m, 4H), 2.66 (s, 3H), 2.15 (s, 3H), 1.92-1.87 (d, 1H), 1.80-1.69 (m, 5H). 1 H NMR (300 MHz, CDCl 3) δ 8.58 (s, 1H), 7.95-7.93 (d, 2H), 7.49-7.44 (d, 2H), 6.99-6.95 (d, 2H), 6.91-6.88 (d 2H), 5.77-5.74 (d, IH), 4.15-4.13 (d, IH), 3.82-3.75 (t, 3H), 3.65-3.62 (s, 3H), 2.15 (s, 3H), 1.92 - 1.87 (d, 1H), 1.80 - 1.69 (m, 5H).
단계 2: 1-(4-(4-((4-((3-아미노페닐)아미노)-3-메틸-1-(테트라히드로-2H-필란-2-일)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)필페라진-1-일)에탄온의 제조Step 2: Preparation of l- (4- (4 - ((4 - ((3-aminophenyl) amino) -3-methyl- 1- (tetrahydro- , 4-d] pyrimidin-6-yl) amino) phenyl) piperazin-1-yl) ethanone
메탄올 (2 mL)에 1-(4-(4-((3-메틸-4-((3-니트로페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)피페라진-1-일)에탄온 (30 mg, 0.052 mmol)을 녹인 후, Zn (17 mg, 0.26 mmol), 암모늄포메이트 (17 mg, 0.26 mmol)을 가하고, 상온에서 4시간 교반하였다. 반응 종료 후, 필터하고, 여액을 농축한 뒤, 에틸아세테이트/물을 가하여 생성물을 유기층으로 추출한 후, 유기층을 건조하고, 농축하여, 생성물을 얻고, 정제 하지 않고 다음 반응을 진행하였다. To a solution of 1- (4- (4 - ((3-methyl-4 - ((3-nitrophenyl) amino) -1- (tetrahydro-2H- (30 mg, 0.052 mmol), Zn (17 mg, 0.26 mmol) and ammonium formate were added to the solution, Mate (17 mg, 0.26 mmol) was added thereto, followed by stirring at room temperature for 4 hours. After completion of the reaction, the reaction mixture was filtered and the filtrate was concentrated. Ethyl acetate / water was added to extract the product as an organic layer. The organic layer was dried and concentrated to obtain the product.
단계 3: N-(3-((6-((4-(4-아세틸피페라진-1-일)페닐)아미노)-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 3: N- (3 - ((6 - ((4- (4-Acetylpiperazin-1-yl) phenyl) Pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide
디클로로메탄 (4 mL)에 1-(4-(4-((4-((3-아미노페닐)아미노)-3-메틸-1-(테트라히드로-2H-필란-2-일)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)필페라진-1-일)에탄온 (22 mg, 0.041 mmol)을 가하고, 여기에 아크릴산 (3.1 uL, 0.045 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (32 mg, 0.21 mmol), 히드록시벤조트리아졸 (28 mg, 0.21 mmol), 디이소프로필에틸아민 (38 mL, 0.21mmol)을 모두 가한 후, 상온에서 14 시간 동안 교반한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (2.7 mg, 3.3%)To a dichloromethane (4 mL) was added 1- (4- (4 - ((4 - ((3-aminophenyl) amino) -3-methyl- 1- (tetrahydro- Yl) ethanone (22 mg, 0.041 mmol) was added to the mixture, and thereto was added acrylic acid (3.1 uL, 0.045 mmol) and diisopropylethylamine (32 mg, 0.21 mmol), hydroxybenzotriazole (28 mg, 0.21 mmol) and diisopropylethylamine (38 mL, 0.21 mmol) were added to a solution of 1-ethyl-3- (3- dimethylaminopyridine) carbodiimide Followed by stirring at room temperature for 14 hours. Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (2.7 mg, 3.3%).
1H NMR (300 MHz, CDCl3) δ 8.25 (b, 1H), 7.59-7.56 (d, 2H), 7.43 (b, 1H), 7.33-7.30 (m, 2H), 7.10 (s, 1H), 6.94-6.93 (d, 2H), 6.87 (s, 1H), 6.51-6.47 (d, 1H), 6.30-6.25 (q, 1H), 5.81-5.77 (t, 2H), 4.17-4.16 (d, 1H), 3.81-3.77 (t, 4H), 3.66-3.61 (m, 4H), 3.16-3.11 (m, 4H), 2.67 (s, 3H), 2.17 (s, 1H), 1.80-1.69 (m, 5H). 1 H NMR (300 MHz, CDCl 3) δ 8.25 (b, 1H), 7.59-7.56 (d, 2H), 7.43 (b, 1H), 7.33-7.30 (m, 2H), 7.10 (s, 1H), 2H), 4.17-4.16 (d, 1H), 6.94-6.93 (d, 2H), 6.87 ), 3.81-3.77 (t, 4H), 3.66-3.61 (m, 4H), 3.16-3.11 (m, 4H), 2.67 ).
단계 4: N-(3-((6-((4-(4-아세틸피페라진-1-일)페닐)아미노)-3-메틸-1H-피라졸로[3,4-d]피리미딘-4-일아미노)페닐)아크릴아미드의 제조Step 4: Preparation of N- (3 - ((6 - ((4- (4-acetylpiperazin-1-yl) phenyl) amino) -3-methyl-lH- pyrazolo [3,4- 4-ylamino) phenyl) acrylamide
N-(3-((6-((4-(4-아세틸피페라진-1-일)페닐) 아미노)-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드 (4 mg 0.0067 mmol)를 메탄올 (1 mL)에 가하고, 여기에 염산 (4M, 1,4-디옥산, 1 mL)을 가하고, 15분간 상온에서 교반 한다. 반응이 종결되면 용매를 제거하고, 에테르로 재결정하여 목적화합물을 얻었다. (3.2 mg, 93%)Phenyl) amino) -3-methyl-l- (tetrahydro-2H-pyran-2-yl) -lH- (4 mg, 0.0067 mmol) was added to methanol (1 mL), and thereto was added hydrochloric acid (4M, 1, 4-dioxane, 1 mL) was added, and the mixture was stirred at room temperature for 15 minutes. When the reaction was completed, the solvent was removed, and recrystallization with ether gave the desired compound. (3.2 mg, 93%).
1H NMR (300 MHz, MeOH-d4) δ 7.85 (s, 1H), 7.67-7.55 (d, 2H), 7.49-.7.33 (m, 2H), 7.29-7.19 (m, 3H), 6.47-6.38 (m, 2H), 5.83-5.77 (d, 1H), 4.17-4.16 (d, 1H), 3.81-3.77 (t, 4H), 3.66-3.61 (m, 4H), 2.67 (s, 3H), 2.17 (s, 1H), 1.80-1.69 (m, 5H). 1 H NMR (300 MHz, MeOH -d 4) δ 7.85 (s, 1H), 7.67-7.55 (d, 2H), 7.49-.7.33 (m, 2H), 7.29-7.19 (m, 3H), 6.47- 4H), 2.67 (s, 3H), 3.67-3.67 (m, 2H), 6.38 (m, 2H), 5.83-5.77 (d, 2.17 (s, 1 H), 1.80 - 1.69 (m, 5 H).
<실시예 38> N-(3-((6-((4-(1-메틸-5, 6-디히드로-1, 2, 4-트리아진-4(1H)-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Example 38 Synthesis of N - (3 - ((6 - ((4- (1 -methyl-5,6-dihydro-1,2,4- Pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide
N-(3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드 (50 mg, 0.13 mmol) 과 HCl (0.08 M, 에톡시에탄올 용액, 1.3 mL) 을 혼합한 후 4-(1-메틸-5,6-디히드로-1,2,4-트리아진-4(1H)-일)아닐린 (27 mg, 0.15 mmol)을 첨가하고, 100 oC에서 6시간 교반시켰다. 반응혼합물을 상온으로 식힌 후 탄산수소나트륨 수용액을 가하여 반응을 종료시키고 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (15 mg, 26%, 0.032 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide (50 mg, 0.13 mmol) and HCl (0.08 M, ethoxyethanol solution, 1.3 mL) were mixed. Then, 4- (1-methyl-5,6-dihydro- 1H) -yl) aniline (27 mg, 0.15 mmol), and the mixture was stirred at 100 ° C for 6 hours. The reaction mixture was cooled to room temperature, and an aqueous solution of sodium hydrogencarbonate was added thereto to terminate the reaction. The reaction mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (15 mg, 26%, 0.032 mmol) as a white solid.
1H-NMR (300 MHz, CD3OD) δ 2.71 (s, 3H), 2.95-2.98 (m, 2H), 3.76-3.79 (m, 2H), 5.78 (dd, J = 3.0 Hz, 8.9 Hz, 1H), 6.39-6.43 (m, 2H), 6.99 (d, J = 8.7 Hz, 2H), 7.24 (s, 1H), 7.27-7.33 (m, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 9.0 Hz, 2H), 8.01 (s, 1H), 8.30 (s, 1H); LC/MS 413.36 [M+H+]. 1 H-NMR (300 MHz, CD 3 OD) δ 2.71 (s, 3H), 2.95-2.98 (m, 2H), 3.76-3.79 (m, 2H), 5.78 (dd, J = 3.0 Hz, 8.9 Hz, 1H), 6.39-6.43 (m, 2H ), 6.99 (d, J = 8.7 Hz, 2H), 7.24 (s, 1H), 7.27-7.33 (m, 1H), 7.40 (d, J = 7.8 Hz, 1H ), 7.48 (d , J = 7.8 Hz, 1H), 7.70 (d, J = 9.0 Hz, 2H), 8.01 (s, 1H), 8.30 LC / MS 413.36 [M + H & lt ; + & gt ; ].
<실시예 39> 1-(6-((6-((4-모포리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Example 39 Synthesis of 1- (6 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) prop-2-en-1-one
단계 1: 1-(6-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 1: l- (6 - ((6-Chloro-1- (tetrahydro-2H-pyran-2-yl) -lH-pyrazolo [3,4- d] pyrimidin- 1-yl) prop-2-en-1-one
4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (100 mg, 0.37 mmol) 을 에탄올 (2 mL)에 녹인 용액에 1-(6-아미노인돌린-1-일)프로페-2-엔-1-온 (76 mg, 0.40 mmol) 과 트리에틸아민 (0.13 mL, 0.92 mmol)을 첨가하고, 상온에서 4시간 교반시켰다. 반응혼합물을 0 oC로 냉각하고, 생성된 고체를 여과하고 에탄올로 세척하고, 흰색 고체인 목적화합물 (118 mg, 76%, 0.24 mmol)를 얻었다.A solution obtained by dissolving 4,6-dichloro-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4- d] pyrimidine (100 mg, 0.37 mmol) in ethanol 1-yl) prop-2-en-1-one (76 mg, 0.40 mmol) and triethylamine (0.13 mL, 0.92 mmol) Lt; / RTI > The reaction mixture was cooled to 0 ° C and the resulting solid was filtered and washed with ethanol to give the title compound as a white solid (118 mg, 76%, 0.24 mmol).
1H-NMR (300 MHz, DMSO-d 6 ) δ 1.56-2.03 (m, 5H), 2.32-2.43 (m, 1H), 3.15-3.19 (m, 2H), 3.65-3.73 (m, 1H), 3.94 (d, J = 11.7 Hz, 1H), 4.24-4.27 (m, 2H), 5.77-5.86 (m, 2H), 6.32 (d, J = 16.5 Hz, 1H), 6.72-6.81 (m, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.67 (brs, 1H), 8.38 (brs, 1H), 10.56 (s, 1H); LC/MS 425.16 [M + H+], 849.63 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 1.56-2.03 (m, 5H), 2.32-2.43 (m, 1H), 3.15-3.19 (m, 2H), 3.65-3.73 (m, 1H), 3.94 (d, J = 11.7 Hz , 1H), 4.24-4.27 (m, 2H), 5.77-5.86 (m, 2H), 6.32 (d, J = 16.5 Hz, 1H), 6.72-6.81 (m, 1H) , 7.30 (d , J = 8.1 Hz, 1H), 7.67 (brs, 1H), 8.38 (brs, 1H), 10.56 (s, 1H); LC / MS 425.16 [M + H & lt ; + & gt ; ], 849.63 [2M + H & lt ; + & gt ; ].
단계 2: 1-(6-((6-((4-모포리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 2: 1- (6 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 4- yl) amino) indolin- Prop-2-en-1-one
1-(6-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온 (50 mg, 0.12 mmol) 과 염산 (0.08M, 에톡시에탄올 용액, 1.2 mL) 을 혼합한 후 4-모폴리노아닐린 (25 mg, 0.14 mmol)을 첨가하고 90 oC에서 6시간 교반시켰다. 반응혼합물을 상온으로 식힌 후 소디움바이카보네이트수용액을 가하여 반응을 종료시키고, 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (15 mg, 27%, 0.031 mmol)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) amino) indolin-l-yl) -1- (6-chloro-1- (tetrahydro- Enol-1-one (50 mg, 0.12 mmol) and hydrochloric acid (0.08 M, ethoxyethanol solution, 1.2 mL) were mixed and then 4-morpholinoaniline (25 mg, 0.14 mmol ) And the mixture was stirred at 90 ° C for 6 hours. After the reaction mixture was cooled to room temperature, sodium bicarbonate aqueous solution was added to terminate the reaction and extracted twice with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and then vacuum distilled to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (15 mg, 27%, 0.031 mmol) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 2.96-3.08 (m, 4H), 3.16-3.18 (m, 2H), 3.73-3.76 (m, 4H), 4.09-4.11 (m, 2H), 4.82 (d, J = 9.3 Hz, 1H), 6.31 (d, J = 18.0 Hz, 1H), 6.74-6.86 (m, 3H), 7.21 (d, J = 8.1 Hz, 2H), 7.63 (t, J = 8.7 Hz, 2H), 8.06 (s, 1H), 8.33 (s, 1H), 8.87 (s, 1H), 9.71 (s, 1H), 12.85 (s, 1H); LC/MS 483.29 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 2.96-3.08 (m, 4H), 3.16-3.18 (m, 2H), 3.73-3.76 (m, 4H), 4.09-4.11 (m, 2H), 4.82 (d, J = 9.3 Hz , 1H), 6.31 (d, J = 18.0 Hz, 1H), 6.74-6.86 (m, 3H), 7.21 (d, J = 8.1 Hz, 2H), 7.63 (t, J = 8.7 Hz, 2H), 8.06 (s, 1H), 8.33 (s, 1H), 8.87 (s, 1H), 9.71 (s, 1H), 12.85 LC / MS 483.29 [M + H & lt ; + & gt ; ].
<실시예 40> 1-(6-((2-((4-모폴리노페닐)아미노)피리도[2, 3-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Example 40 Synthesis of 1- (6 - ((2 - ((4-morpholinophenyl) amino) pyrido [2,3- d] pyrimidin- 4- yl) amino) indolin- Prop-2-en-1-one
단계 1: 1-(6-((2-클로로피리도[2,3-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 1: Preparation of 1- (6 - ((2-chloropyrido [2,3-d] pyrimidin-4- yl) amino) indolin-1-yl) prop-
2,4-디클로로피리도[2,3-d]피리미딘 (100 mg, 0.50 mmol) 을 n-부탄올 (2 mL) 에 녹인 용액에 1-(6-아미노인돌린-1-일)프로페-2-엔-1-온 (103 mg, 0.55 mmol) 과 디이소프로필에틸아민 (0.22 mL, 1.25 mmol)을 첨가하고 상온에서 4시간 교반시켰다. 반응혼합물을 0 oC로 식힌 후 생성된 고체를 여과하고 에탄올로 씻어 노란색 고체인 목적화합물 (166 mg, 95%, 0.47 mmol)를 얻었다.To a solution of 2,4-dichloropyrido [2,3-d] pyrimidine (100 mg, 0.50 mmol) in n-butanol (2 mL) was added 1- (6-aminoindolin- 2-en-1-one (103 mg, 0.55 mmol) and diisopropylethylamine (0.22 mL, 1.25 mmol) were added and the mixture was stirred at room temperature for 4 hours. The reaction mixture was cooled to 0 ° C, and the resulting solid was filtered and washed with ethanol to obtain the desired compound (166 mg, 95%, 0.47 mmol) as a yellow solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.19 (t, J = 8.1 Hz, 2H), 4.28 (t, J = 8.4 Hz, 2H), 5.85 (d, J = 10.5 Hz, 1H), 6.32 (d, J = 16.0 Hz, 1H), 6.73-6.82 (m, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 6.5 Hz, 1H), 7.65-7.69 (m, 1H), 8.46 (s, 1H), 9.03-9.05 (m, 2H), 10.52 (s, 1H); LC/MS 351.16 [M + H+],703.41[2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.19 (t, J = 8.1 Hz, 2H), 4.28 (t, J = 8.4 Hz, 2H), 5.85 (d, J = 10.5 Hz, 1H), 6.32 (d, J = 16.0 Hz , 1H), 6.73-6.82 (m, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 6.5 Hz, 1H), 7.65-7.69 (m , 8.46 (s, 1H), 9.03-9.05 (m, 2H), 10.52 (s, 1H); LC / MS 351.16 [M + H & lt ; + & gt ; ], 703.41 [2M + H & lt ; + & gt ; ].
단계 2: 1-(6-((2-((4-모폴리노페닐)아미노)피리도[2,3-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 2: Preparation of 1- (6 - ((2- ((4-morpholinophenyl) amino) pyrido [2,3- d] pyrimidin-4- yl) amino) indolin- 2-en-1-one
1-(6-((2-클로로피리도[2,3-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온 (50 mg, 0.14 mmol) 과 염산 (0.08M, 에톡시에탄올 용액, 1.4 mL)을 혼합한 후, 4-모폴리노아닐린 (30 mg, 0.17 mmol)을 첨가하고 90 oC에서 6시간 교반시켰다. 반응혼합물을 상온으로 식힌 후, 탄산수소나트륨 수용액을 가하여 반응을 종료시키고, 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼크로마토그라피로 정제하여 노란색 고체인 목적화합물 (25 mg, 36%, 0.051 mmol)를 얻었다.Indolin-1-yl) prop-2-en-1-one (50 mg, 0.14 mmol) was added to a solution of 1- (6-chloropyrido [ mmol) and hydrochloric acid (0.08M, ethoxyethanol solution, 1.4 mL) were mixed, followed by 4-morpholinoaniline (30 mg, 0.17 mmol) and the mixture was stirred at 90 ° C for 6 hours. The reaction mixture was cooled to room temperature, and an aqueous solution of sodium hydrogencarbonate was added to terminate the reaction. The reaction mixture was extracted twice with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The solvent was distilled off under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (25 mg, 36%, 0.051 mmol) as a yellow solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.02 (br, 4H), 3.19 (t, J = 8.4 Hz, 2H), 3.73-3.74 (m, 4H), 4.25 (t, J = 8.4 Hz, 2H), 5.83 (d, J = 8.4 Hz, 2H), 6.31 (d, J = 16.8 Hz, 1H), 6.75-6.84 (m, 3H), 7.19-7.28 (m, 2H), 7.85 (brs, 3H), 8.32-8.40 (m, 1H), 8.75-8.79 (m, 2H), 9.16 (s, 1H), 9.82 (s, 1H); LC/MS 494.29 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.02 (br, 4H), 3.19 (t, J = 8.4 Hz, 2H), 3.73-3.74 (m, 4H), 4.25 (t, J = 8.4 Hz (M, 2H), 7.85 (m, 2H), 5.83 (d , J = 8.4 Hz, 2H), 6.31 (d , J = 16.8 Hz, 1H), 6.75-6.84 3H), 8.32-8.40 (m, 1H), 8.75-8.79 (m, 2H), 9.16 (s, 1H), 9.82 (s, 1H); LC / MS 494.29 [M + H & lt ; + & gt ; ].
<실시예 41> N-(3-((6-((3-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Example 41 Synthesis of N- (3 - ((6 - ((3-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin- Manufacturing
N-(3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드 (100 mg, 0.25 mmol) 과 염산 (0.08 M, 에톡시에탄올 용액, 2.5 mL)을 혼합한 후 3-모폴리노아닐린 (54 mg, 0.30 mmol)을 첨가하고, 90 oC에서 2시간 교반시켰다. 반응혼합물을 상온으로 식힌 후 탄산수소나트륨 수용액을 가하여 반응을 종료시키고, 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 목적화합물 (26 mg, 0.057 mmol, 23%)를 얻었다. N - (3 - ((6- chloro-l- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide (100 mg, 0.25 mmol) and hydrochloric acid (0.08 M, ethoxyethanol solution, 2.5 mL) were mixed, and 3-morpholinoaniline (54 mg, 0.30 mmol) was added and stirred at 90 ° C for 2 hours . The reaction mixture was cooled to room temperature, and an aqueous solution of sodium hydrogencarbonate was added thereto to complete the reaction. The reaction mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and then vacuum distilled to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (26 mg, 0.057 mmol, 23%).
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.06 (brs, 4H), 3.74 (brs, 4H), 5.78 (d, J = 9.6 Hz, 1H), 6.29 (d, J = 18.0 Hz, 1H), 6.44-6.55 (m, 2H), 7.07-7.12 (m, 1H), 7.32-7.38 (m, 3H), 7.46 (s, 1H), 7.92 (s, 1H), 8.12 (s, 2H), 9.79 (s, 1H), 10.13 (s, 1H), 12.98 (s, 1H); LC/MS 457.26 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.06 (brs, 4H), 3.74 (brs, 4H), 5.78 (d, J = 9.6 Hz, 1H), 6.29 (d, J = 18.0 Hz, 1H ), 6.44-6.55 (m, 2H), 7.07-7.12 (m, 1 H), 7.32-7.38 (m, 3H), 7.46 (s, 9.79 (s, 1H), 10.13 (s, 1H), 12.98 (s, 1H); LC / MS 457.26 [M + H & lt ; + & gt ; ].
<실시예 42> N-(3-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Example 42 Synthesis of N - (3 - ((6- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino)
단계 1: N-(3-((6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 1: Preparation of N - (3 - ((6- (4-phenoxyphenyl) -l- (tetrahydro-2H-pyran- 2-yl) -lH- pyrazolo [3,4- d] pyrimidin- - yl) amino) phenyl) acrylamide
N-(3-((6-클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 -4-일)아미노)페닐)아크릴아미드 (50 mg, 0.13 mmol) 을 1,4-디옥산 (2 mL)에 녹인 용액에 4-페녹시페닐보론산 (32 mg, 0.15 mmol) 와 탄산나트륨 (40 mg, 0.37 mmol)수용액 (1 mL)을 첨가한 후, 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고, 마이크로웨이브반응기를 이용하여 110 oC에서 10분 동안 교반시켰다. 반응혼합물을 상온으로 냉각시킨 후, 물을 가하여 반응을 종료시키고, 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여, 흰색인 목적화합물 (49 mg, 0.092 mmol, 74%)를 얻었다. N - (3 - ((6- chloro-l- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide (50 mg, 0.13 mmol) in 1,4-dioxane (2 mL) was added 4-phenoxyphenylboronic acid (32 mg, 0.15 mmol) and sodium carbonate (40 mg, 0.37 mmol) was added and the reaction mixture was degassed with argon for 10 minutes and stirred at 110 ° C for 10 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted with ethyl acetate. The extracted organic layer was dried with magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain 49 mg (0.092 mmol, 74%) of the title compound as a white solid.
1H-NMR (300 MHz, CDCl3) δ 1.79-2.11 (m, 5H), 2.58-2.62 (m, 1H), 3.79-3.86 (m, 1H), 4.13-4.16 (m, 1H), 5.69 (d, J = 10.2 Hz, 1H), 6.08 (d, J = 10.5 Hz, 1H), 6.23 (dd, J = 9.9 Hz, 17.1 Hz, 1H), 6.38 (d, J = 17.1 Hz, 1H), 7.01-7.11 (m, 4H), 7.14-7.16 (m, 1H), 7.21-7.26 (m, 2H), 7.34-7.39 (m, 3H), 7.55 (s, 1H), 7.69 (brs, 1H), 7.88 (s, 2H), 8.45 (d, J = 8.1 Hz, 2H); LC/MS 533.41 [M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.79-2.11 (m, 5H), 2.58-2.62 (m, 1H), 3.79-3.86 (m, 1H), 4.13-4.16 (m, 1H), 5.69 ( d, J = 10.2 Hz, 1H ), 6.08 (d, J = 10.5 Hz, 1H), 6.23 (dd, J = 9.9 Hz, 17.1 Hz, 1H), 6.38 (d, J = 17.1 Hz, 1H), 7.01 (S, 1H), 7.69 (br s, 1H), 7.88 (m, 2H), 7.31-7. (s, 2 H), 8.45 (d, J = 8.1 Hz, 2 H); LC / MS 533.41 [M + H & lt ; + & gt ; ].
단계 2: N-(3-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 2: Preparation of N - (3 - ((6- (4-phenoxyphenyl) -lH- pyrazolo [3,4- d] pyrimidin-4-yl) amino) phenyl) acrylamide
N-(3-((6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드 (30 mg) 을 메탄올 (1 mL) 와 디에틸에테르 (2 mL)에 녹인 용액에 염산 (5 M, 에틸에테르, 2 mL) 용액을 혼합하고, 상온에서 30분 동안 교반시켰다. 반응혼합물을 감압증류한 후, 탄산수소나트륨 수용액을 가하고 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후, 실리카겔 칼럼크로마토그라피로 정제하여, 흰색 고체인 목적화합물 (15 mg, 0.033 mmol, 60%)를 얻었다. N - (3 - ((6- (4- phenoxyphenyl) -1- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d] pyrimidin-4-yl) (5 M, ethyl ether, 2 mL) was dissolved in methanol (1 mL) and diethyl ether (2 mL), and the mixture was stirred at room temperature for 30 minutes . The reaction mixture was distilled off under reduced pressure, followed by addition of an aqueous solution of sodium hydrogencarbonate and extraction with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (15 mg, 0.033 mmol, 60%) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 5.76 (d, J = 10.2 Hz, 1H), 6.26 (d, J = 16.8 Hz, 1H), 6.49 (dd, J = 9.9 Hz, 17.1 Hz, 1H), 7.08 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.1 Hz, 2H), 7.37-7.49 (m, 3H), 7.72 (d, J = 8.1 Hz, 1H), 8.34 (br, 1H), 8.51 (d, J = 8.1 Hz, 2H), 8.58 (s, 1H); LC/MS 449.23 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 5.76 (d, J = 10.2 Hz, 1H), 6.26 (d, J = 16.8 Hz, 1H), 6.49 (dd, J = 9.9 Hz, 17.1 Hz, 1H), 7.08 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.1 Hz, 2H), 7.37-7.49 (m, 3H), 7.72 (d, J = 8.1 Hz, 1H), 8.34 ( br, IH), 8.51 (d, J = 8.1 Hz, 2H), 8.58 (s, IH); LC / MS 449.23 [M + H & lt ; + & gt ; ].
<실시예 43> 1-(6-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Example 43 Synthesis of 1- (6 - ((6- (4-phenoxyphenyl) -lH-pyrazolo [3,4-d] pyrimidin- 4- yl) amino) indolin- 2-en-1-one
단계 1: 1-(6-((6-클로로-1-(1-테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 1: l- (6 - ((6-Chloro-l- (l-tetrahydro-2H-pyran-2-yl) -lH-pyrazolo [3,4- d] pyrimidin- ) Indolin-1-yl) prop-2-en-1-one
4,6-디클로로-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (500 mg, 1.83 mmol) 을 에탄올 (5 mL) 에 녹인 용액에 1-(6-아미노인돌린-1-일)프로페-2-엔-1-온 (380 mg, 2.01 mmol) 와 트리에틸아민 (0.64 mL, 4.6 mmol)을 첨가하고 상온에서 4시간 교반시켰다. 반응혼합물을 0 oC로 냉각시킨 후, 생성된 고체를 여과하고 에탄올로 씻은 후, 흰색 고체인 목적화합물 (770 mg, 1.8 mmol, 76%)를 얻었다.A solution of 4,6-dichloro-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4- d] pyrimidine (500 mg, 1.83 mmol) 2-en-1-one (380 mg, 2.01 mmol) and triethylamine (0.64 mL, 4.6 mmol) were added to the mixture, and the mixture was stirred at room temperature for 4 hours . The reaction mixture was cooled to 0 ° C, and the resulting solid was filtered and washed with ethanol to give the desired compound (770 mg, 1.8 mmol, 76%) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 1.57-2.03 (m, 5H), 2.33-2.44 (m, 1H), 3.52-3.21 (m, 2H), 3.65-3.74 (m, 1H), 3.94-3.98 (m, 1H), 4.25-4.30 (m, 2H), 5.78-5.87 (m, 2H), 6.33 (d, J = 16.5 Hz, 1H), 6.77 (dd, J = 11.1 Hz, 16.5 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.65 (br, 1H), 8.39 (br, 2H), 10.57 (s, 1H); LC/MS 425.23 [M + H+], 849.83 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 1.57-2.03 (m, 5H), 2.33-2.44 (m, 1H), 3.52-3.21 (m, 2H), 3.65-3.74 (m, 1H), 3.94-3.98 (m, 1H), 4.25-4.30 (m, 2H), 5.78-5.87 (m, 2H), 6.33 (d, J = 16.5 Hz, 1H), 6.77 (dd, J = 11.1 Hz, 16.5 Hz , 7.30 (d, J = 8.1 Hz, 1H), 7.65 (br, 1H), 8.39 (br, 2H), 10.57 (s, 1H); LC / MS 425.23 [M + H & lt ; + & gt ; ], 849.83 [2M + H & lt ; + & gt ; ].
단계 2: 1-(6-((6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 2: Preparation of l- (6 - ((6- (4-phenoxyphenyl) -l- (tetrahydro-2H-pyran- 2-yl) -lH- pyrazolo [3,4- d] pyrimidin- Yl) amino) indolin-1-yl) prop-2-en-1-one
1-(6-((6-클로로-1-(1-테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온 (50 mg, 0.12 mmol) 을 1,4-디옥산 (2 mL)에 녹인 용액에 (4- 페녹시페닐 보론산 (30 mg, 0.14 mmol), 탄산나트륨 (37 mg, 0.35 mmol) 수용액 (1 mL), PdCl2(PPh3)2 (6 mg, 0.008 mmol)을 첨가한 후, 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 110 oC에서 10분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후 물을 가하여 반응을 종료시키고 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후에 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (30 mg, 0.054 mmol, 46%)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) amino) indolin-2-ylmethyl] -1- (6-chloro-1- (1-tetrahydro- (4-phenoxyphenylboronic acid (30 mg, 0.14 mmol) was dissolved in 1,4-dioxane (2 mL) mmol), sodium carbonate (37 mg, 0.35 mmol) in water (1 mL), PdCl 2 (PPh 3 ) 2 (6 mg, 0.008 mmol), the reaction mixture was degassed with argon for 10 minutes and stirred at 110 ° C for 10 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted twice with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (30 mg, 0.054 mmol, 46%) as a white solid.
1H-NMR (300 MHz, CDCl3) δ 1.71-2.17 (m, 5H), 2.55-2.58 (m, 1H), 3.16-3.19 (m, 2H), 3.77-3.84 (m, 1H), 4.11-4.14 (m, 3H), 5.62 (brs, 1H), 6.07 (d, J = 16.5 Hz, 1H), 6.77 (dd, J = 10.5 Hz, 1H), 6.41 (brs, 2H), 8.39 (brs, 2H), 7.08-7.17 (m, 6H), 7.35-7.40 (m, 2H), 7.61 (brs, 2H), 8.52-8.55 (m, 3H); LC/MS 475.33 [M+H+], 950.00 [2M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.71-2.17 (m, 5H), 2.55-2.58 (m, 1H), 3.16-3.19 (m, 2H), 3.77-3.84 (m, 1H), 4.11- 4.14 (m, 3H), 5.62 (brs, 1H), 6.07 (d, J = 16.5 Hz, 1H), 6.77 (dd, J = 10.5 Hz, 1H), 6.41 (brs, 2H), 8.39 (brs, 2H ), 7.08-7.17 (m, 6H), 7.35-7.40 (m, 2H), 7.61 (brs, 2H), 8.52-8.55 (m, 3H); LC / MS 475.33 [M + H & lt ; + & gt ; ], 950.00 [2M + H & lt ; + & gt ; ].
단계 3: 1-(6-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 3: Preparation of 1- (6 - ((6- (4-phenoxyphenyl) -lH-pyrazolo [3,4- d] pyrimidin- 4- yl) amino) indolin- Preparation of 2-en-1-one
1-(6-((6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온 (25 mg, 0.051 mmol)을 메탄올 (1 mL) 와 디에틸에테르 (2 mL)에 녹인 용액에 염산 (5 N, 디에틸에테르, 0.2 mL)용액을 혼합하고, 상온에서 30분 동안 교반시켰다. 반응혼합물을 감압증류한 후 탄산수소나트륨 수용액을 가하고, 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 컬럼으로 정제하여 흰색 고체인 목적화합물 (20 mg, 0.042 mmol, 95%)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) -1H-pyrazolo [l, 5- (25 mg, 0.051 mmol) was dissolved in methanol (1 mL) and diethyl ether (2 mL) was added hydrochloric acid (5 N, di Ethyl ether, 0.2 mL) was mixed and stirred at room temperature for 30 minutes. The reaction mixture was distilled off under reduced pressure, and an aqueous solution of sodium hydrogencarbonate was added thereto, followed by extraction with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and then vacuum distilled to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (20 mg, 0.042 mmol, 95%) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 3.15-3.19 (m, 2H), 4.26-4.31 (m, 2H), 5.81 (d, J = 10.2 Hz, 1H), 6.27 (d, J = 16.8 Hz, 1H), 6.79 (dd, J = 11.1 Hz, 17.1 Hz, 1H), 7.06 (d, J = 8.1 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.21-7.26 (m, 1H), 7.30 (d, J = 18.1 Hz, 1H), 7.45-7.49 (m, 2H), 7.60 (d, J = 8.4 Hz, 1H), 8.32 (brs, 1H), 8.57 (d, J = 8.7 Hz, 2H), 9.04 (brs, 1H), 10.06 (s, 1H), 13.60 (s, 1H); LC/MS 475.33 [M+H+], 950.00 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 3.15-3.19 (m, 2H), 4.26-4.31 (m, 2H), 5.81 (d, J = 10.2 Hz, 1H), 6.27 (d, J = 16.8 Hz, 1H), 6.79 ( dd, J = 11.1 Hz, 17.1 Hz, 1H), 7.06 (d, J = 8.1 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.21-7.26 (m , 1H), 7.30 (d, J = 18.1 Hz, 1H), 7.45-7.49 (m, 2H), 7.60 (d, J = 8.4 Hz, 1H), 8.32 (brs, 1H), 8.57 (d, J = 8.7 Hz, 2H), 9.04 (br s, 1H), 10.06 (s, 1H), 13.60 (s, 1H); LC / MS 475.33 [M + H & lt ; + & gt ; ], 950.00 [2M + H & lt ; + & gt ; ].
<실시예 44> 1-(6-((3-메틸-6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Example 44 Synthesis of 1- (6 - ((3-methyl-6- (4-phenoxyphenyl) -1H-pyrazolo [3,4- d] pyrimidin- -Yl) prop-2-en-1-one
단계 1: 4, 6-디클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘의 제조단계 1: 4,6-디클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘의 제조Step 1: Preparation of 4,6-dichloro-3-methyl-1- (tetrahydro-2H-pyran-2-yl) -lH- pyrazolo [3,4- d] pyrimidine Step 1: Preparation of dichloro-3-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazolo [3,4-d] pyrimidine
4,6-디클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (500 mg, 2.46 mmol)을 에틸아세테이트 (5 mL) 에 녹인 용액에 3,4-디히드로-2H-피란 (0.61 mL, 0.56 mmol) 와 p-톨루엔설폰산 (13 mg, 0.074 mmol)을 첨가한 후, 반응혼합물을 50 oC에서 2시간 동안 교반시켰다. 반응혼합물을 감압증류 하여 용매 제거한 후 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (700 mg, 2.5 mmol, 99%)를 얻었다.Pyrazolo [3,4-d] pyrimidine (500 mg, 2.46 mmol) was dissolved in ethyl acetate (5 < mL) 3,4- dihydro -2 H dissolved in a solution to - and then the mixture pyran (0.61 mL, 0.56 mmol) and p- toluenesulfonic acid (13 mg, 0.074 mmol), the reaction mixture was 50 o C 2 Lt; / RTI > The reaction mixture was distilled under reduced pressure to remove the solvent, and the residue was purified by silica gel column chromatography to obtain the target compound (700 mg, 2.5 mmol, 99%) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 1.58-2.04 (m, 5H), 2.36-2.40 (m, 1H), 2.65 (s, 3H), 3.69-3.77 (m, 1H), 3.94-3.98 (m, 1H), 5.88 (d, J = 9.6 Hz, 1H); LC/MS 287.22 [M + H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 1.58-2.04 (m, 5H), 2.36-2.40 (m, 1H), 2.65 (s, 3H), 3.69-3.77 (m, 1H), 3.94- 3.98 (m, 1 H), 5.88 (d, J = 9.6 Hz, 1 H); LC / MS 287.22 [M + H & lt ; + & gt ; ].
단계 2: 1-(6-((6-클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 2: l- (6 - ((6-Chloro-3-methyl-1- (tetrahydro-2H-pyran- ) Amino) indolin-1-yl) prop-2-en-1-one
4,6-디클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (500 mg, 1.74 mmol) 을 에탄올 (5 mL) 에 녹인 용액에 1-(6-아미노인돌린-1-일)프로페-2-엔-1-온 (361 mg, 1.92 mmol) 와 트리에틸아민 (0.61 mL, 4.4 mmol)을 첨가하고 상온에서 4시간 교반시켰다. 반응혼합물을 0 oC로 식힌 후 생성된 고체를 여과하고 에탄올로 세척시킨 후, 흰색 고체인 목적화합물 (710 mg, 1.62 mmol, 76%)를 얻었다.Pyrazolo [3,4-d] pyrimidine (500 mg, 1.74 mmol) was dissolved in ethanol (5 mL) and the mixture was stirred at room temperature for 2 hours. 1-yl) prop-2-en-1-one (361 mg, 1.92 mmol) and triethylamine (0.61 mL, 4.4 mmol) were added to a solution of Lt; / RTI > for 4 hours. The reaction mixture was cooled to 0 ° C, and the resulting solid was filtered and washed with ethanol to give the desired compound (710 mg, 1.62 mmol, 76%) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 1.56-2.00 (m, 5H), 2.35-2.39 (m, 1H), 2.63 (m, 3H), 3.16-3.22 (m, 2H), 3.68-3.69 (m, 1H), 3.93-3.97 (m, 1H), 4.26-4.29 (m, 2H), 5.72 (d, J = 9.9 Hz, 1H), 5.85 (d, J = 11.1 Hz, 1H), 6.32 (d, J = 16.8 Hz, 1H), 6.74-6.77 (m, 1H), 7.28 (s, 1H), 8.33 (s, 1H), 9.21 (s, 1H); LC/MS 439.25 [M+H+], 877.84 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 1.56-2.00 (m, 5H), 2.35-2.39 (m, 1H), 2.63 (m, 3H), 3.16-3.22 (m, 2H), 3.68- (M, 2H), 5.72 (d, J = 9.9 Hz, 1H), 5.85 (d, J = 11.1 Hz, 1H), 6.32 (d , J = 16.8 Hz, 1H), 6.74-6.77 (m, 1H), 7.28 (s, 1H), 8.33 (s, 1H), 9.21 LC / MS 439.25 [M + H & lt ; + & gt ; ], 877.84 [2M + H & lt ; + & gt ; ].
단계 3: 1-(6-((3-메틸-6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 3: l- (6 - ((3-Methyl-6- (4-phenoxyphenyl) -l- (tetrahydro- Pyrimidin-4-yl) amino) indolin-1-yl) prop-2-en-
1-(6-((6-클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온 (50 mg, 0.11 mmol) 을 1,4-디옥산 (2 mL)에 녹인 용액에 4-페녹시페닐 보론산 (29 mg, 0.14 mmol), Na2CO3 (36 mg, 0.34 mmol) 수용액(1 mL), PdCl2(PPh3)2 (6 mg, 0.008 mmol)을 첨가한 후, 반응혼합물을 아르곤으로 10분 동안 디가싱 (degassing) 하고 마이크로웨이브반응기를 이용하여 110 oC에서 10분 동안 교반시켰다. 반응혼합물을 상온으로 식힌 후, 물을 가하여 반응을 종료시키고 에틸아세테이트로 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매를 제거한 후, 실리카겔 칼럼으로 정제하여 흰색 고체인 목적화합물 (53 mg, 0.093 mmol, 82%)를 얻었다.Pyrazolo [3,4-d] pyrimidin-4-yl) amino) -1H-pyrrolo [2,3- (50 mg, 0.11 mmol) in 1,4-dioxane (2 mL) was added 4-phenoxyphenylboronic acid (29 mg, 0.14 mmol), Na 2 CO 3 (36 mg, 0.34 mmol) in water (1 mL), PdCl 2 (PPh 3 ) 2 (6 mg, 0.008 mmol), the reaction mixture was degassed with argon for 10 minutes and stirred at 110 ° C for 10 minutes using a microwave reactor. The reaction mixture was cooled to room temperature, water was added to terminate the reaction, and the mixture was extracted with ethyl acetate. The extracted organic layer was dried with magnesium sulfate, filtered, and distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (53 mg, 0.093 mmol, 82%) as a white solid.
1H-NMR (300 MHz, CDCl3) δ 1.60-2.14 (m, 5H), 2.55-2.66 (m, 1H), 2.73 (s, 3H), 3.18-3.23 (m, 2H), 3.78-3.85 (m, 1H), 4.11-4.24 (m, 3H), 5.78 (brs, 1H), 6.13 (d, J = 10.5 Hz, 1H), 6.35-6.93 (m, 2H), 7.01 (s, 1H), 7.06-7.16 (m, 5H), 7.21 (d, J = 8.1 Hz, 1H), 7.34-7.39 (m, 2H), 7.78 (brs, 1H), 8.54-8.56 (m, 3H); LC/MS 473.49 [M+H+]. 1 H-NMR (300 MHz, CDCl 3) δ 1.60-2.14 (m, 5H), 2.55-2.66 (m, 1H), 2.73 (s, 3H), 3.18-3.23 (m, 2H), 3.78-3.85 ( (m, 2H), 7.01 (s, 1H), 7.06 (d, J = (D, J = 8.1 Hz, 1H), 7.34-7.39 (m, 2H), 7.78 (br s, 1H), 8.54-8.56 (m, 3H); LC / MS 473.49 [M + H & lt ; + & gt ; ].
단계 4: 1-(6-((3-메틸-6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온의 제조Step 4: 1- (6 - ((3-Methyl-6- (4-phenoxyphenyl) -lH-pyrazolo [3,4- d] pyrimidin- 4- yl) amino) indolin- ) Prop-2-en-1-one
1-(6-((3-메틸-6-(4-페녹시페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온 (40 mg) 을 메탄올 (1 mL) 와 디에틸에테르 (2 mL)에 녹인 용액에 염산 (5 N, 디에틸에테르, 0.2 mL) 용액을 혼합하고 상온에서 30분 동안 교반시켰다. 반응혼합물을 감압증류한 후 탄산수소나트륨 수용액을 가하고, 에틸아세테이트로 두 번 추출하였다. 추출한 유기층을 황산마그네슘으로 건조 시킨 후, 여과한 다음, 감압증류 하여 용매 제거한 후 실리카겔 컬럼으로 정제하여 흰색 고체인 목적화합물 (15 mg, 0.031 mmol, 44%)를 얻었다.Pyrazolo [3,4-d] pyrimidin-3-ylmethyl) -1H-pyrazolo [l, 5- One (40 mg) was dissolved in methanol (1 mL) and diethyl ether (2 mL) was added hydrochloric acid (5 N, Diethyl ether, 0.2 mL) was mixed and stirred at room temperature for 30 minutes. The reaction mixture was distilled off under reduced pressure, and an aqueous solution of sodium hydrogencarbonate was added thereto, followed by extraction with ethyl acetate twice. The extracted organic layer was dried with magnesium sulfate, filtered, and then distilled under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography to obtain the target compound (15 mg, 0.031 mmol, 44%) as a white solid.
1H-NMR (300 MHz, DMSO-d 6 ) δ 2.73 (s, 3H), 3.18 (t, J = 7.8 Hz, 2H), 4.29 (t, J = 7.8 Hz, 2H), 5.79 (d, J = 11.1 Hz, 1H), 6.25 (d, J = 16.5 Hz, 1H), 6.79 (dd, J = 9.9 Hz, 16.2 Hz, 1H), 7.02 (d, J = 8.1 Hz, 2H), 7.12 (d, J = 7.8 Hz, 2H), 7.20-7.29 (m, 2H), 7.39-7.48 (m, 3H), 7.39-7.48 (m, 3H), 7.47 (d, J = 8.4 Hz, 2H), 8.64 (s, 1H), 8.91 (br, 1H), 13.21 (s, 1H); LC/MS 489.36 [M + H+], 978.08 [2M+H+]. 1 H-NMR (300 MHz, DMSO- d 6) δ 2.73 (s, 3H), 3.18 (t, J = 7.8 Hz, 2H), 4.29 (t, J = 7.8 Hz, 2H), 5.79 (d, J J = 8.1 Hz, 1H), 6.25 (d, J = 16.5 Hz, 1H), 6.79 (dd, J = 9.9 Hz, J = 7.8 Hz, 2H), 7.20-7.29 (m, 2H), 7.39-7.48 (m, 3H), 7.39-7.48 (m, 3H), 7.47 (d, J = 8.4 Hz, 2H), 8.64 (s , ≪ / RTI > 1H), 8.91 (br, 1H), 13.21 (s, 1H); LC / MS 489.36 [M + H & lt ; + & gt ; ], 978.08 [2M + H & lt ; + & gt ; ].
<실시예 45> N-(3-((3-메틸-4-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드의 제조Example 45 Synthesis of N - (3 - ((3-methyl-4 - ((4-morpholinophenyl) amino) -1 H-pyrazolo [3,4- d] pyrimidin- Phenyl) acrylamide
단계 1: 6-클로로-3-메틸-N-(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-아민의 제조Step 1: 6-Chloro-3-methyl-N- (4- morpholinophenyl) -l- (tetrahydro- -4-amine
4,6-디클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘 (200 mg, 0.69 mmol)을 디메틸포름아미드 (1 mL)에 가하고, 4-모폴리노아닐린 (149 mg, 0.84 mmol), 탄산칼륨 (241 mg, 1.7 mmol)을 가하고, 상온에서 14시간 동안 교반 한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. Pyrazolo [3,4-d] pyrimidine (200 mg, 0.69 mmol) was dissolved in dimethylformamide (2 ml) 1 mL), 4-morpholinoaniline (149 mg, 0.84 mmol), potassium carbonate (241 mg, 1.7 mmol), and the mixture was stirred at room temperature for 14 hours. Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound.
1H NMR (300 MHz, CDCl3) δ 7.33-7.27 (d, 2H), 6.99-6.96 (d, 2H), 5.78-5.74 (m, 1H), 4.13-4.11 (m, 2H), 3.62-3.58 (m, 2H), 3.17-3.14 (t, 4H), 2.62 (s, 3H). 1 H NMR (300 MHz, CDCl 3) δ 7.33-7.27 (d, 2H), 6.99-6.96 (d, 2H), 5.78-5.74 (m, 1H), 4.13-4.11 (m, 2H), 3.62-3.58 (m, 2H), 3.17-3.14 (t, 4H), 2.62 (s, 3H).
단계 2: 3-메틸-N4-(4-모폴리노페닐)-N6-(3-니트로페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민의 제조Step 2: 3-methyl -N 4 - (4- morpholinophenyl) -N 6 - (3-nitrophenyl) -1- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3 , 4-d] pyrimidine-4,6-diamine
6-클로로-3-메틸-N-(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-아민 (100 mg, 0.23 mmol)을 t-부탄올 (2 mL)에 가하고, 3-니트로아닐린 (36 mg, 025 mmol), Pd2(dba)3 (1 mg, 0.023 mmol), X-phos (1 mg, 0.069 mmol), 탄산칼륨 (67 mg, 0.48 mmol)을 넣고, 90 oC에서 14 시간 동안 교반 한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다.(Tetrahydro-2H-pyran-2-yl) -lH-pyrazolo [3,4-d] pyrimidin- Amine (100 mg, 0.23 mmol) was added to t-butanol (2 mL), and 3-nitroaniline (36 mg, 025 mmol), Pd 2 (dba) 3 (1 mg, 0.023 mmol), X- phos (1 mg, 0.069 mmol), potassium carbonate (67 mg, 0.48 mmol), and the mixture was stirred at 90 ° C for 14 hours. Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound.
1H NMR (300 MHz, CDCl3) δ 7.81-7.79 (d, J = 6.1 Hz, 1H), 7.47-7.42 (m ,4H), 7.37-7.32 (t, 1H), 6.90-6.87 (d, J = 8.94 Hz, 2H), 5.87-5.83 (d, J = 10.8 Hz, 1H), ), 4.13-4.11 (m, 2H), 3.62-3.58 (m, 2H), 3.89-3.86 (t, 4H), 3.17-3.14 (t, 4H), 2.62 (s, 3H), 2.09-2.02 (m, 4H), 1 H NMR (300 MHz, CDCl 3) δ 7.81-7.79 (d, J = 6.1 Hz, 1H), 7.47-7.42 (m, 4H), 7.37-7.32 (t, 1H), 6.90-6.87 (d, J = 8.94 Hz, 2H), 5.87-5.83 (d, J = 10.8 Hz, 1H),), 4.13-4.11 (m, 2H), 3.62-3.58 (m, 2H), 3.89-3.86 (t, 4H), 3.17-3.14 (t, 4H), 2.62 (s, 3H), 2.09-2.02 (m, 4H)
단계 3: N6-(3-아미노페닐)-3-메틸-N4-(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민의 제조Step 3: N 6 - (3- aminophenyl) -3-methyl -N 4 - (4- morpholinophenyl) - 1 - (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3 , 4-d] pyrimidine-4,6-diamine
3-메틸-N4-(4-모폴리노페닐)-N6-(3-니트로페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민 (58 mg, 0.11 mmol)을 메탄올 (1 mL)에 가하고, 아연 (36 mg, 0.54 mmol), 암모늄포메이트 (35 mg, 0.55 mmol)을 가하고, 상온에서 4시간 교반한다. 반응 종료 후, 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축한 후, 다음 반응 진행한다.3-methyl -N 4 - (4- morpholinophenyl) -N 6 - (3-nitrophenyl) -1- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3, 4- d] pyrimidine-4,6-diamine (58 mg, 0.11 mmol) was added to methanol (1 mL), zinc (36 mg, 0.54 mmol) and ammonium formate (35 mg, 0.55 mmol) Stir for 4 hours. After completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated.
단계 4: N-(3-((3-메틸-4-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드의 제조Step 4: N - (3 - ((3-Methyl-4 - ((4-morpholinophenyl) amino) -1- (tetrahydro- 4-d] pyrimidin-6-yl) amino) phenyl) acrylamide
N6-(3-아미노페닐)-3-메틸-N4-(4-모폴리노페닐)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4,6-디아민 (40 mg, 0.080 mmol)을 디클로로메탄 (2 mL)에 가하고, 아크릴산 (7 mg, 0.096 mmol), 1-에틸-3-(3-디메틸아미노피리딘)카보디이미드 (23 mg, 0.12 mmol), 히드록시벤조트리아졸 (17 mg, 0.12 mmol), 디이소프로필에틸아민 (30 νL, 0.16 mmol)을 가한 뒤, 상온에서 12시간 교반한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (25 mg, 57%)N 6 - (3- aminophenyl) -3-methyl -N 4 - (4- morpholinophenyl) - 1 - (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3, 4- d] pyrimidin-4,6-diamine (40 mg, 0.080 mmol) was added to dichloromethane (2 mL), and acrylic acid (7 mg, 0.096 mmol) (23 mg, 0.12 mmol), hydroxybenzotriazole (17 mg, 0.12 mmol) and diisopropylethylamine (30 .mu.L, 0.16 mmol) were added thereto, followed by stirring at room temperature for 12 hours. Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (25 mg, 57%).
1H NMR (300 MHz, CDCl3) δ 7.52-7.50 (d, J = 8.85 Hz, 2H), 7.24-7.12 (m, 4H), 6.95-6.92 (d, J = 8.85 Hz, 1H), 6.47-6.41 (m, 1H), 6.29-6.26 (m, 1H), 5.93-5.89 (m, 1H), 5.78-5.74 (m, 1H), 4.13-4.11 (m, 2H), 3.62-3.58 (m, 2H), 3.89-3.86 (t, 4H), 3.17-3.14 (t, 4H), 2.62 (s, 3H), 2.09-2.02 (m, 4H). 1 H NMR (300 MHz, CDCl 3) δ 7.52-7.50 (d, J = 8.85 Hz, 2H), 7.24-7.12 (m, 4H), 6.95-6.92 (d, J = 8.85 Hz, 1H), 6.47- (M, 2H), 3.62-3.58 (m, 2H), 6.41 (m, ), 3.89-3.86 (t, 4H), 3.17-3.14 (t, 4H), 2.62 (s, 3H), 2.09-2.02 (m, 4H).
단계 5: N-(3-((3-메틸-4-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드의 제조Step 5: Preparation of N - (3 - ((3-methyl-4 - ((4-morpholinophenyl) amino) -1H- pyrazolo [3,4- d] pyrimidin- Preparation of acrylamide
N-(3-((3-메틸-4-((4-모폴리노페닐)아미노)-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드 (20 mg, 0.043 mmol)을 메탄올 (0.5 mL)에 가하고, 여기에 염산 (4 N, 디옥산, 1 mL)을 가한 다음, 상온에서 15분 교반 한다. 반응 종료 후, 감압 농축해서 화합물을 얻는다. (18 mg, 92%) N - (3 - ((3- methyl-4 - ((4-morpholinophenyl) amino) -1- (tetrahydro -2H- pyran-2-yl) -1H- pyrazolo [3,4-d (4 N, dioxane, 1 mL) was added to methanol (0.5 mL), followed by the addition of 15 Min. After completion of the reaction, the reaction mixture is concentrated under reduced pressure to obtain a compound. (18 mg, 92%).
1H NMR (300 MHz, CDCl3) δ 7.52-7.50 (d, J = 8.85 Hz, 2H), 7.24-7.12 (m, 4H), 6.95-6.92 (d, J = 8.85), 6.47-6.41 (m, 1H), 6.29-6.26 (m, 1H), 5.93-5.89 (m, 1H), 3.89-3.86 (t, 4H), 3.17-3.14 (t, 4H) 1 H NMR (300 MHz, CDCl 3) δ 7.52-7.50 (d, J = 8.85 Hz, 2H), 7.24-7.12 (m, 4H), 6.95-6.92 (d, J = 8.85), 6.47-6.41 (m 4H), 3.17-3.14 (t, 4H), 3.91-3. 26 (m,
<실시예 46> N-(3-((3-메틸-6-((4-모폴리노페닐)아미노)-1H-피라조로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Example 46 Synthesis of N - (3 - ((3-methyl-6 - ((4-morpholinophenyl) amino) -1 H- pyrazolo [3,4- d] pyrimidin- Phenyl) acrylamide
단계 1: N-(3-((6-클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)단계 1: N-(3-((6-클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 1: N- (3 - ((6-Chloro-3-methyl-1- (tetrahydro-2H-pyran- ) Amino) Step 1: Preparation of N- (3 - ((6-chloro-3-methyl-1- (tetrahydro- 4-yl) amino) phenyl) acrylamide
에탄올 (1 mL)에 4,6-디클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘(200 mg, 0.73 mmol), 트리풀루오르아세트산 (256 νL, 1.8 mmol)을 가하고 상온에서 14 시간 동안 교반 한다. 반응이 종결되면, 여과하여 목적화합물을 얻었다. (175 mg, 58%)To a solution of 4,6-dichloro-3-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H- pyrazolo [3,4- d] pyrimidine (200 mg, 0.73 mmol ), Tributyl acetic acid (256 [mu] L, 1.8 mmol) was added and stirred at room temperature for 14 hours. When the reaction was completed, the desired compound was obtained by filtration. (175 mg, 58%).
1H NMR (300 MHz, CDCl3) δ 7.98 (s, 2H), 7.31-7.30 (d, 1H), 7.19-7.14 (t, 2H), 7.07-7.04 (d, 1H), 6.43-6.37 (d, 1H), 6.24-6.15 (q, 1H), 5.86-5.83 (d, 1H), 5.74-5.71 (d, 1H), 4.15-4.13 (d, 1H), 3.80-3.76 (t, 1H), 2.57 (s, 3H), 2.05-2.04 (m, 2H), 1.89-1.76 (m, 4H). 1 H NMR (300 MHz, CDCl 3) δ 7.98 (s, 2H), 7.31-7.30 (d, 1H), 7.19-7.14 (t, 2H), 7.07-7.04 (d, 1H), 6.43-6.37 (d (D, IH), 3.80-3.76 (t, IH), 2.57 (d, IH) (s, 3H), 2.05-2.04 (m, 2H), 1.89-1.76 (m, 4H).
단계 2: N-(3-((3-메틸-6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드의 제조Step 2: Preparation of N - (3 - ((3-methyl-6 - ((4-morpholinophenyl) amino) -1H- pyrazolo [3,4- d] pyrimidin- Preparation of acrylamide
에톡시에탄올 (0.08 M HCl, 2 mL) 에 N-(3-((6-클로로-3-메틸-1-(테트라히드로-2H-피란-2-일)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드 (42 mg, 0.10 mmol)과 4-모폴리노아닐리 (19 mg, 0.10 mmol)을 가한 후, 110 oC에서 14 시간 동안 교반 한다. 반응이 종료되면 에틸아세테이트와 물로 추출한 다음, 유기층을 무수망초로 건조시키고, 여과, 농축하였다. 농축물을 관크로마토그래피하여 목적화합물을 얻었다. (17 mg, 35%)To a solution of N - (3 - ((6-chloro-3-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H- pyrazolo [3,4 the -d] stirred-4-yl) amino) phenyl) was added to acrylamide (42 mg, 0.10 mmol) and 4-morpholinyl quinoa nilri (19 mg, 0.10 mmol), 14 hours at 110 o C . Upon completion of the reaction, the reaction mixture was extracted with ethyl acetate and water, and the organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The concentrate was subjected to column chromatography to obtain the target compound. (17 mg, 35%).
1H NMR (300 MHz, MeOH) δ 8.05 (s, 1H), 7.51-7.48 (d, 3H), 7.38-7.30 (m, 3H), 6.83-6.81 (d, 2H), 6.42-6.38 (d, 2H), 5.77-5.75 (d, 1H), 3.79 (s, 4H), 3.02 (s, 4H), 2.61 (s, 3H). 1 H NMR (300 MHz, MeOH ) δ 8.05 (s, 1H), 7.51-7.48 (d, 3H), 7.38-7.30 (m, 3H), 6.83-6.81 (d, 2H), 6.42-6.38 (d, 2H), 5.77-5.75 (d, 1H), 3.79 (s, 4H), 3.02 (s, 4H), 2.61 (s, 3H).
하기 표 1 및 2에 상기 실시예 1 내지 46에서 제조한 화합물의 화학구조식을 정리하여 나타내었다.The chemical structures of the compounds prepared in Examples 1 to 46 are summarized in Tables 1 and 2 below.
<실험예 1> 접합 피리미딘 유도체의 브루톤 티로신 키나제(Bruton's tyrosine kinase, BTK) 활성 억제 평가Experimental Example 1 Evaluation of inhibition of Bruton's tyrosine kinase (BTK) activity of a conjugated pyrimidine derivative
본 발명에 따른 접합 피리미딘 유도체의 브루톤 티로신 키나제 활성 억제를 평가하기 위하여, 하기와 같은 실험을 수행하여 그 결과를 표 3에 나타내었다.In order to evaluate the inhibition of the brutonyl tyrosine kinase activity of the conjugated pyrimidine derivatives according to the present invention, the following experiment was carried out, and the results are shown in Table 3.
BTK 효소 평가는 BTK 효소저해 진단키트 (시스바이오, Codolet, 프랑스)를 사용하여 평가하였다. ATP(adenosine triphosphate), BTK, 펩타이드 (biotin-Aca-AAAEEIYGEI-NH2)와 본 발명에 따른 실시예 1-34 화합물을 가하고, 30분 동안 반응시키고, 여기에 EDTA(ethylenediaminetetraacetic acid)를 가하여 반응을 정지시켰다. 여기서 EDTA 용액은 유로피움을 함유하는 항체 (antiphosphoresidue antibody) 와 스트랩타비딘-XL665 (SA-XL665, cisbio)룰 함유하고 있으며, 1시간 동안 인큐베이션 하고 형광도 (fluorescence)를 측정하여, 엔비젼 (Envision)리더로 337 nm에서 여기 (excitation) 되는 665와 620 nm의 발광도 (emission)를 측정하여 값을 정하였다. IC50값은 그래패드 (GraphPad) 프리즘 (5 version)을 사용하여 구하였다. 여기서 커브는 간접적 (non-linear) 리그레션 모델로 로그함수와 반응값으로 구하였다.The BTK enzyme assay was evaluated using the BTK enzyme inhibition assay kit (Cibao, Codolet, France). ATP (adenosine triphosphate), BTK, peptide (biotin-Aca-AAAEEIYGEI-NH2) and the compound of Example 1-34 according to the present invention were added and reacted for 30 minutes. EDTA (ethylenediaminetetraacetic acid) . The EDTA solution contained an antiphosphoresidue antibody and straptavidin-XL665 (SA-XL665, cisbio). The EDTA solution was incubated for 1 hour, and the fluorescence was measured. The Envision ) Was measured by measuring the emission of 665 and 620 nm excited at 337 nm by a reader. IC 50 values were determined using a GraphPad prism (version 5). Here, the curve is an indirect (non-linear) regression model with logarithmic functions and reaction values.
<실험예 2> 접합 피리미딘 유도체의 TMD80 활성 억제 평가Experimental Example 2 Evaluation of inhibition of TMD80 activity of a conjugated pyrimidine derivative
본 발명에 따른 접합 피리미딘 유도체의 TMD80 활성 억제를 평가하기 위하여, 하기와 같은 실험을 수행하여 그 결과를 표 3에 나타내었다.In order to evaluate the inhibition of the TMD80 activity of the conjugated pyrimidine derivatives according to the present invention, the following experiment was carried out and the results are shown in Table 3. < tb > < TABLE >
TMD8 세포들을 96-웰 플레이트에 나누고 (30% 정도 용액상태), 활성화합물을 처리하였다. 72시간 후에, WST-1 시약을 가하고, 흡광도 (450 nm)를 측정하였다. (Spectramax spectrometer, Molecular Devices, 미국). IC50값은 그래패드 (GraphPad) 프리즘 (5 version)을 사용하여 구하였다. 여기서 커브는 간접적 (non-linear) 리그레션 모델로 로그함수와 반응값으로 구하였다.TMD8 cells were divided into 96-well plates (approximately 30% in solution) and treated with the active compound. After 72 hours, the WST-1 reagent was added and the absorbance (450 nm) was measured. (Spectramax spectrometer, Molecular Devices, USA). IC 50 values were determined using a GraphPad prism (version 5). Here, the curve is an indirect (non-linear) regression model with logarithmic functions and reaction values.
IC50 (uM)Btk
IC 50 (uM)
IC50 (uM)TMD80
IC 50 (uM)
IC50 (uM)Btk
IC 50 (uM)
IC50 (uM)TMD80
IC 50 (uM)
상기 표 3에 나타난 바와 같이, 본 발명에 따른 접합 피리미딘 유도체는 10 μM 이하의 IC50 값으로 브루톤 티로신 키나제의 활성을 억제하고, 실시예 3, 5, 12, 14-21, 24, 27, 28, 30, 32, 33, 37-39, 41, 45 및 46 화합물은 0.05 μM 이하즉, 50 nM 이하의 낮은 IC50 값을 나타내어, 우수한 브루톤 티로신 키나제 활성 억제능을 나타냄을 알 수 있으며, 특히, 실시예 14, 15, 19-21, 33, 37-39 및 41 화합물은 0.008 μM, 즉, 8 nM 이하의 현저하게 IC50 값으로 브루톤 티로신 키나제 활성을 억제하는 것을 확인하였다.As shown in Table 3, the conjugated pyrimidine derivatives according to the present invention inhibit the activity of bruton tyrosine kinase with an IC 50 value of 10 μM or less and inhibit the activity of Bruton's tyrosine kinase in Examples 3, 5, 12, 14-21, 24, 27 , 28, 30, 32, 33, 37-39, 41, 45 and 46 exhibited low IC 50 values of 0.05 μM or less, ie, 50 nM or less, indicating excellent inhibition of Bruton's tyrosine kinase activity. In particular, the compounds of Examples 14, 15, 19-21, 33, 37-39 and 41 were found to inhibit bruton tyrosine kinase activity with a significant IC 50 value of 0.008 μM, ie, 8 nM or less.
또한, 본 발명에 따른 접합 피리미딘 유도체는 10 μM 이하의 IC50 값으로 TMD80의 활성을 억제하고, 실시예 11, 21, 27, 28 및 46 화합물은 0.05 μM 이하즉, 50 nM 이하의 낮은 IC50 값을 나타내어, 우수한 TMD80 활성 억제능을 나타내는 것을 확인하였다.In addition, the conjugated pyrimidine derivatives according to the present invention inhibit the activity of TMD80 with an IC 50 value of 10 μM or less, while the compounds of Examples 11, 21, 27, 28 and 46 inhibit the activity of low IC 50 value, indicating excellent TMD80 activity inhibitory activity.
따라서, 본 발명에 따른 접합 피리미딘 유도체는 브루톤 티로신 키나제 또는 TMD80의 활성을 억제하는 능력이 우수하므로, 브루톤 티로신 키나제 활성과 관련된 질환, 특히 암 또는 자가면역질환을 예방 또는 치료하는데 유용하게 사용할 수 있다.Therefore, the conjugated pyrimidine derivative according to the present invention is excellent in the ability to inhibit the activity of brutonyl tyrosine kinase or TMD80, so that it is useful for preventing or treating diseases related to the bruton tyrosine kinase activity, particularly cancer or autoimmune diseases .
<제제예 1> 산제의 제조≪ Formulation Example 1 > Preparation of powders
화학식 1로 표시되는 화합물 2gThe compound represented by the formula (1) 2g
유당 1gLactose 1g
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above components were mixed and packed in airtight bags to prepare powders.
<제제예 2> 정제의 제조≪ Formulation Example 2 > Preparation of tablet
화학식 1로 표시되는 화합물 100 ㎎The compound represented by the formula (1) 100 mg
옥수수전분 100 ㎎Corn starch 100 mg
유당 100 ㎎Lactose 100 mg
스테아린산 마그네슘 2 ㎎Magnesium stearate 2 mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
<제제예 3> 캡슐제의 제조≪ Formulation Example 3 > Preparation of capsules
화학식 1로 표시되는 화합물 100 ㎎The compound represented by the formula (1) 100 mg
옥수수전분 100 ㎎Corn starch 100 mg
유당 100 ㎎Lactose 100 mg
스테아린산 마그네슘 2 ㎎Magnesium stearate 2 mg
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
<제제예 4> 주사제의 제조≪ Formulation Example 4 > Preparation of injection
화학식 1로 표시되는 화합물 100 ㎎The compound represented by the formula (1) 100 mg
만니톨 180 ㎎Mannitol 180 mg
Na2HPO4ㆍ2H2O 26 ㎎Na 2 HPO 4 .2H 2 O 26 mg
증류수 2974 ㎎Distilled water 2974 mg
통상적인 주사제의 제조방법에 따라, 상기 성분들을 제시된 함량으로 함유시켜 주사제를 제조하였다.According to the conventional method for preparing an injectable preparation, an injectable preparation was prepared by incorporating the aforementioned components in the amounts indicated.
<제제예 5> 건강식품의 제조≪ Formulation Example 5 > Preparation of health food
화학식 1로 표시되는 화합물 500ngThe compound represented by the formula (1) 500ng
비타민 혼합물 적량Vitamin mixture Suitable amount
비타민 A 아세테이트 70mg Vitamin A acetate 70 mg
비타민 E 1.0mgVitamin E 1.0 mg
비타민 0.13mgvitamin 0.13 mg
비타민 B2 0.15mgVitamin B2 0.15 mg
비타민 B6 0.5mgVitamin B6 0.5 mg
비타민 B12 0.2mgVitamin B12 0.2 mg
비타민 C 10mgVitamin C 10 mg
비오틴 10mgBiotin 10 mg
니코틴산아미드 1.7mgNicotinic acid amide 1.7 mg
엽산 50mgFolic acid 50 mg
판토텐산 칼슘 0.5mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture Suitable amount
황산제1철 1.75mgFerrous sulfate 1.75 mg
산화아연 0.82mgZinc oxide 0.82 mg
탄산마그네슘 25.3mgMagnesium carbonate 25.3 mg
제1인산칼륨 15mgPotassium monophosphate 15 mg
제2인산칼슘 55mgDicalcium phosphate 55 mg
구연산칼륨 90mgPotassium citrate 90 mg
탄산칼슘 100mgCalcium carbonate 100 mg
염화마그네슘 24.8mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
<제제예 6> 건강음료의 제조≪ Formulation Example 6 > Preparation of health drink
화학식 1로 표시되는 화합물 500ngThe compound represented by the formula (1) 500ng
구연산 1000mgCitric acid 1000 mg
올리고당 100goligosaccharide 100g
매실농축액 2gPlum concentrate 2g
타우린 1gTaurine 1g
정제수를 가하여 전체 900mlPurified water is added to the entire 900ml
통상의 건강 음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 건강 음료 조성물 제조에 사용하였다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The resulting solution was filtered to obtain a sterilized container, which was sealed and sterilized, And used for manufacturing.
상기 조성비는 비교적 기호 음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호 도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is relatively mixed with the ingredient suitable for the favorite drink, it is also possible to arbitrarily modify the blending ratio according to the regional or national preference such as the demand class, demand country, use purpose, and the like.
Claims (14)
[화학식 1]
(상기 화학식 1에서,
n은 0 또는 1이고;
A는 단일 결합, -NH- 또는 -O-이고;
D1은 CR4 또는 N이고, 이때, 상기 R4는 수소 또는 직쇄 또는 측쇄의 C1- 5알킬이고;
D2는 CH 또는 N 이고;
D3은 N 또는 NH이고;
은 단일결합 또는 이중결합이고;
R1은 비치환 또는 치환된 C6- 10아릴이고,
여기서, 상기 치환된 C6- 10아릴은, 직쇄 또는 측쇄의 C1- 5알킬; 아크릴로일아민; 비치환된 C6- 10아릴; 비치환된 C6- 10아릴옥시; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7 원자의 비치환 또는 치환된 헤테로사이클로알킬 또는 헤테로사이클로알케닐;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있으며,
이때, 상기 치환된 헤테로사이클로알킬 및 헤테로사이클로알케닐은, 직쇄 또는 측쇄의 C1- 5알킬; 및 직쇄 또는 측쇄의 C1- 5알킬카보닐;으로 이루어지는 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있고,
R2 및 R3은 독립적으로 각각 독립적으로, 수소; 비치환 또는 치환된 C6- 10아릴; N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7 원자의 비치환 또는 치환된 헤테로사이클로알킬; 비치환된 또는 치환된 C3-7사이클로알킬; 또는 비치환 또는 치환된 인돌리닐이거나;
이들이 결합한 N원자와 함께 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7원자의 비치환 또는 치환된 헤테로사이클로알킬을 형성할 수 있고,
여기서, 상기 치환된 C6- 10아릴, 치환된 헤테로사이클로알킬, 치환된 C3- 7사이클로알킬 및 치환된 인돌리닐은 -NH2; 아크릴로일; 아크릴로일아민; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 7 원자의 비치환 또는 직쇄 또는 측쇄의 C1- 5알킬카보닐로 하나 이상 치환된 헤테로사이클로알킬;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있다).
Claims 1. A compound represented by the following formula (1), an optical isomer thereof or a pharmaceutically acceptable salt thereof:
[Chemical Formula 1]
(In the formula 1,
n is 0 or 1;
A is a single bond, -NH- or -O-;
D 1 is CR 4 or N, wherein said R 4 is hydrogen or linear or branched C 1- 5 alkyl;
D 2 is CH or N;
D 3 is N or NH;
Is a single bond or a double bond;
R 1 is a C 6- 10 aryl unsubstituted or substituted,
Wherein the substituted C 6- 10 aryl, straight or branched C 1- 5 alkyl; Acryloylamine; Unsubstituted C 6- 10 aryl; Unsubstituted C 6- 10 aryloxy; And 5 to 7-membered unsubstituted or substituted heterocycloalkyl or heterocycloalkenyl containing at least one heteroatom selected from the group consisting of N, O and S; and at least one member selected from the group consisting of Which may be substituted with one or more substituents,
In this case, the substituted heterocycloalkyl and heterocycloalkyl alkenyl, linear or branched C 1- 5 alkyl; And linear or branched C 1- 5 alkyl-carbonyl; and 1 or more substituents selected from the group consisting of consisting of one or more optionally substituted,
R 2 and R 3 are each independently and independently hydrogen; Unsubstituted or substituted C 6- 10 aryl; An unsubstituted or substituted heterocycloalkyl of 5 to 7 atoms containing at least one heteroatom selected from the group consisting of N, O and S; Unsubstituted or substituted C 3-7 cycloalkyl; Or an unsubstituted or substituted indolinyl;
Together with the N atom to which they are attached may form an unsubstituted or substituted heterocycloalkyl of 5 to 7 atoms containing at least one heteroatom selected from the group consisting of N, O and S,
Wherein the substituted C 6- 10 aryl, substituted heterocycloalkyl, substituted C 3- 7 cycloalkyl, and substituted indolinyl is -NH 2; Acryloyl; Acryloylamine; And N, O and one or more C 1- to 5-alkyl-carbonyl of from 5 to 7 atoms or an unsubstituted straight or branched chain containing one or more heteroatoms at least one selected from the group consisting of S-substituted heterocycloalkyl; (S) may be substituted with one or more substituents.
n은 0 또는 1이고;
A는 단일 결합, -NH- 또는 -O-이고;
D1은 CR4 또는 N이고, 이때, 상기 R4는 수소 또는 직쇄 또는 측쇄의 C1- 3알킬이고;
D2는 CH 또는 N 이고;
D3은 N 또는 NH이고;
은 단일결합 또는 이중결합이고;
R1은 비치환 또는 치환된 페닐이고,
여기서, 상기 치환된 페닐은, 직쇄 또는 측쇄의 C1- 5알킬; 아크릴로일아민; 비치환된 페닐; 비치환된 페닐옥시; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 6 원자의 비치환 또는 치환된 헤테로사이클로알킬 또는 헤테로사이클로알케닐;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있으며,
이때, 상기 치환된 헤테로사이클로알킬 및 헤테로사이클로알케닐은, 직쇄 또는 측쇄의 C1- 3알킬; 및 직쇄 또는 측쇄의 C1- 3알킬카보닐;으로 이루어지는 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있고,
R2 및 R3은 독립적으로 각각 독립적으로, 수소; 비치환 또는 치환된 페닐; N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 6 원자의 비치환 또는 치환된 헤테로사이클로알킬; 비치환된 또는 치환된 C3-6사이클로알킬; 또는 비치환 또는 치환된 인돌리닐이거나;
이들이 결합한 N원자와 함께 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 6원자의 비치환 또는 치환된 헤테로사이클로알킬을 형성할 수 있고,
여기서, 상기 치환된 페닐, 치환된 헤테로사이클로알킬, 치환된 C3- 6사이클로알킬 및 치환된 인돌리닐은 -NH2; 아크릴로일; 아크릴로일아민; 및 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 하나 이상 포함하는 5 내지 6 원자의 비치환 또는 직쇄 또는 측쇄의 C1- 3알킬카보닐로 하나 이상 치환된 헤테로사이클로알킬;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있는 것을 특징으로 하는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염.
The method according to claim 1,
n is 0 or 1;
A is a single bond, -NH- or -O-;
D 1 is CR 4 or N, wherein said R 4 is hydrogen or linear or branched C 1- 3 alkyl;
D 2 is CH or N;
D 3 is N or NH;
Is a single bond or a double bond;
R < 1 > is unsubstituted or substituted phenyl,
Where the substituted phenyl, linear or branched C 1- 5 alkyl; Acryloylamine; Unsubstituted phenyl; Unsubstituted phenyloxy; And unsubstituted or substituted heterocycloalkyl or heterocycloalkenyl of 5 to 6 atoms each containing at least one heteroatom selected from the group consisting of N, O and S; and at least one selected from the group consisting of Which may be substituted with one or more substituents,
In this case, the substituted heterocycloalkyl and heterocycloalkyl alkenyl, linear or branched C 1- 3 alkyl; And straight chain or C 1- 3 alkyl-carbonyl in the side chain; and 1 or more substituents selected from the group consisting of consisting of one or more optionally substituted,
R 2 and R 3 are each independently and independently hydrogen; Unsubstituted or substituted phenyl; An unsubstituted or substituted heterocycloalkyl of 5 to 6 atoms containing at least one heteroatom selected from the group consisting of N, O and S; Unsubstituted or substituted C 3-6 cycloalkyl; Or an unsubstituted or substituted indolinyl;
Together with the N atom to which they are attached may form an unsubstituted or substituted heterocycloalkyl of 5 to 6 atoms containing at least one heteroatom selected from the group consisting of N, O and S,
Where the substituted phenyl, substituted heterocycloalkyl, substituted C 3- 6 cycloalkyl, and substituted indolinyl is -NH 2; Acryloyl; Acryloylamine; And N, O and one or more of a C 1- 3 alkyl-carbonyl of from 5 to 6 atoms unsubstituted or straight or branched chain containing one or more heteroatoms at least one selected from the group consisting of S-substituted heterocycloalkyl; , Or an optically isomer thereof or a pharmaceutically acceptable salt thereof. The compound of the formula (I) or (II) may be substituted with one or more substituents selected from the group consisting of
n은 0 또는 1이고;
A는 단일 결합, -NH- 또는 -O-이고;
D1은 CR4 또는 N이고, 이때, 상기 R4는 수소 또는 메틸이고;
D2는 CH 또는 N 이고;
D3은 N 또는 NH이고;
은 단일결합 또는 이중결합이고;
R1은 비치환 또는 치환된 페닐이고,
여기서, 상기 치환된 페닐은, 메틸; 아크릴로일아민; 비치환된 페닐; 비치환된 페닐옥시; 및 비치환 또는 치환된 모폴리닐, 피페라지닐, 피페리디닐 또는 1, 4, 5, 6-테트라하이드로-1, 2, 4-트리아지닐;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있으며,
이때, 상기 치환된 모폴리닐, 피페라지닐, 피페리디닐 및 1, 4, 5, 6-테트라하이드로-1, 2, 4-트리아지닐은, 메틸 및 아세틸으로 이루어지는 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있고,
R2 및 R3은 독립적으로 각각 독립적으로, 수소; 비치환 또는 치환된 페닐; 또는 비치환 또는 치환된 피롤리디닐 또는 피페리디닐; 비치환된 또는 치환된 사이클로헥실; 또는 비치환 또는 치환된 인돌리닐이거나;
이들이 결합한 N원자와 함께 비치환 또는 치환된 피페라지닐을 형성할 수 있고,
여기서, 상기 치환된 페닐, 피롤리디닐, 피페리디닐, 피페라지닐, 사이클로헥실 및 인돌리닐은 -NH2; 아크릴로일; 아크릴로일아민; 모폴리닐; 및 아세틸이 치환된 피페라지닐;으로 이루어지는 군으로부터 선택되는 1종 이상의 치환기로 하나 이상 치환될 수 있는 것을 특징으로 하는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염.
The method according to claim 1,
n is 0 or 1;
A is a single bond, -NH- or -O-;
D 1 is CR 4 or N, wherein R 4 is hydrogen or methyl;
D 2 is CH or N;
D 3 is N or NH;
Is a single bond or a double bond;
R < 1 > is unsubstituted or substituted phenyl,
Wherein said substituted phenyl is selected from the group consisting of methyl; Acryloylamine; Unsubstituted phenyl; Unsubstituted phenyloxy; And one or more substituents selected from the group consisting of unsubstituted or substituted morpholinyl, piperazinyl, piperidinyl or 1,4,5,6-tetrahydro-1,2,4-triazinyl; Or more,
Wherein said substituted morpholinyl, piperazinyl, piperidinyl and 1,4,5,6-tetrahydro-1,2,4-triazinyl are optionally substituted with one or more substituents selected from the group consisting of methyl and acetyl Lt; / RTI > may be substituted by one or more,
R 2 and R 3 are each independently and independently hydrogen; Unsubstituted or substituted phenyl; Or unsubstituted or substituted pyrrolidinyl or piperidinyl; Unsubstituted or substituted cyclohexyl; Or an unsubstituted or substituted indolinyl;
Together with the N atom to which they are attached can form an unsubstituted or substituted piperazinyl,
Wherein said substituted phenyl, pyrrolidinyl, piperidinyl, piperazinyl, cyclohexyl, and indolinyl are optionally substituted with --NH 2 ; Acryloyl; Acryloylamine; Morpholinyl; And acetyl-substituted piperazinyl; or an optical isomer thereof or a pharmaceutically acceptable salt thereof.
상기 화학식 1로 표시되는 화합물은 하기 화합물 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염:
<1> 1-(4-(4-((6-(p-톨릴아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온;
<2> 1-(4-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)피페라진-1-일)에탄-1-온;
<3> (R)-N-(1-(6-(4-모폴리노페닐아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드;
<4> (S)-N-(1-(6-((4-모포리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드;
<5> 1-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;
<6> 1-(4-((6-((4-(피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘 -1-일)프로페-2-엔-1-온;
<7> 4(R)-N-(1-(6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)피페리딘-3-일)아크릴아미드;
<8> (S)-1-(3-((6-((4-(4-아세틸피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;
<9> 1-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로판-1-온;
<10> (S)-1-(3-((6-((4-(피페라진-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;
<11> 1-(4-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;
<12> 1-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;
<13> 1-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피페리딘-1-일)프로페-2-엔-1-온;
<14> N-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;
<15> N-((1s, 4s)-4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;
<16> (R)-1-(3-((6-([1, 1'-디페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;
<17> (R)-1-(3-((6-([1, 1'-디페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;
<18> (R)-1-(3-((6-((4-페녹시페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;
<19> (R)-1-(3-((6-((4-(피페리딘-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;
<20> N-((1s, 4s)-4-((3-메틸-6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;
<21> N-(3-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;
<22> N-((1s, 4s)-4-((6-(4-페녹시페닐) -1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;
<23> N-((1s, 4s)-4-((6-(4-페녹시페녹시)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;
<24> N-((1s, 4s)-4-((3-메틸-6-((4-(피페리딘-1-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;
<25> (R)-1-(3-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)피롤리딘-1-일)프로페-2-엔-1-온;
<26> N-((1s, 4s)-4-((6-([1, 1'-비페닐]-4-일아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;
<27> N-((1s, 4s)-4-((2-((4-모폴리노페닐)아미노)-7H-피롤로[2, 3-d]피리미딘-4-일)아미노)시클로헥실)아크릴아미드;
<28> N-(2-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;
<29> N-(4-((6-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;
<30> N4, N6-bis(4-모폴리노페닐)-1H-피라졸로[3,4-d]피리미딘-4, 6-디아민;
<31> N4-(3-아미노페닐)-N2-(4-모폴리노페닐)-7H-피롤로[2, 3-d]피리미딘-2, 4-디아민;
<32> N-(3-((4-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드;
<33> N-(3-((2-((4-모폴리노페닐)아미노)-9H-퓨린-6-일)아미노)페닐)아크릴아미드;
<34> N-(3-((2-((4-모폴리노페닐)아미노)피리도[2, 3-d]피리미딘-4-일)아미노)페닐)아크릴아미드;
<35> N-(3-((4-((4-모폴리노페닐)아미노)피리도[2, 3-d]피리미딘-2-일)아미노)페닐)아크릴아미드;
<36> N2, N4-비스(4-모폴리노페닐)피리도[2, 3-d]피리미딘-2, 4-디아민;
<37> N-(3-((6-((4-(4-아세틸피페라진-1-일)페닐)아미노)-3-메틸-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;
<38> N-(3-((6-((4-(1-메틸-5, 6-디히드로-1, 2, 4-트리아진-4(1H)-일)페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;
<39> 1-(6-((6-((4-모포리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온;
<40> 1-(6-((2-((4-모폴리노페닐)아미노)피리도[2, 3-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온;
<41> N-(3-((6-((3-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;
<42> N-(3-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드;
<43> 1-(6-((6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온;
<44> 1-(6-((3-메틸-6-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-4-일)아미노)인돌린-1-일)프로페-2-엔-1-온;
<45> N-(3-((3-메틸-4-((4-모폴리노페닐)아미노)-1H-피라졸로[3,4-d]피리미딘-6-일)아미노)페닐)아크릴아미드; 및
<46> N-(3-((3-메틸-6-((4-모폴리노페닐)아미노)-1H-피라조로[3,4-d]피리미딘-4-일)아미노)페닐)아크릴아미드.
The method according to claim 1,
The compound represented by the formula (1) is any one selected from the group consisting of the following compounds, an optical isomer thereof or a pharmaceutically acceptable salt thereof:
1) Preparation of 1- (4- (4 - ((6- (p-tolylamino) -1H-pyrazolo [3,4- d] pyrimidin- ) Ethan-1-one;
Amino] phenyl) piperazine (hereinafter referred to as " 1- (4- (4 - ((6- 1-yl) ethan-1-one;
3) Preparation of (R) -N- (1- (6- (4-morpholinophenylamino) -1H-pyrazolo [3,4- d] pyrimidin- ) Acrylamide;
<4> Synthesis of (S) -N- (1- (6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) acrylamide;
<5> A process for preparing 1- (4 - ((6 - ((4- morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) prop-2-en-1-one;
(6) Synthesis of 1- (4 - ((6 - ((4- (piperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- 1-yl) prop-2-en-1-one;
Pyrazolo [3,4-d] pyrimidin-4-yl) piperidine-l-carboxylic acid tert- 3-yl) acrylamide;
(S) -1- (3 - ((6 - ((4- (4-Acetylpiperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidine- 4-yl) amino) piperidin-1-yl) prop-2-en-1-one;
<9> Synthesis of 1- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- Yl) propan-1-one;
(S) -1- (3 - ((6 - ((4- (piperazin-1-yl) phenyl) amino) -1H-pyrazolo [3,4- d] pyrimidin- ) Amino) piperidin-1-yl) prop-2-en-1-one;
(11) Synthesis of 1- (4 - ((6- (4-phenoxyphenyl) -lH-pyrazolo [3,4- d] pyrimidin-4- yl) amino) piperidin- 2-en-1-one;
<12> The compound according to any one of <1> to <13>, wherein the compound is 1- (3 - ((6- ( Yl) prop-2-en-1-one;
[13] d) pyrimidin-4-yl) amino) piperidine-l- Yl) prop-2-en-1-one;
<14> N- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) cyclohexyl) acrylamide;
3,4-d] pyrimidin-4-yl) amino) -1H-pyrazolo [3,4-d] pyrimidin- Cyclohexyl) acrylamide;
(R) -1- (3 - ((6 - ([1,1'-diphenyl] -4-ylamino) -1H-pyrazolo [3,4- d] pyrimidin- ) Amino) pyrrolidin-1-yl) prop-2-en-1-one;
(R) -1- (3 - ((6 - ([1,1'-diphenyl] -4-ylamino) -1 H- pyrazolo [3,4- d] pyrimidin- ) Amino) pyrrolidin-1-yl) prop-2-en-1-one;
(R) -1- (3 - ((6 - ((4-phenoxyphenyl) amino) -lH- pyrazolo [3,4- d] pyrimidin-4- yl) amino) pyrrolidine -1-yl) prop-2-en-1-one;
3,4-d] pyrimidin-4-ylmethyl) -1H-pyrazolo [3,4-d] pyrimidin- Yl) amino) pyrrolidin-1-yl) prop-2-en-1-one;
<20> Synthesis of N - ((1s, 4s) -4 - ((3-methyl- Yl) amino) cyclohexyl) acrylamide;
<21> N- (3 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
(1S, 4S) -4 - ((6- (4-phenoxyphenyl) -lH-pyrazolo [3,4- d] pyrimidin-4-yl) amino) cyclohexyl) amides;
Amino] cyclohexyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) Acrylamide;
Preparation of N - ((1S, 4S) -4 - ((3-Methyl-6 - ((4- (piperidin- 1 -yl) phenyl) amino) -1H-pyrazolo [ ] Pyrimidin-4-yl) amino) cyclohexyl) acrylamide;
Pyrazolo [3,4-d] pyrimidin-4-yl) amino) pyrrolidine-l- (3 - ((6- (4-phenoxyphenyl) Yl) prop-2-en-1-one;
4-ylamino) -lH-pyrazolo [3,4-d] pyrimidin-4 (2S) -Yl) amino) cyclohexyl) acrylamide;
Pyrrolo [2,3-d] pyrimidin-4-yl) amino) -7H-pyrrolo [2,3- d] pyrimidin- Cyclohexyl) acrylamide;
<28> N- (2 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
<29> N- (4 - ((6 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
<30> N 4, N 6 -bis (4-morpholinophenyl) -1H-pyrazolo [3,4-d] pyrimidine-4,6-diamine;
<31> N 4 - (3-aminophenyl) -N 2 - (4-morpholinophenyl) -7H-pyrrolo [2,3-d] pyrimidine-2,4-diamine;
<32> N- (3 - ((4 - ((4-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-6-yl) amino) phenyl) acrylamide;
<33> N- (3 - ((2 - ((4-morpholinophenyl) amino) -9H-purin-6-yl) amino) phenyl) acrylamide;
<34> N- (3 - ((2 - ((4-morpholinophenyl) amino) pyrido [2,3-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
N- (3 - ((4 - ((4-morpholinophenyl) amino) pyrido [2,3-d] pyrimidin-2-yl) amino) phenyl) acrylamide;
N 2, N 4 -bis (4-morpholinophenyl) pyrido [2,3-d] pyrimidine-2,4-diamine;
3-methyl-1H-pyrazolo [3,4-d] pyrimidine-2-carboxylic acid ethyl ester was prepared from N- (3 - ((6- 4-yl) amino) phenyl) acrylamide;
<38> N - (3 - ((6 - ((4- (1- methyl-5, 6-dihydro-1, 2,4-triazine -4 (1H) - yl) phenyl) amino) -1H -Pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
3,4-d] pyrimidin-4-yl) amino) indolin-1-yl) amino] 2-en-1-one;
Amino] pyrido [2,3-d] pyrimidin-4-yl) amino) indolin-1-yl) propane 2-en-1-one;
N- (3 - ((6 - ((3-morpholinophenyl) amino) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
N - (3 - ((6- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-yl) amino) phenyl) acrylamide;
Amino] indolin-1-yl) propyl] -1H-pyrazolo [3,4-d] pyrimidin- 2-en-1-one;
(3-methyl-6- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4- yl) amino) indolin- ) Prop-2-en-1-one;
<45> N - (3 - ((3- methyl-4 - ((4-morpholinophenyl) amino) -1H- pyrazolo [3,4-d] pyrimidin-6-yl) amino) phenyl) Acrylamide; And
<46> N - (3 - ((3- methyl-6 - ((4-morpholinophenyl) amino) -1H- pyrazol twos [3,4-d] pyrimidin-4-yl) amino) phenyl) Acrylamide.
화학식 3으로 표시되는 화합물과 화학식 4로 표시되는 화합물을 반응시켜 화학식 2로 표시되는 화합물을 제조하는 단계(단계 1); 및
상기 단계 1에서 얻은 화학식 2로 표시되는 화합물과 화학식 5로 표시되는 화합물을 반응시켜 화학식 1로 표시되는 화합물을 얻는 단계(단계 2)를 포함하는 제1항의 화학식 1로 표시되는 화합물의 제조방법:
[반응식 1]
(상기 반응식 1에서,
n, A, D1, D2, D3, R1, R2, R3 및 는 제1항의 화학식 1에서 정의한 바와 같고;
X1 및 X2는 각각 독립적으로 동일 또는 상이한 할로겐이고; 및
L1은 수소 또는 이다.
As shown in Scheme 1 below,
Reacting a compound represented by formula (3) with a compound represented by formula (4) to prepare a compound represented by formula (2) (step 1); And
A process for producing a compound represented by the general formula (1) as set forth in claim 1, comprising the step of reacting the compound represented by the general formula (2) and the compound represented by the general formula (5) obtained in the above step 1 to obtain the compound represented by the general formula (1)
[Reaction Scheme 1]
(In the above Reaction Scheme 1,
n, A, D 1, D 2, D 3, R 1, R 2, R 3 and Is as defined in claim 1;
X 1 and X 2 are each independently the same or different halogen; And
L 1 is hydrogen or to be.
화학식 3으로 표시되는 화합물과 화학식 5로 표시되는 화합물을 반응시켜 화학식 6으로 표시되는 화합물을 제조하는 단계(단계 1); 및
상기 단계 1에서 얻은 화학식 6으로 표시되는 화합물과 화학식 4로 표시되는 화합물을 반응시켜 화학식 1로 표시되는 화합물을 얻는 단계(단계 2)를 포함하는 제1항의 화학식 1로 표시되는 화합물의 제조방법:
[반응식 2]
(상기 반응식 2에서,
n, A, D1, D2, D3, R1, R2, R3 및 는 제1항의 화학식 1에서 정의한 바와 같고;
X1 및 X2는 각각 독립적으로 동일 또는 상이한 할로겐이고; 및
L1은 수소 또는 이다.
As shown in Scheme 2 below,
Reacting a compound represented by formula (3) with a compound represented by formula (5) to prepare a compound represented by formula (6) (step 1); And
A process for producing a compound represented by the general formula (1) as set forth in claim 1, comprising the step of reacting the compound represented by the formula (6) and the compound represented by the formula (4) obtained in the step 1 to obtain the compound represented by the formula (1)
[Reaction Scheme 2]
(In the above Reaction Scheme 2,
n, A, D 1, D 2, D 3, R 1, R 2, R 3 and Is as defined in claim 1;
X 1 and X 2 are each independently the same or different halogen; And
L 1 is hydrogen or to be.
A pharmaceutical composition for preventing or treating cancer comprising the compound represented by the general formula (1) of claim 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
상기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염은 브루톤 티로신 키나제(Bruton's tyrosine kinase, BTK)의 활성을 억제하는 것을 특징으로 하는 암의 예방 또는 치료용 약학적 조성물.
8. The method of claim 7,
The pharmaceutical composition for prevention or treatment of cancer, wherein the compound represented by the formula (1), its optical isomer or a pharmaceutically acceptable salt thereof inhibits the activity of Bruton's tyrosine kinase (BTK).
상기 암은 혈액암, 난소암, 자궁경부암, 유방암, 대장암, 간암, 위암, 췌장암, 결장암, 복막 전이암, 피부암, 방광암, 전립선암, 갑상선암, 폐암, 골육종, 섬유성 종양 및 뇌종양으로 이루어지는 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 암의 예방 또는 치료용 약학적 조성물.
8. The method of claim 7,
The cancer is selected from the group consisting of blood cancer, ovarian cancer, cervical cancer, breast cancer, colon cancer, liver cancer, gastric cancer, pancreatic cancer, colon cancer, peritoneal metastasis cancer, skin cancer, bladder cancer, prostate cancer, thyroid cancer, lung cancer, osteosarcoma, And a pharmaceutically acceptable carrier or excipient.
A pharmaceutical composition for preventing or treating an autoimmune disease, which comprises the compound represented by the general formula (1) of claim 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
상기 화학식 1로 표시되는 화합물, 이의 광학 이성질체 또는 이의 약학적으로 허용가능한 염은 브루톤 티로신 키나제(Bruton's tyrosine kinase, BTK)의 활성을 억제하는 것을 특징으로 하는 자가면역질환의 예방 또는 치료용 약학적 조성물.
11. The method of claim 10,
The compound represented by the above-mentioned formula (1), its optical isomer or its pharmaceutically acceptable salt is useful as a pharmaceutical for the prophylactic or therapeutic treatment of autoimmune diseases, which inhibits the activity of Bruton's tyrosine kinase (BTK) Composition.
상기 자가면역질환은 특징으로 류머티스성 관절염, 전신 홍반성 루푸스, 다발성 경화증, 제1형 당뇨병, 갑상선 기능 항진증, 근무력증, 크론병, 강직성 척추염, 건선, 자가면역성 악성빈혈 및 쇼그렌 증후군으로 이루어지는 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 자가면역질환의 예방 또는 치료용 약학적 조성물.
11. The method of claim 10,
The autoimmune disease is characterized in that it is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, hyperthyroidism, myasthenia, Crohn's disease, ankylosing spondylitis, psoriasis, autoimmune malignant anemia and Sjogren's syndrome Or a pharmaceutically acceptable salt or solvate thereof.
A health functional food composition for preventing or ameliorating cancer comprising the compound represented by the general formula (1) of claim 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170075721A KR102032418B1 (en) | 2017-06-15 | 2017-06-15 | Fused-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170075721A KR102032418B1 (en) | 2017-06-15 | 2017-06-15 | Fused-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180137057A true KR20180137057A (en) | 2018-12-27 |
KR102032418B1 KR102032418B1 (en) | 2019-10-16 |
Family
ID=64953292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170075721A KR102032418B1 (en) | 2017-06-15 | 2017-06-15 | Fused-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102032418B1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020198367A1 (en) * | 2019-03-26 | 2020-10-01 | Academia Sinica | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND β-THALASSEMIA |
JP2020529987A (en) * | 2017-08-01 | 2020-10-15 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Pyrazolo and triazolobicyclic compounds as JAK kinase inhibitors |
CN112079830A (en) * | 2019-06-14 | 2020-12-15 | 上海翰森生物医药科技有限公司 | Fused ring-containing derivative inhibitor, preparation method and application thereof |
US11078206B2 (en) | 2017-12-28 | 2021-08-03 | Daewoong Pharmaceutical Co., Ltd. | Amino-fluoropiperidine derivatives as kinase inhibitor |
JP2022505053A (en) * | 2019-03-18 | 2022-01-14 | 上海海雁医薬科技有限公司 | BTK inhibitors, their pharmaceutically acceptable salts and crystalline polymorphs, and their applications |
US11339167B2 (en) | 2017-12-28 | 2022-05-24 | Daewoong Pharmaceutical Co., Ltd. | Substituted piperidines as kinase inhibitors |
WO2022149856A1 (en) * | 2021-01-07 | 2022-07-14 | 주식회사 온코빅스 | Compound for inhibiting bruton's tyrosine kinase, and pharmaceutical use thereof |
US11407754B2 (en) | 2017-12-28 | 2022-08-09 | Daewoong Pharmaceutical Co., Ltd. | Substituted piperidines as kinase inhibitors |
JP2022538493A (en) * | 2019-07-04 | 2022-09-02 | 沈陽薬科大学 | 2-aminopyrimidine compound and use thereof |
CN115368366A (en) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | Pyrimidopyrazole compound and application thereof |
US11667637B2 (en) | 2017-03-09 | 2023-06-06 | Theravance Biopharma R&D Ip, Llc | Fused imidazo-piperidine JAK inhibitors |
WO2023128708A1 (en) * | 2021-12-30 | 2023-07-06 | 한국화학연구원 | Pyrazolopyrimidine derivative and anticancer pharmaceutical composition containing same as active ingredient |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090076037A1 (en) * | 2006-09-25 | 2009-03-19 | Connolly Peter J | Bicyclic pyrimidine kinase inhibitors |
KR20110015414A (en) * | 2008-04-07 | 2011-02-15 | 아이알엠 엘엘씨 | Compounds and compositions as protein kinase inhibitors |
KR20120047208A (en) * | 2009-05-05 | 2012-05-11 | 다나-파버 캔서 인스티튜트 인크. | Egfr inhibitors and methods of treating diseases |
US20120129852A1 (en) * | 2009-08-11 | 2012-05-24 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
KR20160062103A (en) | 2013-09-30 | 2016-06-01 | 파마싸이클릭스 엘엘씨 | Inhibitors of bruton's tyrosine kinase |
-
2017
- 2017-06-15 KR KR1020170075721A patent/KR102032418B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090076037A1 (en) * | 2006-09-25 | 2009-03-19 | Connolly Peter J | Bicyclic pyrimidine kinase inhibitors |
KR20110015414A (en) * | 2008-04-07 | 2011-02-15 | 아이알엠 엘엘씨 | Compounds and compositions as protein kinase inhibitors |
KR20120047208A (en) * | 2009-05-05 | 2012-05-11 | 다나-파버 캔서 인스티튜트 인크. | Egfr inhibitors and methods of treating diseases |
US20120129852A1 (en) * | 2009-08-11 | 2012-05-24 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
KR20160062103A (en) | 2013-09-30 | 2016-06-01 | 파마싸이클릭스 엘엘씨 | Inhibitors of bruton's tyrosine kinase |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11667637B2 (en) | 2017-03-09 | 2023-06-06 | Theravance Biopharma R&D Ip, Llc | Fused imidazo-piperidine JAK inhibitors |
JP2020529987A (en) * | 2017-08-01 | 2020-10-15 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Pyrazolo and triazolobicyclic compounds as JAK kinase inhibitors |
US11078206B2 (en) | 2017-12-28 | 2021-08-03 | Daewoong Pharmaceutical Co., Ltd. | Amino-fluoropiperidine derivatives as kinase inhibitor |
US11339167B2 (en) | 2017-12-28 | 2022-05-24 | Daewoong Pharmaceutical Co., Ltd. | Substituted piperidines as kinase inhibitors |
US11407754B2 (en) | 2017-12-28 | 2022-08-09 | Daewoong Pharmaceutical Co., Ltd. | Substituted piperidines as kinase inhibitors |
JP2022505053A (en) * | 2019-03-18 | 2022-01-14 | 上海海雁医薬科技有限公司 | BTK inhibitors, their pharmaceutically acceptable salts and crystalline polymorphs, and their applications |
CN114945572A (en) * | 2019-03-26 | 2022-08-26 | 刘扶东 | HBF pharmacological inducing compounds for the treatment of sickle cell anemia and beta-thalassemia |
WO2020198367A1 (en) * | 2019-03-26 | 2020-10-01 | Academia Sinica | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND β-THALASSEMIA |
CN112079830A (en) * | 2019-06-14 | 2020-12-15 | 上海翰森生物医药科技有限公司 | Fused ring-containing derivative inhibitor, preparation method and application thereof |
CN112079830B (en) * | 2019-06-14 | 2023-12-22 | 上海翰森生物医药科技有限公司 | Inhibitor containing fused ring derivative, preparation method and application thereof |
JP2022538493A (en) * | 2019-07-04 | 2022-09-02 | 沈陽薬科大学 | 2-aminopyrimidine compound and use thereof |
WO2022149856A1 (en) * | 2021-01-07 | 2022-07-14 | 주식회사 온코빅스 | Compound for inhibiting bruton's tyrosine kinase, and pharmaceutical use thereof |
WO2023128708A1 (en) * | 2021-12-30 | 2023-07-06 | 한국화학연구원 | Pyrazolopyrimidine derivative and anticancer pharmaceutical composition containing same as active ingredient |
CN115368366A (en) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | Pyrimidopyrazole compound and application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR102032418B1 (en) | 2019-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102032418B1 (en) | Fused-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient | |
CN110036014B (en) | Compound with AXL inhibitory activity and preparation and application thereof | |
AU2017287762B2 (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
US9862722B2 (en) | Inhibitors of Bruton's tyrosine kinase | |
US9580432B2 (en) | Fused pyrimidine compound or salt thereof | |
US20100298557A1 (en) | Pyrazolopyrimidine compound | |
KR20070104936A (en) | Chemical compounds | |
CN107206001B (en) | Prophylactic and/or therapeutic agent for immune diseases | |
KR20170074381A (en) | Pyrimido oxazine derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases | |
AU2016213031B2 (en) | Novel salt of fused pyrimidine compound and crystal thereof | |
KR101956815B1 (en) | Triazolo-pyridazine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient | |
TWI394757B (en) | Anthraquinone derivative and antitumor agent using same | |
KR20220062003A (en) | Substituted imidazoquinoxaline compounds and uses thereof | |
KR20170074380A (en) | Dihydropteridin-one derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |